Polypeptide, cdna encoding the polypeptide, and use of the both

ABSTRACT

A new polypeptide prepared from human library by the SST method and a process for preparation of it; a cDNA encoding the polypeptide; a fragment selectively hybridizing with the sequence of the cDNA; a replication or expression plasmid containing the cDNA integrated thereinto; a host cell transformed with plasmid; an antibody against the polypeptide; and a pharmaceutical composition containing the polypeptide or the antibody.

TECHNICAL FIELD

[0001] The present invention relates to novel polypeptides, a method for preparation of them, a cDNA encoding it, a vector containing it, a host cell transformed with the vector, an antibody against the peptide, and a pharmaceutical composition containing the polypeptide or the antibody.

TECHNICAL BACKGROUND

[0002] Until now, when a man skilled in the art intends to obtain a particular polypeptide or a cDNA encoding it, he generally utilizes methods by confirming an aimed biological activity in a tissue or in a cell medium, isolating and purifying the polypeptide and then cloning a gene or methods by “expression-cloning” with the guidance of the said biological activity. However, physiologically active polypeptides in living body have often many kinds of activities. Therefore, it happens increasingly that after cloning a gene, the isolated gene is found to be identical to that encoding a polypeptide already known. In addition, some factors could be generated in only a very slight amount and/or under specific conditions and it makes difficult to isolate and to purify the factor and to confirm its biological activity.

[0003] Recent rapid developments in techniques for constructing cDNAs and sequencing techniques have made it possible to quickly sequence a large amount of cDNAs. By utilizing these techniques, a process, which comprises constructing cDNAs library using various cells or tissues, cloning the cDNA at random, identifying the nucleotide sequences thereof, expressing novel polypeptides encoded by them, is now in progress. Although this process is advantageous in that a gene can be cloned and information regarding its nucleotide sequence can be obtained without any biochemical or genetic analysis, the target gene can be discovered thereby only accidentally in many cases.

[0004] The present inventors have studied cloning method to isolate genes encoding proliferation and/or differentiation factors functioning in hematopoietic systems and immune systems. Focusing their attention on the fact that most of the secretory proteins such as proliferation and/or differentiation factors (for example various cytokines) and membrane proteins such as receptors thereof (hereafter these proteins will be referred to generally as secretory proteins and the like) have sequences called signal peptides in the N-termini, the inventors have conducted extensive studies on a process for efficiently and selectively cloning a gene encoding for a signal peptide. Finally, we have successfully developed a screening method for the signal peptides (signal sequence trap (SST)) by using mammalian cells (See Japanese Patent Application No. Hei 6-13951). We also developed yeast SST method on the same concept. By the method based on the same conception using yeast, (yeast SST method), genes including sequence encoding signal peptide can be identified more easily and efficiently (See U.S. Pat. No. 5,536,637).

DISCLOSURE OF THE PRESENT INVENTION

[0005] The present inventors et al. have diligently performed certain investigation in order to isolate novel factors (polypeptides) useful for treatment, diagnosis and/or study, particularly, secretory proteins containing secretory signal and membrane protein.

[0006] From the result, the present inventors achieved to find novel secretory proteins and membrane proteins produced from cell lines and tissue, for example, human placenta, human adult brain tissue, cell lines derived from human brain tissue, human bone, cell line derived from human bone marrow, and endothelial cell line of vein derived from human umbilical cord and cDNAs encoding them, and then completed the present invention.

[0007] The present invention provides the cDNA sequences identified as clone ON056, ON034, OX003 which were isolated by the said yeast SST method using cDNA libraries prepared from human placenta tissue. Clone ON056, ON034, OX003 were full-length cDNA including full cDNA sequences encoding secretory proteins (Each protein is represented as ON056, ON034, OX003 protein, respectively).

[0008] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of ON056, ON034, OX003 of the present invention. From the above, it was proved that polypeptides of the present invention were new secretary proteins.

[0009] The present invention provides the cDNA sequences identified as clone OA052, OC004, OM017, OM101, OM126, OM160, OMA016a, OMA016b, OMB130, OMB142, OVB100 which were isolated by the said yeast SST method using cDNA libraries prepared from human adult brain tissue and cell lines derived from human brain tissue (T98G, IMR-32, and CCF-STTG1). Clone OA052, OC004, OM017, OM101, OM126, OM160, OMA016a, OMA016b, OMB130, OMB142, OVB100003 were full-length cDNA including full cDNA sequences encoding secretory protein (Each protein is represented as OA052, OC004, OM017, OM101, OM126, OM160, OMA016a, OMA016b, OMB130, OMB142, OVB100 protein, respectively).

[0010] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OA052, OC004, OM017, OM101, OM126, OM160, OMA016a, OMA016b, OMB130, OMB142, OVB100 of the present invention. From these results, it was proved that polypeptides of the present invention were new secretary proteins.

[0011] The present invention provides the cDNA sequences identified as clone OAF062, OAF075, OAG119 which were isolated by the said yeast SST method using cDNA libraries prepared from human bone and bone marrow cell line (HAS303, LP101. Clone OAF062, OAF075, OAG119003 were full-length cDNA including full cDNA sequences encoding secretory protein (Each protein is represented as OAF062, OAF075, OAG119 protein, respectively).

[0012] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OAF062, OAF075, OAG119 of the present invention. From these results, it was proved that polypeptides of the present invention were new secretary proteins.

[0013] The present invention provides the cDNA sequences identified as clone OAH040, OAH058 which were isolated by the said yeast SST method using cDNA libraries prepared from epithelial cell line of human umbilical vein (HUV-EC-C). Clone OAH040, OAH058003 were full-length cDNA including full cDNA sequences encoding secretory protein (Each protein is represented as OAH040, OAH058 protein, respectively).

[0014] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OAH040, OAH058 of the present invention. From these results, it was proved that polypeptides of the present invention were new secretary proteins.

[0015] The present invention provides the cDNA sequences identified as clone OM011, OM028, OMB092, OMB108, OT007 which were isolated by the said yeast SST method using cDNA libraries prepared from human adult brain tissue and cell lines derived from human brain tissue (IMR-32). Clone OM011, OM028, OMB092, OMB108, OT007

membrane protein (Each protein is represented as OM011, OM028, OMB092, OMB108, OT007 protein, respectively).

[0016] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OM011, OM028, OMB092, OMB108, OT007 of the present invention. From these results, it was proved that polypeptides of the present invention were new secretary proteins.

[0017] The present invention provides the cDNA sequences identified as clone OAG051, OUB068 which were isolated by the said yeast SST method using cDNA libraries prepared from human bone and bone marrow cell line (LP101 and U-2OS). Clone OAG051, OUB068

membrane protein (Each protein is represented as OAG051, OUB068 protein, respectively).

[0018] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OAG051, OUB068 of the present invention. From these results, it was proved that polypeptides of the present invention were new secretary proteins.

[0019] That is to say, the present invention relates to

[0020] (1) a polypeptide comprising an amino acid sequence of SEQ ID NOS. 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 73, 76 or 79,

[0021] (2) a cDNA encoding the polypeptide described in (1),

[0022] (3) a cDNA comprising a nucleotide sequence of SEQ ID NOS. 2, 5, 8, 11, 14, 17, 20, 23, 26, 29, 32, 35, 38, 41, 44, 47, 50, 53, 56, 59, 62, 65, 68, 71, 74, 77 or 80, and

[0023] (4) a cDNA comprising a nucleotide sequence of SEQ ID NOS. 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78 or 81.

BRIEF DESCRIPTION OF THE DRAWING

[0024]FIG. 1 is a printed data of electrophoresis (SDS-PAGE). Each prepared fraction and the solubilized fraction obtained from insolble fraction by urea described in Example 1 were subjected to SDS-PAGE. The proteins on the gel were detected by image analyzer (BAS2000) as shown in the FIG. 1. The expression of ON056 in E. coli is shown at the arrowhead in the figure.

DETAILED DESCRIPTION OF THE PRESENT INVENTION

[0025] The present invention relates to a substantially purified form of the polypeptide comprising the amino acid sequence shown in SEQ ID NOS. 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 73, 76 or 79, homologue thereof, fragment thereof or homologue of the fragment.

[0026] Further, the present invention relates to cDNAs encoding the above peptides. More particularly the invention is provided cDNAs comprising nucleotide sequence shown in SEQ ID NOS. 2, 5, 8, 11, 14, 17, 20, 23, 26, 29, 32, 35, 38, 41, 44, 47, 50, 53, 56, 59, 62, 65, 68, 71, 74, 77, 80, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78 or 81, and cDNA containing a fragment which is selectively hybridizing to the cDNA comprising nucleotide sequence shown in SEQ ID NOS. 2, 5, 8, 11, 14, 17, 20, 23, 26, 29, 32, 35, 38, 41, 44, 47, 50, 53, 56, 59, 62, 65, 68, 71, 74, 77, 80, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78 or 81. A said cDNA capable for hybridizing to the cDNA includes the contemporary sequence of the above sequence.

[0027] A polypeptide comprising amino acid sequence shown in SEQ ID NOS. 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 73, 76 or 79 in substantially purified form will generally comprise the polypeptide in a preparation in which more than 90%, e.g. 95%, 98% or 99% of the polypeptide in the preparation is that of the SEQ ID NOS. 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 73, 76 or 79.

[0028] A homologue of polypeptide comprising amino acid sequence shown in SEQ ID NOS. 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 73, 76 or 79 will be generally at least 70%, preferably at least 80 or 90% and more preferably at least 95% homologous to the polypeptide comprising the said amino acid sequence over a region of at least 20, preferably at least 30, for instance 40, 60 or 100 more contiguous amino acids. Such a polypeptide homologue will be referred to a polypeptide of the present invention.

[0029] Generally, a fragment of polypeptide comprising amino acid sequence shown in SEQ ID NOS. 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 73, 76 or 79 or its homologues will be at least 10, preferably at least 15, for example 20, 25, 30, 40, 50 or 60 amino acids in length.

[0030] A cDNA capable of selectively hybridizing to the cDNA comprising nucleotide sequence shown in SEQ ID NOS. 2, 5, 8, 11, 14, 17, 20, 23, 26, 29, 32, 35, 38, 41, 44, 47, 50, 53, 56, 59, 62, 65, 68, 71, 74, 77, 80, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78 or 81 will be generally at least 70%, preferably at least 80 or 90% and more preferably at least 95% homologous to the cDNA comprising the said nucleotide sequence over a region of at least 20, preferably at least 30, for instance 40, 60 or 100 or more contiguous nucleotides. Such a cDNA will be referred to “a cDNA of the present invention”.

[0031] Fragments of the cDNA comprising nucleotide sequence shown in SEQ ID NOS. 2, 5, 8, 11, 14, 17, 20, 23, 26, 29, 32, 35, 38, 41, 44, 47, 50, 53, 56, 59, 62, 65, 68, 71, 74, 77, 80, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78 or 81 will be at least 10, preferably at least 15, for example 20, 25, 30 or 40 nucleotides in length, and will be also referred to “a cDNA of the present invention” as used herein.

[0032] A further embodiment of the present invention provides replication and expression vectors carrying cDNA of the present invention. The vectors may be, for example, plasmid, virus or phage vectors provided with an origin of replication, optionally a promoter for the expression of the said cDNA and optionally a regulator of the promoter. The vector may contain one or more selectable marker genes, for example ampicillin resistance gene. The vector may be used in vitro, for example of the production of RNA corresponding to the cDNA, or used to transfect a host cell.

[0033] A further embodiment of the present invention provides host cells transformed with the vectors for the replication and expression of the cDNA of the present invention, including the cDNA comprising nucleotide sequence shown in SEQ ID NOS. 2, 5, 8, 11, 14, 17, 20, 23, 26, 29, 32, 35, 38, 41, 44, 47, 50, 53, 56, 59, 62, 65, 68, 71, 74, 77, 80, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78 or 81 or the open reading frame thereof. The cells will be chosen to be compatible with the vector and may for example be bacterial, yeast, insect cells or mammalian cells.

[0034] A further embodiment of the present invention provides a method of producing a polypeptide which comprises culturing host cells of the present invention under conditions effective to express a polypeptide of the present invention. Preferably, in addition, such a method is carried out under conditions in which the polypeptide of the present invention is expressed and then produced from the host cells.

[0035] cDNA of the present invention may also be inserted into the vectors described above in an antisense orientation in order to prove for the production of antisense RNA. Such antisense RNA may be used in a method of controlling the levels of a polypeptide of the present invention in a cell.

[0036] The invention also provides monoclonal or polyclonal antibodies against a polypeptide of the present invention. The invention further provides a process for the production of monoclonal or polyclonal antibodies to the polypeptides of the present invention. Monoclonal antibodies may be prepared by common hybridoma technology using polypeptides of the present invention or fragments thereof, as an immunogen. Polyclonal antibodies may also be prepared by common means which comprise inoculating host animals, (for example a rat or a rabbit etc.), with polypeptides of the present invention and recovering immune serum.

[0037] The present invention also provides pharmaceutical compositions containing a polypeptide of the present invention, or an antibody thereof, in association with a pharmaceutically acceptable diluent and/or carrier.

[0038] The polypeptide of the present invention specified in (1) includes that which a part of their amino acid sequence is lacking (e.g., a polypeptide comprised of the only essential sequence for revealing a biological activity in an amino acid sequence shown in SEQ ID NO. 1), that which a part of their amino acid sequence is replaced by other amino acids (e.g., those replaced by an amino acid having a similar property) and that which other amino acids are added or inserted into a part of their amino acid sequence, as well as those comprising the amino acid sequence shown in SEQ ID NOS. 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 73, 76 or 79.

[0039] As known well, there are one to six kinds of codon as that encoding one amino acid (for example, one kind of codon for Methionine (Met), and six kinds of codon for Leucine (Leu) are known). Accordingly, the nucleotide sequence of cDNA can be changed in order to encode the polypeptide having the same amino acid sequence.

[0040] The cDNA of the present invention, specified in (2) includes a group of every nucleotide sequence encoding polypeptides (1) shown in SEQ ID NOS. 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 73, 76 or 79. There is a probability that yield of a polypeptide is improved by changing a nucleotide sequence.

[0041] The cDNA specified in (3) is the embodiment of the cDNA shown in (2), and indicate the sequence of natural form.

[0042] The cDNA shown in (4) indicates the sequence of the cDNA specified in (3) with natural non-translational region.

[0043] cDNA carrying nucleotide sequence shown in SEQ ID NOS. 3 is prepared by the following method:

[0044] Brief description of Yeast SST method (see U.S. Pat. No.5,536,637) is as follows.

[0045] Yeast such as Saccharomyces cerevisiae should secrete invertase into the medium in order to take sucrose or raffinose as a source of energy or carbon. (Invertase is an enzyme to cleave raffinose into sucrose and melibiose, sucrose into fructose and glucose.). It is known that many known mammalian signal sequence make yeast secrete its invertase. From these knowledge, SST method was developed as a screening method to find novel signal peptide which make it possible can to secrete yeast invertase from mammalian cDNA library. SST method uses yeast growth on raffinose medium as a marker. Non-secretory type invertase gene SUC2 (GENBANK Accession No. V 01311) lacking initiation codon ATG was inserted to yeast expression vector to prepare yeast SST vector pSUC2. In this expression vector, ADH promoter, ADH terminator (both were derived from MH5 plasmid (Gammerer, Methods in Enzymol. 101, 192-201, 1983)), 2m ori (as a yeast replication origin), TRP1 (as a yeast selective marker), ColE1 ori (as a E. coli replication origin) and ampicillin resistance gene (as a drug resistance marker) were inserted. Mammalian cDNA was inserted into the upstream of SUC2 gene to prepare yeast SST cDNA library. Yeast lacking secretory type invertase, was transformed with this library. If inserted mammalian cDNA encodes a signal peptide, yeast could survive in raffinose medium as a result of restoring secretion of invertase. Only to culture yeast colonies, prepare plasmids and determine the nucleotide sequence of the insert cDNAs, it is possible to identify novel signal peptide rapidly and easily.

[0046] Preparation of yeast SST cDNA library is as follows:

[0047] (1) mRNA is isolated from the targeted cells, double-strand synthesis is performed by using random primer with certain restriction enzyme (enzyme I) recognition site,

[0048] (2) obtained double-strand cDNA is ligated to adapter containing certain restriction endonuclease (enzyme II) recognition site, differ from enzyme I, digested with enzyme I and fractionated in a appropriate size,

[0049] (3) obtained cDNA fragment is inserted into yeast expression vector on the upstream region of invertase gene which signal peptide is deleted and the library was transformed.

[0050] Detailed description of each step is as follows:

[0051] (1) mRNA is isolated from mammalian organs and cell lines stimulate them with appropriate stimulator if necessary) by known methods (Molecular Cloning (Sambrook, J., Fritsch, E. F. and Maniatis, T, Cold Spring Harbor Laboratory Press, 1989) or Current Protocol in Molecular Biology (F. M. Ausubel et al, John Wiley & Sons, Inc.) if not remark especially).

[0052] TG98G (human glioblastoma cell line: ATCC No. CRL-1690), IMR-32 (human neuroblastoma cell line: ATCC No. CCL-127), U-2OS (human osteosarcoma cell line: ATCC No. HTB-96), CCF-STTG1 (human astrocytoma cell line: ATCC No. CRL-1718), HAS303 (human bone marrow stroma cell line: provide from Professor Keisuke Sotoyama, Dr. Makoto Aizawa of First Medicine, Tokyo Medical College; see J. Cell. Physiol., 148, 245-251, 1991 and Experimental Hematol., 22, 482-487, 1994), LP101 (human bone marrow stroma cell line: provide -from Professor Keisuke Sotoyama, Dr. Makoto Aizawa of First Medicine, Tokyo Medical College; see J. Cell. Physiol., 148, 245-251, 1991 and Experimental Hematol., 22, 482-487, 1994) and HUV-EC-C (endothelial cell of vein derived from human umbilical cord: ATCC No. CRL-1730) are chosen as a cell line. Human placenta and human adult brain are chosen as a tissue source. Double-strand cDNA synthesis using random primer is performed by known methods.

[0053] Any sites may be used as restriction endonuclease recognition site I which is linked to adapter and restriction endonuclease recognition site II which is used in step (2), if both sites are different each other. Preferably, XhoI is used as enzyme I and EcoRI as enzyme II.

[0054] In step (2), cDNA is created blunt-ends with T4 DNA polymerase, ligated enzyme II adapter and digested with enzyme I. Fragment cDNA is analyzed with agarose-gel electrophoresis (AGE) and is selected cDNA fraction ranging in size from 300 to 800 bp. As mentioned above, any enzyme may be used as enzyme II if it is not same the enzyme I.

[0055] In step (3), cDNA fragment obtained in step (2) is inserted into yeast expression vector on the upstream region of invertase gene which signal peptide is deleted. E. coli was transformed with the expression vector. Many vectors are known as yeast expression plasmid vector. For example, YEp24 is also functioned in E. coli. Preferably pSUC2 as described above is used.

[0056] Many host E. coli strains are known for transformation, preferably DH10B competent cell is used. Any known transformation method is available, preferably it is performed by electropolation method. Transformant is cultured by conventional methods to obtain cDNA library for yeast SST method.

[0057] However not every all of the clones do not contain cDNA fragment. Further all of the gene fragments do not encode unknown signal peptides. It is therefore necessary to screen a gene fragment encoding for an unknown signal peptide from the library.

[0058] Therefore, screening of fragments containing a sequence encoding an appropriate signal peptide is performed by transformation of the cDNA library into Saccharomyces cerevisiae (e.g. YT455 strain) which lack invertase (it may be prepared by known methods.). Transformation of yeast is performed by known methods, e.g. lithium acetate method. Transformant is cultured in a selective medium, then transferred to a medium containing raffinose as a carbon source. Survival colonies are selected and then prepared plasmid. Survival colonies on a raffinose-medium indicates that some signal peptide of secretory protein was inserted to this clone.

[0059] As for isolated positive clones, the nucleotide sequence is determined. As to a cDNA encodes unknown protein, full-length clone may be isolated by using cDNA fragment as a probe and then determined to obtain full-length nucleotide sequence. These manipulation is performed by known methods.

[0060] Once the nucleotide sequences shown in SEQ ID NO. 2, 5, 8, 11, 14, 17, 20, 23, 26, 29, 32, 35, 38, 41, 44, 47, 50, 53, 56, 59, 62, 65, 68, 71, 74, 77, 80, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78 or 81 are determined partially or preferably fully, it is possible to obtain DNA encode mammalian protein itself, homologue or subset. cDNA library or mRNA derived from mammals was screened by PCR with any synthesized oligonucleotide primers or by hybridization with any fragment as a probe. It is possible to obtain DNA encodes other mammalian homologue protein from other mammalian cDNA or genome library.

[0061] If a cDNA obtained above contains a nucleotide sequence of cDNA fragment obtained by SST (or consensus sequence thereof), it will be thought that the cDNA encodes signal peptide. So it is clear that the cDNA will be full-length or almost full. (All signal peptides exist at N-termini of a protein and are encoded at 5′-temini of open reading frame of cDNA.)

[0062] The confirmation may be carried out by Northern analysis with the said cDNA as a probe. It is thought that the cDNA is almost complete length, if length of the cDNA is almost the same length of the mRNA obtained in the hybridizing band.

[0063] Once the nucleotide sequences shown in SEQ ID NOS. 2, 5, 8, 11, 14, 17, 20, 23, 26, 29, 32, 35, 38, 41, 44, 47, 50, 53, 56, 59, 62, 65, 68, 71, 74, 77, 80, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78 or 81 are determined, DNAs of the invention are obtained by chemical synthesis, or by hybridization making use of nucleotide fragments which are chemically synthesized as a probe. Furthermore, DNAs of the invention are obtained in desired amount by transforming a vector that contains the DNA into a proper host, and culturing the transformant.

[0064] The polypeptides of the present invention may be prepared by:

[0065] (1) isolating and purifying from an organism or a cultured cell,

[0066] (2) chemically synthesizing, or

[0067] (3) using recombinant cDNA technology,

[0068] preferably, by the method described in (3) in an industrial production.

[0069] Examples of expression system (host-vector system) for producing a polypeptide by using recombinant cDNA technology are the expression systems of bacteria, yeast, insect cells and mammalian cells.

[0070] In the expression of the polypeptide, for example, in E. coli, the expression vector is prepared by adding the initiation codon (ATG) to 5′ end of a cDNA encoding mature peptide, connecting the cDNA thus obtained to the downstream of a proper promoter (e.g., trp promoter, lac promoter, λPL promoter, T7 promoter etc.), and then inserting it into a vector (e.g., pBR322, pUC18, pUC19 etc.) which functions in an E. coli strain.

[0071] Then, an E. coli strain (e.g., E. coli DH1 strain, E. coli JM109 strain, E. coli HB101 strain, etc.) which is transformed with the expression vector described above may be cultured in a appropriate medium to obtain the desired polypeptide. When a signal sequence of bacteria (e.g., signal sequence of pel B) is utilized, the desired polypeptide may be also released in periplasm. Furthermore, a fusion protein with other polypeptide may be also produced readily.

[0072] In the expression of the polypeptide, for example, in a mammalian cells, for example, the expression vector is prepared by inserting the cDNA encoding nucleotide shown in SEQ ID NOS. 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78 or 81 into the downstream of a proper promoter (e.g., SV40 promoter, LTR promoter, metallothionein promoter etc.) in a proper vector (e.g., retrovirus vector, papilloma virus vector, vaccinia virus vector, SV40 vector, etc.). A proper mammalian cell (e.g., monkey COS-7 cell, Chinese hamster CHO cell, mouse L cell etc.) is transformed with the expression vector thus obtained, and then the transformant is cultured in a proper medium to express the aimed secretory protein and membrane protein of the present invention by the following method.

[0073] In case of secretory protein as for the present invention, the aimed polypeptide was expressed in the supernatant of the cells. In addition, fusion protein may be prepared by conjugating cDNA fragment encoding the other polypeptide, for example, Fc portion of antibody.

[0074] On the other hand, in case of membrane protein as for the present invention, the aimed polypeptide was expressed on the cell membrane. A cDNA encoding the nucleotide sequence of SEQ ID NOS. 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78 or 81 with deletion of extracellular region was inserted into the said vector, transfected into the an adequate mammalian cells to secret the aimed soluble polypeptide in the culture medium. In addition, fusion protein may be prepared by conjugating cDNA fragment encoding the said mutant with deletion of extracellular region and other polypeptide, for example, Fc portion of antibody.

[0075] The polypeptide available by the way described above can be isolated and purified by conventional biochemical method.

INDUSTRIAL APPLICABILITY

[0076] It is considered that the polypeptide of the present invention and a cDNA which encodes the polypeptide will show one or more of the effects or biological activities (including those which relates to the assays cited below) The effects or biological activities described in relation to the polypeptide of the present invention are provided by administration or use of the polypeptide or by administration or use of a cDNA molecule which encodes the polypeptide (e.g., vector suitable for gene therapy or cDNA introduction).

[0077] Cytokine Activity and Cell Proliferation/Differentiation Activity

[0078] The protein of the present invention may exhibit cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of a polypeptide of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines.

[0079] Immune Stimulating/Suppressing Activity

[0080] The protein of the present invention may also exhibit immune stimulating or immune suppressing activity. The protein of the present invention may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SCID)), e.g., in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral infection such as HIV as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious diseases causes by viral, bacterial, fungal or other infection may be treatable using the polypeptide of the present invention, including infections by HIV, hepatitis viruses, herpes viruses, mycobacteria, leshmania, malaria and various fungal infections such as candida. Of course, in this regard, the protein of the present invention may also be useful where a boost to the immune system generally would be indicated, i.e., in the treatment of cancer.

[0081] The protein of the present invention may be useful in the treatment of allergic reactions and conditions, such as asthma or other respiratory problems. The protein of the present invention may also be useful in the treatment of the other conditions required to suppress the immuno system (for example, asthma or respiratory disease.)

[0082] The protein of the present invention may also suppress chronic or acute inflammation, such as, for example, that associated with infection such as septic shock or systemic inflammatory response syndrome (SIRS), inflammatory bowel disease, Crohn's disease or resulting from over production of cytokines such as TNF or IL-I wherein the effect was demonstrated by IL- 11.

[0083] Hematopoiesis Regulating Activity

[0084] The protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis. The said biological activities are concerned with the following all or some example(s). e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemia or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelo-suppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either in-vitro or ex-vivo (i.e. in conjunction with bone marrow transplantation) as normal cells or genetically manipulated for gene therapy.

[0085] The activity of the protein of the present invention may, among other means, be measured by the following methods:

[0086] Tissue Generation/Regeneration Activity

[0087] The protein of the present invention also may have utility in compositions used for bone, cartilage, tendon, Ligament and/or nerve tissue growth or regeneration, as well as for wound healing and tissue repair, and in the treatment of bums, incisions and ulcers.

[0088] The protein of the present invention, which induces cartilage and/or bone growth in circumstances where bone is not normally formed, may be applied to the healing of bone fractures and cartilage damage or defects in humans and other animals. Such a preparation employing the protein of the present invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. De novo bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.

[0089] The protein of the present invention may also be used in the treatment of periodontal disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells. The protein of the present invention may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes.

[0090] Another category of tissue regeneration activity that may be attributable to the protein of the present invention is tendon/ligament formation. The protein of the present invention, which induces tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, may be applied to the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and other animals. Such a preparation employing the protein inducing a tendon/Ligament-like tissue may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue. De novo tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide an environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon Ligament cells or progenitors ex vivo for return in vivo to effect tissue repair. The compositions of the present invention may also be useful in the treatment of tendinitis, Carpal tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in the art.

[0091] The protein of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue. i.e. for the treatment of central and peripheral nervous system diseases and neuropathies. as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, the protein of the present invention may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with the invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using the polypeptide of the present invention.

[0092] It is expected that the protein of the present invention may also exhibit activity for generation of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting the proliferation of cells comprising such tissues. Part of the desired effects may be by inhibition of fibrotic scarring to allow normal tissue to regenerate.

[0093] The protein of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.

[0094] Activin/Inhibin Activity

[0095] The protein of the present invention may also exhibit activin- or inhibin-related activities. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thus, the protein of the present invention alone or in heterodimers with a member of the inhibin *a family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals.

[0096] Alternatively, the protein of the present invention, as a homodimer or as a heterodimer with other protein subunits of the inhibin-*b group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary (See U.S. Pat. No. 4,798,885). The protein of the present invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as cows, sheep and pigs.

[0097] Chemotactic/Chemokinetic Activity

[0098] The protein of the present invention may have chemotactic or chemokinetic activity e.g., functioning as a chemokine, for mammalian cells, including, for example, monocytes, neutrophils, T-cells, mast cells, eosinophils and/or endothelial cells. Chemotactic and chemokinetic proteins can be used to mobilize or attract a desired cell population to a desired site of action. Chemotactic or chemokinetic proteins provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting agent.

[0099] If a protein or peptide can stimulate, directly or indirectly, the directed orientation or movement of such cell population, it has chemotactic activity for a particular cell population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis.

Hemostatic and Thrombolytic Activity

[0100] The protein of the present invention may also exhibit hemostatic or thrombolyic activity. As a result, such a protein is expected to be useful in treatment of various coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. A protein of the present invention may also be useful for dissolving or inhibiting formation of thromboses and for treatment and prevention of conditions resulting therefrom such as, for example, infarction or stroke.

[0101] Receptor/Ligand Activity

[0102] The protein of the present invention may also demonstrate activity as receptors, receptor ligands or inhibitors or agonists of receptor/ligand interactions. Examples of such receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, receptors involved in cell-cell interactions and their ligands (including cellular adhesion molecules such as Selectins, Integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses. Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. The protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions.

[0103] Other Activity

[0104] The protein of the present invention may also exhibit one or more of the following additional activities or effects: inhibiting growth of or killing the infecting agents including bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) body characteristics including height, weight, hair color, eye color, skin, other tissue pigmentation, or organ or body part size or shape such as, for example, breast augmentation or diminution etc.; effecting elimination of dietary fat, protein, carbohydrate; effecting behavioral characteristics including appetite, libido, stress, cognition (including cognitive disorders), depression and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic lineages; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases.

[0105] The protein with above activities, is suspected to have following functions by itself or interaction with its ligands or receptors or association with other molecules. For example, proliferation or cell death of B cells, T cells and/or mast cells; specific induction by promotion of class switch of immunoglobulin genes; differentiation of B cells to antibody-forming cells; proliferation, differentiation, or cell death of precursors of granulocytes; proliferation, differentiation, or cell death of precursors of monocytes-macrophages; proliferation, of up regulation or cell death of neutrophils, monocytes-macrophages, eosinophils and/or basophils; proliferation, or cell death of precursors of megakaryocytes; proliferation, differentiation, or cell death of precursors of neutrophils; proliferation, differentiation, or cell death of precursors of T cells and B cells; promotion of production of erythrocytes; sustainment of proliferation of erythrocytes, neutrophils, eosinophils, basophils, monocytes-macrophages, mast cells, precursors of megakaryocyte; promotion of migration of neutrophils, monocytes-macrophages, B cells and/or T cells; proliferation or cell death of thymocytes; suppression of differentiation of adipocytes; proliferation or cell death of natural killer cells; proliferation or cell death of hematopoietic stem cells; suppression of proliferation of stem cells and each hematopoietic precursor cells; promotion of differentiation from mesenchymal stem cells to osteoblasts or chondrocytes, proliferation or cell death of mesenchymal stem cells, osteoblasts or chondrocytes and promotion of bone absorption by activation of osteoclasts and promotion of differentiation from monocytes to osteoclasts.

[0106] The polypeptide of the present invention is also suspected to function to nervous system, so expected to have functions below; differentiation to kinds of neurotransmitter-responsive neurons, survival or cell death of these cells; promotion of proliferation or cell death of glial cells; spread of neural dendrites; survival or cell death of gangriocytes; proliferation, promotion of differentiation, or cell death of astrocytes; proliferation, survival or cell death of peripheral neurons; proliferation or cell death of Schwann cells; proliferation, survival or cell death of motoneurons.

[0107] Furthermore, in the process of development of early embryonic, the polypeptide of the present invention is expected to promote or inhibit the organogenesis of epidermis, brain, backbone, and nervous system by induction of, ectoderm, that of notochord connective tissues (bone, muscle, tendon), hemocytes, heart, kidney, and genital organs by induction of mesoderm, and that of digestive apparatus (stomach, intestine, liver, pancreas), respiratory apparatus (lung, trachea) by induction of endoderm. In adult, also, this polypeptide is thought to proliferate or inhibit the above organs.

[0108] Therefore, the polypeptide of the present invention itself is expected to be used as an agent for the prevention or treatment of disease of progression or suppression of immune, nervous, or bone metabolic function, hypoplasia or overgrowth of hematopoietic cells: for example, inflammatory disease (rheumatism, ulcerative colitis, etc.), decrease of hematopoietic stem cells after bone marrow transplantation, decrease of leukocytes, platelets, B-cells, or T-cells after radiation exposure or chemotherapeutic dosage against cancer or leukemia, anemia, infectious disease, cancer, leukemia, AIDS, bone metabolic disease (osteoporosis etc.), various degenerative disease (Alzheimer's disease, multiple sclerosis, etc.), or nervous lesion.

[0109] In addition, since the polypeptide of the present invention is thought to induce the differentiation or growth of organs derived from ectoderm, mesoderm, and endoderm, this polypeptide is expected to be an agent for tissue repair (epidermis, bone, muscle, tendon, heart, kidney, stomach, intestine, liver, pancreas, lung, and trachea, etc.).

[0110] By using polyclonal or monoclonal antibodies against the polypeptide of the present invention, quantitation of the said polypeptide in the body can be performed. It can be used in the study of relationship between this polypeptide and disease or diagnosis of disease, and so on. Polyclonal and monoclonal antibodies can be prepared using this polypeptide or its fragment as an antigen by conventional methods.

[0111] Identification, purification or molecular cloning of known or unknown proteins which bind the polypeptide of the present invention (preferably polypeptide of extracellular domain) can be performed using the polypeptide of the present invention by, for example, preparation of the affinity-column.

[0112] Identification of the downstream signal transmission molecules which interact with the polypeptide of the present invention in cytoplasma and molecular cloning of the gene can be performed by west-western method using the polypeptide of the present invention (preferably polypeptide of transmembrane region or intracellular domain), or by yeast two-hybrid system using the cDNA (preferably cDNA encoding transmembrane region or cytoplasmic domain of the polypeptide).

[0113] Agonists/antagonists of this receptor polypeptide and inhibitors between receptor and signal transduction molecules can be screened using the polypeptide of the present invention.

[0114] cDNAs of the present invention are useful not only the important and essential template for the production of the polypeptide of the present invention which is expected to be largely useful, but also be useful for diagnosis or therapy (for example, treatment of gene lacking, treatment to stop the expression of the polypeptide by antisense cDNA (mRNA)). Genomic cDNA may be isolated with the cDNA of the present invention, as a probe. As the same manner, a human gene encoding which can be highly homologous to the cDNA of the present invention, that is, which encodes a polypeptide highly homologous to the polypeptide of the present invention and a gene of animals excluding mouse which can be highly homologous to the cDNA of the present invention, also may be isolated.

[0115] Application to Medicaments

[0116] The polypeptide of the present invention or the antibody specific for the polypeptide of the present invention is administered systemically or topically and in general orally or parenterally, preferably parenterally, intravenously and intraventricularly, for preventing or treating the said diseases.

[0117] The doses to be administered depend upon age, body weight, symptom, desired therapeutic effect, route of administration, and duration of the treatment etc. In human adults, one dose per person is generally between 100 μg and 100 mg, by oral administration, up to several times per day, and between 10 μg and 100 mg, by parental administration up to several times per day.

[0118] As mentioned above, the doses to be used depend upon various conditions. Therefore, there are cases in which doses lower than or greater than the ranges specified above may be used.

[0119] The compounds of the present invention, may be administered as solid compositions, liquid compositions or other compositions for oral administration, as injections, liniments or suppositories etc. for parental administration.

[0120] Solid compositions for oral administration include compressed tablets, pills, capsules, dispersible powders, and granules. Capsules include soft or hard capsules.

[0121] In such compositions, one or more of the active compound(s) is or are admixed with at least one inert diluent (such as lactose, mannitol, glucose, hydroxypropyl cellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone, magnesium metasilicate aluminate, etc.). The compositions may also comprise, as is normal practice, additional substances other than inert diluents: e.g. lubricating agents (such as magnesium stearate etc.), disintegrating agents (such as cellulose calcium glycolate, etc.), stabilizing agents (such as human serum albumin, lactose etc.), and assisting agents for dissolving (such as arginine, asparaginic acid etc.).

[0122] The tablets or pills may, if desired, be coated with a film of gastric or enteric materials (such as sugar, gelatin, hydroxypropyl cellulose or hydroxypropylmethyl cellulose phthalate, etc.), or be coated with more than two films. And then, coating may include containment within capsules of absorbable materials such as gelatin.

[0123] Liquid compositions for oral administration include pharmaceutically-acceptable emulsions, solutions, syrups and elixirs. In such compositions, one or more of the active compound(s) is or are contained in inert diluent(s) commonly used (purified water, ethanol etc.). Besides inert diluents, such compositions may also comprise adjuvants (such as wetting agents, suspending agents, etc.), sweetening agents, flavoring agents, perfuming agents, and preserving agents.

[0124] Other compositions for oral administration include spray compositions which may be prepared by known methods and which comprise one or more of the active compound(s). Spray compositions may comprise additional substances other than inert diluents: e.g. stabilizing agents (sodium sulfite etc.), isotonic buffer (sodium chloride, sodium citrate, citric acid, etc.). For preparation of such spray compositions, for example, the method described in the U.S. Pat. No. 2,868,691 or 3,095,355 (herein incorporated in their entireties by reference) may be used.

[0125] Injections for parental administration include sterile aqueous or non-aqueous solutions, suspensions and emulsions. In such compositions, one or more active compound(s) is or are admixed with at least one inert aqueous diluent(s) (distilled water for injection, physiological salt solution, etc.) or inert non-aqueous diluents(s)(propylene glycol, polyethylene glycol, olive oil, ethanol, POLYSOLBATE 80 (Trade mark) etc.).

[0126] Injections may comprise additional compound other than inert diluents: e.g. preserving agents, wetting agents, emulsifying agents, dispersing agents, stabilizing agent (such as human serum albumin, lactose, etc.), and assisting agents such as assisting agents for dissolving (arginine, asparaginic acid, etc.).

BEST MODE CARRYING OUT THE INVENTION

[0127] The invention is illustrated by the following examples, but not limit the invention.

Example 1: Clone ON056

[0128] (1) Preparation of Poly(A)⁺RNA

[0129] Total RNA was prepared from human placenta tissue by TRIzol reagent (Trade Mark, marketed by GIBCO BRL Co.). Poly(A)⁺RNA was purified from the total RNA by mRNA Purification Kit (Trade name, marketed by Pharmacia Co.).

[0130] (2) Preparation of Yeast SST cDNA Library

[0131] Double strand cDNA was synthesized by Super Script Plasmid System for cDNA Synthesis and Plasmid Cloning (Trade name, marketed by GIBCO BRL Co.) with above poly(A)⁺RNA as template and random 9mer as primer which was containing XhoI site:

5′-CGA TTG AAT TCT AGA CCT GCC TCG AGN NNN NNN NN-3′  (SEQ ID NO. 82).

[0132] cDNA was ligated EcoRI adapter by DNA ligation kit ver. 2 (Trade name, marketed by Takara Shuzo Co.; this kit was used in all ligating steps hereafter.) and digested by XhoI. cDNAs were separated by agarose-gel electrophoresis. 300˜800 bp cDNAs were isolated and were ligated to EcoRI/NotI site of pSUC2 (see U.S. Pat. No. 5,536,637). E. coli DH10B strains were transformed by pSUC2 with electropolation to obtain yeast SST cDNA library.

[0133] (3) Screening by SST Method and Determination of Nucleotide Sequence of SST Positive Clone

[0134] Plasmids of the said cDNA library were prepared. Yeast YTK12 strains were transformed by the plasmids with lithium acetate method (Current Protocols In Molecular Biology 13.7.1). The transformed yeast were plated on triptphan-free medium (CMD-Trp medium) for selection. The plate was incubated for 48 hour at 30° C. Replica of the colony (transformant) which was obtained by Accutran Replica Plater (Trade name, marketed by Schleicher & Schuell) were placed onto YPR plate containing raffinose for carbon source, and the plate was incubated for 14 days at 30° C. After 3 days, each colony appeared was streaked on YPR plate again. The plates were incubated for 48 hours at 30° C. Single colony was inoculated to YPD medium and was incubated for 48 hours at 30° C. Then plasmids were prepared. Insert cDNA was amplified by PCR with two kind primers which exist end side of cloning site on pSUC2 (sense strand primers were biotinylated). Biotinylated single strand of cDNAs were purified with Dynabeads (Trade name, marketed by DYNAL Co.) and the nucleotide sequences were determined. Sequencing was performed by Dye Terminator Cycle Sequencing Ready Reaction with DNA Sequencing kit (Trade name, marketed by Applied Biosystems Inc.) and sequence was determined by DNA sequencer 373 (Applied Biosystems Inc.) (All sequencing hereafter was carried out with this method.).

[0135] We tried to carry out cloning of full-length cDNA which was proved to be new one according to the homology search for the obtained nucleotide sequences and deduced amino acid sequences in data base. We also confirmed that each cDNA contains signal peptide in view of function and structure, by comparison with known peptide which has signal peptide and deduced amino acid sequence.

[0136] (4) Cloning of a Full-length cDNA and Determination of Nucleotide Sequence

[0137] A full-length cDNA was cloned using GENETRAPPER cDNA Positive Selection System (marketed by GIBCO BRL Co.). First, dT-primed cDNA library was prepared from poly (A)⁺RNA in human placenta tissue using pSPORT1 plasmid (marketed by GIBCO BRL Co.), as a vector, by Super Script Plasmid System for cDNA Synthesis and Plasmid Cloning. Next, after preparing biotinylated primer ON056-F1 (27mer):

5′ biotin-AACATGAATCTTTCGCTCGTCCTGGCT-3′  (SEQ ID NO. 83)

[0138] based on the information of nucleotide sequence obtained by SST, plasmid hybridized specifically with the biotinylated primer were recovered from the cDNA library according to the method of Gene Trapper Kit and then transfected into E. coli DH10B. Colony hybridization with ON056 SST cDNA which was labeled with ³²P-dCTP, as a probe, was performed by using Random Primer DNA Labeling kit (Trade name, marketed by Takara Shuzo Co.) according to known method to isolate the positive clone and to prepare the plasmid. Nucleotide sequences of 5′-end were determined, and the existence of nucleotide sequence ON056 SST cDNA was confirmed. Nucleotide sequence of full-length ON056 SST cDNA was determined and then sequence shown in SEQ ID NO. 3 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 1 and 2, respectively, were obtained.

[0139] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of ON056 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretary protein.

[0140] However, the search using BLASTX, BLASTP and FASTA revealed a significant homology between clone ON056 (region of 1st˜334th amino acid in SEQ ID NO. 1) and Human Cathepsin L (Swiss Prot Accession P07711) (region of 1st˜334th amino acid) or between clone ON056 (region of 22nd˜334th amino acid in SEQ ID NO. 1) and Human Cathepsin K (Swiss Prot Accession P43235) (region of 19th˜329th amino acid). Based on these homologies, clone ON0566 and Human Cathepsin L family were expected to share at least some activity.

[0141] (5) Expression of Protein Using E. coli

[0142] The coding region cDNA fragments without sequence encoding signal peptide were amplified by PCR and inserted into the downstream of initiation codon ATG in pET expression vector (marketed by Novagen Co.) for E. coli inframe to construct the plasmid for expression. The obtained plasmids were transfected into E. coli BL21 (DE3) and the transformant was cultured with IPTG to induce the expression of protein. The obtained E. coli was harvested and lysed with ultra-sonication or detergent. The insoluble fraction was solubilized with urea and subjected to SDS-PAGE. The expression of ON056 protein was confirmed by Coomassie staining (arrow in FIG. 1).

[0143] (6) Expression of the Protein Using Mammalian Cell

[0144] Thus obtained full-length cDNA was conjugated into XhoI (or EcoRI)-NotI site of the pED6 expression vector of mammalian cells (See Kaufman et al., Nucleic Acids Res. 19, 4485-4490 (1991)) to construct plasmid to express the secretory protein or membrane protein. The obtained plasmids were transfected into Cos 7 cells using Lypofectine (Trade name, marketed by GIBCO BRL Co.). After 24 hours, the transfection mixture was removed. The cells were cultured in the Met and Cys-free medium with ³⁵S-labeled Met and ³⁵S-labeled Cys for 5 hours. The supernatants were harvested and 10-fold concentrated with Centricon-10 (Trade name, marketed by Amicon Co.). The samples were separated on SDS-PAGE gels. After drying the acrylamidogel, the expression of ³⁵S-labeled protein was detected using BAS2000 (marketed by Fuji Film Co.).

Example 2: Clone ON034

[0145] In Example relating to clone ON034 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

[0146] (1) Preparation of Poly(A)⁺RNA

[0147] Total RNA was prepared from human placenta tissue by TRIzol reagent. Poly(A)⁺RNA was purified from the total RNA by mRNA Purification Kit.

[0148] (2) Cloning of a Full-length cDNA and Determination of Nucleotide Sequence

[0149] A full-length cDNA was cloned using GENETRAPPER cDNA Positive Selection System. First, dT-primed cDNA library was prepared from poly (A)+RNA in human placenta tissue using pSPORT1 plasmid, as a vector, by Super Script Plasmid System for cDNA Synthesis and Plasmid Cloning. Next, after preparing biotinylated primer ON034-F1 (28mer):

5′biotin-TGAAGCCCATCACTACATCGCCATTACG-3′  (SEQ ID NO.: 84)

[0150] based on the information of nucleotide sequence obtained by SST, plasmid hybridized specifically with the biotinylated primer were recovered from the cDNA library according to the method of Gene Trapper Kit and then transfected into E. coli DH10B. Colony hybridization with ON034 SST cDNA which was labeled with 32P-dCTP, as a probe, was performed by using Random Primer DNA Labeling kit according to known method to isolate the positive clone and to prepare the plasmid. Nucleotide sequence of full-length ON034 SST cDNA was determined by the same procedure as ON056 and then sequence shown in SEQ ID NO. 6 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 4 and 5, respectively, were obtained.

[0151] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of ON034 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretary protein.

Example 3: Clone OX003

[0152] In Example relating to clone OX003 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

[0153] (1) Preparation of Poly(A)⁺RNA

[0154] Total RNA was prepared from human placenta tissue by TRIzol reagent. Poly(A)⁺RNA was purified from the total RNA by mRNA Purification Kit.

[0155] (2) Cloning of a Full-length cDNA and Determination of Nucleotide Sequence

[0156] A full-length cDNA was cloned using Marathon cDNA Amplification Kit (Trade name, marketed by Clontech Co.) according to 3′ RACE (Rapid Amplification of cDNA End) method. Double strand cDNA was prepared from the origin of each clone, i.e., poly (A)⁺RNA in human placenta tissue. 27mer primer OX003-F1:

5′-CAAAACCCACAAGAAATTCACCAAGGC-3′  (SEQ ID NOS. 85)

[0157] containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. PCR was performed with the said primer and adapter primer attached in the kit. Due to insufficient amplification of cDNA by only one-time PCR, 23mer primer OX003-F2:

5′-TCACCAAGGCTAACATGGTGGCC-3′  (SEQ ID NOS. 86)

[0158] was prepared additionally at 3′ end of OX003-F1 primer and then nested PCR was performed. cDNA which was amplified with clone OX003 specifically was separated with agarose-gel electrophoresis, ligated to pT7 Blue-2 T-Vector (Trade name, marketed by Novagen Co.) and transfected into E. coli DH5a to prepare the plasmid. First, Nucleotide sequences of 5′-end were determined, and the existence of nucleotide sequence OX003 SST cDNA was confirmed. Nucleotide sequence of full-length OX003 SST cDNA was determined and then sequence shown in SEQ ID NO. 9 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 7 and 8, respectively, were obtained.

[0159] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OX003 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretary protein.

Example 4: Clone OA052

[0160] In Example relating to clone OA052 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

[0161] (1) Preparation of Poly(A)⁺RNA

[0162] Total RNA was prepared from human glioblastoma cell line T98G (ATCC No. CRL-1690) by TRIzol reagent. Poly(A)⁺RNA was purified from the total RNA by mRNA Purification Kit.

[0163] (2) Cloning of a Full-length cDNA and Determination of Nucleotide Sequence

[0164] A full-length cDNA was cloned using Marathon cDNA Amplification Kit according to 3′ RACE method as described in Example of OX003. Double strand cDNA conjugating adapter was prepared from the origin of each clone, i.e., poly (A)⁺RNA in human glioblastoma cell line T98G according to the method of the said kit. 27mer primer OA052-F1:

5′-ATGCCTAGAAGAGGACTGATTCTTCAC-3′  (SEQ ID NO. 87)

[0165] containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. PCR was performed with the said primer and adapter primer attached in the kit. cDNA which was amplified with clone OA052 specifically was separated with recloning by the same method as Example of OX003. Full nucleotide sequence was determined and then sequence shown in SEQ ID NO. 12 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 10 and 11, respectively, were obtained.

[0166] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OA052 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretary protein.

Example 5: Clone OC004

[0167] In Example relating to clone OC004 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

[0168] (1) Preparation of Poly(A)⁺RNA

[0169] Total RNA was prepared from human adult brain tissue by TRIzol reagent. Poly(A)⁺RNA was purified from the total RNA by mRNA Purification Kit.

[0170] (2) Cloning of a Full-length cDNA and Determination of Nucleotide Sequence

[0171] A full-length cDNA was cloned using Marathon cDNA Amplification Kit according to 3′ RACE method as described in Example of OX003. Double strand cDNA was prepared from the origin of each clone, i.e., poly (A)⁺RNA in human adult brain tissue. 27mer primer OC004-F1:

5′-ATGAGGAAAGGGAACCTTCTGCTGAGC-3′  (SEQ ID NOS. 88)

[0172] containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. PCR was performed with the said primer and adapter primer attached in the kit. Due to insufficient amplification of cDNA by only one-time PCR, 18mer primer OC004-F2:

5′-TGAGCTTCCAGAGCTGTC-3′  (SEQ ID NOS. 89)

[0173] was prepared additionally at 3′ end of OC004-F1 primer and then nested PCR was performed. cDNA which was amplified with clone OC004 specifically was separated with recloning by the same method as Example of OX003. Full nucleotide sequence was determined and then sequence shown in SEQ ID NO. 15 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 13 and 14, respectively, were obtained.

[0174] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OC004 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretary protein.

Example 6: Clone OM017

[0175] In Example relating to clone OM017 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

[0176] (1) Preparation of Poly(A)⁺RNA

[0177] Total RNA was prepared from human adult brain tissue by TRIzol reagent. Poly(A)⁺RNA was purified from the total RNA by mRNA Purification Kit.

[0178] (2) Cloning of a Full-length cDNA and Determination of Nucleotide Sequence

[0179] A full-length cDNA was cloned using Marathon cDNA Amplification Kit according to 3′ RACE method as described in Example of OX003. Double strand cDNA was prepared from the origin of each clone, i.e., poly (A)⁺RNA in human adult brain tissue. 27mer primer OM017-F3:

5′-GGGAAATGAAACATTTCTGTAACCTGC-3′  (SEQ ID NOS. 90)

[0180] containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. PCR was performed with the said primer and adapter primer attached in the kit. Due to insufficient amplification of cDNA by only one-time PCR, 27mer primer OM017-F1:

5′-ATGAAACATTTCTGTAACCTGCTTTGT-3′  (SEQ ID NOS. 91)

[0181] was prepared additionally at 3′ end of OM017-F3 primer and then nested PCR was performed. cDNA which was amplified with clone OM017 specifically was separated with reckoning by the same method as Example of OX003. Full nucleotide sequence was determined and then sequence shown in SEQ ID NO. 18 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 16 and 17, respectively, were obtained.

[0182] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OM017 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretary protein.

[0183] However, the search using BLASTX, BLASTP and FASTA revealed a significant homology between clone OM017 (region of 433th˜709th, 42nd˜225th, 170th˜399th and 1st˜224th amino acid in SEQ ID NO. 16) and Human DXS6673E (Candidate gene for Mental Retardation) (PRF Code 2218282A (Genbank Accession X95808) ) (region of 1083rd˜1358th, 758th˜932nd, 850th˜1081st and 739th˜965th amino acid) Based on these homologies, clone OM017 and Human DXS6673E were expected to share at least some activity.

Example 7: Clone OM101

[0184] In Example relating to clone OM101 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

[0185] (1) Preparation of Poly(A)⁺RNA

[0186] Total RNA was prepared from human adult brain tissue by TRIzol reagent. Poly(A)⁺RNA was purified from the total RNA by mRNA Purification Kit.

[0187] (2) Cloning of a Full-length cDNA and Determination of Nucleotide Sequence

[0188] A full-length cDNA was cloned using Marathon cDNA Amplification Kit according to 3′ RACE method as described in Example of OX003. Double strand cDNA was prepared from the origin of each clone, i.e., poly (A)⁺RNA in human adult brain tissue. 27mer primer OM101-F3:

5′-TGAAGTTGCAGATAATGAGGACTTACC-3′  (SEQ ID NOS. 92)

[0189] containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. PCR was performed with the said primer and adapter primer attached in the kit. Due to insufficient amplification of cDNA by only one-time PCR, 27mer primer OM101-F1:

5′-ATGAGGACTTACCATTATATACCATTA-3′  (SEQ ID NOS. 93)

[0190] was prepared additionally at 3′ end of OM0101-F3 primer and then nested PCR was performed. cDNA which was amplified with clone OM101 specifically was separated with reckoning by the same method as Example of OX003. Full nucleotide sequence was determined and then sequence shown in SEQ ID NO. 21 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 19 and 20, respectively, were obtained.

[0191] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OM101 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretary protein.

[0192] However, the search using BLASTX, BLASTP and FASTA revealed a significant homology between clone OM101 (region of 1st˜77th amino acid in SEQ ID NO. 19), and a lot of Cadherin family such as Human Cadherin-6 (Swiss Prot Accession P55285) (region of 1st˜77th amino acid) and Human Brain-Cadherin (Swiss Prot Accession P55289) (region of 1st˜78th amino acid). Based on these homologies, clone OM101 and Human Cadherin-6 and the other Cadherin family were expected to share at least some activity.

Example 8: Clone OM126

[0193] In Example relating to clone OM126 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

[0194] (1) Preparation of Poly(A)⁺RNA

[0195] Total RNA was prepared from human adult brain tissue by TRIzol reagent. Poly(A)⁺RNA was purified from the total RNA by mRNA Purification Kit.

[0196] (2) Cloning of a Full-length cDNA and Determination of Nucleotide Sequence

[0197] Double strand cDNA was prepared from the origin of each clone, i.e., poly (A)⁺RNA in human adult brain tissue. 27mer primer OM126-F3:

5′-AGGAAGGATGAGGAAGACCAGGCTCTG-3′  (SEQ ID NOS. 94)

[0198] containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. cDNA which was amplified with clone OM126 specifically was separated with reckoning by the same method as Example of OX003. Full nucleotide sequence was determined and then sequence shown in SEQ ID NO. 24 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 22 and 23, respectively, were obtained.

[0199] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OM126 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretary protein.

[0200] However, the search using BLASTX, BLASTP and FASTA revealed a significant homology between clone OM126 (region of 25th˜115th amino acid in SEQ ID NO.22), and immunoglobulin domain. Based on these homologies, clone OM126 and immunoglobulin superfamily were expected to share at least some activity.

Example 9: Clone OM160

[0201] In Example relating to clone OM160 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

[0202] (1) Preparation of Poly(A)⁺RNA

[0203] Total RNA was prepared from human adult brain tissue by TRIzol reagent. Poly(A)⁺RNA was purified from the total RNA by mRNA Purification Kit.

[0204] (2) Cloning of a Full-length cDNA and Determination of Nucleotide Sequence

[0205] A full-length cDNA was cloned using GENETRAPPER cDNA Positive Selection System. First, dT-primed cDNA library was prepared from poly (A)+RNA in human adult brain tissue using pSPORT1 plasmid, as a vector, by Super Script Plasmid System for cDNA Synthesis and Plasmid Cloning. Next, after preparing biotinylated primer ON160-F1 (27mer):

5′ biotin-ATGCTTCAGTGGAGGAGAAGACACTGC-3′  (SEQ ID NO. 95)

[0206] based on the information of nucleotide sequence obtained by SST, plasmid hybridized specifically with the biotinylated primer were recovered from the cDNA library according to the method of Gene Trapper Kit and then transfected into E. coli DH10B. Colony hybridization with OM160 SST cDNA which was labeled with 32P-dCTP, as a probe, was performed by using Random Primer DNA Labeling kit according to known method to isolate the positive clone and to prepare the plasmid. Nucleotide sequence of full-length OM160 SST cDNA was determined by the same procedure as ON056 and then sequence shown in SEQ ID NO. 27 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 25 and 26, respectively, were obtained.

[0207] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OM160 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretary protein.

[0208] However, the search using BLASTX, BLASTP and FASTA revealed a significant homology between clone OM160 (region of 153rd˜395th amino acid in SEQ ID NO. 25) and Drosophila neurogenic secreted signaling protein (Genepept Accession U41449) (region of 80th˜317th amino acid). Based on these homologies, clone OM160 and Drosophila neurogenic secreted signaling protein were expected to share at least some activity.

Example 10: Clone OMA016

[0209] In Example relating to clone OMA016 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

[0210] (1) Preparation of Poly(A)⁺RNA

[0211] Total RNA was prepared from human adult brain tissue by TRIzol reagent. Poly(A)⁺RNA was purified from the total RNA by mRNA Purification

[0212] (2) Cloning of a Full-length cDNA and Determination of Nucleotide Sequence

[0213] A full-length cDNA was cloned using Marathon cDNA Amplification Kit according to 3′ RACE method as described in Example of OX003. Double strand cDNA was prepared from the origin of each clone, i.e., poly (A)⁺RNA in human adult brain tissue. 27mer primer OMA016-F1:

5′-AGAAATGGTGAATGCCTGCTGGTGTGG-3′  (SEQ ID NOS. 96)

[0214] containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. PCR was performed with the said primer and adapter primer attached in the kit. There existed two kinds of cDNAs which were amplified with clone OMA016 specifically and which were named OMA016a and OMA016b. These two were separated with recloning by the same method as Example of OX003. Full nucleotide sequences were determined and then sequences shown in SEQ ID NOS. 30 and 33 were obtained. Each open reading frame was determined and reduced amino acid sequences and nucleotide sequences shown in SEQ ID NOS. 28, 31 and SEQ ID NOS. 29, 32, respectively, were obtained.

[0215] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OMA016a and OMAO16b of the present invention. From these results, it was proved that polypeptide of the present invention was new secretary protein.

Example 11: Clone OMB130

[0216] In Example relating to clone OMB130 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

[0217] (1) Preparation of Poly(A)⁺RNA

[0218] Total RNA was prepared from human adult brain tissue by TRIzol reagent. Poly(A)⁺RNA was purified from the total RNA by mRNA Purification

[0219] (2) Cloning of a Full-length cDNA and Determination of Nucleotide Sequence

[0220] Double strand cDNA was prepared from the origin of each clone, i.e., poly (A)⁺RNA in human adult brain tissue. 27mer primer OMB130-F1:

5′-TCCTCTGACTTTTCTTCTGCAAGCTCC-3′  (SEQ ID NOS. 97)

[0221] containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. cDNA which was amplified with clone OMB130 specifically was separated with reckoning by the same method as Example of OX003. Full nucleotide sequence was determined and then sequence shown in SEQ ID NO. 36 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 34 and 35, respectively, were obtained.

[0222] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OMB130 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretary protein.

[0223] However, the search using BLASTX, BLASTP and FASTA revealed a significant homology between clone OMB130 (region of 10th˜177th amino acid in SEQ ID NO. 34), and Monkey Hepatitis A virus receptor (PRF Code 2220266A (Genbank Accession X98252) (region of 6th˜173rd amino acid. Based on these homologies, clone OMB130 and Monkey Hepatitis A virus receptor were expected to share at least some activity.

Example 12: Clone OMB142

[0224] In Example relating to clone OMB142 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

[0225] (1) Preparation of Poly(A)⁺RNA

[0226] Total RNA was prepared from human adult brain tissue by TRIzol reagent. Poly(A)⁺RNA was purified from the total RNA by mRNA Purification Kit.

[0227] (2) Cloning of a Full-length cDNA and Determination of Nucleotide Sequence

[0228] A full-length cDNA was cloned using Marathon cDNA Amplification Kit according to 3′ RACE method as described in Example of OX003. Double strand cDNA was prepared from the origin of each clone, i.e., poly (A)⁺RNA in human adult brain tissue. 27mer primer OMB142-F2:

5′-GCCCAAGGTCAAGGAGATGGTACGGAT-3′  (SEQ ID NOS. 98)

[0229] containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. PCR was performed with the said primer and adapter primer attached in the kit. Due to insufficient amplification of cDNA by only one-time PCR, 28mer primer OMB142-F1:

5′-GGAGATGGTACGGATCTTAAGGACTGTG-3′  (SEQ ID NOS. 99)

[0230] was prepared additionally at 3′ end of OMB142-F2 primer and then nested PCR was performed. cDNA which was amplified with clone OMB142 specifically was separated with recloning by the same method as Example of OX003. Full nucleotide sequence was determined and then sequence shown in SEQ ID NO. 39 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 37 and 38, respectively, were obtained.

[0231] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OMB142 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretary protein.

Example 13: Clone OTB033

[0232] In Example relating to clone OTB033 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

[0233] (1) Preparation of Poly(A)⁺RNA

[0234] Total RNA was prepared from human neuroblastoma cell line IMR-32 (ATCC No. CCL-127) by TRIzol reagent. Poly(A)⁺RNA was purified from the total RNA by mRNA Purification Kit.

[0235] (2) Cloning of a Full-length cDNA and Determination of Nucleotide Sequence

[0236] A full-length cDNA was cloned using Marathon cDNA Amplification Kit according to 3′ RACE method as described in Example of OX003. Double strand cDNA was prepared from the origin of each clone, i.e., poly (A)⁺RNA of IMR-32. 27mer primer OTB033-F1:

5′-TGCACTATCCAAAAGCTCCATGTACAC-3′  (SEQ ID NOS. 100)

[0237] containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. PCR was performed with the said primer and adapter primer attached in the kit. Due to insufficient amplification of cDNA by only one-time PCR, 19mer primer OTB003-F2:

5′-CCATGTACACAGTGGGGGC-3′  (SEQ ID NOS.101)

[0238] was prepared additionally at 3′ end of OTB033-F1 primer and then nested PCR was performed. cDNA which was amplified with clone OTB033 specifically was separated with recloning by the same method as Example of OX003. Full nucleotide sequence was determined and then sequence shown in SEQ ID NO. 42 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 40 and 41, respectively, were obtained.

[0239] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OTB033 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretary protein.

Example 14: Clone OVB100

[0240] In Example relating to clone OVB100 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

[0241] (1) Preparation of Poly(A)⁺RNA

[0242] Total RNA was prepared from human astrocytoma cell line CCF-STTG1 (ATCC No. CRL-1718) by TRIzol reagent. Poly(A)⁺RNA was purified from the total RNA by mRNA Purification Kit.

[0243] (2) Cloning of a Full-length cDNA and Determination of Nucleotide Sequence

[0244] A full-length cDNA was cloned using Marathon cDNA Amplification Kit according to 3′ RACE method as described in Example of OX003. Double strand cDNA was prepared from the origin of each clone, i.e., poly (A)⁺RNA of CCF-STTG1. 27mer primer OVB100-F1:

5′-CACTTGGTGTTTGATTTACCTAAGCAC-3′  (SEQ ID NOS. 102)

[0245] containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. cDNA which was amplified with clone OVB100 specifically was separated with recloning by the same method as Example of OX003. Full nucleotide sequence was determined and then sequence shown in SEQ ID NO. 45 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 43 and 44, respectively, were obtained.

[0246] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OVB100 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretary protein.

Example 15: Clone OAF062

[0247] In Example relating to clone OAF062 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

[0248] (1) Preparation of Poly(A)⁺RNA

[0249] Total RNA was prepared from human bone marrow stroma cell line HAS303 (provided from Prof. Keisuke Sotoyama, Dr. Makoto Aizawa, First Medicine, Tokyo Medical College) by TRIzol reagent. Poly(A)⁺RNA was purified from the total RNA by mRNA Purification Kit.

[0250] (2) Cloning of a Full-length cDNA and Determination of Nucleotide Sequence

[0251] A full-length cDNA was cloned using Marathon cDNA Amplification Kit according to 3′ RACE method as described in Example of OX003. A full-length cDNA was cloned using Marathon cDNA Amplification Kit according to 3′ RACE method as described in Example of OX003. Double strand cDNA was prepared from the origin of each clone, i.e., poly (A)⁺RNA of HAS303. 27mer primer OAF062-F2:

5′-GAGTTTCGTAAGCAAAATAGAGGACAG-3′  (SEQ ID NOS. 103)

[0252] containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. PCR was performed with the said primer and adapter primer attached in the kit. Due to insufficient amplification of cDNA by only one-time PCR, 27mer primer OAF062-F3:

5′-TAGAGGACAGAAATGCAGTTCATGAAC-3′  (SEQ ID NOS. 104)

[0253] was prepared additionally at 3′ end of OAF062-F2 primer and then nested PCR was performed. cDNA which was amplified with clone OAF062 specifically was separated with reckoning by the same method as Example of OX003. Full nucleotide sequence was determined and then sequence shown in SEQ ID NO.48 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 46 and 47, respectively, were obtained.

[0254] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OAF062 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretary protein.

Example 16: Clone OAF075

[0255] In Example relating to clone OAF075 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

[0256] (1) Preparation of Poly(A)⁺RNA

[0257] Total RNA was prepared from human bone marrow stroma cell line HAS303 (provided from Prof. Keisuke Sotoyama, Dr. Makoto Aizawa, First Medicine, Tokyo Medical College) by TRIzol reagent. Poly(A)⁺RNA was purified from the total RNA by mRNA Purification Kit.

[0258] (2) Cloning of a Full-length cDNA and Determination of Nucleotide Sequence

[0259] A full-length cDNA was cloned using Marathon cDNA Amplification Kit according to 3′ RACE method as described in Example of OX003. Double strand cDNA was prepared from the origin of each clone, i.e., poly (A)⁺RNA of HAS303. 28mer primer OAF075-F1:

5′-GACATGAGGTGGATACTGTTCATTGGGG-3′  (SEQ ID NOS. 105)

[0260] containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. cDNA which was amplified with clone OAF075 specifically was separated with recloning by the same method as Example of OX003. Full nucleotide sequence was determined and then sequence shown in SEQ ID NO. 51 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 49 and 50, respectively, were obtained.

[0261] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OAF075 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretary protein.

[0262] However, the search using BLASTX, BLASTP and FASTA revealed a significant homology between clone OAF075 (region of 1st˜421st amino acid in SEQ ID NO. 49), and Human Carboxypeptidase A2 (Swiss Prot Accession P48052) (region of 1st˜417th amino acid), Human Carboxypeptidase A1 (Swiss Prot Accession P15085) (region of 1st˜417th amino acid), Human Carboxypeptidase B (Swiss Prot Accession P15086) (region of 5th˜416th amino acid) and Human Mast Cell Carboxypeptidase A (Swiss Prot Accession P15088) (region of 1st˜412th amino acid). Based on these homologies, clone OAF075 and Carboxypeptidase family were expected to share at least some activity.

Example 17: Clone OAG119

[0263] In Example relating to clone OAG119 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

[0264] (1) Preparation of Poly(A)⁺RNA

[0265] Total RNA was prepared from human bone marrow stroma cell line LP101 (provided from Prof. Keisuke Sotoyama, Dr. Makoto Aizawa, First Medicine, Tokyo Medical College) by TRIzol reagent. Poly(A)⁺RNA was purified from the total RNA by mRNA Purification Kit.

[0266] (2) Cloning of a Full-length cDNA and Determination of Nucleotide Sequence

[0267] A full-length cDNA was cloned using Marathon cDNA Amplification Kit according to 3′ RACE method as described in Example of OX003. Double strand cDNA was prepared from the origin of each clone, i.e., poly (A)⁺RNA of LP101. 28mer primer OAG119-F1:

5′-TGGCGTGTAACTATGCTCATCATTGTTC-3′  (SEQ ID NOS. 106)

[0268] containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. cDNA which was amplified with clone OAG119 specifically was separated with reckoning by the same method as Example of OX003. Full nucleotide sequence was determined and then sequence shown in SEQ ID NO. 54 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 52 and 53, respectively, were obtained.

[0269] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OAG119 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretary protein.

Example 18: Clone OAH040

[0270] In Example relating to clone OAH040 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

[0271] (1) Preparation of Poly(A)⁺RNA

[0272] Total RNA was prepared from endothelial cell line of vein derived from human umbilical cord UV-EC-C (ATCC No. CRL-1730) by TRIzol reagent. Poly(A)⁺RNA was purified from the total RNA by mRNA Purification Kit.

[0273] (2) Cloning of a Full-length cDNA and Determination of Nucleotide Sequence

[0274] A full-length cDNA was cloned using Marathon cDNA Amplification Kit according to 3′ RACE method as described in Example of OX003. Double strand cDNA was prepared from the origin of each clone, i.e., poly (A)⁺RNA of HUV-EC-C. 28mer primer OAH040-F1:

5′-TTAGCCCACCCATGTTGATAGAACACCC-3′  (SEQ ID NOS. 107)

[0275] containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. cDNA which was amplified with clone OAH040 specifically was separated with reckoning by the same method as Example of OX003. Full nucleotide sequence was determined and then sequence shown in SEQ ID NO. 57 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 55 and 56, respectively, were obtained.

[0276] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OAH040 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretary protein.

Example 19: Clone OAH058

[0277] In Example relating to clone OAH058 of the present invention, the same procedure as in Example of OAH056 was used except for the following points.

[0278] (1) Preparation of Poly(A)⁺RNA

[0279] Total RNA was prepared from endothelial cell line of vein derived from human umbilical cord HUV-EC-C (ATCC No. CRL-1730) by TRIzol reagent. Poly(A)⁺RNA was purified from the total RNA by mRNA Purification Kit.

[0280] (2) Cloning of a Full-length cDNA and Determination of Nucleotide Sequence

[0281] A full-length cDNA was cloned using Marathon cDNA Amplification Kit according to 3′ RACE method as described in Example of OX003. Double strand cDNA was prepared from the origin of each clone, i.e., poly (A)⁺RNA of HUV-EC-C. 28mer primer OAH058-F1:

5′-ACAATGTTGGCCTGTC TGCAAGCTTGTG-3′  (SEQ ID NOS. 108)

[0282] containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. cDNA which was amplified with clone OAH058 specifically was separated with recloning by the same method as Example of OX003. Full nucleotide sequence was determined and then sequence shown in SEQ ID NO. 60 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 58 and 59, respectively, were obtained.

[0283] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OAH058 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretary protein.

Example 20: Clone OM011

[0284] In Example relating to clone OM011 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

[0285] (1) Preparation of Poly(A)⁺RNA

[0286] Total RNA was prepared from human adult brain tissue by TRIzol reagent. Poly(A)⁺RNA was purified from the total RNA by mRNA Purification Kit.

[0287] (2) Cloning of a Full-length cDNA and Determination of Nucleotide Sequence

[0288] A full-length cDNA was cloned using GENETRAPPER cDNA Positive Selection System. First, dT-primed cDNA library was prepared from poly (A)⁺RNA in human adult brain tissue using pSPORT1 plasmid, as a vector, by Super Script Plasmid System for cDNA Synthesis and Plasmid Cloning. Next, after preparing biotinylated primer OM011-F1 (27mer):

5′ biotin-GAAGTGACTCTTCCTCTAGTTTGCCAC-3′  (SEQ ID NOS. 109)

[0289] based on the information of nucleotide sequence obtained by SST, plasmid hybridized specifically with the biotinylated primer were recovered from the cDNA library according to the method of Gene Trapper Kit and then transfected into E. coli DH10B. Colony hybridization with OM011 SST cDNA which was labeled with 32P-dCTP, as a probe, was performed by using Random Primer DNA Labeling kit according to known method to isolate the positive clone and to prepare the plasmid. Nucleotide sequence of full-length OM011 SST cDNA was determined by the same procedure as ON056 and then sequence shown in SEQ ID NO. 63 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 61 and 62, respectively, were obtained.

[0290] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OM011 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretary protein.

[0291] However, the search using BLASTX, BLASTP and FASTA revealed a significant homology between clone OM011 (region of 26th˜396th amino acid in SEQ ID NO. 61) and Human Plasma-cell Glycoprotein PC-1 (Alkaline Phosphodiesterase I) (Swiss Prot Accession P22413) (region of 158th˜543rd amino acid). Based on these homologies, clone OM011 and Human Plasma-cell Glycoprotein PC-1 were expected to share at least some activity.

Example 21: Clone OM028

[0292] In Example relating to clone OM028 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

[0293] (1) Preparation of Poly(A)⁺RNA

[0294] Total RNA was prepared from human adult brain tissue by TRIzol reagent. Poly(A)⁺RNA was purified from the total RNA by mRNA Purification Kit.

[0295] (2) Cloning of a Full-length cDNA and Determination of Nucleotide Sequence

[0296] A full-length cDNA was cloned using GENETRAPPER cDNA Positive Selection System. First, dT-primed cDNA library was prepared from poly (A)+RNA in human adult brain tissue using pSPORT1 plasmid, as a vector, by Super Script Plasmid System for cDNA Synthesis and Plasmid Cloning. Next, after preparing biotinylated primer OM028-F1 (27mer):

5′ biotin-ATGAAGGACATGCCACTCCGAATTCAT-3′  (SEQ ID NOS. 110)

[0297] based on the information of nucleotide sequence obtained by SST, plasmid hybridized specifically with the biotinylated primer were recovered from the cDNA library according to the method of Gene Trapper Kit and then transfected into E. coli DH10B. Colony hybridization with OM028 SST cDNA which was labeled with 32P-dCTP, as a probe, was performed by using Random Primer DNA Labeling kit according to known method to isolate the positive clone and to prepare the plasmid. Nucleotide sequence of full-length OM028 SST cDNA was determined by the same procedure as ON056 and then sequence shown in SEQ ID NO. 66 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 64 and 65, respectively, were obtained.

[0298] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OM028 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretary protein.

[0299] However, the search using BLASTX, BLASTP and FASTA revealed a significant homology between clone OM028 (region of 1st˜708th amino acid in SEQ ID NO. 64) and many proteins containing Leu-rich repeat such as Mouse Leu-rich repeat protein (PRF Code 2212307A (GENBANK Accession D49802) (region of 1st˜707th amino acid). Based on these homologies, clone OM028 and certain proteins containing Leu-rich repeat were expected to share at least some activity.

Example 22: Clone OMB092

[0300] In Example relating to clone OMB092 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

[0301] (1) Preparation of Poly(A)⁺RNA

[0302] Total RNA was prepared from human adult brain tissue by TRIzol reagent. Poly(A)⁺RNA was purified from the total RNA by mRNA Purification Kit.

[0303] (2) Cloning of a Full-length cDNA and Determination of Nucleotide Sequence

[0304] A full-length cDNA was cloned using Marathon cDNA Amplification Kit according to 3′ RACE method as described in Example of OX003. Double strand cDNA was prepared from the origin of each clone, i.e., poly (A)⁺RNA in human adult brain tissue. 27mer primer OMB092-F1:

5′-ACTCACCTGGATCCCTAAGGGCACAGC-3′  (SEQ ID NOS. 111)

[0305] containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. PCR was performed with the said primer and adapter primer attached in the kit. Due to insufficient amplification of cDNA by only one-time PCR, 28mer primer OMB092-F2:

5′-AGAATGAGCTATTACGGCAGCAGCTATC-3′  (SEQ ID NOS. 112)

[0306] was prepared additionally at 3′ end of OMB092-F1 primer and then nested PCR was performed. cDNA which was amplified with clone OMB092 specifically was separated with recloning by the same method as Example of OX003. Full nucleotide sequence was determined and then sequence shown in SEQ ID NO. 69 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 67 and 68, respectively, were obtained.

[0307] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OMB092 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretary protein.

[0308] However, the search using BLASTX, BLASTP and FASTA revealed a significant homology between clone OMB092 (region of 1st˜254th amino acid in SEQ ID NO. 67) and many Potassium Channels family such as Rat Inward Rectifier Potassium Channel BIR9 (Swiss Prot Accession P52191) (region of 1st˜254th amino acid). Based on these homologies, clone OMB092 and Potassium Channel were expected to share at least some activity.

Example 23: Clone OMB108

[0309] In Example relating to clone OMB108 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

[0310] (1) Preparation of Poly(A)⁺RNA

[0311] Total RNA was prepared from human adult brain tissue by TRIzol reagent. Poly(A)⁺RNA was purified from the total RNA by mRNA Purification Kit.

[0312] (2) Cloning of a Full-length cDNA and Determination of Nucleotide Sequence

[0313] A full-length cDNA was cloned using Marathon cDNA Amplification Kit according to 3′ RACE method as described in Example of OX003. Double strand cDNA was prepared from the origin of each clone, i.e., poly (A)⁺RNA in human adult brain tissue. 27mer primer OMB108-F1:

5′-CTCTCTCCATCTGCTGTGGTTATGGCC-3′  (SEQ ID NOS. 113)

[0314] containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. PCR was performed with the said primer and adapter primer attached in the kit. Due to insufficient amplification of cDNA by only one-time PCR, 22mer primer OMB108-F2:

[0315] 5′-TGGTTATGGCCTGTCGCTGGAG-3′  (SEQ ID NOS. 114)

[0316] was prepared additionally at 3′ end of OMB108-F1 primer and then nested PCR was performed. cDNA which was amplified with clone OMB108 specifically was separated with recloning by the same method as Example of OX003. Full nucleotide sequence was determined and then sequence shown in SEQ ID NO. 72 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 70 and 71, respectively, were obtained.

[0317] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OMB108 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretary protein.

[0318] However, the search using BLASTX, BLASTP and FASTA revealed a significant homology between clone OMB108 (region of 164th˜256th and 374th˜487th amino acid in SEQ ID NO. 70) and LDL-repeat region of many LDL receptors family such as Human Low-Density Lipoprotein Receptor Related Protein 10 (Swiss Prot Accession Q07954) or OMB108 (region of 47th˜158th and 259th˜370th amino acid in SEQ ID NO. 70) and CUB domain included in Human Bone Morphogenetic Protein 1 (Swiss Prot Accession P13497). That is to say, clone OMB108 proved to possess the common sequences of two parts of CUB domain and five parts of LDL-repeat at the extracell domain. Based on these homologies, clone OMB108, protein including LDL-repeat and protein including CUB domain were expected to share at least some activity.

Example 24: Clone OT007

[0319] In Example relating to clone OT007 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

[0320] (1) Preparation of Poly(A)⁺RNA

[0321] Total RNA was prepared from human neuroblastoma cell line IMR-32 (ATCC No. CCL-127) by TRIzol reagent. Poly(A)⁺RNA was purified from the total RNA by mRNA Purification Kit.

[0322] (2) Cloning of a Full-length cDNA and Determination of Nucleotide Sequence

[0323] A full-length cDNA was cloned using GENETRAPPER cDNA Positive Selection System. First, dT-primed cDNA library was prepared from poly (A)⁺RNA in IMR-32 using pSPORT1 plasmid, as a vector, by Super Script Plasmid System for cDNA Synthesis and Plasmid Cloning. Next, after preparing biotinylated primer OT007-F1 (27mer):

5′ biotin-AAAATGACTCCCCAGTCGCTGCTGCAG-3′  (SEQ ID NOS. 115)

[0324] based on the information of nucleotide sequence obtained by SST, plasmid hybridized specifically with the biotinylated primer were recovered from the cDNA library according to the method of Gene Trapper Kit and then transfected into E. coli DH10B. Colony hybridization with OT007 SST cDNA which was labeled with 32P-dCTP, as a probe, was performed by using Random Primer DNA Labeling kit according to known method to isolate the positive clone and to prepare the plasmid. Nucleotide sequence of full-length OT007 SST cDNA was determined by the same procedure as ON056 and then sequence shown in SEQ ID NO. 75 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 73 and 74, respectively, were obtained.

[0325] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OT007 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretary protein.

[0326] However, the search using BLASTX, BLASTP and FASTA revealed a significant homology between clone OT007 (region of 217th˜660th amino acid in SEQ ID NO. 73) and transmembrane region of Secretin/Vasoactive Intestinal Peptide receptor superfamily such as Human Seven Transmembrane-domain receptor (Genepept Accession X82892), Rat Latrophilin-related protein 1 (Genepept Accession U78105), Human CD97 (Swiss Prot Accession P48960) etc. Based on these homologies, clone OT007 and certain proteins containing seven transmembrane region type of Secretin/Vasoactive Intestinal Peptide were expected to share at least some activity.

Example 25: Clone OAG051

[0327] In Example relating to clone OAG051 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

[0328] (1) Preparation of Poly(A)⁺RNA

[0329] Total RNA was prepared from human bone marrow stroma cell line LP101 (provided from Prof. Keisuke Sotoyama, Dr. Makoto Aizawa, First Medicine, Tokyo Medical College) by TRIzol reagent. Poly(A)⁺RNA was purified from the total RNA by mRNA Purification Kit.

[0330] (2) Cloning of a Full-length cDNA and Determination of Nucleotide Sequence

[0331] A full-length cDNA was cloned using Marathon cDNA Amplification Kit according to 3′ RACE method as described in Example of OX003. Double strand cDNA was prepared from the origin of each clone, i.e., poly (A)⁺RNA of LP101. 27mer primer OAG051-F1:

[0332] 5′-GGAAATGTTTACATTTTTT GTTGACGTG-3′  (SEQ ID NOS. 116)

[0333] containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. cDNA which was amplified with clone OAG051 specifically was separated with recloning by the same method as Example of OX003. Full nucleotide sequence was determined and then sequence shown in SEQ ID NO. 78 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 76 and 77, respectively, were obtained.

[0334] It was indicated from the results of homology search for the public database of, the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OAG051 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretary protein.

[0335] However, the search using BLASTX, BLASTP and FASTA revealed a significant homology between clone OAG051 and many Frizzled family, for example, clone OAG051 (region of 4th˜703rd amino acid in SEQ ID NO. 76) and Mouse Frizzled-6 (PRF Code2208383E (Genebank Accession U43319) (region of 6th˜708th amino acid) or clone OAG051 (region of 1st˜627th amino acid in SEQ ID NO. 76) and Mouse Frizzled-3 (PRF Code 2208383E (Genebank Accession U43205) (region of 7th˜618th amino acid). Based on these homologies, clone clone OAG051 and Frizzled family were expected to share at least some activity.

Example 26: Clone OUB068

[0336] In Example relating to clone OUB068 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

[0337] (1) Preparation of Poly(A)⁺RNA

[0338] Total RNA was prepared from human osteosarcoma cell line U-2OS (ATCC No. HTB-96) by TRIzol reagent. Poly(A)⁺RNA was purified from the total RNA by mRNA Purification Kit.

[0339] (2) Cloning of a Full-length cDNA and Determination of Nucleotide Sequence

[0340] A full-length cDNA was cloned using GENETRAPPER cDNA Positive Selection System. First, dT-primed cDNA library was prepared from poly (A)⁺RNA in U-2OS using pSPORT1 plasmid, as a vector, by Super Script Plasmid System for cDNA Synthesis and Plasmid Cloning. Next, after preparing biotinylated primer OUB068-F1 (27mer):

5′ biotin-CACTCATGAAGGAAATTCCAGCGCTGC-3′  (SEQ ID NOS. 117)

[0341] based on the information of nucleotide sequence obtained by SST, plasmid hybridized specifically with the biotinylated primer were recovered from the cDNA library according to the method of Gene Trapper Kit and then transfected into E. coli DH10B. Colony hybridization with OUB068 SST cDNA which was labeled with 32P-dCTP, as a probe, was performed by using Random Primer DNA Labeling kit according to known method to isolate the positive clone and to prepare the plasmid. Nucleotide sequence of full-length OUB068 SST cDNA was determined by the same procedure as ON056 and then sequence shown in SEQ ID NO. 81 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 79 and 80, respectively, were obtained.

[0342] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OUB068 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretary protein.

[0343] However, the search using BLASTX, BLASTP and FASTA revealed a significant homology between clone OUB068 (region of 5th˜386th amino acid in SEQ ID NO. 79) and Xenopus Unknown Transmembrane Protein (Genepept Accession X92871) (region of 3rd˜407th amino acid). Based on these homologies, clone OUB068 and Xenopus Unknown Transmembrane Protein were expected to share at least some activity.

0 SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 117 <210> SEQ ID NO 1 <211> LENGTH: 334 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 1 Met Asn Leu Ser Leu Val Leu Ala Ala Phe Cys Leu Gly Ile Ala Ser -15 -10 -5 Ala Val Pro Lys Phe Asp Gln Asn Leu Asp Thr Lys Trp Tyr Gln Trp -1 1 5 10 15 Lys Ala Thr His Arg Arg Leu Tyr Gly Ala Asn Glu Glu Gly Trp Arg 20 25 30 Arg Ala Val Trp Glu Lys Asn Met Lys Met Ile Glu Leu His Asn Gly 35 40 45 Glu Tyr Ser Gln Gly Lys His Gly Phe Thr Met Ala Met Asn Ala Phe 50 55 60 Gly Asp Met Thr Asn Glu Glu Phe Arg Gln Met Met Gly Cys Phe Arg 65 70 75 Asn Gln Lys Phe Arg Lys Gly Lys Val Phe Arg Glu Pro Leu Phe Leu 80 85 90 95 Asp Leu Pro Lys Ser Val Asp Trp Arg Lys Lys Gly Tyr Val Thr Pro 100 105 110 Val Lys Asn Gln Lys Gln Cys Gly Ser Cys Trp Ala Phe Ser Ala Thr 115 120 125 Gly Ala Leu Glu Gly Gln Met Phe Arg Lys Thr Gly Lys Leu Val Ser 130 135 140 Leu Ser Glu Gln Asn Leu Val Asp Cys Ser Arg Pro Gln Gly Asn Gln 145 150 155 Gly Cys Asn Gly Gly Phe Met Ala Arg Ala Phe Gln Tyr Val Lys Glu 160 165 170 175 Asn Gly Gly Leu Asp Ser Glu Glu Ser Tyr Pro Tyr Val Ala Val Asp 180 185 190 Glu Ile Cys Lys Tyr Arg Pro Glu Asn Ser Val Ala Asn Asp Thr Gly 195 200 205 Phe Thr Val Val Ala Pro Gly Lys Glu Lys Ala Leu Met Lys Ala Val 210 215 220 Ala Thr Val Gly Pro Ile Ser Val Ala Met Asp Ala Gly His Ser Ser 225 230 235 Phe Gln Phe Tyr Lys Ser Gly Ile Tyr Phe Glu Pro Asp Cys Ser Ser 240 245 250 255 Lys Asn Leu Asp His Gly Val Leu Val Val Gly Tyr Gly Phe Glu Gly 260 265 270 Ala Asn Ser Asn Asn Ser Lys Tyr Trp Leu Val Lys Asn Ser Trp Gly 275 280 285 Pro Glu Trp Gly Ser Asn Gly Tyr Val Lys Ile Ala Lys Asp Lys Asn 290 295 300 Asn His Cys Gly Ile Ala Thr Ala Ala Ser Tyr Pro Asn Val 305 310 315 <210> SEQ ID NO 2 <211> LENGTH: 1002 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 2 atgaatcttt cgctcgtcct ggctgccttt tgcttgggaa tagcctccgc tgttccaaaa 60 tttgaccaaa atttggatac aaagtggtac cagtggaagg caacacacag aagattatat 120 ggcgcgaatg aagaaggatg gaggagagca gtgtgggaaa agaatatgaa aatgattgaa 180 ctgcacaatg gggaatacag ccaagggaaa catggcttca caatggccat gaatgctttt 240 ggtgacatga ccaatgaaga attcaggcag atgatgggtt gctttcgaaa ccagaaattc 300 aggaagggga aagtgttccg tgagcctctg tttcttgatc ttcccaaatc tgtggattgg 360 agaaagaaag gctacgtgac gccagtgaag aatcagaaac agtgtggttc ttgttgggct 420 tttagtgcga ctggtgctct tgaaggacag atgttccgga aaactgggaa acttgtctca 480 ctgagcgagc agaatctggt ggactgttcg cgtcctcaag gcaatcaggg ctgcaatggt 540 ggcttcatgg ctagggcctt ccagtatgtc aaggagaacg gaggcctgga ctctgaggaa 600 tcctatccat atgtagcagt ggatgaaatc tgtaagtaca gacctgagaa ttctgttgct 660 aatgacactg gcttcacagt ggtcgcacct ggaaaggaga aggccctgat gaaagcagtc 720 gcaactgtgg ggcccatctc cgttgctatg gatgcaggcc attcgtcctt ccagttctac 780 aaatcaggca tttattttga accagactgc agcagcaaaa acctggatca tggtgttctg 840 gtggttggct acggctttga aggagcaaat tcgaataaca gcaagtattg gctcgtcaaa 900 aacagctggg gtccagaatg gggctcgaat ggctatgtaa aaatagccaa agacaagaac 960 aaccactgtg gaatcgccac agcagccagc taccccaatg tg 1002 <210> SEQ ID NO 3 <211> LENGTH: 1370 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: sig_peptide <222> LOCATION: (60)..(110) <221> NAME/KEY: mat_peptide <222> LOCATION: (111)..(1061) <221> NAME/KEY: CDS <222> LOCATION: (60)..(1061) <400> SEQUENCE: 3 ctcagaggct tgtttgctga gggtgcctgc gcagctgcga cggctgctgg ttttgaaac 59 atg aat ctt tcg ctc gtc ctg gct gcc ttt tgc ttg gga ata gcc tcc 107 Met Asn Leu Ser Leu Val Leu Ala Ala Phe Cys Leu Gly Ile Ala Ser -15 -10 -5 gct gtt cca aaa ttt gac caa aat ttg gat aca aag tgg tac cag tgg 155 Ala Val Pro Lys Phe Asp Gln Asn Leu Asp Thr Lys Trp Tyr Gln Trp -1 1 5 10 15 aag gca aca cac aga aga tta tat ggc gcg aat gaa gaa gga tgg agg 203 Lys Ala Thr His Arg Arg Leu Tyr Gly Ala Asn Glu Glu Gly Trp Arg 20 25 30 aga gca gtg tgg gaa aag aat atg aaa atg att gaa ctg cac aat ggg 251 Arg Ala Val Trp Glu Lys Asn Met Lys Met Ile Glu Leu His Asn Gly 35 40 45 gaa tac agc caa ggg aaa cat ggc ttc aca atg gcc atg aat gct ttt 299 Glu Tyr Ser Gln Gly Lys His Gly Phe Thr Met Ala Met Asn Ala Phe 50 55 60 ggt gac atg acc aat gaa gaa ttc agg cag atg atg ggt tgc ttt cga 347 Gly Asp Met Thr Asn Glu Glu Phe Arg Gln Met Met Gly Cys Phe Arg 65 70 75 aac cag aaa ttc agg aag ggg aaa gtg ttc cgt gag cct ctg ttt ctt 395 Asn Gln Lys Phe Arg Lys Gly Lys Val Phe Arg Glu Pro Leu Phe Leu 80 85 90 95 gat ctt ccc aaa tct gtg gat tgg aga aag aaa ggc tac gtg acg cca 443 Asp Leu Pro Lys Ser Val Asp Trp Arg Lys Lys Gly Tyr Val Thr Pro 100 105 110 gtg aag aat cag aaa cag tgt ggt tct tgt tgg gct ttt agt gcg act 491 Val Lys Asn Gln Lys Gln Cys Gly Ser Cys Trp Ala Phe Ser Ala Thr 115 120 125 ggt gct ctt gaa gga cag atg ttc cgg aaa act ggg aaa ctt gtc tca 539 Gly Ala Leu Glu Gly Gln Met Phe Arg Lys Thr Gly Lys Leu Val Ser 130 135 140 ctg agc gag cag aat ctg gtg gac tgt tcg cgt cct caa ggc aat cag 587 Leu Ser Glu Gln Asn Leu Val Asp Cys Ser Arg Pro Gln Gly Asn Gln 145 150 155 ggc tgc aat ggt ggc ttc atg gct agg gcc ttc cag tat gtc aag gag 635 Gly Cys Asn Gly Gly Phe Met Ala Arg Ala Phe Gln Tyr Val Lys Glu 160 165 170 175 aac gga ggc ctg gac tct gag gaa tcc tat cca tat gta gca gtg gat 683 Asn Gly Gly Leu Asp Ser Glu Glu Ser Tyr Pro Tyr Val Ala Val Asp 180 185 190 gaa atc tgt aag tac aga cct gag aat tct gtt gct aat gac act ggc 731 Glu Ile Cys Lys Tyr Arg Pro Glu Asn Ser Val Ala Asn Asp Thr Gly 195 200 205 ttc aca gtg gtc gca cct gga aag gag aag gcc ctg atg aaa gca gtc 779 Phe Thr Val Val Ala Pro Gly Lys Glu Lys Ala Leu Met Lys Ala Val 210 215 220 gca act gtg ggg ccc atc tcc gtt gct atg gat gca ggc cat tcg tcc 827 Ala Thr Val Gly Pro Ile Ser Val Ala Met Asp Ala Gly His Ser Ser 225 230 235 ttc cag ttc tac aaa tca ggc att tat ttt gaa cca gac tgc agc agc 875 Phe Gln Phe Tyr Lys Ser Gly Ile Tyr Phe Glu Pro Asp Cys Ser Ser 240 245 250 255 aaa aac ctg gat cat ggt gtt ctg gtg gtt ggc tac ggc ttt gaa gga 923 Lys Asn Leu Asp His Gly Val Leu Val Val Gly Tyr Gly Phe Glu Gly 260 265 270 gca aat tcg aat aac agc aag tat tgg ctc gtc aaa aac agc tgg ggt 971 Ala Asn Ser Asn Asn Ser Lys Tyr Trp Leu Val Lys Asn Ser Trp Gly 275 280 285 cca gaa tgg ggc tcg aat ggc tat gta aaa ata gcc aaa gac aag aac 1019 Pro Glu Trp Gly Ser Asn Gly Tyr Val Lys Ile Ala Lys Asp Lys Asn 290 295 300 aac cac tgt gga atc gcc aca gca gcc agc tac ccc aat gtg 1061 Asn His Cys Gly Ile Ala Thr Ala Ala Ser Tyr Pro Asn Val 305 310 315 tgagctgatg gatggtgagg aggaaggact taaggacagc atgtctgggg aaattttatc 1121 ttgaaactga ccaaacgctt attgtgtaag ataaaccagt tgaatcatgg aggatccaag 1181 ttgagatttt aattctgtga catttttaca agggtaaaat gttaccacta ctttaattat 1241 tgttatacac agctttatga tatcaaagac tcattgctta attctaagac ttttgaattt 1301 tcatttttta aaaagatgta caaaacagtt tgaaataaat tttaattcgt atataaaaaa 1361 aaaaaaaaa 1370 <210> SEQ ID NO 4 <211> LENGTH: 111 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 4 Met Leu Pro Leu Cys Ser Leu Phe Leu Phe Gly Ser Ser Ser Val Gly -10 -5 -1 1 Val Lys Gln Tyr Gln Ala Leu Glu Leu Pro Leu Val Val Phe Val Thr 5 10 15 Tyr Leu Lys Met Ala Ala Cys Phe Leu Arg Ile Ser Gly Ser Ala Leu 20 25 30 Pro Val Phe Ile Cys Thr Phe Phe Ser His Cys Ala Ser Cys Thr His 35 40 45 50 Thr Pro Leu Pro His His Leu Pro Asn Leu Arg Leu Phe Gln Gln Phe 55 60 65 Leu Phe Arg Ala Gly Pro Cys Trp Asp Met Ile Ser Ile Lys Ser Glu 70 75 80 Gly Pro Asn Cys Ser Cys Pro Cys Ser Pro Tyr His Arg Pro Leu 85 90 95 <210> SEQ ID NO 5 <211> LENGTH: 333 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 5 atgttaccac tttgttcttt attccttttt ggatcatctt cagtgggggt aaaacagtat 60 caagctctag agctccctct ggtggttttt gtgacatatt tgaagatggc agcttgcttt 120 ttgagaattt ctggctctgc tctccctgtt tttatctgta cttttttttc tcattgtgcc 180 tcttgcacac acacacccct tccccaccat ctacccaatt tgcgcctgtt ccagcagttt 240 ctcttcaggg cagggccgtg ttgggacatg atttctatta agagtgaggg cccaaattgc 300 tcttgcccct gcagccctta tcacagaccc ctg 333 <210> SEQ ID NO 6 <211> LENGTH: 1086 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: sig_peptide <222> LOCATION: (151)..(192) <221> NAME/KEY: mat_peptide <222> LOCATION: (193)..(483) <221> NAME/KEY: CDS <222> LOCATION: (151)..(483) <400> SEQUENCE: 6 ttaattttaa actttgacac ctttaccctg ctaaacaata cagtacagtg accttcaaac 60 atttcagcag ccttcgggtt gttacatatt tattcttttt tgaagcccat cactacatcg 120 ccattacgtt ttacactgtg tatgtaacaa atg tta cca ctt tgt tct tta ttc 174 Met Leu Pro Leu Cys Ser Leu Phe -10 ctt ttt gga tca tct tca gtg ggg gta aaa cag tat caa gct cta gag 222 Leu Phe Gly Ser Ser Ser Val Gly Val Lys Gln Tyr Gln Ala Leu Glu -5 -1 1 5 10 ctc cct ctg gtg gtt ttt gtg aca tat ttg aag atg gca gct tgc ttt 270 Leu Pro Leu Val Val Phe Val Thr Tyr Leu Lys Met Ala Ala Cys Phe 15 20 25 ttg aga att tct ggc tct gct ctc cct gtt ttt atc tgt act ttt ttt 318 Leu Arg Ile Ser Gly Ser Ala Leu Pro Val Phe Ile Cys Thr Phe Phe 30 35 40 tct cat tgt gcc tct tgc aca cac aca ccc ctt ccc cac cat cta ccc 366 Ser His Cys Ala Ser Cys Thr His Thr Pro Leu Pro His His Leu Pro 45 50 55 aat ttg cgc ctg ttc cag cag ttt ctc ttc agg gca ggg ccg tgt tgg 414 Asn Leu Arg Leu Phe Gln Gln Phe Leu Phe Arg Ala Gly Pro Cys Trp 60 65 70 gac atg att tct att aag agt gag ggc cca aat tgc tct tgc ccc tgc 462 Asp Met Ile Ser Ile Lys Ser Glu Gly Pro Asn Cys Ser Cys Pro Cys 75 80 85 90 agc cct tat cac aga ccc ctg tagtcattat tggaacatgc tggtcttggg 513 Ser Pro Tyr His Arg Pro Leu 95 cctgcttttc tcagtcactg gagttctcca gtttgtaaga cggctcctcg cctcccctct 573 gcttcttcct gtacaaaggc cgtcaccctg caagccttgt tgctctcaac atgggttgtc 633 tctacttgtt cctattttag agttactgca gaatgccttg ccatctagct tggttgtagc 693 tggtaaccat aggtttttgt ttttttgcta tccttattgc actatgtttt atggaacaat 753 tggagaagat taaaaattca ccctgcccac tgggcgtggt ggctcacgcc tgtaatccca 813 gctctttggg aggccgaggc aggcagatca cgaggtcagg agatcgagac catcgtggct 873 aatacagtga aaccccgtct ctactaaaaa tgcaaaaaaa attagccggg catggtggtg 933 ggcgcctgta gtcccagcta cttgggaggc tgaggcagga gaatggcatg aattcgggag 993 gcggagcttg cagtgagcca agatcacgcc actgtactcc agcctgggca acagagcgag 1053 actccgtctc aaaaaaaaaa aaaaaaaaaa aaa 1086 <210> SEQ ID NO 7 <211> LENGTH: 111 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 7 Met Val Ala Thr Ser Thr Ala Val Ile Ser Gly Val Met Ser Leu Leu -25 -20 -15 Gly Leu Ala Leu Ala Pro Ala Thr Gly Gly Gly Ser Leu Leu Leu Ser -10 -5 -1 1 5 Thr Ala Gly Gln Gly Leu Ala Thr Ala Ala Gly Val Thr Ser Ile Val 10 15 20 Ser Gly Thr Leu Glu Arg Ser Lys Asn Lys Glu Ala Gln Ala Arg Ala 25 30 35 Glu Asp Ile Leu Pro Thr Tyr Asp Gln Glu Asp Arg Glu Asp Glu Glu 40 45 50 Glu Lys Ala Asp Tyr Val Thr Ala Ala Gly Lys Ile Ile Tyr Asn Leu 55 60 65 70 Arg Asn Thr Leu Lys Tyr Ala Lys Lys Asn Val Arg Ala Phe Trp 75 80 85 <210> SEQ ID NO 8 <211> LENGTH: 333 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 8 atggtggcca cctctactgc tgtcatctct ggagtgatga gcctcctggg tttagccctt 60 gccccagcaa caggaggagg aagcctgctg ctctccaccg ctggtcaagg tttggcaaca 120 gcagctgggg tcaccagcat cgtgagtggt acgttggaac gctccaaaaa taaagaagcc 180 caagcacggg cggaagacat actgcccacc tacgaccaag aggacaggga ggatgaggaa 240 gagaaggcag actatgtcac agctgctgga aagattatct ataatcttag aaacaccttg 300 aagtatgcca agaaaaacgt ccgtgcattt tgg 333 <210> SEQ ID NO 9 <211> LENGTH: 2604 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: sig_peptide <222> LOCATION: (173)..(250) <221> NAME/KEY: mat_peptide <222> LOCATION: (251)..(505) <221> NAME/KEY: CDS <222> LOCATION: (173)..(505) <400> SEQUENCE: 9 cgctcctctg tgtgaagacg tggagctaca agacggagat ctgtcccccg aagaaaaaat 60 atttttgaga gaatttccca gattgaaaga agatctgaaa gggaacattg acaagctccg 120 tgccctcgca gacgatattg acaaaaccca caagaaattc accaaggcta ac atg gtg 178 Met Val -25 gcc acc tct act gct gtc atc tct gga gtg atg agc ctc ctg ggt tta 226 Ala Thr Ser Thr Ala Val Ile Ser Gly Val Met Ser Leu Leu Gly Leu -20 -15 -10 gcc ctt gcc cca gca aca gga gga gga agc ctg ctg ctc tcc acc gct 274 Ala Leu Ala Pro Ala Thr Gly Gly Gly Ser Leu Leu Leu Ser Thr Ala -5 -1 1 5 ggt caa ggt ttg gca aca gca gct ggg gtc acc agc atc gtg agt ggt 322 Gly Gln Gly Leu Ala Thr Ala Ala Gly Val Thr Ser Ile Val Ser Gly 10 15 20 acg ttg gaa cgc tcc aaa aat aaa gaa gcc caa gca cgg gcg gaa gac 370 Thr Leu Glu Arg Ser Lys Asn Lys Glu Ala Gln Ala Arg Ala Glu Asp 25 30 35 40 ata ctg ccc acc tac gac caa gag gac agg gag gat gag gaa gag aag 418 Ile Leu Pro Thr Tyr Asp Gln Glu Asp Arg Glu Asp Glu Glu Glu Lys 45 50 55 gca gac tat gtc aca gct gct gga aag att atc tat aat ctt aga aac 466 Ala Asp Tyr Val Thr Ala Ala Gly Lys Ile Ile Tyr Asn Leu Arg Asn 60 65 70 acc ttg aag tat gcc aag aaa aac gtc cgt gca ttt tgg taactcagag 515 Thr Leu Lys Tyr Ala Lys Lys Asn Val Arg Ala Phe Trp 75 80 85 ccaacccacg ctcggccaat gctaccaagc gtcttctgac cactggccaa gtctcctccc 575 ggagccgcgt gcaggtgcaa aaggcctttg cgggaacaac actggcgatg accaaaaatg 635 ctcgcgtgct gggaggtgtg atgtccgcct tctcccttgg ctatgacttg gccactctct 695 caaaggaatg gaagcacctg aaggaaggag caaggacaaa gtttgcggaa gagttgagag 755 ccaaggcctt ggagctggag aggaaactca cagaactcac ccagctctac aagagcttgc 815 agcagaaagt gaggtcaagg gccagagggg tggggaagga tttaactggg acctgcgaaa 875 ccgaggctta ctggaaggag ttaagggagc atgtgtggat gtggctgtgg ctgtgtgtgt 935 gtctgtgtgt ctgtgtgtat gtacagttta catgaatgtt cctcaggaca tggcatacaa 995 tggccttgga ggtccaaata atatcaagta catcttggag atgagggtgc ctgtcctgga 1055 cagacctcgg catgccttct gtttctcctt caatgctcct taaggcctat gtgctgggaa 1115 aagggtcttc cctgtttgtt tgtttgtttg tttgtttgtt tgttttgaga cggggtctct 1175 gttgcactcc agtctgggtg tcagaatgag accccatctc aaaaaaaaaa aaaaaaaaaa 1235 aaaagaagaa gaatacagtc atgtatctct tggtgacagg gacgcattct gataaatgtg 1295 tcattaggca attgcattgt agtgtgatta tcacagattg tacttataca aaacttagat 1355 ggcatagcct actgcatacc taggctatat gggagagcct attgctccca ggctacgcac 1415 ctgtacagca tgtgactact gaatactata ggcaattgca gcacaatggg aaatatttgt 1475 gtatctaaac atatgtaaac agagaaaaag gaaagtaaaa atatggcata aaagataaga 1535 attggctctc ctgtacaggg cacttactac gaatggagct tgcagggctg agagttgctc 1595 cagatgagtc agtgagtggt gaatgaatgt gaaggcctag ggcattactg tatactactg 1655 taggctttat aaacacagca cacttagggt acacaaaatg catattaaaa cattttcttc 1715 cttcagtata ttaggcaata ggaatttttc aagtccacta taaatcttat caaaccatgg 1775 ttgtatatgc agttgaccga aacattgtta ttggacacat aactatagtt gaaagaataa 1835 gcaaaaagtc tatctaggtg tgctgtcttg agcaactttt aattattctc ccgtcctgca 1895 atatgagtta atcttctctg atcgatgtag attccaggaa ggggtgtcca ggacaattac 1955 cttccttctg gagaaacttc ccttaatcaa ataagagaac ttcaaagaaa atccctccct 2015 gtgctttgga agggaaggga ggtgggcagc agtgggtcag agatagacct ttgttctctt 2075 atttctgagg cccttcagtc tcctttattc aaagcactca gcatgccaaa gcaccctatt 2135 ttagggtatc tttttctgag ccctaaacac tgtgttgggg atgtcaactg tgacaggaaa 2195 atatcttggg gccccagaat cactaaggaa aactcaagct tagggaaact tcttagggca 2255 aacccacctc ccactctatt caaagttatc tctctgctca ctgagataga tacatatctg 2315 attgcctcct ttggaaaggc taatcagaaa ctcaaaagaa tgcaactgtt tgtgtctcac 2375 ctatctgtga cctggaagct ccctccccac tgaaccaatg ttcttcttac atatattgat 2435 taatgtctta tgtctcccta aaatgtataa aaccaaggta tgccccaacc atcttggtca 2495 catgtcatca ggacttcctg agtctgtgtc acagtgtgtc ctcaaccttg gcaaaataaa 2555 ctttctaaat taacaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaa 2604 <210> SEQ ID NO 10 <211> LENGTH: 542 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 10 Met Pro Arg Arg Gly Leu Ile Leu His Thr Arg Thr His Trp Leu Leu -30 -25 -20 Leu Gly Leu Ala Leu Leu Cys Ser Leu Val Leu Phe Met Tyr Leu Leu -15 -10 -5 Glu Cys Ala Pro Gln Thr Asp Gly Asn Ala Ser Leu Pro Gly Val Val -1 1 5 10 Gly Glu Asn Tyr Gly Lys Glu Tyr Tyr Gln Ala Leu Leu Gln Glu Gln 15 20 25 30 Glu Glu His Tyr Gln Thr Arg Ala Thr Ser Leu Lys Arg Gln Ile Ala 35 40 45 Gln Leu Lys Gln Glu Leu Gln Glu Met Ser Glu Lys Met Arg Ser Leu 50 55 60 Gln Glu Arg Arg Asn Val Gly Ala Asn Gly Ile Gly Tyr Gln Ser Asn 65 70 75 Lys Glu Gln Ala Pro Ser Asp Leu Leu Glu Phe Leu His Ser Gln Ile 80 85 90 Asp Lys Ala Glu Val Ser Ile Gly Ala Lys Leu Pro Ser Glu Tyr Gly 95 100 105 110 Val Ile Pro Phe Glu Ser Phe Thr Leu Met Lys Val Phe Gln Leu Glu 115 120 125 Met Gly Leu Thr Arg His Pro Glu Glu Lys Pro Val Arg Lys Asp Lys 130 135 140 Arg Asp Glu Leu Val Glu Val Ile Glu Ala Gly Leu Glu Val Ile Asn 145 150 155 Asn Pro Asp Glu Asp Asp Glu Gln Glu Asp Glu Glu Gly Pro Leu Gly 160 165 170 Glu Lys Leu Ile Phe Asn Glu Asn Asp Phe Val Glu Gly Tyr Tyr Arg 175 180 185 190 Thr Glu Arg Asp Lys Gly Thr Gln Tyr Glu Leu Phe Phe Lys Lys Ala 195 200 205 Asp Leu Thr Glu Tyr Arg His Val Thr Leu Phe Arg Pro Phe Gly Pro 210 215 220 Leu Met Lys Val Lys Ser Glu Met Ile Asp Ile Thr Arg Ser Ile Ile 225 230 235 Asn Ile Ile Val Pro Leu Ala Glu Arg Thr Glu Ala Phe Val Gln Phe 240 245 250 Met Gln Asn Phe Arg Asp Val Cys Ile His Gln Asp Lys Lys Ile His 255 260 265 270 Leu Thr Val Val Tyr Phe Gly Lys Glu Gly Leu Ser Lys Val Lys Ser 275 280 285 Ile Leu Glu Ser Val Thr Ser Glu Ser Asn Phe His Asn Tyr Thr Leu 290 295 300 Val Ser Leu Asn Glu Glu Phe Asn Arg Gly Arg Gly Leu Asn Val Gly 305 310 315 Ala Arg Ala Trp Asp Lys Gly Glu Val Leu Met Phe Phe Cys Asp Val 320 325 330 Asp Ile Tyr Phe Ser Ala Glu Phe Leu Asn Ser Cys Arg Leu Asn Ala 335 340 345 350 Glu Pro Gly Lys Lys Val Phe Tyr Pro Val Val Phe Ser Leu Tyr Asn 355 360 365 Pro Ala Ile Val Tyr Ala Asn Gln Glu Val Pro Pro Pro Val Glu Gln 370 375 380 Gln Leu Val His Lys Lys Asp Ser Gly Phe Trp Arg Asp Phe Gly Phe 385 390 395 Gly Met Thr Cys Gln Tyr Arg Ser Asp Phe Leu Thr Ile Gly Gly Phe 400 405 410 Asp Met Glu Val Arg Gly Trp Gly Gly Glu Asp Val His Leu Tyr Arg 415 420 425 430 Lys Tyr Leu His Gly Asp Leu Ile Val Ile Arg Thr Pro Val Pro Gly 435 440 445 Pro Phe His Leu Trp His Glu Lys Arg Cys Ala Asp Glu Leu Thr Pro 450 455 460 Glu Gln Tyr Arg Met Cys Ile Gln Ser Lys Ala Met Asn Glu Ala Ser 465 470 475 His Ser His Leu Gly Met Leu Val Phe Arg Glu Glu Ile Glu Thr His 480 485 490 Leu His Lys Gln Ala Tyr Arg Thr Asn Ser Glu Ala Val Gly 495 500 505 <210> SEQ ID NO 11 <211> LENGTH: 1626 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 11 atgcctagaa gaggactgat tcttcacacc cggacccact ggttgctgtt gggccttgct 60 ttgctctgca gtttggtatt atttatgtac ctcctggaat gtgcccccca gactgatgga 120 aatgcatctc ttcctggtgt tgttggggaa aattatggta aagagtatta tcaagccctc 180 ctacaggaac aagaagaaca ttatcagacc agggcaacca gtctgaaacg ccaaattgcc 240 caactaaaac aagaattaca agaaatgagt gagaagatgc ggtcactgca agaaagaagg 300 aatgtagggg ctaatggcat aggctatcag agcaacaaag agcaagcacc tagtgatctt 360 ttagagtttc ttcattccca aattgacaaa gctgaagtta gcataggggc caaactaccc 420 agtgagtatg gggtcattcc ctttgaaagt tttaccttaa tgaaagtatt tcaattggaa 480 atgggtctca ctcgccatcc tgaagaaaag ccagttagaa aagacaaacg agatgaattg 540 gtggaagtta ttgaagcggg cttggaggtc attaataatc ctgatgaaga tgatgaacaa 600 gaagatgagg agggtcccct tggagagaaa ctgatattta atgaaaatga cttcgtagaa 660 ggttattatc gcactgagag agataagggc acacagtatg aactcttttt taagaaagca 720 gaccttacgg aatatagaca tgtgaccctc ttccgccctt ttggacctct catgaaagtg 780 aagagtgaga tgattgacat cactagatca attattaata tcattgtgcc acttgctgaa 840 agaactgaag catttgtaca atttatgcag aacttcaggg atgtttgtat tcatcaagac 900 aagaagattc atctcacagt ggtgtatttt ggtaaagaag gactgtctaa ggtcaagtct 960 atcctagaat ctgtcaccag tgagtctaat tttcacaatt acaccttggt ctcattgaat 1020 gaagaattta atcgtggacg aggactaaat gtgggtgccc gagcttggga caagggagag 1080 gtcttgatgt ttttctgtga tgttgatatc tatttctcag ccgaattcct taacagctgc 1140 cggttaaatg ctgagccagg taagaaggtg ttttaccctg tggtgttcag tctttacaat 1200 cctgccattg tttatgccaa ccaggaagtg ccaccacctg tggagcagca gctggttcac 1260 aaaaaggatt ctggcttttg gcgagatttt ggctttggaa tgacttgtca gtatcgttca 1320 gatttcctga ccattggtgg atttgacatg gaagtgagag gttggggtgg agaagatgtt 1380 catctttatc gaaaatactt acatggtgac ctcattgtga ttcggactcc ggttcctggt 1440 cctttccacc tctggcatga aaagcgctgt gctgatgagc tgacccccga gcagtaccgc 1500 atgtgcatcc agtctaaagc catgaatgag gcctctcact cccacctggg aatgctggtc 1560 ttcagggagg aaatagagac gcatcttcat aaacaggcat acaggacaaa cagtgaagct 1620 gttggt 1626 <210> SEQ ID NO 12 <211> LENGTH: 3451 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: sig_peptide <222> LOCATION: (41)..(142) <221> NAME/KEY: mat_peptide <222> LOCATION: (143)..(1666) <221> NAME/KEY: CDS <222> LOCATION: (41)..(1666) <400> SEQUENCE: 12 aggcctagcg attttgttag gcaaatacac attaataaga atg cct aga aga gga 55 Met Pro Arg Arg Gly -30 ctg att ctt cac acc cgg acc cac tgg ttg ctg ttg ggc ctt gct ttg 103 Leu Ile Leu His Thr Arg Thr His Trp Leu Leu Leu Gly Leu Ala Leu -25 -20 -15 ctc tgc agt ttg gta tta ttt atg tac ctc ctg gaa tgt gcc ccc cag 151 Leu Cys Ser Leu Val Leu Phe Met Tyr Leu Leu Glu Cys Ala Pro Gln -10 -5 -1 1 act gat gga aat gca tct ctt cct ggt gtt gtt ggg gaa aat tat ggt 199 Thr Asp Gly Asn Ala Ser Leu Pro Gly Val Val Gly Glu Asn Tyr Gly 5 10 15 aaa gag tat tat caa gcc ctc cta cag gaa caa gaa gaa cat tat cag 247 Lys Glu Tyr Tyr Gln Ala Leu Leu Gln Glu Gln Glu Glu His Tyr Gln 20 25 30 35 acc agg gca acc agt ctg aaa cgc caa att gcc caa cta aaa caa gaa 295 Thr Arg Ala Thr Ser Leu Lys Arg Gln Ile Ala Gln Leu Lys Gln Glu 40 45 50 tta caa gaa atg agt gag aag atg cgg tca ctg caa gaa aga agg aat 343 Leu Gln Glu Met Ser Glu Lys Met Arg Ser Leu Gln Glu Arg Arg Asn 55 60 65 gta ggg gct aat ggc ata ggc tat cag agc aac aaa gag caa gca cct 391 Val Gly Ala Asn Gly Ile Gly Tyr Gln Ser Asn Lys Glu Gln Ala Pro 70 75 80 agt gat ctt tta gag ttt ctt cat tcc caa att gac aaa gct gaa gtt 439 Ser Asp Leu Leu Glu Phe Leu His Ser Gln Ile Asp Lys Ala Glu Val 85 90 95 agc ata ggg gcc aaa cta ccc agt gag tat ggg gtc att ccc ttt gaa 487 Ser Ile Gly Ala Lys Leu Pro Ser Glu Tyr Gly Val Ile Pro Phe Glu 100 105 110 115 agt ttt acc tta atg aaa gta ttt caa ttg gaa atg ggt ctc act cgc 535 Ser Phe Thr Leu Met Lys Val Phe Gln Leu Glu Met Gly Leu Thr Arg 120 125 130 cat cct gaa gaa aag cca gtt aga aaa gac aaa cga gat gaa ttg gtg 583 His Pro Glu Glu Lys Pro Val Arg Lys Asp Lys Arg Asp Glu Leu Val 135 140 145 gaa gtt att gaa gcg ggc ttg gag gtc att aat aat cct gat gaa gat 631 Glu Val Ile Glu Ala Gly Leu Glu Val Ile Asn Asn Pro Asp Glu Asp 150 155 160 gat gaa caa gaa gat gag gag ggt ccc ctt gga gag aaa ctg ata ttt 679 Asp Glu Gln Glu Asp Glu Glu Gly Pro Leu Gly Glu Lys Leu Ile Phe 165 170 175 aat gaa aat gac ttc gta gaa ggt tat tat cgc act gag aga gat aag 727 Asn Glu Asn Asp Phe Val Glu Gly Tyr Tyr Arg Thr Glu Arg Asp Lys 180 185 190 195 ggc aca cag tat gaa ctc ttt ttt aag aaa gca gac ctt acg gaa tat 775 Gly Thr Gln Tyr Glu Leu Phe Phe Lys Lys Ala Asp Leu Thr Glu Tyr 200 205 210 aga cat gtg acc ctc ttc cgc cct ttt gga cct ctc atg aaa gtg aag 823 Arg His Val Thr Leu Phe Arg Pro Phe Gly Pro Leu Met Lys Val Lys 215 220 225 agt gag atg att gac atc act aga tca att att aat atc att gtg cca 871 Ser Glu Met Ile Asp Ile Thr Arg Ser Ile Ile Asn Ile Ile Val Pro 230 235 240 ctt gct gaa aga act gaa gca ttt gta caa ttt atg cag aac ttc agg 919 Leu Ala Glu Arg Thr Glu Ala Phe Val Gln Phe Met Gln Asn Phe Arg 245 250 255 gat gtt tgt att cat caa gac aag aag att cat ctc aca gtg gtg tat 967 Asp Val Cys Ile His Gln Asp Lys Lys Ile His Leu Thr Val Val Tyr 260 265 270 275 ttt ggt aaa gaa gga ctg tct aag gtc aag tct atc cta gaa tct gtc 1015 Phe Gly Lys Glu Gly Leu Ser Lys Val Lys Ser Ile Leu Glu Ser Val 280 285 290 acc agt gag tct aat ttt cac aat tac acc ttg gtc tca ttg aat gaa 1063 Thr Ser Glu Ser Asn Phe His Asn Tyr Thr Leu Val Ser Leu Asn Glu 295 300 305 gaa ttt aat cgt gga cga gga cta aat gtg ggt gcc cga gct tgg gac 1111 Glu Phe Asn Arg Gly Arg Gly Leu Asn Val Gly Ala Arg Ala Trp Asp 310 315 320 aag gga gag gtc ttg atg ttt ttc tgt gat gtt gat atc tat ttc tca 1159 Lys Gly Glu Val Leu Met Phe Phe Cys Asp Val Asp Ile Tyr Phe Ser 325 330 335 gcc gaa ttc ctt aac agc tgc cgg tta aat gct gag cca ggt aag aag 1207 Ala Glu Phe Leu Asn Ser Cys Arg Leu Asn Ala Glu Pro Gly Lys Lys 340 345 350 355 gtg ttt tac cct gtg gtg ttc agt ctt tac aat cct gcc att gtt tat 1255 Val Phe Tyr Pro Val Val Phe Ser Leu Tyr Asn Pro Ala Ile Val Tyr 360 365 370 gcc aac cag gaa gtg cca cca cct gtg gag cag cag ctg gtt cac aaa 1303 Ala Asn Gln Glu Val Pro Pro Pro Val Glu Gln Gln Leu Val His Lys 375 380 385 aag gat tct ggc ttt tgg cga gat ttt ggc ttt gga atg act tgt cag 1351 Lys Asp Ser Gly Phe Trp Arg Asp Phe Gly Phe Gly Met Thr Cys Gln 390 395 400 tat cgt tca gat ttc ctg acc att ggt gga ttt gac atg gaa gtg aga 1399 Tyr Arg Ser Asp Phe Leu Thr Ile Gly Gly Phe Asp Met Glu Val Arg 405 410 415 ggt tgg ggt gga gaa gat gtt cat ctt tat cga aaa tac tta cat ggt 1447 Gly Trp Gly Gly Glu Asp Val His Leu Tyr Arg Lys Tyr Leu His Gly 420 425 430 435 gac ctc att gtg att cgg act ccg gtt cct ggt cct ttc cac ctc tgg 1495 Asp Leu Ile Val Ile Arg Thr Pro Val Pro Gly Pro Phe His Leu Trp 440 445 450 cat gaa aag cgc tgt gct gat gag ctg acc ccc gag cag tac cgc atg 1543 His Glu Lys Arg Cys Ala Asp Glu Leu Thr Pro Glu Gln Tyr Arg Met 455 460 465 tgc atc cag tct aaa gcc atg aat gag gcc tct cac tcc cac ctg gga 1591 Cys Ile Gln Ser Lys Ala Met Asn Glu Ala Ser His Ser His Leu Gly 470 475 480 atg ctg gtc ttc agg gag gaa ata gag acg cat ctt cat aaa cag gca 1639 Met Leu Val Phe Arg Glu Glu Ile Glu Thr His Leu His Lys Gln Ala 485 490 495 tac agg aca aac agt gaa gct gtt ggt tgaaatcata attaatgcgt 1686 Tyr Arg Thr Asn Ser Glu Ala Val Gly 500 505 tactgtatga accacaaaac agcactattt atttagcctt acttctactt ccagatgcag 1746 tgcctctttt ggagaagaca tgtttatttt tcatgttctt tctgacatta ctttagcaat 1806 tcaacttgat gtgagaagaa aaaacaaatg tttcaacaca aaatctctgt tttgtgagaa 1866 tactgcacta tggaataatt gacaaattga aatctcatat ttgtcccaaa agttgttttg 1926 agttagttct acctggtgcc catgttctga ttgtgtgtgg gattgcatgg tgtcctgatt 1986 gcatctaggt ggagcggatg gaatgtgctg ggccactgtt gggtggagag cagcacattc 2046 ttacagagga gatggagcgt tatgagcata gtatgtggat aggtatcttc acctgcccgc 2106 ccctgagtca gcctccttga cttgatagct tgaagaatcc ttttccactg aaatagagga 2166 taattaattg acacatctga aatccccaat caatcaatca agagaaaggt agaactaaaa 2226 actccttaac ttactgttgc ttacacccct gaaagtctgt ttttaagcaa atgggtaata 2286 gtagaaaata ggttagaatc tatggcttga ttaaaaatat gttattacat tatcatgttc 2346 aggattagga ttagtagtca gttgctgtaa actattttga acaaacagaa aagaacacgg 2406 aaacattttt aacagagcat ttaattatgt tggaatacag gatcctagct ctgtctggga 2466 acattagctt atgtgagcca gctctatcag ggtcttccca tggtggttca gaatagatga 2526 gcatagcatg gttttgtttg tttttgcttt caattttcta atttggcatg gatccatatg 2586 tatttactat cctttttcta atatattaat atatgctaca tttgtatttg cattactata 2646 atactttgag ttgaaaaaga gtttcattgt ggagagaaaa agcaaatggt atgccacaag 2706 atcactctga tttgagaaaa gggaggaggg gaagatagtc tgaatggaaa tctgaaatac 2766 ggaatgtttt agagaaatat gtcacttgca tatagaatgt tttaattgag gtataaatta 2826 atgagacaaa gtgaaaaaga aattatattc agataggact gcactacatt atttgtcaca 2886 catggatctg ttaccatcag gtcaattcct agtatgcata aattttttaa cccttttaaa 2946 agagacctat gttgaaaacc cctgaaaatt cactgaagaa aaatcattac tctttttctc 3006 agtaaatcat atcatctgaa atattacaaa tttcaaattt ctaggtgcta tattaattca 3066 atattacaat aactcttacc taattattct tacaagtttt aagttgtggt agtttagtga 3126 tttttttaaa agatgtgtga aatgttctct gcaaaataat tcaggccact gtctcctttt 3186 atatattatt ataattattt attatgaaga ccagtgaatt acgatattta aagtgagaga 3246 acttaattat ttgcaaaggt aagttacagc ttgttttttg agagaatcaa atgagtttac 3306 ttttgttcct gttgttttta actagcttta agtttaaaga tggaagctaa gcaatggaaa 3366 tgctatacgt ttttgacatt tattaaatgg taccaataaa gtattttatt accaaaaaaa 3426 aaaaaaaaaa aaaaaaaaaa aaaaa 3451 <210> SEQ ID NO 13 <211> LENGTH: 119 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 13 Met Arg Lys Gly Asn Leu Leu Leu Ser Trp Leu Leu Gly Pro Glu Leu -15 -10 -5 Pro Glu Leu Ser Pro Arg Ala Arg Lys Ala Asp Leu Lys Asp Glu Asn -1 1 5 10 15 Leu Lys Phe Ser Cys Trp Trp Glu Pro Arg Lys Thr Ala Gly Val Leu 20 25 30 Thr Trp Pro Phe Leu Ala Glu Leu Ala Glu Val Gly Val Leu Ala Asp 35 40 45 Gly Met Tyr Leu Gly Ala Val Ser Val Ala Gln Gln Arg Cys Arg Ala 50 55 60 Asp Trp Leu Ser His Trp Val Leu Pro Ala Gly Ser Pro Leu His Trp 65 70 75 Ala Phe Thr Gln Pro Cys Ser Trp Val Ser Leu Pro Cys Lys Gln Ser 80 85 90 95 His Asn Asn Thr Arg Ile Val 100 <210> SEQ ID NO 14 <211> LENGTH: 357 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 14 atgaggaaag ggaaccttct gctgagctgg cttctggggc ctgagcttcc agagctgtcc 60 ccaagggcta ggaaggccga cctgaaggat gagaacctca aattcagttg ctggtgggag 120 ccaaggaaga cggcgggtgt tctaacgtgg ccctttctgg ctgagctggc ggaagtgggc 180 gttttggccg atgggatgta tctcggcgct gtgtctgtgg cccagcaaag gtgcagggct 240 gactggctga gccactgggt tctacccgca ggctccccac tgcactgggc tttcacacag 300 ccatgctctt gggtttccct cccttgtaag cagagtcata ataacacacg aatagtc 357 <210> SEQ ID NO 15 <211> LENGTH: 814 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: sig_peptide <222> LOCATION: (62)..(112) <221> NAME/KEY: mat_peptide <222> LOCATION: (113)..(418) <221> NAME/KEY: CDS <222> LOCATION: (62)..(418) <400> SEQUENCE: 15 caaaaatata agcatcagct gaggtgatat tagttcagtc acctaacaac tcctagaaga 60 g atg agg aaa ggg aac ctt ctg ctg agc tgg ctt ctg ggg cct gag ctt 109 Met Arg Lys Gly Asn Leu Leu Leu Ser Trp Leu Leu Gly Pro Glu Leu -15 -10 -5 cca gag ctg tcc cca agg gct agg aag gcc gac ctg aag gat gag aac 157 Pro Glu Leu Ser Pro Arg Ala Arg Lys Ala Asp Leu Lys Asp Glu Asn -1 1 5 10 15 ctc aaa ttc agt tgc tgg tgg gag cca agg aag acg gcg ggt gtt cta 205 Leu Lys Phe Ser Cys Trp Trp Glu Pro Arg Lys Thr Ala Gly Val Leu 20 25 30 acg tgg ccc ttt ctg gct gag ctg gcg gaa gtg ggc gtt ttg gcc gat 253 Thr Trp Pro Phe Leu Ala Glu Leu Ala Glu Val Gly Val Leu Ala Asp 35 40 45 ggg atg tat ctc ggc gct gtg tct gtg gcc cag caa agg tgc agg gct 301 Gly Met Tyr Leu Gly Ala Val Ser Val Ala Gln Gln Arg Cys Arg Ala 50 55 60 gac tgg ctg agc cac tgg gtt cta ccc gca ggc tcc cca ctg cac tgg 349 Asp Trp Leu Ser His Trp Val Leu Pro Ala Gly Ser Pro Leu His Trp 65 70 75 gct ttc aca cag cca tgc tct tgg gtt tcc ctc cct tgt aag cag agt 397 Ala Phe Thr Gln Pro Cys Ser Trp Val Ser Leu Pro Cys Lys Gln Ser 80 85 90 95 cat aat aac aca cga ata gtc taacgctggg tattctggtc agcagaggtc 448 His Asn Asn Thr Arg Ile Val 100 cttgagtcac agtgttactg aaatggttct gagcctgaga atctctttgg cctctgaaag 508 ggcagggcag gtgggcaccg acttcctgcc agtcctttca ggtttcctgt tcaaagccag 568 tcctgttggt ggaggggatc accgagagtg tctgtatcat tttgtagccc ttttctctga 628 cgttttctgg tagaaaatgt cccttgtcaa aatgctaata attatcataa taatctgctt 688 tccaaccaac ttccacaagt gacaacctgt gtagaactgt gataaaggtt tgcataatgt 748 agggtttgta ccaagtgtgt gtaagtttct gttaaataaa aagtctgttt ccaaaaaaaa 808 aaaaaa 814 <210> SEQ ID NO 16 <211> LENGTH: 714 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 16 Met Lys His Phe Cys Asn Leu Leu Cys Ile Leu Met Phe Cys Asn Gln -15 -10 -5 -1 Gln Ser Val Cys Asp Pro Pro Ser Gln Asn Asn Ala Ala Asn Ile Ser 1 5 10 15 Met Val Gln Ala Ala Ser Ala Gly Pro Pro Ser Leu Arg Lys Asp Ser 20 25 30 Thr Pro Val Ile Ala Asn Val Val Ser Leu Ala Ser Ala Pro Ala Ala 35 40 45 Gln Pro Thr Val Asn Ser Asn Ser Val Leu Gln Gly Ala Val Pro Thr 50 55 60 Val Thr Ala Lys Ile Ile Gly Asp Ala Ser Thr Gln Thr Asp Ala Leu 65 70 75 80 Lys Leu Pro Pro Ser Gln Pro Pro Arg Leu Leu Lys Asn Lys Ala Leu 85 90 95 Leu Cys Lys Pro Ile Thr Gln Thr Lys Ala Thr Ser Cys Lys Pro His 100 105 110 Thr Gln Asn Lys Glu Cys Gln Thr Glu Asp Thr Pro Ser Gln Pro Gln 115 120 125 Ile Ile Val Val Pro Val Pro Val Pro Val Phe Val Pro Ile Pro Leu 130 135 140 His Leu Tyr Thr Gln Tyr Ala Pro Val Pro Phe Gly Ile Pro Val Pro 145 150 155 160 Met Pro Val Pro Met Leu Ile Pro Ser Ser Met Asp Ser Glu Asp Lys 165 170 175 Val Thr Glu Ser Ile Glu Asp Ile Lys Glu Lys Leu Pro Thr His Pro 180 185 190 Phe Glu Ala Asp Leu Leu Glu Met Ala Glu Met Ile Ala Glu Asp Glu 195 200 205 Glu Lys Lys Thr Leu Ser Gln Gly Glu Ser Gln Thr Ser Glu His Glu 210 215 220 Leu Phe Leu Asp Thr Lys Ile Phe Glu Lys Asp Gln Gly Ser Thr Tyr 225 230 235 240 Ser Gly Asp Leu Glu Ser Glu Ala Val Ser Thr Leu His Ser Trp Glu 245 250 255 Glu Glu Leu Asn His Tyr Ala Leu Lys Ser Asn Ala Val Gln Glu Ala 260 265 270 Asp Ser Glu Leu Lys Gln Phe Ser Lys Gly Glu Thr Glu Gln Asp Leu 275 280 285 Glu Ala Asp Phe Pro Ser Asp Ser Phe Asp Pro Leu Asn Lys Gly Gln 290 295 300 Gly Ile Gln Ala Arg Ser Arg Thr Arg Arg Arg His Arg Asp Gly Phe 305 310 315 320 Pro Gln Pro Arg Arg Arg Gly Arg Lys Lys Ser Ile Val Ala Val Glu 325 330 335 Pro Arg Ser Leu Ile Gln Gly Ala Phe Gln Gly Cys Ser Val Ser Gly 340 345 350 Met Thr Leu Lys Tyr Met Tyr Gly Val Asn Ala Trp Lys Asn Trp Val 355 360 365 Gln Trp Lys Asn Ala Lys Glu Glu Gln Gly Asp Leu Lys Cys Gly Gly 370 375 380 Val Glu Gln Ala Ser Ser Ser Pro Arg Ser Asp Pro Leu Gly Ser Thr 385 390 395 400 Gln Asp His Ala Leu Ser Gln Glu Ser Ser Glu Pro Gly Cys Arg Val 405 410 415 Arg Ser Ile Lys Leu Lys Glu Asp Ile Leu Ser Cys Thr Phe Ala Glu 420 425 430 Leu Ser Leu Gly Leu Cys Gln Phe Ile Gln Glu Val Arg Arg Pro Asn 435 440 445 Gly Glu Lys Tyr Asp Pro Asp Ser Ile Leu Tyr Leu Cys Leu Gly Ile 450 455 460 Gln Gln Tyr Leu Phe Glu Asn Gly Arg Ile Asp Asn Ile Phe Thr Glu 465 470 475 480 Pro Tyr Ser Arg Phe Met Ile Glu Leu Thr Lys Leu Leu Lys Ile Trp 485 490 495 Glu Pro Thr Ile Leu Pro Asn Gly Tyr Met Phe Ser Arg Ile Glu Glu 500 505 510 Glu His Leu Trp Glu Cys Lys Gln Leu Gly Ala Tyr Ser Pro Ile Val 515 520 525 Leu Leu Asn Thr Leu Leu Phe Phe Asn Thr Lys Tyr Phe Gln Leu Lys 530 535 540 Asn Val Thr Glu His Leu Lys Leu Ser Phe Ala His Val Met Arg Arg 545 550 555 560 Thr Arg Thr Leu Lys Tyr Ser Thr Lys Met Thr Tyr Leu Arg Phe Phe 565 570 575 Pro Pro Leu Gln Lys Gln Glu Ser Glu Pro Asp Lys Leu Thr Val Gly 580 585 590 Lys Arg Lys Arg Asn Glu Asp Asp Glu Val Pro Val Gly Val Glu Met 595 600 605 Ala Glu Asn Thr Asp Asn Pro Leu Arg Cys Pro Val Arg Leu Tyr Glu 610 615 620 Phe Tyr Leu Ser Lys Cys Ser Glu Ser Val Lys Gln Arg Asn Asp Val 625 630 635 640 Phe Tyr Leu Gln Pro Glu Arg Ser Cys Val Pro Asn Ser Pro Met Trp 645 650 655 Tyr Ser Ala Phe Pro Ile Asp Pro Gly Thr Leu Asp Thr Met Leu Thr 660 665 670 Arg Ile Leu Met Val Arg Glu Val His Glu Glu Leu Ala Lys Ala Lys 675 680 685 Ser Glu Asp Ser Asp Val Glu Leu Ser Asp 690 695 <210> SEQ ID NO 17 <211> LENGTH: 2142 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 17 atgaaacatt tctgtaacct gctttgtatc ttgatgttct gtaatcagca aagtgtatgt 60 gacccgcctt cacaaaataa tgcagcaaat atttccatgg ttcaagctgc ttcagcagga 120 cccccatctc tgagaaaaga ttcgactcca gttatagcca atgtagtatc attggcaagt 180 gcccctgctg ctcagcctac agtgaattct aacagtgtct tacaaggtgc agttccaaca 240 gtaacagcga aaatcatcgg tgatgcaagt actcaaacag atgccctgaa actgccacct 300 tcccaacctc caaggctttt gaagaacaaa gctttattat gcaaacccat cacacagact 360 aaagccacct cttgcaaacc acatacccaa aacaaagaat gccagacaga agacactcca 420 agtcagcccc agattattgt ggtgccagtt cccgtaccag tgtttgttcc catacctctt 480 cacctttata ctcaatatgc tccagtccca tttggaattc cagttccaat gcctgtccct 540 atgcttattc catcttcaat ggatagtgaa gataaagtca cagagagtat tgaagacatt 600 aaagaaaagc ttcccacaca tccatttgaa gctgatctcc ttgagatggc agaaatgatt 660 gcagaagatg aagagaagaa gactctatct cagggagagt cccaaacttc tgaacacgaa 720 ctctttctag acaccaagat atttgaaaaa gaccaaggaa gtacatacag tggtgatctt 780 gaatcagagg cagtatctac tctacatagc tgggaggaag agctgaatca ctatgcctta 840 aagtcaaatg ctgtgcaaga ggctgattca gaattgaagc agttctcaaa aggggaaact 900 gaacaggacc tggaagcaga ttttccatca gactcctttg acccacttaa taaaggacag 960 ggaatccagg cacgttcccg aacaagacga cgacacagag atggcttccc ccaacccaga 1020 cgaagaggac ggaagaagtc tatagtggct gtggagccca ggagtcttat tcaaggagcc 1080 tttcaaggct gctcagtgtc cgggatgaca ctgaaataca tgtatggggt aaatgcttgg 1140 aagaactggg ttcagtggaa aaatgccaag gaagagcagg gggatctaaa atgtggaggg 1200 gttgaacagg cctcatctag cccacgttct gaccccttag gaagtactca agaccatgca 1260 ctctctcaag aatcctcaga gccaggctgt agagtccgct ctatcaagct gaaggaagac 1320 attctgtcct gcacttttgc tgagttgagt ttgggcttat gccagtttat ccaagaggtg 1380 cggagaccaa atggtgaaaa atatgatcca gacagtatct tatacttgtg ccttggaatt 1440 caacagtacc tgtttgaaaa tggtagaata gataacattt ttactgagcc ctattccaga 1500 tttatgattg aacttaccaa actcttgaaa atatgggaac ctacaatact tcctaatggt 1560 tacatgttct ctcgcattga ggaagagcat ttgtgggagt gcaaacagct gggcgcttac 1620 tcaccaatcg tccttttaaa caccctcctt ttcttcaata ccaaatactt ccaactaaag 1680 aatgttactg agcacttgaa gctttccttt gcccatgtga tgagacggac caggactctg 1740 aagtacagta ccaagatgac atatctgagg ttcttcccac ctttacagaa gcaggagtca 1800 gaaccagata aactgactgt tggcaagagg aaacgaaatg aagatgatga ggttccagtg 1860 ggggtggaga tggcagagaa tactgacaat ccactaagat gcccagtccg actttatgag 1920 ttttacctgt caaaatgttc tgaaagtgtg aagcaaagga atgatgtgtt ttaccttcaa 1980 cctgagcgct cctgtgtccc gaatagcccc atgtggtact ccgcattccc gatagaccct 2040 ggaaccctgg acaccatgtt aacacgtatt ctcatggtga gggaggtaca tgaagaactt 2100 gccaaagcca aatctgaaga ctctgatgtt gaattatcag at 2142 <210> SEQ ID NO 18 <211> LENGTH: 2662 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: sig_peptide <222> LOCATION: (6)..(53) <221> NAME/KEY: mat_peptide <222> LOCATION: (54)..(2147) <221> NAME/KEY: CDS <222> LOCATION: (6)..(2147) <400> SEQUENCE: 18 gggaa atg aaa cat ttc tgt aac ctg ctt tgt atc ttg atg ttc tgt aat 50 Met Lys His Phe Cys Asn Leu Leu Cys Ile Leu Met Phe Cys Asn -15 -10 -5 cag caa agt gta tgt gac ccg cct tca caa aat aat gca gca aat att 98 Gln Gln Ser Val Cys Asp Pro Pro Ser Gln Asn Asn Ala Ala Asn Ile -1 1 5 10 15 tcc atg gtt caa gct gct tca gca gga ccc cca tct ctg aga aaa gat 146 Ser Met Val Gln Ala Ala Ser Ala Gly Pro Pro Ser Leu Arg Lys Asp 20 25 30 tcg act cca gtt ata gcc aat gta gta tca ttg gca agt gcc cct gct 194 Ser Thr Pro Val Ile Ala Asn Val Val Ser Leu Ala Ser Ala Pro Ala 35 40 45 gct cag cct aca gtg aat tct aac agt gtc tta caa ggt gca gtt cca 242 Ala Gln Pro Thr Val Asn Ser Asn Ser Val Leu Gln Gly Ala Val Pro 50 55 60 aca gta aca gcg aaa atc atc ggt gat gca agt act caa aca gat gcc 290 Thr Val Thr Ala Lys Ile Ile Gly Asp Ala Ser Thr Gln Thr Asp Ala 65 70 75 ctg aaa ctg cca cct tcc caa cct cca agg ctt ttg aag aac aaa gct 338 Leu Lys Leu Pro Pro Ser Gln Pro Pro Arg Leu Leu Lys Asn Lys Ala 80 85 90 95 tta tta tgc aaa ccc atc aca cag act aaa gcc acc tct tgc aaa cca 386 Leu Leu Cys Lys Pro Ile Thr Gln Thr Lys Ala Thr Ser Cys Lys Pro 100 105 110 cat acc caa aac aaa gaa tgc cag aca gaa gac act cca agt cag ccc 434 His Thr Gln Asn Lys Glu Cys Gln Thr Glu Asp Thr Pro Ser Gln Pro 115 120 125 cag att att gtg gtg cca gtt ccc gta cca gtg ttt gtt ccc ata cct 482 Gln Ile Ile Val Val Pro Val Pro Val Pro Val Phe Val Pro Ile Pro 130 135 140 ctt cac ctt tat act caa tat gct cca gtc cca ttt gga att cca gtt 530 Leu His Leu Tyr Thr Gln Tyr Ala Pro Val Pro Phe Gly Ile Pro Val 145 150 155 cca atg cct gtc cct atg ctt att cca tct tca atg gat agt gaa gat 578 Pro Met Pro Val Pro Met Leu Ile Pro Ser Ser Met Asp Ser Glu Asp 160 165 170 175 aaa gtc aca gag agt att gaa gac att aaa gaa aag ctt ccc aca cat 626 Lys Val Thr Glu Ser Ile Glu Asp Ile Lys Glu Lys Leu Pro Thr His 180 185 190 cca ttt gaa gct gat ctc ctt gag atg gca gaa atg att gca gaa gat 674 Pro Phe Glu Ala Asp Leu Leu Glu Met Ala Glu Met Ile Ala Glu Asp 195 200 205 gaa gag aag aag act cta tct cag gga gag tcc caa act tct gaa cac 722 Glu Glu Lys Lys Thr Leu Ser Gln Gly Glu Ser Gln Thr Ser Glu His 210 215 220 gaa ctc ttt cta gac acc aag ata ttt gaa aaa gac caa gga agt aca 770 Glu Leu Phe Leu Asp Thr Lys Ile Phe Glu Lys Asp Gln Gly Ser Thr 225 230 235 tac agt ggt gat ctt gaa tca gag gca gta tct act cta cat agc tgg 818 Tyr Ser Gly Asp Leu Glu Ser Glu Ala Val Ser Thr Leu His Ser Trp 240 245 250 255 gag gaa gag ctg aat cac tat gcc tta aag tca aat gct gtg caa gag 866 Glu Glu Glu Leu Asn His Tyr Ala Leu Lys Ser Asn Ala Val Gln Glu 260 265 270 gct gat tca gaa ttg aag cag ttc tca aaa ggg gaa act gaa cag gac 914 Ala Asp Ser Glu Leu Lys Gln Phe Ser Lys Gly Glu Thr Glu Gln Asp 275 280 285 ctg gaa gca gat ttt cca tca gac tcc ttt gac cca ctt aat aaa gga 962 Leu Glu Ala Asp Phe Pro Ser Asp Ser Phe Asp Pro Leu Asn Lys Gly 290 295 300 cag gga atc cag gca cgt tcc cga aca aga cga cga cac aga gat ggc 1010 Gln Gly Ile Gln Ala Arg Ser Arg Thr Arg Arg Arg His Arg Asp Gly 305 310 315 ttc ccc caa ccc aga cga aga gga cgg aag aag tct ata gtg gct gtg 1058 Phe Pro Gln Pro Arg Arg Arg Gly Arg Lys Lys Ser Ile Val Ala Val 320 325 330 335 gag ccc agg agt ctt att caa gga gcc ttt caa ggc tgc tca gtg tcc 1106 Glu Pro Arg Ser Leu Ile Gln Gly Ala Phe Gln Gly Cys Ser Val Ser 340 345 350 ggg atg aca ctg aaa tac atg tat ggg gta aat gct tgg aag aac tgg 1154 Gly Met Thr Leu Lys Tyr Met Tyr Gly Val Asn Ala Trp Lys Asn Trp 355 360 365 gtt cag tgg aaa aat gcc aag gaa gag cag ggg gat cta aaa tgt gga 1202 Val Gln Trp Lys Asn Ala Lys Glu Glu Gln Gly Asp Leu Lys Cys Gly 370 375 380 ggg gtt gaa cag gcc tca tct agc cca cgt tct gac ccc tta gga agt 1250 Gly Val Glu Gln Ala Ser Ser Ser Pro Arg Ser Asp Pro Leu Gly Ser 385 390 395 act caa gac cat gca ctc tct caa gaa tcc tca gag cca ggc tgt aga 1298 Thr Gln Asp His Ala Leu Ser Gln Glu Ser Ser Glu Pro Gly Cys Arg 400 405 410 415 gtc cgc tct atc aag ctg aag gaa gac att ctg tcc tgc act ttt gct 1346 Val Arg Ser Ile Lys Leu Lys Glu Asp Ile Leu Ser Cys Thr Phe Ala 420 425 430 gag ttg agt ttg ggc tta tgc cag ttt atc caa gag gtg cgg aga cca 1394 Glu Leu Ser Leu Gly Leu Cys Gln Phe Ile Gln Glu Val Arg Arg Pro 435 440 445 aat ggt gaa aaa tat gat cca gac agt atc tta tac ttg tgc ctt gga 1442 Asn Gly Glu Lys Tyr Asp Pro Asp Ser Ile Leu Tyr Leu Cys Leu Gly 450 455 460 att caa cag tac ctg ttt gaa aat ggt aga ata gat aac att ttt act 1490 Ile Gln Gln Tyr Leu Phe Glu Asn Gly Arg Ile Asp Asn Ile Phe Thr 465 470 475 gag ccc tat tcc aga ttt atg att gaa ctt acc aaa ctc ttg aaa ata 1538 Glu Pro Tyr Ser Arg Phe Met Ile Glu Leu Thr Lys Leu Leu Lys Ile 480 485 490 495 tgg gaa cct aca ata ctt cct aat ggt tac atg ttc tct cgc att gag 1586 Trp Glu Pro Thr Ile Leu Pro Asn Gly Tyr Met Phe Ser Arg Ile Glu 500 505 510 gaa gag cat ttg tgg gag tgc aaa cag ctg ggc gct tac tca cca atc 1634 Glu Glu His Leu Trp Glu Cys Lys Gln Leu Gly Ala Tyr Ser Pro Ile 515 520 525 gtc ctt tta aac acc ctc ctt ttc ttc aat acc aaa tac ttc caa cta 1682 Val Leu Leu Asn Thr Leu Leu Phe Phe Asn Thr Lys Tyr Phe Gln Leu 530 535 540 aag aat gtt act gag cac ttg aag ctt tcc ttt gcc cat gtg atg aga 1730 Lys Asn Val Thr Glu His Leu Lys Leu Ser Phe Ala His Val Met Arg 545 550 555 cgg acc agg act ctg aag tac agt acc aag atg aca tat ctg agg ttc 1778 Arg Thr Arg Thr Leu Lys Tyr Ser Thr Lys Met Thr Tyr Leu Arg Phe 560 565 570 575 ttc cca cct tta cag aag cag gag tca gaa cca gat aaa ctg act gtt 1826 Phe Pro Pro Leu Gln Lys Gln Glu Ser Glu Pro Asp Lys Leu Thr Val 580 585 590 ggc aag agg aaa cga aat gaa gat gat gag gtt cca gtg ggg gtg gag 1874 Gly Lys Arg Lys Arg Asn Glu Asp Asp Glu Val Pro Val Gly Val Glu 595 600 605 atg gca gag aat act gac aat cca cta aga tgc cca gtc cga ctt tat 1922 Met Ala Glu Asn Thr Asp Asn Pro Leu Arg Cys Pro Val Arg Leu Tyr 610 615 620 gag ttt tac ctg tca aaa tgt tct gaa agt gtg aag caa agg aat gat 1970 Glu Phe Tyr Leu Ser Lys Cys Ser Glu Ser Val Lys Gln Arg Asn Asp 625 630 635 gtg ttt tac ctt caa cct gag cgc tcc tgt gtc ccg aat agc ccc atg 2018 Val Phe Tyr Leu Gln Pro Glu Arg Ser Cys Val Pro Asn Ser Pro Met 640 645 650 655 tgg tac tcc gca ttc ccg ata gac cct gga acc ctg gac acc atg tta 2066 Trp Tyr Ser Ala Phe Pro Ile Asp Pro Gly Thr Leu Asp Thr Met Leu 660 665 670 aca cgt att ctc atg gtg agg gag gta cat gaa gaa ctt gcc aaa gcc 2114 Thr Arg Ile Leu Met Val Arg Glu Val His Glu Glu Leu Ala Lys Ala 675 680 685 aaa tct gaa gac tct gat gtt gaa tta tca gat taaaacggaa gtgaggttct 2167 Lys Ser Glu Asp Ser Asp Val Glu Leu Ser Asp 690 695 tattttcata catattggta tgcaccaaac tgtgaatgca tccagctgtt ggaaaatgat 2227 gtataagtct aagtcctctt gacttgacca taagatcatg gaaaacagat gacttgtgaa 2287 ccccacagtg tggatgtgca aatgaaaatt gaaggaaaga atatgaactg agaaatgttc 2347 tttggcagtg atatagttct tagacatctt cagaatgact aatttctccg agtggtgcat 2407 aatcttattt tgtttgggag taacaaatcg tggaatattt ttaaggaaaa ctgttgtata 2467 aaactttacc atagtaacct tagaccttag agaggtagct ttggagtgaa actttggctg 2527 caataggcta ctttggcaag ccctccgtaa aagtcagagg agagatcagt acagagctaa 2587 gagtgacatc aaatgaggac tgtgggaccc agatttgaag acccaataaa aatactcaac 2647 tttttaaaaa aaaaa 2662 210> SEQ ID NO 19 <211> LENGTH: 81 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 19 Met Arg Thr Tyr His Tyr Ile Pro Leu Phe Ile Trp Thr Tyr Met Phe -20 -15 -10 His Thr Val Asp Thr Ile Leu Leu Gln Glu Lys Pro Asn Ser Tyr Leu -5 -1 1 5 Ser Ser Lys Lys Ile Ala Gly Leu Thr Lys Asp Asp Gly Lys Met Leu 10 15 20 Arg Arg Thr Lys Arg Gly Trp Met Trp Asn Gln Phe Phe Leu Leu Glu 25 30 35 40 Glu Tyr Thr Gly Thr Asp Thr Gln Tyr Val Gly Lys Val Arg Ile Phe 45 50 55 Val <210> SEQ ID NO 20 <211> LENGTH: 243 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 20 atgaggactt accattatat accattattc atctggacct atatgttcca tacagttgac 60 accatcctat tacaagaaaa acctaacagt tatttatcaa gcaaaaagat agcgggtctg 120 acaaaagatg acggtaaaat gctacgtcgc accaagcgtg gctggatgtg gaatcagttc 180 ttcttattgg aagagtacac aggtactgac acacaatatg taggcaaggt aagaattttt 240 gta 243 <210> SEQ ID NO 21 <211> LENGTH: 630 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: sig_peptide <222> LOCATION: (160)..(231) <221> NAME/KEY: mat_peptide <222> LOCATION: (232)..(402) <221> NAME/KEY: CDS <222> LOCATION: (160)..(402) <400> SEQUENCE: 21 aagatcagct gtgaagatac tataaaaagg gaagagaagg accgagacag aagcaacaac 60 ggaactgtca gtgcggagta gggctaaact cagttccatt gttaagcaag gaaaaacaaa 120 caatacattg aatttgacaa cccactgaag ttgcagata atg agg act tac cat 174 Met Arg Thr Tyr His -20 tat ata cca tta ttc atc tgg acc tat atg ttc cat aca gtt gac acc 222 Tyr Ile Pro Leu Phe Ile Trp Thr Tyr Met Phe His Thr Val Asp Thr -15 -10 -5 atc cta tta caa gaa aaa cct aac agt tat tta tca agc aaa aag ata 270 Ile Leu Leu Gln Glu Lys Pro Asn Ser Tyr Leu Ser Ser Lys Lys Ile -1 1 5 10 gcg ggt ctg aca aaa gat gac ggt aaa atg cta cgt cgc acc aag cgt 318 Ala Gly Leu Thr Lys Asp Asp Gly Lys Met Leu Arg Arg Thr Lys Arg 15 20 25 ggc tgg atg tgg aat cag ttc ttc tta ttg gaa gag tac aca ggt act 366 Gly Trp Met Trp Asn Gln Phe Phe Leu Leu Glu Glu Tyr Thr Gly Thr 30 35 40 45 gac aca caa tat gta ggc aag gta aga att ttt gta tgagaaatct 412 Asp Thr Gln Tyr Val Gly Lys Val Arg Ile Phe Val 50 55 aaaagctgaa agtgacagct atttattttt ttccagcaac ttttcttttc actagtgatt 472 attaaaaaat atttaactaa ttatgttctg aaggtgtgat attgcaaact attttagtgg 532 ggaagaacaa ggaaccatat ttgggttcta aatgtaaatc aatgtcaata ataagcgtaa 592 gctactaagt catatgtgga tggatgtgat cattatta 630 <210> SEQ ID NO 22 <211> LENGTH: 150 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 22 Met Arg Lys Thr Arg Leu Trp Gly Leu Leu Trp Met Leu Phe Val Ser -20 -15 -10 -5 Glu Leu Arg Ala Ala Thr Lys Leu Thr Glu Glu Lys Tyr Glu Leu Lys -1 1 5 10 Glu Gly Gln Thr Leu Asp Val Lys Cys Asp Tyr Thr Leu Glu Lys Phe 15 20 25 Ala Ser Ser Gln Lys Ala Trp Gln Ile Ile Arg Asp Gly Glu Met Pro 30 35 40 Lys Thr Leu Ala Cys Thr Glu Arg Pro Ser Lys Asn Ser His Pro Val 45 50 55 60 Gln Val Gly Arg Ile Ile Leu Glu Asp Tyr His Asp His Gly Leu Leu 65 70 75 Arg Val Arg Met Val Asn Leu Gln Val Glu Asp Ser Gly Leu Tyr Gln 80 85 90 Cys Val Ile Tyr Gln Pro Pro Lys Glu Pro His Met Leu Phe Asp Arg 95 100 105 Ile Arg Leu Val Val Thr Lys Gly Phe Arg Cys Ser Thr Leu Ser Phe 110 115 120 Ser Trp Leu Val Asp Ser 125 130 <210> SEQ ID NO 23 <211> LENGTH: 450 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 23 atgaggaaga ccaggctctg ggggctgctg tggatgctct ttgtctcaga actccgagct 60 gcaactaaat taactgagga aaagtatgaa ctgaaagagg ggcagaccct ggatgtgaaa 120 tgtgactaca cgctagagaa gtttgccagc agccagaaag cttggcagat aataagggac 180 ggagagatgc ccaagaccct ggcatgcaca gagaggcctt caaagaattc ccatccagtc 240 caagtgggga ggatcatact agaagactac catgatcatg gtttactgcg cgtccgaatg 300 gtcaaccttc aagtggaaga ttctggactg tatcagtgtg tgatctacca gcctcccaag 360 gagcctcaca tgctgttcga tcgcatccgc ttggtggtga ccaaggggtt ccggtgttca 420 acattgtcat tctcctggct ggtggattcc 450 <210> SEQ ID NO 24 <211> LENGTH: 701 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: sig_peptide <222> LOCATION: (19)..(78) <221> NAME/KEY: mat_peptide <222> LOCATION: (79)..(468) <221> NAME/KEY: CDS <222> LOCATION: (19)..(468) <400> SEQUENCE: 24 agctggtgca caggaagg atg agg aag acc agg ctc tgg ggg ctg ctg tgg 51 Met Arg Lys Thr Arg Leu Trp Gly Leu Leu Trp -20 -15 -10 atg ctc ttt gtc tca gaa ctc cga gct gca act aaa tta act gag gaa 99 Met Leu Phe Val Ser Glu Leu Arg Ala Ala Thr Lys Leu Thr Glu Glu -5 -1 1 5 aag tat gaa ctg aaa gag ggg cag acc ctg gat gtg aaa tgt gac tac 147 Lys Tyr Glu Leu Lys Glu Gly Gln Thr Leu Asp Val Lys Cys Asp Tyr 10 15 20 acg cta gag aag ttt gcc agc agc cag aaa gct tgg cag ata ata agg 195 Thr Leu Glu Lys Phe Ala Ser Ser Gln Lys Ala Trp Gln Ile Ile Arg 25 30 35 gac gga gag atg ccc aag acc ctg gca tgc aca gag agg cct tca aag 243 Asp Gly Glu Met Pro Lys Thr Leu Ala Cys Thr Glu Arg Pro Ser Lys 40 45 50 55 aat tcc cat cca gtc caa gtg ggg agg atc ata cta gaa gac tac cat 291 Asn Ser His Pro Val Gln Val Gly Arg Ile Ile Leu Glu Asp Tyr His 60 65 70 gat cat ggt tta ctg cgc gtc cga atg gtc aac ctt caa gtg gaa gat 339 Asp His Gly Leu Leu Arg Val Arg Met Val Asn Leu Gln Val Glu Asp 75 80 85 tct gga ctg tat cag tgt gtg atc tac cag cct ccc aag gag cct cac 387 Ser Gly Leu Tyr Gln Cys Val Ile Tyr Gln Pro Pro Lys Glu Pro His 90 95 100 atg ctg ttc gat cgc atc cgc ttg gtg gtg acc aag ggg ttc cgg tgt 435 Met Leu Phe Asp Arg Ile Arg Leu Val Val Thr Lys Gly Phe Arg Cys 105 110 115 tca aca ttg tca ttc tcc tgg ctg gtg gat tcc tgagtaagag cctggtcttc 488 Ser Thr Leu Ser Phe Ser Trp Leu Val Asp Ser 120 125 130 tctgtcctgt ttgctgtcac gctgaggtca tttgtaccct aggcccacga acccacgaga 548 atgtcctctg acttccagcc acatccatct ggcagttgtg ccaagggagg agggaggagg 608 taaaaggcag ggagttaata acatgaatta aatctgtaat caccagctaa agaaaaaaaa 668 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaa 701 <210> SEQ ID NO 25 <211> LENGTH: 422 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 25 Met Leu Gln Trp Arg Arg Arg His Cys Cys Phe Ala Lys Met Thr Trp -35 -30 -25 Asn Ala Lys Arg Ser Leu Phe Arg Thr His Leu Ile Gly Val Leu Ser -20 -15 -10 Leu Val Phe Leu Phe Ala Met Phe Leu Phe Phe Asn His His Asp Trp -5 -1 1 5 10 Leu Pro Gly Arg Ala Gly Phe Lys Glu Asn Pro Val Thr Tyr Thr Phe 15 20 25 Arg Gly Phe Arg Ser Thr Lys Ser Glu Thr Asn His Ser Ser Leu Arg 30 35 40 Asn Ile Trp Lys Glu Thr Val Pro Gln Thr Leu Arg Pro Gln Thr Ala 45 50 55 Thr Asn Ser Asn Asn Thr Asp Leu Ser Pro Gln Gly Val Thr Gly Leu 60 65 70 Glu Asn Thr Leu Ser Ala Asn Gly Ser Ile Tyr Asn Glu Lys Gly Thr 75 80 85 90 Gly His Pro Asn Ser Tyr His Phe Lys Tyr Ile Ile Asn Glu Pro Glu 95 100 105 Lys Cys Gln Glu Lys Ser Pro Phe Leu Ile Leu Leu Ile Ala Ala Glu 110 115 120 Pro Gly Gln Ile Glu Ala Arg Arg Ala Ile Arg Gln Thr Trp Gly Asn 125 130 135 Glu Ser Leu Ala Pro Gly Ile Gln Ile Thr Arg Ile Phe Leu Leu Gly 140 145 150 Leu Ser Ile Lys Leu Asn Gly Tyr Leu Gln Arg Ala Ile Leu Glu Glu 155 160 165 170 Ser Arg Gln Tyr His Asp Ile Ile Gln Gln Glu Tyr Leu Asp Thr Tyr 175 180 185 Tyr Asn Leu Thr Ile Lys Thr Leu Met Gly Met Asn Trp Val Ala Thr 190 195 200 Tyr Cys Pro His Ile Pro Tyr Val Met Lys Thr Asp Ser Asp Met Phe 205 210 215 Val Asn Thr Glu Tyr Leu Ile Asn Lys Leu Leu Lys Pro Asp Leu Pro 220 225 230 Pro Arg His Asn Tyr Phe Thr Gly Tyr Leu Met Arg Gly Tyr Ala Pro 235 240 245 250 Asn Arg Asn Lys Asp Ser Lys Trp Tyr Met Pro Pro Asp Leu Tyr Pro 255 260 265 Ser Glu Arg Tyr Pro Val Phe Cys Ser Gly Thr Gly Tyr Val Phe Ser 270 275 280 Gly Asp Leu Ala Glu Lys Ile Phe Lys Val Ser Leu Gly Ile Arg Arg 285 290 295 Leu His Leu Glu Asp Val Tyr Val Gly Ile Cys Leu Ala Lys Leu Arg 300 305 310 Ile Asp Pro Val Pro Pro Pro Asn Glu Phe Val Phe Asn His Trp Arg 315 320 325 330 Val Ser Tyr Ser Ser Cys Lys Tyr Ser His Leu Ile Thr Ser His Gln 335 340 345 Phe Gln Pro Ser Glu Leu Ile Lys Tyr Trp Asn His Leu Gln Gln Asn 350 355 360 Lys His Asn Ala Cys Ala Asn Ala Ala Lys Glu Lys Ala Gly Arg Tyr 365 370 375 Arg His Arg Lys Leu His 380 <210> SEQ ID NO 26 <211> LENGTH: 1266 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 26 atgcttcagt ggaggagaag acactgctgc tttgcaaaga tgacctggaa tgccaaaagg 60 tctctgttcc gcactcatct tattggagta ctttctctag tgtttctttt tgctatgttt 120 ttgtttttca atcatcatga ctggctgcca ggcagagctg gattcaaaga aaaccctgtg 180 acatacactt tccgaggatt tcggtcaaca aaaagtgaga caaaccacag ctcccttcgg 240 aacatttgga aagaaacagt ccctcaaacc ctgaggcctc aaacagcaac taactctaat 300 aacacagacc tgtcaccaca aggagttaca ggcctggaga atacacttag tgccaatgga 360 agtatttaca atgaaaaagg tactggacat ccaaattctt accatttcaa atatattatt 420 aatgagcctg aaaaatgcca agagaaaagt ccttttttaa tactactaat agctgcagag 480 cctggacaaa tagaagctag aagagctatt cggcaaactt ggggcaatga aagtctagca 540 cctggtattc aaatcacaag aatatttttg ttgggcttaa gtattaagct aaatggctac 600 cttcaacgtg caatactgga agaaagcaga caatatcatg atataattca acaggaatac 660 ttagatacgt actataattt gaccattaaa acactaatgg gcatgaactg ggttgcaaca 720 tactgtccac atattccata tgttatgaaa actgacagtg acatgtttgt caacactgaa 780 tatttaatca ataagttact gaagccagat ctgcctccca gacataacta tttcactggt 840 tacctaatgc gaggatatgc acccaatcga aacaaagata gcaagtggta catgccacca 900 gacctctacc caagtgagcg ttatcctgtc ttctgttctg gaactggtta tgttttttct 960 ggagatctgg cagaaaagat ttttaaagtt tctttaggta tccgccgttt gcacttggaa 1020 gatgtatatg tagggatctg tcttgccaag ttgagaattg atcctgtacc ccctcccaat 1080 gagtttgtgt tcaatcactg gcgagtctct tattcgagct gtaaatacag ccacctaatt 1140 acctctcatc agttccagcc tagtgaactg ataaaatact ggaaccattt acaacaaaat 1200 aagcacaatg cctgtgccaa cgcagcaaaa gaaaaggcag gcaggtatcg ccaccgtaaa 1260 ctacat 1266 <210> SEQ ID NO 27 <211> LENGTH: 2420 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: sig_peptide <222> LOCATION: (698)..(811) <221> NAME/KEY: mat_peptide <222> LOCATION: (812)..(1963) <221> NAME/KEY: CDS <222> LOCATION: (698)..(1963) <400> SEQUENCE: 27 gcctgtgcag cagctgagga accgtggatt tcatattata gactaaaacc ccattaaaac 60 tgctcaaaat ccttcctgca gctgccaggc aacaacgaaa gaagagaggt aaatcctatt 120 cttttccaat acaactgaag cactacattt tagctctggc tgctttacat tgcagctcag 180 tgttattagt agaaatatgg atactgagac gagaacacag cactgcattg tccagccagg 240 aaaatagcag atgtaaaaag cttcaatgca tcaactgtcg ggaagagtca acagtgctac 300 aagcagaacg ggcaactaca gctcttttgt ttaacgaaag agagaaaatg aaagaaaggg 360 aaaatttcag aagactagga cccatatgaa caaggagggt aactcgaaga caagcagaca 420 gatggacact ttggatactg tgaaaagcaa tcgcaggagg cagactgttg ggggatgtgc 480 gcatgttcga tagcatcttt tttgctgaag tgatggcgtg ccaaaagtat tttcagtggg 540 cataatcctc ttcacataaa tggcctgacc aaggaagaat gactacaaga gagacaatgt 600 gactgaatta gaaaatgatt gccaaagaat agtattaagg agaagaaaac atttttggtc 660 accaatctct catataccac tactggatat ttacaac atg ctt cag tgg agg aga 715 Met Leu Gln Trp Arg Arg -35 aga cac tgc tgc ttt gca aag atg acc tgg aat gcc aaa agg tct ctg 763 Arg His Cys Cys Phe Ala Lys Met Thr Trp Asn Ala Lys Arg Ser Leu -30 -25 -20 ttc cgc act cat ctt att gga gta ctt tct cta gtg ttt ctt ttt gct 811 Phe Arg Thr His Leu Ile Gly Val Leu Ser Leu Val Phe Leu Phe Ala -15 -10 -5 -1 atg ttt ttg ttt ttc aat cat cat gac tgg ctg cca ggc aga gct gga 859 Met Phe Leu Phe Phe Asn His His Asp Trp Leu Pro Gly Arg Ala Gly 1 5 10 15 ttc aaa gaa aac cct gtg aca tac act ttc cga gga ttt cgg tca aca 907 Phe Lys Glu Asn Pro Val Thr Tyr Thr Phe Arg Gly Phe Arg Ser Thr 20 25 30 aaa agt gag aca aac cac agc tcc ctt cgg aac att tgg aaa gaa aca 955 Lys Ser Glu Thr Asn His Ser Ser Leu Arg Asn Ile Trp Lys Glu Thr 35 40 45 gtc cct caa acc ctg agg cct caa aca gca act aac tct aat aac aca 1003 Val Pro Gln Thr Leu Arg Pro Gln Thr Ala Thr Asn Ser Asn Asn Thr 50 55 60 gac ctg tca cca caa gga gtt aca ggc ctg gag aat aca ctt agt gcc 1051 Asp Leu Ser Pro Gln Gly Val Thr Gly Leu Glu Asn Thr Leu Ser Ala 65 70 75 80 aat gga agt att tac aat gaa aaa ggt act gga cat cca aat tct tac 1099 Asn Gly Ser Ile Tyr Asn Glu Lys Gly Thr Gly His Pro Asn Ser Tyr 85 90 95 cat ttc aaa tat att att aat gag cct gaa aaa tgc caa gag aaa agt 1147 His Phe Lys Tyr Ile Ile Asn Glu Pro Glu Lys Cys Gln Glu Lys Ser 100 105 110 cct ttt tta ata cta cta ata gct gca gag cct gga caa ata gaa gct 1195 Pro Phe Leu Ile Leu Leu Ile Ala Ala Glu Pro Gly Gln Ile Glu Ala 115 120 125 aga aga gct att cgg caa act tgg ggc aat gaa agt cta gca cct ggt 1243 Arg Arg Ala Ile Arg Gln Thr Trp Gly Asn Glu Ser Leu Ala Pro Gly 130 135 140 att caa atc aca aga ata ttt ttg ttg ggc tta agt att aag cta aat 1291 Ile Gln Ile Thr Arg Ile Phe Leu Leu Gly Leu Ser Ile Lys Leu Asn 145 150 155 160 ggc tac ctt caa cgt gca ata ctg gaa gaa agc aga caa tat cat gat 1339 Gly Tyr Leu Gln Arg Ala Ile Leu Glu Glu Ser Arg Gln Tyr His Asp 165 170 175 ata att caa cag gaa tac tta gat acg tac tat aat ttg acc att aaa 1387 Ile Ile Gln Gln Glu Tyr Leu Asp Thr Tyr Tyr Asn Leu Thr Ile Lys 180 185 190 aca cta atg ggc atg aac tgg gtt gca aca tac tgt cca cat att cca 1435 Thr Leu Met Gly Met Asn Trp Val Ala Thr Tyr Cys Pro His Ile Pro 195 200 205 tat gtt atg aaa act gac agt gac atg ttt gtc aac act gaa tat tta 1483 Tyr Val Met Lys Thr Asp Ser Asp Met Phe Val Asn Thr Glu Tyr Leu 210 215 220 atc aat aag tta ctg aag cca gat ctg cct ccc aga cat aac tat ttc 1531 Ile Asn Lys Leu Leu Lys Pro Asp Leu Pro Pro Arg His Asn Tyr Phe 225 230 235 240 act ggt tac cta atg cga gga tat gca ccc aat cga aac aaa gat agc 1579 Thr Gly Tyr Leu Met Arg Gly Tyr Ala Pro Asn Arg Asn Lys Asp Ser 245 250 255 aag tgg tac atg cca cca gac ctc tac cca agt gag cgt tat cct gtc 1627 Lys Trp Tyr Met Pro Pro Asp Leu Tyr Pro Ser Glu Arg Tyr Pro Val 260 265 270 ttc tgt tct gga act ggt tat gtt ttt tct gga gat ctg gca gaa aag 1675 Phe Cys Ser Gly Thr Gly Tyr Val Phe Ser Gly Asp Leu Ala Glu Lys 275 280 285 att ttt aaa gtt tct tta ggt atc cgc cgt ttg cac ttg gaa gat gta 1723 Ile Phe Lys Val Ser Leu Gly Ile Arg Arg Leu His Leu Glu Asp Val 290 295 300 tat gta ggg atc tgt ctt gcc aag ttg aga att gat cct gta ccc cct 1771 Tyr Val Gly Ile Cys Leu Ala Lys Leu Arg Ile Asp Pro Val Pro Pro 305 310 315 320 ccc aat gag ttt gtg ttc aat cac tgg cga gtc tct tat tcg agc tgt 1819 Pro Asn Glu Phe Val Phe Asn His Trp Arg Val Ser Tyr Ser Ser Cys 325 330 335 aaa tac agc cac cta att acc tct cat cag ttc cag cct agt gaa ctg 1867 Lys Tyr Ser His Leu Ile Thr Ser His Gln Phe Gln Pro Ser Glu Leu 340 345 350 ata aaa tac tgg aac cat tta caa caa aat aag cac aat gcc tgt gcc 1915 Ile Lys Tyr Trp Asn His Leu Gln Gln Asn Lys His Asn Ala Cys Ala 355 360 365 aac gca gca aaa gaa aag gca ggc agg tat cgc cac cgt aaa cta cat 1963 Asn Ala Ala Lys Glu Lys Ala Gly Arg Tyr Arg His Arg Lys Leu His 370 375 380 tagaaaagac aatttttttt caaatgtgca atttgtaaat attgctaaaa gcatgtatag 2023 ttagaactga ttacatccgt aggacaagtt ttagttaaaa ctcatcacat aaagaaattc 2083 aagaagtatt tttttaattt ctgaagaagt taattcttaa aactataaca ttatataaca 2143 aaaaaggttt cccaaaacaa tctatttaaa aaactgtata aggagattct gtgtattaac 2203 atgcaataac aagcatgcat aaatcaatgg ttcaagtctt ctgttagggg ccaataaaat 2263 gtatctgcat atgttttcca cataaatttt aattcaagaa atgacagtca aaagatcctt 2323 cattttagat taagcttttc attttaatat ataatttaat gtaaataaaa catcactatc 2383 aattttaagg aaaaaaaaaa aaaaaaaaaa aaaaaaa 2420 <210> SEQ ID NO 28 <211> LENGTH: 521 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 28 Met Val Asn Ala Cys Trp Cys Gly Leu Leu Ala Ala Leu Ser Leu Leu -20 -15 -10 Leu Asp Ala Ser Thr Asp Glu Val Ala Thr Glu Asn Ile Leu Lys Ala -5 -1 1 5 10 Glu Leu Thr Met Ala Ala Leu Cys Gly Arg Leu Gly Leu Val Thr Ser 15 20 25 Arg Asp Ala Phe Ile Thr Ala Ile Cys Lys Gly Ser Leu Pro Pro His 30 35 40 Tyr Ala Leu Thr Val Leu Asn Thr Thr Thr Ala Ala Thr Leu Ser Asn 45 50 55 Lys Ser Tyr Ser Val Gln Gly Gln Ser Val Met Met Ile Ser Pro Ser 60 65 70 75 Ser Glu Ser His Gln Gln Val Val Ala Val Gly Gln Pro Leu Ala Val 80 85 90 Gln Pro Gln Gly Thr Val Met Leu Thr Ser Lys Asn Ile Gln Cys Met 95 100 105 Arg Thr Leu Leu Asn Leu Ala His Cys His Gly Ala Val Leu Gly Thr 110 115 120 Ser Trp Gln Leu Val Leu Ala Thr Leu Gln His Leu Val Trp Ile Leu 125 130 135 Gly Leu Lys Pro Ser Ser Gly Gly Ala Leu Lys Pro Gly Arg Ala Val 140 145 150 155 Glu Gly Pro Ser Thr Val Leu Thr Thr Ala Val Met Thr Asp Leu Pro 160 165 170 Val Ile Ser Asn Ile Leu Ser Arg Leu Phe Glu Ser Ser Gln Tyr Leu 175 180 185 Asp Asp Val Ser Leu His His Leu Ile Asn Ala Leu Cys Ser Leu Ser 190 195 200 Leu Glu Ala Met Asp Met Ala Tyr Gly Asn Asn Lys Glu Pro Ser Leu 205 210 215 Phe Ala Val Ala Lys Leu Leu Glu Thr Gly Leu Val Asn Met His Arg 220 225 230 235 Ile Glu Ile Leu Trp Arg Pro Leu Thr Gly His Leu Leu Glu Lys Val 240 245 250 Cys Gln His Pro Asn Ser Arg Met Gly Glu Trp Gly Ala Glu Ala Leu 255 260 265 Thr Ser Leu Ile Lys Ala Gly Leu Thr Phe Asn His Asp Pro Pro Leu 270 275 280 Ser Gln Asn Gln Arg Leu Gln Leu Leu Leu Leu Asn Pro Leu Lys Glu 285 290 295 Met Ser Asn Ile Asn His Pro Asp Ile Arg Leu Lys Gln Leu Glu Cys 300 305 310 315 Val Leu Gln Ile Leu Gln Ser Gln Gly Asp Asn Leu Gly Pro Gly Trp 320 325 330 Pro Leu Val Leu Gly Val Met Gly Ala Ile Arg Asn Asp Gln Gly Glu 335 340 345 Ser Leu Ile Arg Thr Ala Phe Gln Cys Leu Gln Leu Val Val Thr Asp 350 355 360 Phe Leu Pro Thr Met Pro Cys Thr Cys Leu Gln Ile Val Val Asp Val 365 370 375 Ala Gly Ser Phe Gly Leu His Asn Gln Glu Leu Asn Ile Ser Leu Thr 380 385 390 395 Ser Ile Gly Leu Leu Trp Asn Ile Ser Asp Tyr Phe Phe Gln Arg Gly 400 405 410 Glu Thr Ile Glu Lys Glu Leu Asn Lys Glu Glu Ala Ala Gln Gln Lys 415 420 425 Gln Ala Glu Glu Lys Gly Val Val Leu Asn Arg Pro Phe His Pro Ala 430 435 440 Pro Pro Phe Asp Cys Leu Trp Leu Cys Leu Tyr Ala Lys Leu Gly Glu 445 450 455 Leu Cys Val Asp Pro Arg Pro Ala Val Arg Lys Ser Ala Gly Gln Thr 460 465 470 475 Leu Phe Ser Thr Ile Gly Ala His Gly Thr Leu Leu Gln His Ser Thr 480 485 490 Trp Arg Thr Val Ile Trp Lys Val Leu 495 500 <210> SEQ ID NO 29 <211> LENGTH: 1563 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 29 atggtgaatg cctgctggtg tggtcttctt gctgcactct cactccttct tgatgccagc 60 acagatgaag ttgccactga gaatatttta aaagctgaac tgactatggc tgctctttgt 120 ggaagactgg gccttgtaac ttcaagagat gcctttataa ctgcaatatg caaaggttcc 180 ctgcctcccc attatgctct tactgtattg aataccacca ctgcagctac actttccaac 240 aaatcatatt ccgttcaggg ccaaagtgtt atgatgataa gtccatcaag tgaatctcac 300 caacaagttg tggcagtggg tcaaccttta gcagtccagc ctcaagggac agtaatgctg 360 acttccaaaa atatccagtg tatgaggact ttacttaact tggcgcattg ccatggggct 420 gttcttggaa catcatggca acttgtcttg gcaactcttc agcatcttgt gtggattctg 480 ggattaaagc ctagtagtgg cggtgccttg aaacctggga gagctgtaga aggacccagt 540 acagttctaa caacagcagt gatgacagat ttaccagtga tttccaatat actttcaaga 600 ttgtttgaaa gctcacagta tcttgatgat gtatcactgc atcatttaat aaatgcactt 660 tgctccttgt ctctagaagc aatggatatg gcctatggaa ataataagga accatctctt 720 tttgctgttg ccaaattgtt agaaactggt ttagttaata tgcaccgaat agaaattctg 780 tggagacctc tgactggcca tctacttgag aaggtctgcc agcatccaaa ctctcgaatg 840 ggagaatggg gagcagaagc tttaacttct cttattaaag caggattaac atttaaccat 900 gatcctccac tctcacaaaa ccagaggctg cagttgcttt tattgaaccc gttaaaggag 960 atgtccaata ttaatcatcc agatattcga ctcaagcagt tagaatgcgt gttgcagatt 1020 ctgcagagtc agggagacaa tcttgggcct ggatggccat tagtgcttgg agtcatggga 1080 gcaatcagaa atgatcaagg agaatccttg atacgaactg cattccagtg tcttcagttg 1140 gttgtgacag attttctacc aacaatgcct tgtacttgcc tgcaaatagt tgtagatgtt 1200 gcaggtagct ttggcctcca taaccaagaa ctcaatatta gtttaacttc aataggttta 1260 ttgtggaata tttcagatta ttttttccaa agaggggaaa ctattgaaaa agaactaaat 1320 aaggaagagg cagcacagca aaagcaggca gaagagaaag gagttgtttt aaatcggcca 1380 ttccaccctg caccgccatt tgattgcttg tggttatgtc tttatgcaaa attgggtgaa 1440 ctatgtgtgg atccccgtcc tgctgtcagg aagagtgcag ggcaaactct gttttctaca 1500 attggtgcgc atggaacttt attacagcat tcaacctggc gcactgttat ctggaaggta 1560 ttg 1563 <210> SEQ ID NO 30 <211> LENGTH: 1768 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: sig_peptide <222> LOCATION: (8)..(70) <221> NAME/KEY: mat_peptide <222> LOCATION: (71)..(1570) <221> NAME/KEY: CDS <222> LOCATION: (8)..(1570) <400> SEQUENCE: 30 ggaagaa atg gtg aat gcc tgc tgg tgt ggt ctt ctt gct gca ctc tca 49 Met Val Asn Ala Cys Trp Cys Gly Leu Leu Ala Ala Leu Ser -20 -15 -10 ctc ctt ctt gat gcc agc aca gat gaa gtt gcc act gag aat att tta 97 Leu Leu Leu Asp Ala Ser Thr Asp Glu Val Ala Thr Glu Asn Ile Leu -5 -1 1 5 aaa gct gaa ctg act atg gct gct ctt tgt gga aga ctg ggc ctt gta 145 Lys Ala Glu Leu Thr Met Ala Ala Leu Cys Gly Arg Leu Gly Leu Val 10 15 20 25 act tca aga gat gcc ttt ata act gca ata tgc aaa ggt tcc ctg cct 193 Thr Ser Arg Asp Ala Phe Ile Thr Ala Ile Cys Lys Gly Ser Leu Pro 30 35 40 ccc cat tat gct ctt act gta ttg aat acc acc act gca gct aca ctt 241 Pro His Tyr Ala Leu Thr Val Leu Asn Thr Thr Thr Ala Ala Thr Leu 45 50 55 tcc aac aaa tca tat tcc gtt cag ggc caa agt gtt atg atg ata agt 289 Ser Asn Lys Ser Tyr Ser Val Gln Gly Gln Ser Val Met Met Ile Ser 60 65 70 cca tca agt gaa tct cac caa caa gtt gtg gca gtg ggt caa cct tta 337 Pro Ser Ser Glu Ser His Gln Gln Val Val Ala Val Gly Gln Pro Leu 75 80 85 gca gtc cag cct caa ggg aca gta atg ctg act tcc aaa aat atc cag 385 Ala Val Gln Pro Gln Gly Thr Val Met Leu Thr Ser Lys Asn Ile Gln 90 95 100 105 tgt atg agg act tta ctt aac ttg gcg cat tgc cat ggg gct gtt ctt 433 Cys Met Arg Thr Leu Leu Asn Leu Ala His Cys His Gly Ala Val Leu 110 115 120 gga aca tca tgg caa ctt gtc ttg gca act ctt cag cat ctt gtg tgg 481 Gly Thr Ser Trp Gln Leu Val Leu Ala Thr Leu Gln His Leu Val Trp 125 130 135 att ctg gga tta aag cct agt agt ggc ggt gcc ttg aaa cct ggg aga 529 Ile Leu Gly Leu Lys Pro Ser Ser Gly Gly Ala Leu Lys Pro Gly Arg 140 145 150 gct gta gaa gga ccc agt aca gtt cta aca aca gca gtg atg aca gat 577 Ala Val Glu Gly Pro Ser Thr Val Leu Thr Thr Ala Val Met Thr Asp 155 160 165 tta cca gtg att tcc aat ata ctt tca aga ttg ttt gaa agc tca cag 625 Leu Pro Val Ile Ser Asn Ile Leu Ser Arg Leu Phe Glu Ser Ser Gln 170 175 180 185 tat ctt gat gat gta tca ctg cat cat tta ata aat gca ctt tgc tcc 673 Tyr Leu Asp Asp Val Ser Leu His His Leu Ile Asn Ala Leu Cys Ser 190 195 200 ttg tct cta gaa gca atg gat atg gcc tat gga aat aat aag gaa cca 721 Leu Ser Leu Glu Ala Met Asp Met Ala Tyr Gly Asn Asn Lys Glu Pro 205 210 215 tct ctt ttt gct gtt gcc aaa ttg tta gaa act ggt tta gtt aat atg 769 Ser Leu Phe Ala Val Ala Lys Leu Leu Glu Thr Gly Leu Val Asn Met 220 225 230 cac cga ata gaa att ctg tgg aga cct ctg act ggc cat cta ctt gag 817 His Arg Ile Glu Ile Leu Trp Arg Pro Leu Thr Gly His Leu Leu Glu 235 240 245 aag gtc tgc cag cat cca aac tct cga atg gga gaa tgg gga gca gaa 865 Lys Val Cys Gln His Pro Asn Ser Arg Met Gly Glu Trp Gly Ala Glu 250 255 260 265 gct tta act tct ctt att aaa gca gga tta aca ttt aac cat gat cct 913 Ala Leu Thr Ser Leu Ile Lys Ala Gly Leu Thr Phe Asn His Asp Pro 270 275 280 cca ctc tca caa aac cag agg ctg cag ttg ctt tta ttg aac ccg tta 961 Pro Leu Ser Gln Asn Gln Arg Leu Gln Leu Leu Leu Leu Asn Pro Leu 285 290 295 aag gag atg tcc aat att aat cat cca gat att cga ctc aag cag tta 1009 Lys Glu Met Ser Asn Ile Asn His Pro Asp Ile Arg Leu Lys Gln Leu 300 305 310 gaa tgc gtg ttg cag att ctg cag agt cag gga gac aat ctt ggg cct 1057 Glu Cys Val Leu Gln Ile Leu Gln Ser Gln Gly Asp Asn Leu Gly Pro 315 320 325 gga tgg cca tta gtg ctt gga gtc atg gga gca atc aga aat gat caa 1105 Gly Trp Pro Leu Val Leu Gly Val Met Gly Ala Ile Arg Asn Asp Gln 330 335 340 345 gga gaa tcc ttg ata cga act gca ttc cag tgt ctt cag ttg gtt gtg 1153 Gly Glu Ser Leu Ile Arg Thr Ala Phe Gln Cys Leu Gln Leu Val Val 350 355 360 aca gat ttt cta cca aca atg cct tgt act tgc ctg caa ata gtt gta 1201 Thr Asp Phe Leu Pro Thr Met Pro Cys Thr Cys Leu Gln Ile Val Val 365 370 375 gat gtt gca ggt agc ttt ggc ctc cat aac caa gaa ctc aat att agt 1249 Asp Val Ala Gly Ser Phe Gly Leu His Asn Gln Glu Leu Asn Ile Ser 380 385 390 tta act tca ata ggt tta ttg tgg aat att tca gat tat ttt ttc caa 1297 Leu Thr Ser Ile Gly Leu Leu Trp Asn Ile Ser Asp Tyr Phe Phe Gln 395 400 405 aga ggg gaa act att gaa aaa gaa cta aat aag gaa gag gca gca cag 1345 Arg Gly Glu Thr Ile Glu Lys Glu Leu Asn Lys Glu Glu Ala Ala Gln 410 415 420 425 caa aag cag gca gaa gag aaa gga gtt gtt tta aat cgg cca ttc cac 1393 Gln Lys Gln Ala Glu Glu Lys Gly Val Val Leu Asn Arg Pro Phe His 430 435 440 cct gca ccg cca ttt gat tgc ttg tgg tta tgt ctt tat gca aaa ttg 1441 Pro Ala Pro Pro Phe Asp Cys Leu Trp Leu Cys Leu Tyr Ala Lys Leu 445 450 455 ggt gaa cta tgt gtg gat ccc cgt cct gct gtc agg aag agt gca ggg 1489 Gly Glu Leu Cys Val Asp Pro Arg Pro Ala Val Arg Lys Ser Ala Gly 460 465 470 caa act ctg ttt tct aca att ggt gcg cat gga act tta tta cag cat 1537 Gln Thr Leu Phe Ser Thr Ile Gly Ala His Gly Thr Leu Leu Gln His 475 480 485 tca acc tgg cgc act gtt atc tgg aag gta ttg taaaatagat tggactatca 1590 Ser Thr Trp Arg Thr Val Ile Trp Lys Val Leu 490 495 500 gcttttaatg agtcatgctt atatattaat actttttcag ttaaacttat ttcttttaat 1650 ttttaaagaa tttccatgca tttgtgtatt tgacaaaaca ggaaataact gtgtcatatt 1710 gtaaattgta cctcataaag agcaaattaa atattaacag ccttaaaaaa aaaaaaaa 1768 <210> SEQ ID NO 31 <211> LENGTH: 459 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 31 Met Val Asn Ala Cys Trp Cys Gly Leu Leu Ala Ala Leu Ser Leu Leu -20 -15 -10 Leu Asp Ala Ser Thr Asp Glu Val Ala Thr Glu Asn Ile Leu Lys Ala -5 -1 1 5 10 Glu Leu Thr Met Ala Ala Leu Cys Gly Arg Leu Gly Leu Val Thr Ser 15 20 25 Arg Asp Ala Phe Ile Thr Ala Ile Cys Lys Gly Ser Leu Pro Pro His 30 35 40 Tyr Ala Leu Thr Val Leu Asn Thr Thr Thr Ala Ala Thr Leu Ser Asn 45 50 55 Lys Ser Tyr Ser Val Gln Gly Gln Ser Val Met Met Ile Ser Pro Ser 60 65 70 75 Ser Glu Ser His Gln Gln Val Val Ala Val Gly Gln Pro Leu Ala Val 80 85 90 Gln Pro Gln Gly Thr Val Met Leu Thr Ser Lys Asn Ile Gln Cys Met 95 100 105 Arg Thr Leu Leu Asn Leu Ala His Cys His Gly Ala Val Leu Gly Thr 110 115 120 Ser Trp Gln Leu Val Leu Ala Thr Leu Gln His Leu Val Trp Ile Leu 125 130 135 Gly Leu Lys Pro Ser Ser Gly Gly Ala Leu Lys Pro Gly Arg Ala Val 140 145 150 155 Glu Gly Pro Ser Thr Val Leu Thr Thr Ala Val Met Thr Asp Leu Pro 160 165 170 Val Ile Ser Asn Ile Leu Ser Arg Leu Phe Glu Ser Ser Arg Tyr Leu 175 180 185 Asp Asp Val Ser Leu His His Leu Ile Asn Ala Leu Cys Ser Leu Ser 190 195 200 Leu Glu Ala Met Asp Met Ala Tyr Gly Asn Asn Lys Glu Pro Ser Leu 205 210 215 Phe Ala Val Ala Lys Leu Leu Glu Thr Gly Leu Val Asn Met His Arg 220 225 230 235 Ile Glu Ile Leu Trp Arg Pro Leu Thr Gly His Leu Leu Glu Val Cys 240 245 250 Gln His Pro Asn Ser Arg Met Arg Glu Trp Gly Ala Glu Ala Leu Thr 255 260 265 Ser Leu Ile Lys Ala Gly Leu Thr Phe Asn His Asp Pro Pro Leu Ser 270 275 280 Gln Asn Gln Arg Leu Gln Leu Leu Leu Leu Asn Pro Leu Lys Glu Met 285 290 295 Ser Asn Ile Asn His Pro Asp Ile Arg Leu Lys Gln Leu Glu Cys Val 300 305 310 315 Leu Gln Ile Leu Gln Ser Gln Gly Asp Ser Leu Gly Pro Gly Trp Pro 320 325 330 Leu Val Leu Gly Val Met Gly Ala Ile Arg Asn Asp Gln Gly Glu Ser 335 340 345 Leu Ile Arg Thr Ala Phe Gln Cys Leu Gln Leu Val Val Thr Glu Ile 350 355 360 Ile Phe Val Leu Lys Ala Val Ser Thr Leu Ile Asp Ser Leu Lys Lys 365 370 375 Thr Gln Pro Glu Asn Val Asp Gly Asn Thr Trp Ala Gln Val Ile Ala 380 385 390 395 Leu Tyr Pro Thr Leu Val Glu Cys Ile Ala Cys Pro Ser Ser Glu Val 400 405 410 Cys Ser Ala Leu Lys Glu Ala Leu Val Pro Phe Lys Asp Phe Met Gln 415 420 425 Pro Pro Ala Ser Arg Val Gln Asn Gly Glu Ser 430 435 <210> SEQ ID NO 32 <211> LENGTH: 1377 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 32 atggtgaatg cctgctggtg tggtcttctt gctgcactct cactccttct tgatgccagc 60 acagatgaag ttgccactga gaatatttta aaagctgaac tgactatggc tgctctttgt 120 ggaagactgg gccttgtaac ttcaagagat gcctttataa ctgcaatatg caaaggttcc 180 ctgcctcccc attatgctct tactgtattg aataccacca ctgcagctac actttccaac 240 aaatcatatt ccgttcaggg ccaaagtgtt atgatgataa gtccatcaag tgaatctcac 300 caacaagttg tggcagtggg tcaaccttta gcagtccagc ctcaagggac agtaatgctg 360 acttccaaaa atatccagtg tatgaggact ttacttaact tggcgcattg ccatggggct 420 gttcttggaa catcatggca acttgtcttg gcaactcttc agcatcttgt gtggattctg 480 ggattaaagc ctagtagtgg cggtgccttg aaacctggga gagctgtaga aggacccagt 540 acagttctaa caacagcagt gatgacagat ttaccagtga tttccaatat actttcaaga 600 ttgtttgaaa gctcacggta tcttgatgat gtatcactgc atcatttaat aaatgcactt 660 tgctccttgt ctctagaagc aatggatatg gcctatggaa ataataagga accatctctt 720 tttgctgttg ccaaattgtt agaaactggt ttagttaata tgcaccgaat agaaattctg 780 tggagacctc tgactggcca tctacttgag gtctgccagc atccaaactc tcgaatgaga 840 gaatggggag cagaagcttt aacttctctt attaaagcag gattaacatt taaccatgat 900 cctccactct cacaaaacca gaggctgcag ttgcttttat tgaacccgtt aaaggagatg 960 tccaatatta atcatccaga tattcgactc aagcagttag aatgcgtgtt gcagattctg 1020 cagagtcagg gagacagtct tgggcctgga tggccattag tgcttggagt catgggagca 1080 atcagaaatg atcaaggaga atccttgata cgaactgcat tccagtgtct tcagttggtt 1140 gtaacagaaa ttatatttgt tttaaaagca gtcagtactc ttattgattc acttaagaaa 1200 actcagcctg agaatgttga tggaaatacc tgggcacaag taattgcctt atacccaact 1260 ttagtagaat gcatcgcctg tccttcttca gaagtctgtt ctgcacttaa agaggcacta 1320 gttcctttta aggatttcat gcagccacca gcatccagag ttcaaaatgg agaatct 1377 <210> SEQ ID NO 33 <211> LENGTH: 2009 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: sig_peptide <222> LOCATION: (8)..(70) <221> NAME/KEY: mat_peptide <222> LOCATION: (71)..(1384) <221> NAME/KEY: CDS <222> LOCATION: (8)..(1384) <400> SEQUENCE: 33 ggaagaa atg gtg aat gcc tgc tgg tgt ggt ctt ctt gct gca ctc tca 49 Met Val Asn Ala Cys Trp Cys Gly Leu Leu Ala Ala Leu Ser -20 -15 -10 ctc ctt ctt gat gcc agc aca gat gaa gtt gcc act gag aat att tta 97 Leu Leu Leu Asp Ala Ser Thr Asp Glu Val Ala Thr Glu Asn Ile Leu -5 -1 1 5 aaa gct gaa ctg act atg gct gct ctt tgt gga aga ctg ggc ctt gta 145 Lys Ala Glu Leu Thr Met Ala Ala Leu Cys Gly Arg Leu Gly Leu Val 10 15 20 25 act tca aga gat gcc ttt ata act gca ata tgc aaa ggt tcc ctg cct 193 Thr Ser Arg Asp Ala Phe Ile Thr Ala Ile Cys Lys Gly Ser Leu Pro 30 35 40 ccc cat tat gct ctt act gta ttg aat acc acc act gca gct aca ctt 241 Pro His Tyr Ala Leu Thr Val Leu Asn Thr Thr Thr Ala Ala Thr Leu 45 50 55 tcc aac aaa tca tat tcc gtt cag ggc caa agt gtt atg atg ata agt 289 Ser Asn Lys Ser Tyr Ser Val Gln Gly Gln Ser Val Met Met Ile Ser 60 65 70 cca tca agt gaa tct cac caa caa gtt gtg gca gtg ggt caa cct tta 337 Pro Ser Ser Glu Ser His Gln Gln Val Val Ala Val Gly Gln Pro Leu 75 80 85 gca gtc cag cct caa ggg aca gta atg ctg act tcc aaa aat atc cag 385 Ala Val Gln Pro Gln Gly Thr Val Met Leu Thr Ser Lys Asn Ile Gln 90 95 100 105 tgt atg agg act tta ctt aac ttg gcg cat tgc cat ggg gct gtt ctt 433 Cys Met Arg Thr Leu Leu Asn Leu Ala His Cys His Gly Ala Val Leu 110 115 120 gga aca tca tgg caa ctt gtc ttg gca act ctt cag cat ctt gtg tgg 481 Gly Thr Ser Trp Gln Leu Val Leu Ala Thr Leu Gln His Leu Val Trp 125 130 135 att ctg gga tta aag cct agt agt ggc ggt gcc ttg aaa cct ggg aga 529 Ile Leu Gly Leu Lys Pro Ser Ser Gly Gly Ala Leu Lys Pro Gly Arg 140 145 150 gct gta gaa gga ccc agt aca gtt cta aca aca gca gtg atg aca gat 577 Ala Val Glu Gly Pro Ser Thr Val Leu Thr Thr Ala Val Met Thr Asp 155 160 165 tta cca gtg att tcc aat ata ctt tca aga ttg ttt gaa agc tca cgg 625 Leu Pro Val Ile Ser Asn Ile Leu Ser Arg Leu Phe Glu Ser Ser Arg 170 175 180 185 tat ctt gat gat gta tca ctg cat cat tta ata aat gca ctt tgc tcc 673 Tyr Leu Asp Asp Val Ser Leu His His Leu Ile Asn Ala Leu Cys Ser 190 195 200 ttg tct cta gaa gca atg gat atg gcc tat gga aat aat aag gaa cca 721 Leu Ser Leu Glu Ala Met Asp Met Ala Tyr Gly Asn Asn Lys Glu Pro 205 210 215 tct ctt ttt gct gtt gcc aaa ttg tta gaa act ggt tta gtt aat atg 769 Ser Leu Phe Ala Val Ala Lys Leu Leu Glu Thr Gly Leu Val Asn Met 220 225 230 cac cga ata gaa att ctg tgg aga cct ctg act ggc cat cta ctt gag 817 His Arg Ile Glu Ile Leu Trp Arg Pro Leu Thr Gly His Leu Leu Glu 235 240 245 gtc tgc cag cat cca aac tct cga atg aga gaa tgg gga gca gaa gct 865 Val Cys Gln His Pro Asn Ser Arg Met Arg Glu Trp Gly Ala Glu Ala 250 255 260 265 tta act tct ctt att aaa gca gga tta aca ttt aac cat gat cct cca 913 Leu Thr Ser Leu Ile Lys Ala Gly Leu Thr Phe Asn His Asp Pro Pro 270 275 280 ctc tca caa aac cag agg ctg cag ttg ctt tta ttg aac ccg tta aag 961 Leu Ser Gln Asn Gln Arg Leu Gln Leu Leu Leu Leu Asn Pro Leu Lys 285 290 295 gag atg tcc aat att aat cat cca gat att cga ctc aag cag tta gaa 1009 Glu Met Ser Asn Ile Asn His Pro Asp Ile Arg Leu Lys Gln Leu Glu 300 305 310 tgc gtg ttg cag att ctg cag agt cag gga gac agt ctt ggg cct gga 1057 Cys Val Leu Gln Ile Leu Gln Ser Gln Gly Asp Ser Leu Gly Pro Gly 315 320 325 tgg cca tta gtg ctt gga gtc atg gga gca atc aga aat gat caa gga 1105 Trp Pro Leu Val Leu Gly Val Met Gly Ala Ile Arg Asn Asp Gln Gly 330 335 340 345 gaa tcc ttg ata cga act gca ttc cag tgt ctt cag ttg gtt gta aca 1153 Glu Ser Leu Ile Arg Thr Ala Phe Gln Cys Leu Gln Leu Val Val Thr 350 355 360 gaa att ata ttt gtt tta aaa gca gtc agt act ctt att gat tca ctt 1201 Glu Ile Ile Phe Val Leu Lys Ala Val Ser Thr Leu Ile Asp Ser Leu 365 370 375 aag aaa act cag cct gag aat gtt gat gga aat acc tgg gca caa gta 1249 Lys Lys Thr Gln Pro Glu Asn Val Asp Gly Asn Thr Trp Ala Gln Val 380 385 390 att gcc tta tac cca act tta gta gaa tgc atc gcc tgt cct tct tca 1297 Ile Ala Leu Tyr Pro Thr Leu Val Glu Cys Ile Ala Cys Pro Ser Ser 395 400 405 gaa gtc tgt tct gca ctt aaa gag gca cta gtt cct ttt aag gat ttc 1345 Glu Val Cys Ser Ala Leu Lys Glu Ala Leu Val Pro Phe Lys Asp Phe 410 415 420 425 atg cag cca cca gca tcc aga gtt caa aat gga gaa tct tgaccggcta 1394 Met Gln Pro Pro Ala Ser Arg Val Gln Asn Gly Glu Ser 430 435 caatatattt gaaagcagga agatagtcta aaaaatgttt gctcctaatt gagtcttctg 1454 tgagaaggac atttcttact gcagataatt cttggcagct gttgttggcc tcctttaaat 1514 tctacttacc tgagttcagt aattcatatt acaggcttgc acatcaacaa aggctcctga 1574 atgaacagca gtgcaaggct ttaataaatt aaactgatgg gagggataat taacactaca 1634 gtatacatgc taccatatct ccagttggtg atttaaagtg agcttatgta cagtttgtgg 1694 tgtatgtgtt aatgatgtac tttttaaaaa gaaagaagag atatttcaat tcagtcagat 1754 ttattagtct ggtgtttttg cacccttttt caagtacaaa atcgtactag aattttatgc 1814 aagatggtac tgtaacattc catattatct ataaccagcc tctgttaaca aagggaactg 1874 atatacttgt gtgtataata aatggtacag ttctgtataa aatagtgcat ttatttaaat 1934 tttaaaagta ttgataatgt taaatgctta aagctctatt tattactaaa aaaaaaaaaa 1994 aaaaaaaaaa aaaaa 2009 <210> SEQ ID NO 34 <211> LENGTH: 185 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 34 Met Phe Ser His Leu Pro Phe Asp Cys Val Leu Leu Leu Leu Leu Leu -20 -15 -10 Leu Leu Thr Arg Ser Ser Glu Val Glu Tyr Arg Ala Glu Val Gly Gln -5 -1 1 5 10 Asn Ala Tyr Leu Pro Cys Phe Tyr Thr Pro Ala Ala Pro Gly Asn Leu 15 20 25 Val Pro Val Cys Trp Gly Lys Gly Ala Cys Pro Val Phe Glu Cys Gly 30 35 40 Asn Val Val Leu Arg Thr Asp Glu Arg Asp Val Asn Tyr Trp Thr Ser 45 50 55 Arg Tyr Trp Leu Asn Gly Asp Phe Arg Lys Gly Asp Val Ser Leu Thr 60 65 70 75 Ile Glu Asn Val Thr Leu Ala Asp Ser Gly Ile Tyr Cys Cys Arg Ile 80 85 90 Gln Ile Pro Gly Ile Met Asn Asp Glu Lys Phe Asn Leu Lys Leu Val 95 100 105 Ile Lys Pro Ala Lys Val Thr Pro Ala Pro Thr Leu Gln Arg Asp Phe 110 115 120 Thr Ala Ala Phe Pro Arg Met Leu Thr Thr Arg Gly His Gly Pro Ala 125 130 135 Glu Thr Gln Thr Leu Gly Ser Leu Pro Asp Ile Asn Leu Thr Gly Ile 140 145 150 155 Leu Ile Ala Lys Arg Arg Tyr Arg Ile 160 <210> SEQ ID NO 35 <211> LENGTH: 555 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 35 atgttttcac atcttccctt tgactgtgtc ctgctgctgc tgctgctact acttacaagg 60 tcctcagaag tggaatacag agcggaggtc ggtcagaatg cctatctgcc ctgcttctac 120 accccagccg ccccagggaa cctcgtgccc gtctgctggg gcaaaggagc ctgtcctgtg 180 tttgaatgtg gcaacgtggt gctcaggact gatgaaaggg atgtgaatta ttggacatcc 240 agatactggc taaatgggga tttccgcaaa ggagatgtgt ccctgaccat agagaatgtg 300 actctagcag acagtgggat ctactgctgc cggatccaaa tcccaggcat aatgaatgat 360 gaaaaattta acctgaagtt ggtcatcaaa ccagccaagg tcacccctgc accgactctg 420 cagagagact tcactgcagc ctttccaagg atgcttacca ccaggggaca tggcccagca 480 gagacacaga cactggggag cctccctgat ataaatctaa caggtattct catagcaaag 540 agaagataca gaatt 555 <210> SEQ ID NO 36 <211> LENGTH: 2091 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: sig_peptide <222> LOCATION: (53)..(115) <221> NAME/KEY: mat_peptide <222> LOCATION: (116)..(607) <221> NAME/KEY: CDS <222> LOCATION: (53)..(607) <400> SEQUENCE: 36 gttaaaactg tgcctaacag aggtgtcctc tgacttttct tctgcaagct cc atg ttt 58 Met Phe -20 tca cat ctt ccc ttt gac tgt gtc ctg ctg ctg ctg ctg cta cta ctt 106 Ser His Leu Pro Phe Asp Cys Val Leu Leu Leu Leu Leu Leu Leu Leu -15 -10 -5 aca agg tcc tca gaa gtg gaa tac aga gcg gag gtc ggt cag aat gcc 154 Thr Arg Ser Ser Glu Val Glu Tyr Arg Ala Glu Val Gly Gln Asn Ala -1 1 5 10 tat ctg ccc tgc ttc tac acc cca gcc gcc cca ggg aac ctc gtg ccc 202 Tyr Leu Pro Cys Phe Tyr Thr Pro Ala Ala Pro Gly Asn Leu Val Pro 15 20 25 gtc tgc tgg ggc aaa gga gcc tgt cct gtg ttt gaa tgt ggc aac gtg 250 Val Cys Trp Gly Lys Gly Ala Cys Pro Val Phe Glu Cys Gly Asn Val 30 35 40 45 gtg ctc agg act gat gaa agg gat gtg aat tat tgg aca tcc aga tac 298 Val Leu Arg Thr Asp Glu Arg Asp Val Asn Tyr Trp Thr Ser Arg Tyr 50 55 60 tgg cta aat ggg gat ttc cgc aaa gga gat gtg tcc ctg acc ata gag 346 Trp Leu Asn Gly Asp Phe Arg Lys Gly Asp Val Ser Leu Thr Ile Glu 65 70 75 aat gtg act cta gca gac agt ggg atc tac tgc tgc cgg atc caa atc 394 Asn Val Thr Leu Ala Asp Ser Gly Ile Tyr Cys Cys Arg Ile Gln Ile 80 85 90 cca ggc ata atg aat gat gaa aaa ttt aac ctg aag ttg gtc atc aaa 442 Pro Gly Ile Met Asn Asp Glu Lys Phe Asn Leu Lys Leu Val Ile Lys 95 100 105 cca gcc aag gtc acc cct gca ccg act ctg cag aga gac ttc act gca 490 Pro Ala Lys Val Thr Pro Ala Pro Thr Leu Gln Arg Asp Phe Thr Ala 110 115 120 125 gcc ttt cca agg atg ctt acc acc agg gga cat ggc cca gca gag aca 538 Ala Phe Pro Arg Met Leu Thr Thr Arg Gly His Gly Pro Ala Glu Thr 130 135 140 cag aca ctg ggg agc ctc cct gat ata aat cta aca ggt att ctc ata 586 Gln Thr Leu Gly Ser Leu Pro Asp Ile Asn Leu Thr Gly Ile Leu Ile 145 150 155 gca aag aga aga tac aga att taagcctcat ctctttggcc aacctccctc 637 Ala Lys Arg Arg Tyr Arg Ile 160 cctcaggatt ggcaaatgca gtagcagagg gaattcgctc agaagaaaac atctatacca 697 ttgaagagaa cgtatatgaa gtggaggagc ccaatgagta ttattgctat gtcagcagca 757 ggcagcaacc ctcacaacct ttgggttgtc gctttgcaat gccatagatc caaccacctt 817 atttttgagc ttggtgtttt gtctttttca gaaactatga gctgtgtcac ctgactggtt 877 ttggaggttc tgtccactgc tatggagcag agttttccca ttttcagaag ataatgactc 937 acatgggaat tgaactggga cctgcactga acttaaacag gcatgtcatt gcctctgtat 997 ttaagccaac agagttaccc aacccagaga ctgttaatca tggatgttag agctcaaacg 1057 ggcttttata tacactagga attcttgacg tggggtctct ggagctccag gaaattcggg 1117 cacatcatat gtccatgaaa cttcagataa actagggaaa actgggtgct gaggtgaaag 1177 cataactttt ttggcacaga aagtctaaag gggccactga ttttcaaaga gatctgtgat 1237 ccctttttgt tttttgtttt tgagatggag tcttgctctg ttgcccaggc tggagtgcaa 1297 tggcacaatc tcggctcact gcaagccccg cctcctgggt tcaagcgatt ctcctgcctc 1357 agcctcctga gtggctggga ttacaggcat gcaccaccat gcccagctaa tttgttgtat 1417 ttttagtaga gacagggttt caccatgttg gccagtgtgg tctcaaactc ctgacctcat 1477 gatttgcctg cctcggcccc ccaaagcact gggattacag gcgtgagcca ccacatccag 1537 ccagtgatcc ttaaaagatt aagagatgac tggactaggt ctaccttgat cttgaagatt 1597 cccttggaat gttgagattt aggcttattt gagcactacc tgcccaactg tcagtgccag 1657 tgcatagccc ttcttttgtc tcccttatga agactgccct gcagggctga gatgtggcag 1717 gagctcccag ggaaaaagga agtgcatttg attggtgtgt attggccaag ttttgcttgt 1777 tgtgtgcttg aaagaaaata tctctgacca acttctgtat tcgtggacca aactgaagct 1837 atatttttca cagaagaaga agcagtgacg gggacacaaa ttctgttgcc tggtggaaag 1897 aaggcaaagg ccttcagcaa tctatattac cagcgctgga tcctttgaca gagagtggtc 1957 cctaaactta aatttcaaga cggtataggc ttgatctgtc ttgcttattg ttgccccctg 2017 cgcctagcac aattctgaca cacaattgga acttactaaa aatttttttt actgaaaaaa 2077 aaaaaaaaaa aaaa 2091 <210> SEQ ID NO 37 <211> LENGTH: 98 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 37 Met Val Arg Ile Leu Arg Thr Val Pro Phe Leu Pro Leu Leu Gly Gly -15 -10 -5 -1 Cys Ile Asp Asp Thr Ile Leu Ser Arg Gln Gly Phe Ile Asn Tyr Ser 1 5 10 15 Lys Leu Pro Ser Leu Pro Leu Val Gln Gly Glu Leu Val Gly Gly Leu 20 25 30 Thr Cys Leu Thr Ala Gln Thr His Ser Leu Leu Gln His Gln Pro Leu 35 40 45 Gln Leu Thr Thr Leu Leu Asp Gln Tyr Ile Arg Glu Gln Arg Glu Lys 50 55 60 Asp Ser Val Met Ser Ala Asn Gly Lys Pro Asp Pro Asp Thr Val Pro 65 70 75 80 Asp Ser <210> SEQ ID NO 38 <211> LENGTH: 294 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 38 atggtacgga tcttaaggac tgtgccattc ctgccgctgc taggtggctg cattgatgac 60 accatcctca gcaggcaggg ctttatcaac tactccaagc tccccagcct gcccctggtg 120 cagggggagc ttgtaggagg cctcacctgc ctcacagccc agacccactc cctgctccag 180 caccagcccc tccagctgac caccctgttg gaccagtaca tcagagagca acgcgagaag 240 gattctgtca tgtcggccaa tgggaagcca gatcctgaca ctgttccgga ctcg 294 <210> SEQ ID NO 39 <211> LENGTH: 1094 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: sig_peptide <222> LOCATION: (22)..(69) <221> NAME/KEY: mat_peptide <222> LOCATION: (70)..(315) <221> NAME/KEY: CDS <222> LOCATION: (22)..(315) <400> SEQUENCE: 39 gaagagccca aggtcaagga g atg gta cgg atc tta agg act gtg cca ttc 51 Met Val Arg Ile Leu Arg Thr Val Pro Phe -15 -10 ctg ccg ctg cta ggt ggc tgc att gat gac acc atc ctc agc agg cag 99 Leu Pro Leu Leu Gly Gly Cys Ile Asp Asp Thr Ile Leu Ser Arg Gln -5 -1 1 5 10 ggc ttt atc aac tac tcc aag ctc ccc agc ctg ccc ctg gtg cag ggg 147 Gly Phe Ile Asn Tyr Ser Lys Leu Pro Ser Leu Pro Leu Val Gln Gly 15 20 25 gag ctt gta gga ggc ctc acc tgc ctc aca gcc cag acc cac tcc ctg 195 Glu Leu Val Gly Gly Leu Thr Cys Leu Thr Ala Gln Thr His Ser Leu 30 35 40 ctc cag cac cag ccc ctc cag ctg acc acc ctg ttg gac cag tac atc 243 Leu Gln His Gln Pro Leu Gln Leu Thr Thr Leu Leu Asp Gln Tyr Ile 45 50 55 aga gag caa cgc gag aag gat tct gtc atg tcg gcc aat ggg aag cca 291 Arg Glu Gln Arg Glu Lys Asp Ser Val Met Ser Ala Asn Gly Lys Pro 60 65 70 gat cct gac act gtt ccg gac tcg tagccagcct gtttagccag ccctgcgcat 345 Asp Pro Asp Thr Val Pro Asp Ser 75 80 aaatacactc tgcgttattg gctgtgctct cctcaatggg acatgtggaa gaacttgggg 405 tcgaggagtg tgtttgtcac ttggttttca ctagtaatga tattgtcagg tatagggcca 465 cttggagatg cagaggattc catttcagat gtcagtcacc ggcttcgtcc ttagttttcc 525 caacttggga cgtgatagga gcaaagtctc tccattctcc aggtccaagg cagagatcct 585 gaaaagatag ggctattgtc ccctgcctcc ttggtcactg cctcttgctg cacgggctcc 645 tgagcccacc cccttggggc acaacctgcc actgccacag tagctcaacc aagcagttgt 705 gctgagaatg gcacctggtg agagcctgct gtgtgccagg ctttgtgctg agtgctgtac 765 atgtattagt tcctttactg ctgaccacat tgtacccatt tcacagagaa ggagcagaga 825 aattaagtgg cttgctcaag gtcatgcagt tagtaagtgg cagaacaggg acttggaacc 885 aagccctctg ctctgaagac cgcgtcctga atttcttcac tagagcttcc tcatcaggtt 945 acccagaagt gggtcccatc caccatccag gtgtgcttgg atgttagttc tccaccctcg 1005 aggtgtacgc tgtgaaaagt ttgggagcac tgctttataa taaaatgaaa tatattataa 1065 aaaaaaaaaa aaaaaaaaaa aaaaaaaaa 1094 <210> SEQ ID NO 40 <211> LENGTH: 474 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 40 Met Tyr Thr Val Gly Ala Pro His Thr Trp Pro His Ile Val Ala Ala -20 -15 -10 Leu Val Trp Leu Ile Asp Cys Ile Lys Ile His Thr Ala Met Lys Glu -5 -1 1 5 Ser Ser Pro Leu Phe Asp Asp Gly Gln Pro Trp Gly Glu Glu Thr Glu 10 15 20 25 Asp Gly Ile Met His Asn Lys Leu Phe Leu Asp Tyr Thr Ile Lys Cys 30 35 40 Tyr Glu Ser Phe Met Ser Gly Ala Asp Ser Phe Asp Glu Met Asn Ala 45 50 55 Glu Leu Gln Ser Lys Leu Lys Asp Leu Phe Asn Val Asp Ala Phe Lys 60 65 70 Leu Glu Ser Leu Glu Ala Lys Asn Arg Ala Leu Asn Glu Gln Ile Ala 75 80 85 Arg Leu Glu Gln Glu Arg Glu Lys Glu Pro Asn Arg Leu Glu Ser Leu 90 95 100 105 Arg Lys Leu Lys Ala Ser Leu Gln Gly Asp Val Gln Lys Tyr Gln Ala 110 115 120 Tyr Met Ser Asn Leu Glu Ser His Ser Ala Ile Leu Asp Gln Lys Leu 125 130 135 Asn Gly Leu Asn Glu Glu Ile Ala Arg Val Glu Leu Glu Cys Glu Thr 140 145 150 Ile Lys Gln Glu Asn Thr Arg Leu Gln Asn Ile Ile Asp Asn Gln Lys 155 160 165 Tyr Ser Val Ala Asp Ile Glu Arg Ile Asn His Glu Arg Asn Glu Leu 170 175 180 185 Gln Gln Thr Ile Asn Lys Leu Thr Lys Asp Leu Glu Ala Glu Gln Gln 190 195 200 Lys Leu Trp Asn Glu Glu Leu Lys Tyr Ala Arg Gly Lys Glu Ala Ile 205 210 215 Glu Thr Gln Leu Ala Glu Tyr His Lys Leu Ala Arg Lys Leu Lys Leu 220 225 230 Ile Pro Lys Gly Ala Glu Asn Ser Lys Gly Tyr Asp Phe Glu Ile Lys 235 240 245 Phe Asn Pro Glu Ala Gly Ala Asn Cys Leu Val Lys Tyr Arg Ala Gln 250 255 260 265 Val Tyr Val Pro Leu Lys Glu Leu Leu Asn Glu Thr Glu Glu Glu Ile 270 275 280 Asn Lys Ala Leu Asn Lys Lys Met Gly Leu Glu Asp Thr Leu Glu Gln 285 290 295 Leu Asn Ala Met Ile Thr Glu Ser Lys Arg Ser Val Gly Thr Leu Lys 300 305 310 Glu Glu Val Gln Lys Leu Asp Asp Leu Tyr Gln Gln Lys Ile Lys Glu 315 320 325 Ala Glu Glu Glu Asp Glu Lys Cys Ala Ser Glu Leu Glu Ser Leu Glu 330 335 340 345 Lys His Lys His Leu Leu Glu Ser Thr Val Asn Gln Gly Leu Ser Glu 350 355 360 Ala Met Asn Glu Leu Asp Ala Val Gln Arg Glu Tyr Gln Leu Val Val 365 370 375 Gln Thr Thr Thr Glu Glu Arg Arg Lys Val Gly Asn Asn Leu Gln Arg 380 385 390 Leu Leu Glu Met Val Ala Thr His Val Gly Ser Val Glu Lys His Leu 395 400 405 Glu Glu Gln Ile Ala Lys Val Asp Arg Glu Tyr Glu Glu Cys Met Ser 410 415 420 425 Glu Asp Leu Ser Glu Asn Ile Lys Glu Ile Arg Asp Lys Tyr Glu Lys 430 435 440 Lys Ala Thr Leu Ile Lys Ser Ser Glu Glu 445 450 <210> SEQ ID NO 41 <211> LENGTH: 1422 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 41 atgtacacag tgggggctcc tcatacatgg cctcacattg tggcagcctt agtttggcta 60 atagactgca tcaagataca tactgccatg aaagaaagct cacctttatt tgatgatggg 120 cagccttggg gagaagaaac tgaagatgga attatgcata ataagttgtt tttggactac 180 accataaaat gctatgagag ttttatgagt ggtgccgaca gctttgatga gatgaatgca 240 gagctgcagt caaaactgaa ggatttattt aatgtggatg cttttaagct ggaatcatta 300 gaagcaaaaa acagagcatt gaatgaacag attgcaagat tggaacaaga aagagaaaaa 360 gaaccgaatc gtctagagtc gttgagaaaa ctgaaggctt ccttacaagg agatgttcaa 420 aagtatcagg catacatgag caatttggag tctcattcag ccattcttga ccagaaatta 480 aatggtctca atgaggaaat tgctagagta gaactagaat gtgaaacaat aaaacaggag 540 aacactcgac tacagaatat cattgacaac cagaagtact cagttgcaga cattgagcga 600 ataaatcatg aaagaaatga attgcagcag actattaata aattaaccaa ggacctggaa 660 gctgaacaac agaagttgtg gaatgaggag ttaaaatatg ccagaggcaa agaagcgatt 720 gaaacacaat tagcagagta tcacaaattg gctagaaaat taaaacttat tcctaaaggt 780 gctgagaatt ccaaaggtta tgactttgaa attaagttta atcccgaggc tggtgccaac 840 tgccttgtca aatacagggc tcaagtttat gtacctctta aggaactcct gaatgaaact 900 gaagaagaaa ttaataaagc cctaaataaa aaaatgggtt tggaggatac tttagaacaa 960 ttgaatgcaa tgataacaga aagcaagaga agtgtgggaa ctctgaaaga agaagttcaa 1020 aagctggatg atctttacca acaaaaaatt aaggaagcag aggaagagga tgaaaaatgt 1080 gccagtgagc ttgagtcctt ggagaaacac aagcacctgc tagaaagtac tgttaaccag 1140 gggctcagtg aagctatgaa tgaattagat gctgttcagc gggaatacca actagttgtg 1200 caaaccacga ctgaagaaag acgaaaagtg ggaaataact tgcaacgtct gttagagatg 1260 gttgctacac atgttgggtc tgtagagaaa catcttgagg agcagattgc taaagttgat 1320 agagaatatg aagaatgcat gtcagaagat ctctcggaaa atattaaaga gattagagat 1380 aagtatgaga agaaagctac tctaattaag tcttctgaag aa 1422 <210> SEQ ID NO 42 <211> LENGTH: 1613 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: sig_peptide <222> LOCATION: (99)..(167) <221> NAME/KEY: mat_peptide <222> LOCATION: (168)..(1520) <221> NAME/KEY: CDS <222> LOCATION: (99)..(1520) <400> SEQUENCE: 42 tgtgcccctc atacgaactt cctgacacaa agtttgaaga agaggttcca agaatcttta 60 aagaccttgg gtatcctttt gcactatcca aaagctcc atg tac aca gtg ggg gct 116 Met Tyr Thr Val Gly Ala -20 cct cat aca tgg cct cac att gtg gca gcc tta gtt tgg cta ata gac 164 Pro His Thr Trp Pro His Ile Val Ala Ala Leu Val Trp Leu Ile Asp -15 -10 -5 tgc atc aag ata cat act gcc atg aaa gaa agc tca cct tta ttt gat 212 Cys Ile Lys Ile His Thr Ala Met Lys Glu Ser Ser Pro Leu Phe Asp -1 1 5 10 15 gat ggg cag cct tgg gga gaa gaa act gaa gat gga att atg cat aat 260 Asp Gly Gln Pro Trp Gly Glu Glu Thr Glu Asp Gly Ile Met His Asn 20 25 30 aag ttg ttt ttg gac tac acc ata aaa tgc tat gag agt ttt atg agt 308 Lys Leu Phe Leu Asp Tyr Thr Ile Lys Cys Tyr Glu Ser Phe Met Ser 35 40 45 ggt gcc gac agc ttt gat gag atg aat gca gag ctg cag tca aaa ctg 356 Gly Ala Asp Ser Phe Asp Glu Met Asn Ala Glu Leu Gln Ser Lys Leu 50 55 60 aag gat tta ttt aat gtg gat gct ttt aag ctg gaa tca tta gaa gca 404 Lys Asp Leu Phe Asn Val Asp Ala Phe Lys Leu Glu Ser Leu Glu Ala 65 70 75 aaa aac aga gca ttg aat gaa cag att gca aga ttg gaa caa gaa aga 452 Lys Asn Arg Ala Leu Asn Glu Gln Ile Ala Arg Leu Glu Gln Glu Arg 80 85 90 95 gaa aaa gaa ccg aat cgt cta gag tcg ttg aga aaa ctg aag gct tcc 500 Glu Lys Glu Pro Asn Arg Leu Glu Ser Leu Arg Lys Leu Lys Ala Ser 100 105 110 tta caa gga gat gtt caa aag tat cag gca tac atg agc aat ttg gag 548 Leu Gln Gly Asp Val Gln Lys Tyr Gln Ala Tyr Met Ser Asn Leu Glu 115 120 125 tct cat tca gcc att ctt gac cag aaa tta aat ggt ctc aat gag gaa 596 Ser His Ser Ala Ile Leu Asp Gln Lys Leu Asn Gly Leu Asn Glu Glu 130 135 140 att gct aga gta gaa cta gaa tgt gaa aca ata aaa cag gag aac act 644 Ile Ala Arg Val Glu Leu Glu Cys Glu Thr Ile Lys Gln Glu Asn Thr 145 150 155 cga cta cag aat atc att gac aac cag aag tac tca gtt gca gac att 692 Arg Leu Gln Asn Ile Ile Asp Asn Gln Lys Tyr Ser Val Ala Asp Ile 160 165 170 175 gag cga ata aat cat gaa aga aat gaa ttg cag cag act att aat aaa 740 Glu Arg Ile Asn His Glu Arg Asn Glu Leu Gln Gln Thr Ile Asn Lys 180 185 190 tta acc aag gac ctg gaa gct gaa caa cag aag ttg tgg aat gag gag 788 Leu Thr Lys Asp Leu Glu Ala Glu Gln Gln Lys Leu Trp Asn Glu Glu 195 200 205 tta aaa tat gcc aga ggc aaa gaa gcg att gaa aca caa tta gca gag 836 Leu Lys Tyr Ala Arg Gly Lys Glu Ala Ile Glu Thr Gln Leu Ala Glu 210 215 220 tat cac aaa ttg gct aga aaa tta aaa ctt att cct aaa ggt gct gag 884 Tyr His Lys Leu Ala Arg Lys Leu Lys Leu Ile Pro Lys Gly Ala Glu 225 230 235 aat tcc aaa ggt tat gac ttt gaa att aag ttt aat ccc gag gct ggt 932 Asn Ser Lys Gly Tyr Asp Phe Glu Ile Lys Phe Asn Pro Glu Ala Gly 240 245 250 255 gcc aac tgc ctt gtc aaa tac agg gct caa gtt tat gta cct ctt aag 980 Ala Asn Cys Leu Val Lys Tyr Arg Ala Gln Val Tyr Val Pro Leu Lys 260 265 270 gaa ctc ctg aat gaa act gaa gaa gaa att aat aaa gcc cta aat aaa 1028 Glu Leu Leu Asn Glu Thr Glu Glu Glu Ile Asn Lys Ala Leu Asn Lys 275 280 285 aaa atg ggt ttg gag gat act tta gaa caa ttg aat gca atg ata aca 1076 Lys Met Gly Leu Glu Asp Thr Leu Glu Gln Leu Asn Ala Met Ile Thr 290 295 300 gaa agc aag aga agt gtg gga act ctg aaa gaa gaa gtt caa aag ctg 1124 Glu Ser Lys Arg Ser Val Gly Thr Leu Lys Glu Glu Val Gln Lys Leu 305 310 315 gat gat ctt tac caa caa aaa att aag gaa gca gag gaa gag gat gaa 1172 Asp Asp Leu Tyr Gln Gln Lys Ile Lys Glu Ala Glu Glu Glu Asp Glu 320 325 330 335 aaa tgt gcc agt gag ctt gag tcc ttg gag aaa cac aag cac ctg cta 1220 Lys Cys Ala Ser Glu Leu Glu Ser Leu Glu Lys His Lys His Leu Leu 340 345 350 gaa agt act gtt aac cag ggg ctc agt gaa gct atg aat gaa tta gat 1268 Glu Ser Thr Val Asn Gln Gly Leu Ser Glu Ala Met Asn Glu Leu Asp 355 360 365 gct gtt cag cgg gaa tac caa cta gtt gtg caa acc acg act gaa gaa 1316 Ala Val Gln Arg Glu Tyr Gln Leu Val Val Gln Thr Thr Thr Glu Glu 370 375 380 aga cga aaa gtg gga aat aac ttg caa cgt ctg tta gag atg gtt gct 1364 Arg Arg Lys Val Gly Asn Asn Leu Gln Arg Leu Leu Glu Met Val Ala 385 390 395 aca cat gtt ggg tct gta gag aaa cat ctt gag gag cag att gct aaa 1412 Thr His Val Gly Ser Val Glu Lys His Leu Glu Glu Gln Ile Ala Lys 400 405 410 415 gtt gat aga gaa tat gaa gaa tgc atg tca gaa gat ctc tcg gaa aat 1460 Val Asp Arg Glu Tyr Glu Glu Cys Met Ser Glu Asp Leu Ser Glu Asn 420 425 430 att aaa gag att aga gat aag tat gag aag aaa gct act cta att aag 1508 Ile Lys Glu Ile Arg Asp Lys Tyr Glu Lys Lys Ala Thr Leu Ile Lys 435 440 445 tct tct gaa gaa tgaagataaa atgttgatca tgtatatata tccatagtga 1560 Ser Ser Glu Glu 450 ataaaattgt ctcagtaaag taaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaa 1613 <210> SEQ ID NO 43 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 43 Met Tyr Tyr Ile Leu Ile Tyr Pro Phe Pro Leu Phe Leu Phe Leu Leu -20 -15 -10 Ser Leu Leu Ile Tyr Asn Gln Lys Met Lys Lys Ser Val His Leu Val -5 -1 1 5 10 Phe Asp Leu Pro Lys His Leu Val Asn Leu Ile Phe Val Thr Leu Trp 15 20 25 Met Val Asn Leu Thr Phe Thr Gln Val Gly Phe Cys Phe Val Glu Asn 30 35 40 Asp Leu Leu Gly Gly Thr Thr Thr Thr Glu Arg Thr Lys Leu 45 50 55 <210> SEQ ID NO 44 <211> LENGTH: 234 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 44 atgtattata ttttaatcta tccttttcct ttgtttttgt tcttattatc tcttctgata 60 tataaccaaa aaatgaaaaa atctgtacac ttggtgtttg atttacctaa gcacctagtt 120 aatttaatct ttgtaacact ttggatggtt aacttaacct ttactcaagt tggtttttgt 180 tttgttgaaa atgacttact tggtggaacc actactactg aaagaacgaa actt 234 <210> SEQ ID NO 45 <211> LENGTH: 511 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: sig_peptide <222> LOCATION: (49)..(114) <221> NAME/KEY: mat_peptide <222> LOCATION: (115)..(282) <221> NAME/KEY: CDS <222> LOCATION: (49)..(282) <400> SEQUENCE: 45 attttatcaa ttgtttgtat ttccctttaa ggtaacattt taaatgaa atg tat tat 57 Met Tyr Tyr -20 att tta atc tat cct ttt cct ttg ttt ttg ttc tta tta tct ctt ctg 105 Ile Leu Ile Tyr Pro Phe Pro Leu Phe Leu Phe Leu Leu Ser Leu Leu -15 -10 -5 ata tat aac caa aaa atg aaa aaa tct gta cac ttg gtg ttt gat tta 153 Ile Tyr Asn Gln Lys Met Lys Lys Ser Val His Leu Val Phe Asp Leu -1 1 5 10 cct aag cac cta gtt aat tta atc ttt gta aca ctt tgg atg gtt aac 201 Pro Lys His Leu Val Asn Leu Ile Phe Val Thr Leu Trp Met Val Asn 15 20 25 tta acc ttt act caa gtt ggt ttt tgt ttt gtt gaa aat gac tta ctt 249 Leu Thr Phe Thr Gln Val Gly Phe Cys Phe Val Glu Asn Asp Leu Leu 30 35 40 45 ggt gga acc act act act gaa aga acg aaa ctt tgatattaca ttgttaagta 302 Gly Gly Thr Thr Thr Thr Glu Arg Thr Lys Leu 50 55 tcagagctgt tacagagcaa gtccttttaa agagatgtaa aaattaagta cctgtgccaa 362 actgattttt attagaaacc ctgttttctt taagtaaaag tatattctac cagcatggct 422 tggtaagaaa aatcccctat ctttttttcc ctgtcctcaa aattcagaat ttttccggaa 482 aaaaaaaaaa aaaaaaaaaa aaaaaaaaa 511 <210> SEQ ID NO 46 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 46 Met Gln Phe Met Asn Leu Leu Val Gly Phe Ser Cys Ser Trp Gly Asn -15 -10 -5 -1 1 Thr Cys Ala Cys His Thr Arg Pro Phe Leu Ala Pro Ser Val Phe Ser 5 10 15 Leu Cys Asp Gly Gly Leu Ile Val Ser Val Phe Thr Gln Gly Trp Phe 20 25 30 Pro Gly Cys Thr Ala Pro Val Pro Thr Pro Thr Val Pro Leu Ile Arg 35 40 45 Cys His Asp Phe Ser Ala Thr Ser Pro 50 55 <210> SEQ ID NO 47 <211> LENGTH: 219 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 47 atgcagttca tgaacttgct ggttggtttt tcctgctcct ggggtaacac atgcgcttgt 60 catacacgcc ccttccttgc cccttcagta ttctctcttt gcgatggagg tctcatagtg 120 agtgtcttca ctcaagggtg gtttcctggc tgcacggcac ctgttccaac acctactgtg 180 cctctcatca ggtgtcacga tttttctgcc acttcacct 219 <210> SEQ ID NO 48 <211> LENGTH: 903 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: sig_peptide <222> LOCATION: (31)..(75) <221> NAME/KEY: mat_peptide <222> LOCATION: (76)..(249) <221> NAME/KEY: CDS <222> LOCATION: (31)..(249) <400> SEQUENCE: 48 ggagtttcgt aagcaaaata gaggacagaa atg cag ttc atg aac ttg ctg gtt 54 Met Gln Phe Met Asn Leu Leu Val -15 -10 ggt ttt tcc tgc tcc tgg ggt aac aca tgc gct tgt cat aca cgc ccc 102 Gly Phe Ser Cys Ser Trp Gly Asn Thr Cys Ala Cys His Thr Arg Pro -5 -1 1 5 ttc ctt gcc cct tca gta ttc tct ctt tgc gat gga ggt ctc ata gtg 150 Phe Leu Ala Pro Ser Val Phe Ser Leu Cys Asp Gly Gly Leu Ile Val 10 15 20 25 agt gtc ttc act caa ggg tgg ttt cct ggc tgc acg gca cct gtt cca 198 Ser Val Phe Thr Gln Gly Trp Phe Pro Gly Cys Thr Ala Pro Val Pro 30 35 40 aca cct act gtg cct ctc atc agg tgt cac gat ttt tct gcc act tca 246 Thr Pro Thr Val Pro Leu Ile Arg Cys His Asp Phe Ser Ala Thr Ser 45 50 55 cct tagggagctt ccagtgattg attttaggag gcccacgcca agctccccag 299 Pro gaaatgactg ccttccttgg gaccaaggac cgttccaacg gcattcactg ccagttctaa 359 taggcgagga aaatgcccga ggcgctgtct tctgtccccc acacgtacca gaaagtgaaa 419 aatgcagcga gtcctctggg cggttatgag cctccaggcg catgctgtcc agttggacgg 479 aacatctggc ggttggttga ttgctctctt ttgtcttggt cgctgcttct agaatctatg 539 caggggatag cagtgaggtc agaagtcttt cccgggagag agatggcctg ggttatcatt 599 gctgatagct ttggctgcat gagttgggct tccccttacc cagggctgca cagccaggtg 659 tgggggtcac cggcaggtgg gctggtggct gcagcctcag agccctccca ggttgctgct 719 gtttccagtg aatcacattt cgtcatttga agcccatgag gaccattgtg tggatccatg 779 gtgattctag acttcagata tatttaggaa ggcgcagatt tcaaatctgt gtttgatttt 839 ctgtaataag agaaatccaa tttgtaaaac ttgaaaaaaa aaaaaaaaaa aaaaaaaaaa 899 aaaa 903 <210> SEQ ID NO 49 <211> LENGTH: 421 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 49 Met Arg Trp Ile Leu Phe Ile Gly Ala Leu Ile Gly Ser Ser Ile Cys -15 -10 -5 -1 Gly Gln Glu Lys Phe Phe Gly Asp Gln Val Phe Arg Ile Asn Val Arg 1 5 10 15 Asn Gly Asp Glu Ile Ser Lys Leu Ser Gln Leu Val Asn Ser Asn Asn 20 25 30 Leu Lys Leu Asn Phe Trp Lys Ser Pro Ser Ser Phe Asn Arg Pro Val 35 40 45 Asp Val Leu Val Pro Ser Val Ser Leu Gln Ala Phe Lys Ser Phe Leu 50 55 60 Arg Ser Gln Gly Leu Glu Tyr Ala Val Thr Ile Glu Asp Leu Gln Ala 65 70 75 80 Leu Leu Asp Asn Glu Asp Asp Glu Met Gln His Asn Glu Gly Gln Glu 85 90 95 Arg Ser Ser Asn Asn Phe Asn Tyr Gly Ala Tyr His Ser Leu Glu Ala 100 105 110 Thr Tyr His Glu Met Asp Asn Ile Ala Ala Asp Phe Pro Asp Leu Ala 115 120 125 Arg Arg Val Lys Ile Gly His Ser Phe Glu Asn Arg Thr Met Tyr Val 130 135 140 Leu Lys Phe Ser Thr Gly Lys Gly Val Arg Arg Pro Ala Val Trp Leu 145 150 155 160 Asn Ala Gly Ile His Ser Arg Glu Trp Ile Ser Gln Ala Thr Ala Ile 165 170 175 Trp Thr Ala Arg Lys Ile Val Ser Asp Tyr Gln Arg Asp Pro Ala Ile 180 185 190 Thr Ser Ile Leu Glu Lys Met Asp Ile Phe Leu Leu Pro Val Ala Asn 195 200 205 Pro Asp Gly Tyr Val Tyr Thr Gln Thr Gln Asn Arg Leu Trp Arg Lys 210 215 220 Thr Arg Ser Arg Asn Pro Gly Ser Ser Cys Ile Gly Ala Asp Pro Asn 225 230 235 240 Arg Asn Trp Asn Ala Ser Phe Ala Gly Lys Gly Ala Ser Asp Asn Pro 245 250 255 Cys Ser Glu Val Tyr His Gly Pro His Ala Asn Ser Glu Val Glu Val 260 265 270 Lys Ser Val Val Asp Phe Ile Gln Lys His Gly Asn Phe Lys Gly Phe 275 280 285 Ile Asp Leu His Ser Tyr Ser Gln Leu Leu Met Tyr Pro Tyr Gly Tyr 290 295 300 Ser Val Lys Lys Ala Pro Asp Ala Glu Glu Leu Asp Lys Val Ala Arg 305 310 315 320 Leu Ala Ala Lys Ala Leu Ala Ser Val Ser Gly Thr Glu Tyr Gln Val 325 330 335 Gly Pro Thr Cys Thr Thr Val Tyr Pro Ala Ser Gly Ser Ser Ile Asp 340 345 350 Trp Ala Tyr Asp Asn Gly Ile Lys Phe Ala Phe Thr Phe Glu Leu Arg 355 360 365 Asp Thr Gly Thr Tyr Gly Phe Leu Leu Pro Ala Asn Gln Ile Ile Pro 370 375 380 Thr Ala Glu Glu Thr Trp Leu Gly Leu Lys Thr Ile Met Glu His Val 385 390 395 400 Arg Asp Asn Leu Tyr 405 <210> SEQ ID NO 50 <211> LENGTH: 1263 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 50 atgaggtgga tactgttcat tggggccctt attgggtcca gcatctgtgg ccaagaaaaa 60 ttttttgggg accaagtttt taggattaat gtcagaaatg gagacgagat cagcaaattg 120 agtcaactag tgaattcaaa caacttgaag ctcaatttct ggaaatctcc ctcctccttc 180 aatcggcctg tggatgtcct ggtcccatct gtcagtctgc aggcatttaa atccttcctg 240 agatcccagg gcttagagta cgcagtgaca attgaggacc tgcaggccct tttagacaat 300 gaagatgatg aaatgcaaca caatgaaggg caagaacgga gcagtaataa cttcaactac 360 ggggcttacc attccctgga agctacttac cacgagatgg acaacattgc cgcagacttt 420 cctgacctgg cgaggagggt gaagattgga cattcgtttg aaaaccggac gatgtatgta 480 ctgaagttca gcactgggaa aggcgtgagg cggccggccg tttggctgaa tgcaggcatc 540 cattcccgag agtggatctc ccaggccact gcaatctgga cggcaaggaa gattgtatct 600 gattaccaga gggatccagc tatcacctcc atcttggaga aaatggatat tttcttgttg 660 cctgtggcca atcctgatgg atatgtgtat actcaaactc aaaaccgatt atggaggaag 720 acgcggtccc gaaatcctgg aagctcctgc attggtgctg acccaaatag aaactggaac 780 gctagttttg caggaaaggg agccagcgac aacccttgct ccgaagtgta ccatggaccc 840 cacgccaatt cggaagtgga ggtgaaatca gtggtagatt tcatccaaaa acatgggaat 900 ttcaagggct tcatcgacct gcacagctac tcgcagctgc tgatgtatcc atatgggtac 960 tcagtcaaaa aggccccaga tgccgaggaa ctcgacaagg tggcgaggct tgcggccaaa 1020 gctctggctt ctgtgtcggg cactgagtac caagtgggtc ccacctgcac cactgtctat 1080 ccagctagcg ggagcagcat cgactgggcg tatgacaacg gcatcaaatt tgcattcaca 1140 tttgagttga gagataccgg gacctatggc ttcctcctgc cagctaacca gatcatcccc 1200 actgcagagg agacgtggct ggggctgaag accatcatgg agcatgtgcg ggacaacctc 1260 tac 1263 <210> SEQ ID NO 51 <211> LENGTH: 2796 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: sig_peptide <222> LOCATION: (11)..(58) <221> NAME/KEY: mat_peptide <222> LOCATION: (59)..(1273) <221> NAME/KEY: CDS <222> LOCATION: (11)..(1273) <400> SEQUENCE: 51 ccccggggac atg agg tgg ata ctg ttc att ggg gcc ctt att ggg tcc 49 Met Arg Trp Ile Leu Phe Ile Gly Ala Leu Ile Gly Ser -15 -10 -5 agc atc tgt ggc caa gaa aaa ttt ttt ggg gac caa gtt ttt agg att 97 Ser Ile Cys Gly Gln Glu Lys Phe Phe Gly Asp Gln Val Phe Arg Ile -1 1 5 10 aat gtc aga aat gga gac gag atc agc aaa ttg agt caa cta gtg aat 145 Asn Val Arg Asn Gly Asp Glu Ile Ser Lys Leu Ser Gln Leu Val Asn 15 20 25 tca aac aac ttg aag ctc aat ttc tgg aaa tct ccc tcc tcc ttc aat 193 Ser Asn Asn Leu Lys Leu Asn Phe Trp Lys Ser Pro Ser Ser Phe Asn 30 35 40 45 cgg cct gtg gat gtc ctg gtc cca tct gtc agt ctg cag gca ttt aaa 241 Arg Pro Val Asp Val Leu Val Pro Ser Val Ser Leu Gln Ala Phe Lys 50 55 60 tcc ttc ctg aga tcc cag ggc tta gag tac gca gtg aca att gag gac 289 Ser Phe Leu Arg Ser Gln Gly Leu Glu Tyr Ala Val Thr Ile Glu Asp 65 70 75 ctg cag gcc ctt tta gac aat gaa gat gat gaa atg caa cac aat gaa 337 Leu Gln Ala Leu Leu Asp Asn Glu Asp Asp Glu Met Gln His Asn Glu 80 85 90 ggg caa gaa cgg agc agt aat aac ttc aac tac ggg gct tac cat tcc 385 Gly Gln Glu Arg Ser Ser Asn Asn Phe Asn Tyr Gly Ala Tyr His Ser 95 100 105 ctg gaa gct act tac cac gag atg gac aac att gcc gca gac ttt cct 433 Leu Glu Ala Thr Tyr His Glu Met Asp Asn Ile Ala Ala Asp Phe Pro 110 115 120 125 gac ctg gcg agg agg gtg aag att gga cat tcg ttt gaa aac cgg acg 481 Asp Leu Ala Arg Arg Val Lys Ile Gly His Ser Phe Glu Asn Arg Thr 130 135 140 atg tat gta ctg aag ttc agc act ggg aaa ggc gtg agg cgg ccg gcc 529 Met Tyr Val Leu Lys Phe Ser Thr Gly Lys Gly Val Arg Arg Pro Ala 145 150 155 gtt tgg ctg aat gca ggc atc cat tcc cga gag tgg atc tcc cag gcc 577 Val Trp Leu Asn Ala Gly Ile His Ser Arg Glu Trp Ile Ser Gln Ala 160 165 170 act gca atc tgg acg gca agg aag att gta tct gat tac cag agg gat 625 Thr Ala Ile Trp Thr Ala Arg Lys Ile Val Ser Asp Tyr Gln Arg Asp 175 180 185 cca gct atc acc tcc atc ttg gag aaa atg gat att ttc ttg ttg cct 673 Pro Ala Ile Thr Ser Ile Leu Glu Lys Met Asp Ile Phe Leu Leu Pro 190 195 200 205 gtg gcc aat cct gat gga tat gtg tat act caa act caa aac cga tta 721 Val Ala Asn Pro Asp Gly Tyr Val Tyr Thr Gln Thr Gln Asn Arg Leu 210 215 220 tgg agg aag acg cgg tcc cga aat cct gga agc tcc tgc att ggt gct 769 Trp Arg Lys Thr Arg Ser Arg Asn Pro Gly Ser Ser Cys Ile Gly Ala 225 230 235 gac cca aat aga aac tgg aac gct agt ttt gca gga aag gga gcc agc 817 Asp Pro Asn Arg Asn Trp Asn Ala Ser Phe Ala Gly Lys Gly Ala Ser 240 245 250 gac aac cct tgc tcc gaa gtg tac cat gga ccc cac gcc aat tcg gaa 865 Asp Asn Pro Cys Ser Glu Val Tyr His Gly Pro His Ala Asn Ser Glu 255 260 265 gtg gag gtg aaa tca gtg gta gat ttc atc caa aaa cat ggg aat ttc 913 Val Glu Val Lys Ser Val Val Asp Phe Ile Gln Lys His Gly Asn Phe 270 275 280 285 aag ggc ttc atc gac ctg cac agc tac tcg cag ctg ctg atg tat cca 961 Lys Gly Phe Ile Asp Leu His Ser Tyr Ser Gln Leu Leu Met Tyr Pro 290 295 300 tat ggg tac tca gtc aaa aag gcc cca gat gcc gag gaa ctc gac aag 1009 Tyr Gly Tyr Ser Val Lys Lys Ala Pro Asp Ala Glu Glu Leu Asp Lys 305 310 315 gtg gcg agg ctt gcg gcc aaa gct ctg gct tct gtg tcg ggc act gag 1057 Val Ala Arg Leu Ala Ala Lys Ala Leu Ala Ser Val Ser Gly Thr Glu 320 325 330 tac caa gtg ggt ccc acc tgc acc act gtc tat cca gct agc ggg agc 1105 Tyr Gln Val Gly Pro Thr Cys Thr Thr Val Tyr Pro Ala Ser Gly Ser 335 340 345 agc atc gac tgg gcg tat gac aac ggc atc aaa ttt gca ttc aca ttt 1153 Ser Ile Asp Trp Ala Tyr Asp Asn Gly Ile Lys Phe Ala Phe Thr Phe 350 355 360 365 gag ttg aga gat acc ggg acc tat ggc ttc ctc ctg cca gct aac cag 1201 Glu Leu Arg Asp Thr Gly Thr Tyr Gly Phe Leu Leu Pro Ala Asn Gln 370 375 380 atc atc ccc act gca gag gag acg tgg ctg ggg ctg aag acc atc atg 1249 Ile Ile Pro Thr Ala Glu Glu Thr Trp Leu Gly Leu Lys Thr Ile Met 385 390 395 gag cat gtg cgg gac aac ctc tac taggcgatgg ctctgctctg tctacattta 1303 Glu His Val Arg Asp Asn Leu Tyr 400 405 tttgtaccca cacgtgcacg cactgaggcc attgttaaag gagctctttc ctacctgtgt 1363 gagtcagagc cctctgggtt tgtggagcac acaggcctgc ccctctccag ccagctccct 1423 ggagtcgtgt gtcctggcgg tgtccctgca agaactggtt ctgccagcct gctcaatttt 1483 ggtcctgctg tttttgatga gccttttgtc tgtttctcct tccaccctgc tggctgggcg 1543 gctgcactca gcatcacccc ttcctgggtg gcatgtctct ctctacctca tttttagaac 1603 caaagaacat ctgagatgat tctctaccct catccacatc tagccaagcc agtgaccttg 1663 ctctggtggc actgtgggag acaccacttg tctttaggtg ggtctcaaag atgatgtaga 1723 atttccttta atttctcgca gtcttcctgg aaaatatttt cctttgagca gcaaatcttg 1783 tagggatatc agtgaaggtc tctccctccc tcctctcctg tttttttttt tgagacagag 1843 ttttgctctt gttgcccaga ctggagtgtg atggctcgac cttggctcac cacaacctct 1903 gcctcctggg ttcaagcaat tctcctgcct cagcctcttg agtagcttgg tttataggcg 1963 catgccacca tgcctggcta attttgtgtt tttagtagag acagggtttc tccatgttgg 2023 tcaggctggt ctcaaactcc caacctcagg tgatctgccc tccttggcct cccagagtgc 2083 tgggattaca ggtgtgagcc actgtgccgg tcccgtcccc tcctttttta ggcctgaata 2143 caaagtagaa gatcactttc cttcactgtg ctgagaattt ctagatacta cagttcttac 2203 tcctctcttc cctttgttat tcagtgtgac caggatggcg ggaggggatc tgtgtcactg 2263 taggtactgt gcccaggaag gctgggtgaa gtgaccatct aaattgcagg atggtgaaat 2323 tatccccatc tgtcctaatg ggcttacctc ctctttgcct tttgaactca cttcaaagat 2383 ctaggcctca tcttacaggt cctaaatcac tcatctggcc tggataatct cactgccctg 2443 gcacattccc atttgtgctg tggtgtatcc tgtgtttcct tgtcctggtt tgtgtgtgtg 2503 tgtgtgtgtg tgtgtgtgtg tgtgtgtgtt tgtgtgtgtg tgtctgtcta ttttgtatcc 2563 tggaccacaa gttcctaagt agagcaagaa ttcatcaacc agctgcctct tgtttcattt 2623 cacctcagca cgtaccatct gtccttttgt tgttgttgtt ttgtttttgt ttttttgctt 2683 ttaccaaaca tgtctgtaaa tcttaacctc ctgcctagga tttgtacagc atctggtgtg 2743 tgcttataag ccaataaata ttcaatgtca aaaaaaaaaa aaaaaaaaaa aaa 2796 <210> SEQ ID NO 52 <211> LENGTH: 111 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 52 Met Leu Ile Ile Val Leu Val Asn Ala Phe Val Ser Ile Thr Val Glu -10 -5 -1 1 Asn Phe Phe Leu Asp Met Val Leu Trp Lys Val Val Phe Asn Arg Asp 5 10 15 Lys Gln Gly Glu Tyr Arg Phe Ser Thr Thr Gln Pro Pro Gln Glu Ser 20 25 30 Val Asp Arg Trp Gly Lys Cys Cys Leu Pro Trp Ala Leu Gly Cys Arg 35 40 45 50 Lys Lys Thr Pro Lys Ala Lys Tyr Met Tyr Leu Ala Gln Glu Leu Leu 55 60 65 Val Asp Pro Glu Trp Pro Pro Lys Pro Gln Thr Thr Thr Glu Ala Lys 70 75 80 Ala Leu Val Lys Glu Asn Gly Ser Cys Gln Ile Ile Thr Ile Thr 85 90 95 <210> SEQ ID NO 53 <211> LENGTH: 333 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 53 atgctcatca ttgttcttgt caatgccttt gtgtctatca cagtggagaa cttcttcctt 60 gacatggtcc tttggaaagt tgtgttcaac cgagacaaac aaggagagta tcggttcagc 120 accacacagc caccgcagga gtcagtggat cggtggggaa aatgctgctt accctgggcc 180 ctgggctgta gaaagaagac accaaaggca aagtacatgt atctggcgca ggagctcttg 240 gttgatccag aatggccacc aaaacctcag acaaccacag aagctaaagc tttagttaag 300 gagaatggat catgtcaaat catcaccata aca 333 <210> SEQ ID NO 54 <211> LENGTH: 3635 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: sig_peptide <222> LOCATION: (36)..(77) <221> NAME/KEY: mat_peptide <222> LOCATION: (78)..(368) <221> NAME/KEY: CDS <222> LOCATION: (36)..(368) <400> SEQUENCE: 54 agatagtgtg tgtaccatat cagtggcgtg taact atg ctc atc att gtt ctt 53 Met Leu Ile Ile Val Leu -10 gtc aat gcc ttt gtg tct atc aca gtg gag aac ttc ttc ctt gac atg 101 Val Asn Ala Phe Val Ser Ile Thr Val Glu Asn Phe Phe Leu Asp Met -5 -1 1 5 gtc ctt tgg aaa gtt gtg ttc aac cga gac aaa caa gga gag tat cgg 149 Val Leu Trp Lys Val Val Phe Asn Arg Asp Lys Gln Gly Glu Tyr Arg 10 15 20 ttc agc acc aca cag cca ccg cag gag tca gtg gat cgg tgg gga aaa 197 Phe Ser Thr Thr Gln Pro Pro Gln Glu Ser Val Asp Arg Trp Gly Lys 25 30 35 40 tgc tgc tta ccc tgg gcc ctg ggc tgt aga aag aag aca cca aag gca 245 Cys Cys Leu Pro Trp Ala Leu Gly Cys Arg Lys Lys Thr Pro Lys Ala 45 50 55 aag tac atg tat ctg gcg cag gag ctc ttg gtt gat cca gaa tgg cca 293 Lys Tyr Met Tyr Leu Ala Gln Glu Leu Leu Val Asp Pro Glu Trp Pro 60 65 70 cca aaa cct cag aca acc aca gaa gct aaa gct tta gtt aag gag aat 341 Pro Lys Pro Gln Thr Thr Thr Glu Ala Lys Ala Leu Val Lys Glu Asn 75 80 85 gga tca tgt caa atc atc acc ata aca tagcagtgaa tcagtctcag 388 Gly Ser Cys Gln Ile Ile Thr Ile Thr 90 95 tggtattgct gatagcagta ttcaggaata tgtgatttta ggagtttctg atcctgtgtg 448 tcagaatggc actagttcag tttatgtccc ttctgatata gtagcttatt tgacagcttt 508 gctcttcctt aaaataaaaa cagaaaaata tatcgtccta acagttaaat taacaatcaa 568 tccataaagt cctatatctt cattcagcaa cccaaatatt acatacattt ccagaatttt 628 cttgattgtt actttcagtg atattcttta tattgggtac aggagaagtt tggtgtttgg 688 taggtttttc aacattagtt tttgagacta gtttacctct tcacatttat gctcacaacc 748 ctcttgttag aaaagtctgt gtttatatac aggctgtaag tttgtgattg ataaaaagaa 808 gatgagtgtt aattagcctc cagtgaaaat atactgaaag cctgttttca tttgattcca 868 atgtttcttc caaagaattc tgtataaaca tatgccaatt ccctatgatg gtctagagtt 928 aggaatgagt gtttatggtg ttgcttatag aacaactcag gtaatctcca tttctggttt 988 tatattttct gtacaaactg cctgggtttt atttttctaa tcagcaaggt gcttcactgc 1048 cttcttgaga cgcctctcaa agctcttaaa tggctcctgt gctatgtgtg gtgttggcag 1108 tctaatttgc ttctgttaaa tgttgtagaa cctttttcac taggaaataa gattcatttc 1168 tttcggcagt agatgtagat tcatctttta acgtttcttc aaatttgttt ctgtcaggct 1228 ttgtgttatt ttaaatggtt ttttaaaatt ttcttctatg ttttcaatta cctaaagaca 1288 taggataata gtttttttta agttagaatt ttacctcata aaattttttg aggtttgatg 1348 tatgtctctg tcttatcaat aatgaggctt aaaaaatact ggatttgaat ggctgccgtt 1408 ttttcaaagc aatatgaatt tgatgagttt gttttatgcc attaggtggc gccagaggtc 1468 agaacatgtc tattttgaat tggatcgtta caaatgagca tatttgatgc ggaaatttct 1528 gggagaaaaa aaattgagga aataaagtta aaaaattgac attcattgag ccaaaagaga 1588 tgtggagaaa catttttcac ctttctgttt ggcctgatta acatttaaat tcttgccaaa 1648 attaaggtaa cttttaaaaa caccttttat aggtggatcc agcagtctgg caacgcccac 1708 agttaccaca acacagaaaa ctgatcgtgc tataaaatgg acgctaaact atgaaaacag 1768 tgtgacattg ttctctgttc ttccagagcc agtaacatgc ttgctcgtgc tttctacttc 1828 tagctgatca ttcttttccc aacatatatt tacaaattta ccaaatttta cctagaattt 1888 taggaccaaa tggttctcac tctttatgct gcaaagacct ggatgatgtt tggtaactat 1948 agaaaaatag aaattacact caggatcact gttactgcta ttgccactga tgattcctgc 2008 aaaatataat cgaagttttc catcaaatgt ataatatgct attaatacac attagatgat 2068 aacagttgtt ccatgaatga ttctatgaag ctatgcatct tagacctctt gagctgtgaa 2128 ttagcactat tttctatagt tacttattct ctggatcatt ttataatttc catattaatt 2188 tcaaatatgc tcgtgttatt cttcagtgat ttccacaatt gtgcatttta ttctttggtt 2248 taagtactga agcatataat gaaagtaatt gctaagtagc agcttaaaaa ttcaattatc 2308 cgattgtatt taacatcttt aagagcatga tcataaagag ctatttttga cacccccccc 2368 cactttttta acatttagag ttaataaggg ttttatatct cttctgtcca tattgttttc 2428 aaaggaatga ggtgtttagg tggctggaaa agcatttgta ggaagttaga tttgaatata 2488 gacaaggtgg gttattcacg ttgagaatgt tatttgaaga atgcctgtga agccaggtgt 2548 gggttctact cagtgccata gatagactga gtcttctctc gtaggtcacc attacatagt 2608 aattttgatt ctgaatttca cattaaatta tttgagttta tacagaccta aattttaaaa 2668 tctgtacata tattattttg atgtattaag atgaatattg ctgatttaaa ttttatttat 2728 gcacatactt aaaggacaga aatgtctggg aaagtaattg ttaaataatg atatgtaact 2788 ttttaacttt ttaaataaat aacaagattt ttaatgtgtg tctccctcag ggttgtttaa 2848 agtttttttt ctccctcaag tataaatagt ggtaactata tgttttgtat cttctagcac 2908 caactgctgt aaagcaatgc tgcaaataat gcttgaatac aagtggctaa gccaacaaca 2968 gaataaatac ttttatagta gttttataat cctgaaattc gaaagctttc ccaattgcac 3028 ttgcatctaa acaaaactgt tgcagttttt actctattta ttttgttccc catgtttatg 3088 aaagtcctgc acagtttcaa aggcatggta aataatatat caatgtttat gtagtctgtt 3148 acagaaacag ctatagataa cattatccag tgaagagcaa aattcaagct ttagaaaata 3208 ttcatgcatg caattttgac atatctaaaa ataggttttt gtatatttat ggtgggaggt 3268 ggttgggaac ttttaacaaa atggggtgtt aatttttgta cagtctgtgg gcatttacac 3328 atttttaatg tattaaaatt tggtaattat gtgtacatta aattaataaa agttacttct 3388 agttatgatt tgtgaattcc ctaagacctt ggattttttt aagtaacttt atatcagaaa 3448 tgatactgca tctttatatt tttaaaattg tattgctgct caagaatggt accctcttgt 3508 caaaaaggca tacattcata attgtacatt cagcattgta aataatctta tgaaaccttt 3568 tttgattgaa gctattcaaa ataaaaattt taatgaacga aaaaaaaaaa aaaaaaaaaa 3628 aaaaaaa 3635 <210> SEQ ID NO 55 <211> LENGTH: 1109 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 55 Met Leu Ile Glu His Pro Leu Arg Cys Leu Val Leu Cys Ala Gln Val -15 -10 -5 His Ala Gly Met Trp Arg Arg Asn Gly Phe Ser Leu Val Asn Gln Ile -1 1 5 10 Tyr Tyr Tyr His Asn Val Lys Cys Arg Arg Glu Met Phe Asp Lys Asp 15 20 25 30 Val Val Met Leu Gln Thr Gly Val Ser Met Met Asp Pro Asn His Phe 35 40 45 Leu Met Ile Met Leu Ser Arg Phe Glu Leu Tyr Gln Ile Phe Ser Thr 50 55 60 Pro Asp Tyr Gly Lys Arg Phe Ser Ser Glu Ile Thr His Lys Asp Val 65 70 75 Val Gln Gln Asn Asn Thr Leu Ile Glu Glu Met Leu Tyr Leu Ile Ile 80 85 90 Met Leu Val Gly Glu Arg Phe Ser Pro Gly Val Gly Gln Val Asn Ala 95 100 105 110 Thr Asp Glu Ile Lys Arg Glu Ile Ile His Gln Leu Ser Ile Lys Pro 115 120 125 Met Ala His Ser Glu Leu Val Lys Ser Leu Pro Glu Asp Glu Asn Lys 130 135 140 Glu Thr Gly Met Glu Ser Val Ile Glu Ala Val Ala His Phe Lys Lys 145 150 155 Pro Gly Leu Thr Gly Arg Gly Met Tyr Glu Leu Lys Pro Glu Cys Ala 160 165 170 Lys Glu Phe Asn Leu Tyr Phe Tyr His Phe Ser Arg Ala Glu Gln Ser 175 180 185 190 Lys Ala Glu Glu Ala Gln Arg Lys Leu Lys Arg Gln Asn Arg Glu Asp 195 200 205 Thr Ala Leu Pro Pro Pro Val Leu Pro Pro Phe Cys Pro Leu Phe Ala 210 215 220 Ser Leu Val Asn Ile Leu Gln Ser Asp Val Met Leu Cys Ile Met Gly 225 230 235 Thr Ile Leu Gln Trp Ala Val Glu His Asn Gly Tyr Ala Trp Ser Glu 240 245 250 Ser Met Leu Gln Arg Val Leu His Leu Ile Gly Met Ala Leu Gln Glu 255 260 265 270 Glu Lys Gln His Leu Glu Asn Val Thr Glu Glu His Val Val Thr Phe 275 280 285 Thr Phe Thr Gln Lys Ile Ser Lys Pro Gly Glu Ala Pro Lys Asn Ser 290 295 300 Pro Ser Ile Leu Ala Met Leu Glu Thr Leu Gln Asn Ala Pro Tyr Leu 305 310 315 Glu Val His Lys Asp Met Ile Arg Trp Ile Leu Lys Thr Phe Asn Ala 320 325 330 Val Lys Lys Met Arg Glu Ser Ser Pro Thr Ser Pro Val Ala Glu Thr 335 340 345 350 Glu Gly Thr Ile Met Glu Glu Ser Ser Arg Asp Lys Asp Lys Ala Glu 355 360 365 Arg Lys Arg Lys Ala Glu Ile Ala Arg Leu Arg Arg Glu Lys Ile Met 370 375 380 Ala Gln Met Ser Glu Met Gln Arg His Phe Ile Asp Glu Asn Lys Glu 385 390 395 Leu Phe Gln Gln Thr Leu Glu Leu Asp Ala Ser Thr Ser Ala Val Leu 400 405 410 Asp His Ser Pro Val Ala Ser Asp Met Thr Leu Thr Ala Leu Gly Pro 415 420 425 430 Ala Gln Thr Gln Val Pro Glu Gln Arg Gln Phe Val Thr Cys Ile Leu 435 440 445 Cys Gln Glu Glu Gln Glu Val Lys Val Glu Ser Arg Ala Met Val Leu 450 455 460 Ala Ala Phe Val Gln Arg Ser Thr Val Leu Ser Lys Asn Arg Ser Lys 465 470 475 Phe Ile Gln Asp Pro Glu Lys Tyr Asp Pro Leu Phe Met His Pro Asp 480 485 490 Leu Ser Cys Gly Thr His Thr Ser Ser Cys Gly His Ile Met His Ala 495 500 505 510 His Cys Trp Gln Arg Tyr Phe Asp Ser Val Gln Ala Lys Glu Gln Arg 515 520 525 Arg Gln Gln Arg Leu Arg Leu His Thr Ser Tyr Asp Val Glu Asn Gly 530 535 540 Glu Phe Leu Cys Pro Leu Cys Glu Cys Leu Ser Asn Thr Val Ile Pro 545 550 555 Leu Leu Leu Ser Pro Arg Asn Ile Phe Asn Asn Arg Leu Asn Phe Ser 560 565 570 Asp Gln Pro Asn Leu Thr Gln Trp Ile Arg Thr Ile Ser Gln Gln Ile 575 580 585 590 Lys Ala Leu Gln Phe Leu Arg Lys Glu Glu Ser Thr Pro Asn Asn Ala 595 600 605 Ser Thr Lys Asn Ser Glu Asn Val Asp Glu Leu Gln Leu Pro Glu Gly 610 615 620 Phe Arg Pro Asp Phe Arg Pro Lys Ile Pro Tyr Ser Glu Ser Ile Lys 625 630 635 Glu Met Leu Thr Thr Phe Gly Thr Ala Thr Tyr Lys Val Gly Leu Lys 640 645 650 Val His Pro Asn Glu Glu Asp Pro Arg Val Pro Ile Met Cys Trp Gly 655 660 665 670 Ser Cys Ala Tyr Thr Ile Gln Ser Ile Glu Arg Ile Leu Ser Asp Glu 675 680 685 Asp Lys Pro Leu Phe Gly Pro Leu Pro Cys Arg Leu Asp Asp Cys Leu 690 695 700 Arg Ser Leu Thr Arg Phe Ala Ala Ala His Trp Thr Val Ala Ser Val 705 710 715 Ser Val Val Gln Gly His Phe Cys Lys Leu Phe Ala Ser Leu Val Pro 720 725 730 Asn Asp Ser His Glu Glu Leu Pro Cys Ile Leu Asp Ile Asp Met Phe 735 740 745 750 His Leu Leu Val Gly Leu Val Leu Ala Phe Pro Ala Leu Gln Cys Gln 755 760 765 Asp Phe Ser Gly Ile Ser Leu Gly Thr Gly Asp Leu His Ile Phe His 770 775 780 Leu Val Thr Met Ala His Ile Ile Gln Ile Leu Leu Thr Ser Cys Thr 785 790 795 Glu Glu Asn Gly Met Asp Gln Glu Asn Pro Pro Cys Glu Glu Glu Ser 800 805 810 Ala Val Leu Ala Leu Tyr Lys Thr Leu His Gln Tyr Thr Gly Ser Ala 815 820 825 830 Leu Lys Glu Ile Pro Ser Gly Trp His Leu Trp Arg Ser Val Arg Ala 835 840 845 Gly Ile Met Pro Phe Leu Lys Cys Ser Ala Leu Phe Phe His Tyr Leu 850 855 860 Asn Gly Val Pro Ser Pro Pro Asp Ile Gln Val Pro Gly Thr Ser His 865 870 875 Phe Glu His Leu Cys Ser Tyr Leu Ser Leu Pro Asn Asn Leu Ile Cys 880 885 890 Leu Phe Gln Glu Asn Ser Glu Ile Met Asn Ser Leu Ile Glu Ser Trp 895 900 905 910 Cys Arg Asn Ser Glu Val Lys Arg Tyr Leu Glu Gly Glu Arg Asp Ala 915 920 925 Ile Arg Tyr Pro Arg Glu Ser Asn Lys Leu Ile Asn Leu Pro Glu Asp 930 935 940 Tyr Ser Ser Leu Ile Asn Gln Ala Ser Asn Phe Ser Cys Pro Lys Ser 945 950 955 Gly Gly Asp Lys Ser Arg Ala Pro Thr Leu Cys Leu Val Cys Gly Ser 960 965 970 Leu Leu Cys Ser Gln Ser Tyr Cys Cys Gln Thr Glu Leu Glu Gly Glu 975 980 985 990 Asp Val Gly Ala Cys Thr Ala His Thr Tyr Ser Cys Gly Ser Gly Val 995 1000 1005 Gly Ile Phe Leu Arg Val Arg Glu Cys Gln Val Leu Phe Leu Ala Gly 1010 1015 1020 Lys Thr Lys Gly Cys Phe Tyr Ser Pro Pro Tyr Leu Asp Asp Tyr Gly 1025 1030 1035 Glu Thr Asp Gln Gly Leu Arg Arg Gly Asn Pro Leu His Leu Cys Lys 1040 1045 1050 Glu Arg Phe Lys Lys Ile Gln Lys Leu Trp His Gln His Ser Val Thr 1055 1060 1065 1070 Glu Glu Ile Gly His Ala Gln Glu Ala Asn Gln Thr Leu Val Gly Ile 1075 1080 1085 Asp Trp Gln His Leu 1090 <210> SEQ ID NO 56 <211> LENGTH: 3327 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 56 atgttgatag aacaccctct tagatgtctt gttctgtgtg cccaagtaca tgccggaatg 60 tggagaagaa atgggttctc tctagtaaac cagatttatt actaccataa tgtgaaatgc 120 agacgtgaga tgtttgacaa ggatgtagta atgcttcaga caggtgtctc catgatggat 180 ccaaatcatt tcctgatgat catgctcagc cgctttgaac tttatcagat tttcagtact 240 ccagactatg gaaaaagatt tagttctgag attacccata aggatgttgt tcagcagaac 300 aatactctaa tagaagaaat gctatacctc attataatgc ttgttggaga gagatttagt 360 cctggagttg gacaggtaaa tgctacagat gaaatcaagc gagagattat ccatcagttg 420 agtatcaagc ctatggctca tagtgaattg gtaaagtctt tacctgaaga tgagaacaag 480 gagactggca tggagagtgt aatcgaagca gttgcccatt tcaagaaacc tggattaaca 540 ggacgaggca tgtatgaact gaaaccagaa tgtgccaaag agttcaactt gtatttctat 600 cacttttcaa gggcagaaca gtccaaggca gaagaagcgc aacggaaatt gaaaagacaa 660 aatagagaag atacagcact cccacctccg gtgttgcctc cattctgccc tctgtttgca 720 agcctggtta acattttgca gtcagatgtc atgttgtgca tcatgggaac aattctgcaa 780 tgggctgtgg aacataatgg atatgcctgg tcagagtcca tgctgcaaag ggtgttacat 840 ttaattggca tggcactaca agaagaaaaa caacatttag agaatgtcac ggaagagcat 900 gtagtaacat ttaccttcac tcagaagata tcaaaacctg gtgaagcgcc aaaaaattct 960 cctagcatac tagctatgct ggaaacacta caaaatgctc cctacctaga agtccacaaa 1020 gacatgattc ggtggatatt gaagactttt aatgctgtta aaaagatgag ggagagttca 1080 cctaccagtc ccgtggcaga gacagaagga accataatgg aagagagttc aagggacaaa 1140 gacaaagctg agaggaagag aaaagcagag attgccagac tgcgcagaga aaagatcatg 1200 gctcagatgt ctgaaatgca gcggcatttt attgatgaaa acaaagaact ctttcagcag 1260 acattagaac tggatgcctc aacctctgct gttcttgatc atagccctgt ggcttcagat 1320 atgacactta cagcactggg ccccgcacaa actcaggttc ctgaacaaag acaattcgtt 1380 acatgtatat tgtgtcaaga ggagcaagaa gttaaagtgg aaagcagggc aatggtcttg 1440 gcagcatttg ttcagagatc aactgtatta tcaaaaaaca gaagtaaatt tattcaagat 1500 ccagaaaaat atgatccatt attcatgcac cctgatctgt cttgtggaac acacactagt 1560 agctgtgggc acattatgca tgcccattgt tggcaaaggt attttgattc cgttcaagct 1620 aaagaacagc gaaggcaaca gagattacgc ttacatacga gctatgatgt agaaaacgga 1680 gaattccttt gccccctttg tgaatgcttg agtaatactg ttattcctct gctgctttct 1740 ccaagaaata tttttaacaa caggttaaat ttttcagacc aaccaaatct gactcagtgg 1800 attagaacaa tatctcagca aataaaagca ttacagtttc ttaggaaaga agaaagtact 1860 cctaataatg cctctacaaa gaattcagaa aatgtggatg aattacagct ccctgaaggg 1920 ttcaggcctg attttcgtcc taagatccct tattctgaga gcataaaaga aatgctaacg 1980 acatttggaa ctgctaccta caaggtggga ctaaaggttc atcccaatga agaggatcct 2040 cgtgttccca taatgtgttg gggtagctgc gcgtacacca tccaaagcat agaaagaatt 2100 ttgagtgatg aagataaacc attgtttggt cctttacctt gcagactgga tgactgtctt 2160 aggtcattga cgagatttgc cgcagcacac tggacagtgg catcagtttc agtggtgcaa 2220 ggacattttt gtaaactttt tgcatcactg gtgcctaatg acagccatga ggaacttcca 2280 tgcatattag atattgacat gtttcattta ttggtgggct tggtgcttgc atttcctgcg 2340 ttgcagtgtc aggatttttc agggatcagc cttggcactg gagaccttca cattttccat 2400 ctggttacta tggcacacat catacagatc ttacttacct catgtacaga agagaatggc 2460 atggatcaag aaaatccccc ttgtgaagaa gaatcagcag ttcttgcttt gtataaaaca 2520 cttcaccagt atacgggaag tgccttgaaa gaaataccat ccggctggca tctgtggagg 2580 agtgtcagag ctggaatcat gcctttcctg aagtgttctg ctttattttt tcattactta 2640 aatggagttc cttccccacc cgacattcaa gttcctggaa caagccattt tgaacattta 2700 tgtagctatc tttccctacc aaacaacctc atttgccttt ttcaagaaaa tagtgagata 2760 atgaattcac tgattgaaag ttggtgccgt aacagtgaag ttaaaagata tctagaaggt 2820 gaaagagatg ctataagata tccaagagaa tctaacaaat taataaacct tccagaggat 2880 tacagcagcc tcattaatca agcatccaat ttctcgtgcc cgaaatcagg tggtgataag 2940 agcagagccc caactctgtg ccttgtgtgc ggatctctgc tgtgctccca gagttactgc 3000 tgccagactg aactggaagg ggaggatgta ggagcctgca cagctcacac ctactcctgt 3060 ggctctggag tgggcatctt cctgagagta cgggaatgtc aggtgctatt tttagctggc 3120 aaaaccaaag gctgttttta ttctcctcct taccttgatg actatgggga gaccgaccag 3180 ggactcagac ggggaaatcc tttacattta tgcaaagagc gattcaagaa gattcagaag 3240 ctctggcacc aacacagtgt cacagaggaa attggacatg cacaggaagc caatcagaca 3300 ctggttggca ttgactggca acattta 3327 <210> SEQ ID NO 57 <211> LENGTH: 3502 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: sig_peptide <222> LOCATION: (56)..(109) <221> NAME/KEY: mat_peptide <222> LOCATION: (110)..(3382) <221> NAME/KEY: CDS <222> LOCATION: (56)..(3382) <400> SEQUENCE: 57 tttttgtttt ctgttttttt attttttgta tatatagagt gaacttagcc caccc atg 58 Met ttg ata gaa cac cct ctt aga tgt ctt gtt ctg tgt gcc caa gta cat 106 Leu Ile Glu His Pro Leu Arg Cys Leu Val Leu Cys Ala Gln Val His -15 -10 -5 gcc gga atg tgg aga aga aat ggg ttc tct cta gta aac cag att tat 154 Ala Gly Met Trp Arg Arg Asn Gly Phe Ser Leu Val Asn Gln Ile Tyr -1 1 5 10 15 tac tac cat aat gtg aaa tgc aga cgt gag atg ttt gac aag gat gta 202 Tyr Tyr His Asn Val Lys Cys Arg Arg Glu Met Phe Asp Lys Asp Val 20 25 30 gta atg ctt cag aca ggt gtc tcc atg atg gat cca aat cat ttc ctg 250 Val Met Leu Gln Thr Gly Val Ser Met Met Asp Pro Asn His Phe Leu 35 40 45 atg atc atg ctc agc cgc ttt gaa ctt tat cag att ttc agt act cca 298 Met Ile Met Leu Ser Arg Phe Glu Leu Tyr Gln Ile Phe Ser Thr Pro 50 55 60 gac tat gga aaa aga ttt agt tct gag att acc cat aag gat gtt gtt 346 Asp Tyr Gly Lys Arg Phe Ser Ser Glu Ile Thr His Lys Asp Val Val 65 70 75 cag cag aac aat act cta ata gaa gaa atg cta tac ctc att ata atg 394 Gln Gln Asn Asn Thr Leu Ile Glu Glu Met Leu Tyr Leu Ile Ile Met 80 85 90 95 ctt gtt gga gag aga ttt agt cct gga gtt gga cag gta aat gct aca 442 Leu Val Gly Glu Arg Phe Ser Pro Gly Val Gly Gln Val Asn Ala Thr 100 105 110 gat gaa atc aag cga gag att atc cat cag ttg agt atc aag cct atg 490 Asp Glu Ile Lys Arg Glu Ile Ile His Gln Leu Ser Ile Lys Pro Met 115 120 125 gct cat agt gaa ttg gta aag tct tta cct gaa gat gag aac aag gag 538 Ala His Ser Glu Leu Val Lys Ser Leu Pro Glu Asp Glu Asn Lys Glu 130 135 140 act ggc atg gag agt gta atc gaa gca gtt gcc cat ttc aag aaa cct 586 Thr Gly Met Glu Ser Val Ile Glu Ala Val Ala His Phe Lys Lys Pro 145 150 155 gga tta aca gga cga ggc atg tat gaa ctg aaa cca gaa tgt gcc aaa 634 Gly Leu Thr Gly Arg Gly Met Tyr Glu Leu Lys Pro Glu Cys Ala Lys 160 165 170 175 gag ttc aac ttg tat ttc tat cac ttt tca agg gca gaa cag tcc aag 682 Glu Phe Asn Leu Tyr Phe Tyr His Phe Ser Arg Ala Glu Gln Ser Lys 180 185 190 gca gaa gaa gcg caa cgg aaa ttg aaa aga caa aat aga gaa gat aca 730 Ala Glu Glu Ala Gln Arg Lys Leu Lys Arg Gln Asn Arg Glu Asp Thr 195 200 205 gca ctc cca cct ccg gtg ttg cct cca ttc tgc cct ctg ttt gca agc 778 Ala Leu Pro Pro Pro Val Leu Pro Pro Phe Cys Pro Leu Phe Ala Ser 210 215 220 ctg gtt aac att ttg cag tca gat gtc atg ttg tgc atc atg gga aca 826 Leu Val Asn Ile Leu Gln Ser Asp Val Met Leu Cys Ile Met Gly Thr 225 230 235 att ctg caa tgg gct gtg gaa cat aat gga tat gcc tgg tca gag tcc 874 Ile Leu Gln Trp Ala Val Glu His Asn Gly Tyr Ala Trp Ser Glu Ser 240 245 250 255 atg ctg caa agg gtg tta cat tta att ggc atg gca cta caa gaa gaa 922 Met Leu Gln Arg Val Leu His Leu Ile Gly Met Ala Leu Gln Glu Glu 260 265 270 aaa caa cat tta gag aat gtc acg gaa gag cat gta gta aca ttt acc 970 Lys Gln His Leu Glu Asn Val Thr Glu Glu His Val Val Thr Phe Thr 275 280 285 ttc act cag aag ata tca aaa cct ggt gaa gcg cca aaa aat tct cct 1018 Phe Thr Gln Lys Ile Ser Lys Pro Gly Glu Ala Pro Lys Asn Ser Pro 290 295 300 agc ata cta gct atg ctg gaa aca cta caa aat gct ccc tac cta gaa 1066 Ser Ile Leu Ala Met Leu Glu Thr Leu Gln Asn Ala Pro Tyr Leu Glu 305 310 315 gtc cac aaa gac atg att cgg tgg ata ttg aag act ttt aat gct gtt 1114 Val His Lys Asp Met Ile Arg Trp Ile Leu Lys Thr Phe Asn Ala Val 320 325 330 335 aaa aag atg agg gag agt tca cct acc agt ccc gtg gca gag aca gaa 1162 Lys Lys Met Arg Glu Ser Ser Pro Thr Ser Pro Val Ala Glu Thr Glu 340 345 350 gga acc ata atg gaa gag agt tca agg gac aaa gac aaa gct gag agg 1210 Gly Thr Ile Met Glu Glu Ser Ser Arg Asp Lys Asp Lys Ala Glu Arg 355 360 365 aag aga aaa gca gag att gcc aga ctg cgc aga gaa aag atc atg gct 1258 Lys Arg Lys Ala Glu Ile Ala Arg Leu Arg Arg Glu Lys Ile Met Ala 370 375 380 cag atg tct gaa atg cag cgg cat ttt att gat gaa aac aaa gaa ctc 1306 Gln Met Ser Glu Met Gln Arg His Phe Ile Asp Glu Asn Lys Glu Leu 385 390 395 ttt cag cag aca tta gaa ctg gat gcc tca acc tct gct gtt ctt gat 1354 Phe Gln Gln Thr Leu Glu Leu Asp Ala Ser Thr Ser Ala Val Leu Asp 400 405 410 415 cat agc cct gtg gct tca gat atg aca ctt aca gca ctg ggc ccc gca 1402 His Ser Pro Val Ala Ser Asp Met Thr Leu Thr Ala Leu Gly Pro Ala 420 425 430 caa act cag gtt cct gaa caa aga caa ttc gtt aca tgt ata ttg tgt 1450 Gln Thr Gln Val Pro Glu Gln Arg Gln Phe Val Thr Cys Ile Leu Cys 435 440 445 caa gag gag caa gaa gtt aaa gtg gaa agc agg gca atg gtc ttg gca 1498 Gln Glu Glu Gln Glu Val Lys Val Glu Ser Arg Ala Met Val Leu Ala 450 455 460 gca ttt gtt cag aga tca act gta tta tca aaa aac aga agt aaa ttt 1546 Ala Phe Val Gln Arg Ser Thr Val Leu Ser Lys Asn Arg Ser Lys Phe 465 470 475 att caa gat cca gaa aaa tat gat cca tta ttc atg cac cct gat ctg 1594 Ile Gln Asp Pro Glu Lys Tyr Asp Pro Leu Phe Met His Pro Asp Leu 480 485 490 495 tct tgt gga aca cac act agt agc tgt ggg cac att atg cat gcc cat 1642 Ser Cys Gly Thr His Thr Ser Ser Cys Gly His Ile Met His Ala His 500 505 510 tgt tgg caa agg tat ttt gat tcc gtt caa gct aaa gaa cag cga agg 1690 Cys Trp Gln Arg Tyr Phe Asp Ser Val Gln Ala Lys Glu Gln Arg Arg 515 520 525 caa cag aga tta cgc tta cat acg agc tat gat gta gaa aac gga gaa 1738 Gln Gln Arg Leu Arg Leu His Thr Ser Tyr Asp Val Glu Asn Gly Glu 530 535 540 ttc ctt tgc ccc ctt tgt gaa tgc ttg agt aat act gtt att cct ctg 1786 Phe Leu Cys Pro Leu Cys Glu Cys Leu Ser Asn Thr Val Ile Pro Leu 545 550 555 ctg ctt tct cca aga aat att ttt aac aac agg tta aat ttt tca gac 1834 Leu Leu Ser Pro Arg Asn Ile Phe Asn Asn Arg Leu Asn Phe Ser Asp 560 565 570 575 caa cca aat ctg act cag tgg att aga aca ata tct cag caa ata aaa 1882 Gln Pro Asn Leu Thr Gln Trp Ile Arg Thr Ile Ser Gln Gln Ile Lys 580 585 590 gca tta cag ttt ctt agg aaa gaa gaa agt act cct aat aat gcc tct 1930 Ala Leu Gln Phe Leu Arg Lys Glu Glu Ser Thr Pro Asn Asn Ala Ser 595 600 605 aca aag aat tca gaa aat gtg gat gaa tta cag ctc cct gaa ggg ttc 1978 Thr Lys Asn Ser Glu Asn Val Asp Glu Leu Gln Leu Pro Glu Gly Phe 610 615 620 agg cct gat ttt cgt cct aag atc cct tat tct gag agc ata aaa gaa 2026 Arg Pro Asp Phe Arg Pro Lys Ile Pro Tyr Ser Glu Ser Ile Lys Glu 625 630 635 atg cta acg aca ttt gga act gct acc tac aag gtg gga cta aag gtt 2074 Met Leu Thr Thr Phe Gly Thr Ala Thr Tyr Lys Val Gly Leu Lys Val 640 645 650 655 cat ccc aat gaa gag gat cct cgt gtt ccc ata atg tgt tgg ggt agc 2122 His Pro Asn Glu Glu Asp Pro Arg Val Pro Ile Met Cys Trp Gly Ser 660 665 670 tgc gcg tac acc atc caa agc ata gaa aga att ttg agt gat gaa gat 2170 Cys Ala Tyr Thr Ile Gln Ser Ile Glu Arg Ile Leu Ser Asp Glu Asp 675 680 685 aaa cca ttg ttt ggt cct tta cct tgc aga ctg gat gac tgt ctt agg 2218 Lys Pro Leu Phe Gly Pro Leu Pro Cys Arg Leu Asp Asp Cys Leu Arg 690 695 700 tca ttg acg aga ttt gcc gca gca cac tgg aca gtg gca tca gtt tca 2266 Ser Leu Thr Arg Phe Ala Ala Ala His Trp Thr Val Ala Ser Val Ser 705 710 715 gtg gtg caa gga cat ttt tgt aaa ctt ttt gca tca ctg gtg cct aat 2314 Val Val Gln Gly His Phe Cys Lys Leu Phe Ala Ser Leu Val Pro Asn 720 725 730 735 gac agc cat gag gaa ctt cca tgc ata tta gat att gac atg ttt cat 2362 Asp Ser His Glu Glu Leu Pro Cys Ile Leu Asp Ile Asp Met Phe His 740 745 750 tta ttg gtg ggc ttg gtg ctt gca ttt cct gcg ttg cag tgt cag gat 2410 Leu Leu Val Gly Leu Val Leu Ala Phe Pro Ala Leu Gln Cys Gln Asp 755 760 765 ttt tca ggg atc agc ctt ggc act gga gac ctt cac att ttc cat ctg 2458 Phe Ser Gly Ile Ser Leu Gly Thr Gly Asp Leu His Ile Phe His Leu 770 775 780 gtt act atg gca cac atc ata cag atc tta ctt acc tca tgt aca gaa 2506 Val Thr Met Ala His Ile Ile Gln Ile Leu Leu Thr Ser Cys Thr Glu 785 790 795 gag aat ggc atg gat caa gaa aat ccc cct tgt gaa gaa gaa tca gca 2554 Glu Asn Gly Met Asp Gln Glu Asn Pro Pro Cys Glu Glu Glu Ser Ala 800 805 810 815 gtt ctt gct ttg tat aaa aca ctt cac cag tat acg gga agt gcc ttg 2602 Val Leu Ala Leu Tyr Lys Thr Leu His Gln Tyr Thr Gly Ser Ala Leu 820 825 830 aaa gaa ata cca tcc ggc tgg cat ctg tgg agg agt gtc aga gct gga 2650 Lys Glu Ile Pro Ser Gly Trp His Leu Trp Arg Ser Val Arg Ala Gly 835 840 845 atc atg cct ttc ctg aag tgt tct gct tta ttt ttt cat tac tta aat 2698 Ile Met Pro Phe Leu Lys Cys Ser Ala Leu Phe Phe His Tyr Leu Asn 850 855 860 gga gtt cct tcc cca ccc gac att caa gtt cct gga aca agc cat ttt 2746 Gly Val Pro Ser Pro Pro Asp Ile Gln Val Pro Gly Thr Ser His Phe 865 870 875 gaa cat tta tgt agc tat ctt tcc cta cca aac aac ctc att tgc ctt 2794 Glu His Leu Cys Ser Tyr Leu Ser Leu Pro Asn Asn Leu Ile Cys Leu 880 885 890 895 ttt caa gaa aat agt gag ata atg aat tca ctg att gaa agt tgg tgc 2842 Phe Gln Glu Asn Ser Glu Ile Met Asn Ser Leu Ile Glu Ser Trp Cys 900 905 910 cgt aac agt gaa gtt aaa aga tat cta gaa ggt gaa aga gat gct ata 2890 Arg Asn Ser Glu Val Lys Arg Tyr Leu Glu Gly Glu Arg Asp Ala Ile 915 920 925 aga tat cca aga gaa tct aac aaa tta ata aac ctt cca gag gat tac 2938 Arg Tyr Pro Arg Glu Ser Asn Lys Leu Ile Asn Leu Pro Glu Asp Tyr 930 935 940 agc agc ctc att aat caa gca tcc aat ttc tcg tgc ccg aaa tca ggt 2986 Ser Ser Leu Ile Asn Gln Ala Ser Asn Phe Ser Cys Pro Lys Ser Gly 945 950 955 ggt gat aag agc aga gcc cca act ctg tgc ctt gtg tgc gga tct ctg 3034 Gly Asp Lys Ser Arg Ala Pro Thr Leu Cys Leu Val Cys Gly Ser Leu 960 965 970 975 ctg tgc tcc cag agt tac tgc tgc cag act gaa ctg gaa ggg gag gat 3082 Leu Cys Ser Gln Ser Tyr Cys Cys Gln Thr Glu Leu Glu Gly Glu Asp 980 985 990 gta gga gcc tgc aca gct cac acc tac tcc tgt ggc tct gga gtg ggc 3130 Val Gly Ala Cys Thr Ala His Thr Tyr Ser Cys Gly Ser Gly Val Gly 995 1000 1005 atc ttc ctg aga gta cgg gaa tgt cag gtg cta ttt tta gct ggc aaa 3178 Ile Phe Leu Arg Val Arg Glu Cys Gln Val Leu Phe Leu Ala Gly Lys 1010 1015 1020 acc aaa ggc tgt ttt tat tct cct cct tac ctt gat gac tat ggg gag 3226 Thr Lys Gly Cys Phe Tyr Ser Pro Pro Tyr Leu Asp Asp Tyr Gly Glu 1025 1030 1035 acc gac cag gga ctc aga cgg gga aat cct tta cat tta tgc aaa gag 3274 Thr Asp Gln Gly Leu Arg Arg Gly Asn Pro Leu His Leu Cys Lys Glu 1040 1045 1050 1055 cga ttc aag aag att cag aag ctc tgg cac caa cac agt gtc aca gag 3322 Arg Phe Lys Lys Ile Gln Lys Leu Trp His Gln His Ser Val Thr Glu 1060 1065 1070 gaa att gga cat gca cag gaa gcc aat cag aca ctg gtt ggc att gac 3370 Glu Ile Gly His Ala Gln Glu Ala Asn Gln Thr Leu Val Gly Ile Asp 1075 1080 1085 tgg caa cat tta taattattgc accaccaaaa aacacaaact tggatttttt 3422 Trp Gln His Leu 1090 taacccagtt ggctttttaa gaaagaaaga agttctgctg aatttggaaa taaattcttt 3482 atttaaactt taaaaaaaaa 3502 <210> SEQ ID NO 58 <211> LENGTH: 1726 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 58 Met Leu Ala Cys Leu Gln Ala Cys Ala Gly Ser Val Ser Gln Glu Leu -10 -5 -1 1 Ser Glu Thr Ile Leu Thr Met Val Ala Asn Cys Ser Asn Val Met Asn 5 10 15 Lys Ala Arg Gln Pro Pro Pro Gly Val Met Pro Lys Gly Arg Pro Pro 20 25 30 35 Ser Ala Ser Ser Leu Asp Ala Ile Ser Pro Val Gln Ile Asp Pro Leu 40 45 50 Ala Gly Met Thr Ser Leu Ser Ile Gly Gly Ser Ala Ala Pro His Thr 55 60 65 Gln Ser Met Gln Gly Phe Pro Pro Asn Leu Gly Ser Ala Phe Ser Thr 70 75 80 Pro Gln Ser Pro Ala Lys Ala Phe Pro Pro Leu Ser Thr Pro Asn Gln 85 90 95 Thr Thr Ala Phe Ser Gly Ile Gly Gly Leu Ser Ser Gln Leu Pro Val 100 105 110 115 Gly Gly Leu Gly Thr Gly Ser Leu Thr Gly Ile Gly Thr Gly Ala Leu 120 125 130 Gly Leu Pro Ala Val Asn Asn Asp Pro Phe Val Gln Arg Lys Leu Gly 135 140 145 Thr Ser Gly Leu Asn Gln Pro Thr Phe Gln Gln Ser Lys Met Lys Pro 150 155 160 Ser Asp Leu Ser Gln Val Trp Pro Glu Ala Asn Gln His Phe Ser Lys 165 170 175 Glu Ile Asp Asp Glu Ala Asn Ser Tyr Phe Gln Arg Ile Tyr Asn His 180 185 190 195 Pro Pro His Pro Thr Met Ser Val Asp Glu Val Leu Glu Met Leu Gln 200 205 210 Arg Phe Lys Asp Ser Thr Ile Lys Arg Glu Arg Glu Val Phe Asn Cys 215 220 225 Met Leu Arg Asn Leu Phe Glu Glu Tyr Arg Phe Phe Pro Gln Tyr Pro 230 235 240 Asp Lys Glu Leu His Ile Thr Ala Cys Leu Phe Gly Gly Ile Ile Glu 245 250 255 Lys Gly Leu Val Thr Tyr Met Ala Leu Gly Leu Ala Leu Arg Tyr Val 260 265 270 275 Leu Glu Ala Leu Arg Lys Pro Phe Gly Ser Lys Met Tyr Tyr Phe Gly 280 285 290 Ile Ala Ala Leu Asp Arg Phe Lys Asn Arg Leu Lys Asp Tyr Pro Gln 295 300 305 Tyr Cys Gln His Leu Ala Ser Ile Ser His Phe Met Gln Phe Pro His 310 315 320 His Leu Gln Glu Tyr Ile Glu Tyr Gly Gln Gln Ser Arg Asp Pro Pro 325 330 335 Val Lys Met Gln Gly Ser Ile Thr Thr Pro Gly Ser Ile Ala Leu Ala 340 345 350 355 Gln Ala Gln Ala Gln Ala Gln Val Pro Ala Lys Ala Pro Leu Ala Gly 360 365 370 Gln Val Ser Thr Met Val Thr Thr Ser Thr Thr Thr Thr Val Ala Lys 375 380 385 Thr Val Thr Val Thr Arg Pro Thr Gly Val Ser Phe Lys Lys Asp Val 390 395 400 Pro Pro Ser Ile Asn Thr Thr Asn Ile Asp Thr Leu Leu Val Ala Thr 405 410 415 Asp Gln Thr Glu Arg Ile Val Glu Pro Pro Glu Asn Ile Gln Glu Lys 420 425 430 435 Ile Ala Phe Ile Phe Asn Asn Leu Ser Gln Ser Asn Met Thr Gln Lys 440 445 450 Val Glu Glu Leu Lys Glu Thr Val Lys Glu Glu Phe Met Pro Trp Val 455 460 465 Ser Gln Tyr Leu Val Met Lys Arg Val Ser Ile Glu Pro Asn Phe His 470 475 480 Ser Leu Tyr Ser Asn Phe Leu Asp Thr Leu Lys Asn Pro Glu Phe Asn 485 490 495 Lys Met Val Leu Asn Glu Thr Tyr Arg Asn Ile Lys Val Leu Leu Thr 500 505 510 515 Ser Asp Lys Ala Ala Ala Asn Phe Ser Asp Arg Ser Leu Leu Lys Asn 520 525 530 Leu Gly His Trp Leu Gly Met Ile Thr Leu Ala Lys Asn Lys Pro Ile 535 540 545 Leu His Thr Asp Leu Asp Val Lys Ser Leu Leu Leu Glu Ala Tyr Val 550 555 560 Lys Gly Gln Gln Glu Leu Leu Tyr Val Val Pro Phe Val Ala Lys Val 565 570 575 Leu Glu Ser Ser Ile Arg Ser Val Val Phe Arg Pro Pro Asn Pro Trp 580 585 590 595 Thr Met Ala Ile Met Asn Val Leu Ala Glu Leu His Gln Glu His Asp 600 605 610 Leu Lys Leu Asn Leu Lys Phe Glu Ile Glu Val Leu Cys Lys Asn Leu 615 620 625 Ala Leu Asp Ile Asn Glu Leu Lys Pro Gly Asn Leu Leu Lys Asp Lys 630 635 640 Asp Arg Leu Lys Asn Leu Asp Glu Gln Leu Ser Ala Pro Lys Lys Asp 645 650 655 Val Lys Gln Pro Glu Glu Leu Pro Pro Ile Thr Thr Thr Thr Thr Ser 660 665 670 675 Thr Thr Pro Ala Thr Asn Thr Thr Cys Thr Ala Thr Val Pro Pro Gln 680 685 690 Pro Gln Tyr Ser Tyr His Asp Ile Asn Val Tyr Ser Leu Ala Gly Leu 695 700 705 Ala Pro His Ile Thr Leu Asn Pro Thr Ile Pro Leu Phe Gln Ala His 710 715 720 Pro Gln Leu Lys Gln Cys Val Arg Gln Ala Ile Glu Arg Ala Val Gln 725 730 735 Glu Leu Val His Pro Val Val Asp Arg Ser Ile Lys Ile Ala Met Thr 740 745 750 755 Thr Cys Glu Gln Ile Val Arg Lys Asp Phe Ala Leu Asp Ser Glu Glu 760 765 770 Ser Arg Met Arg Ile Ala Ala His His Met Met Arg Asn Leu Thr Ala 775 780 785 Gly Met Ala Met Ile Thr Cys Arg Glu Pro Leu Leu Met Ser Ile Ser 790 795 800 Thr Asn Leu Lys Asn Ser Phe Ala Ser Ala Leu Arg Thr Ala Ser Pro 805 810 815 Gln Gln Arg Glu Met Met Asp Gln Ala Ala Ala Gln Leu Ala Gln Asp 820 825 830 835 Asn Cys Glu Leu Ala Cys Cys Phe Ile Gln Lys Thr Ala Val Glu Lys 840 845 850 Ala Gly Pro Glu Met Asp Lys Arg Leu Ala Thr Glu Phe Glu Leu Arg 855 860 865 Lys His Ala Arg Gln Glu Gly Arg Arg Tyr Cys Asp Pro Val Val Leu 870 875 880 Thr Tyr Gln Ala Glu Arg Met Pro Glu Gln Ile Arg Leu Lys Val Gly 885 890 895 Gly Val Asp Pro Lys Gln Leu Ala Val Tyr Glu Glu Phe Ala Arg Asn 900 905 910 915 Val Pro Gly Phe Leu Pro Thr Asn Asp Leu Ser Gln Pro Thr Gly Phe 920 925 930 Leu Ala Gln Pro Met Lys Gln Ala Trp Ala Thr Asp Asp Val Ala Gln 935 940 945 Ile Tyr Asp Lys Cys Ile Thr Glu Leu Glu Gln His Leu His Ala Ile 950 955 960 Pro Pro Thr Leu Ala Met Asn Pro Gln Ala Gln Ala Leu Arg Ser Leu 965 970 975 Leu Glu Val Val Val Leu Ser Arg Asn Ser Arg Asp Ala Ile Ala Ala 980 985 990 995 Leu Gly Leu Leu Gln Lys Ala Val Glu Gly Leu Leu Asp Ala Thr Ser 1000 1005 1010 Gly Ala Asp Ala Asp Leu Leu Leu Arg Tyr Arg Glu Cys His Leu Leu 1015 1020 1025 Val Leu Lys Ala Leu Gln Asp Gly Arg Ala Tyr Gly Ser Pro Trp Cys 1030 1035 1040 Asn Lys Gln Ile Thr Arg Cys Leu Ile Glu Cys Arg Asp Glu Tyr Lys 1045 1050 1055 Tyr Asn Val Glu Ala Val Glu Leu Leu Ile Arg Asn His Leu Val Asn 1060 1065 1070 1075 Met Gln Gln Tyr Asp Phe His Leu Ala Gln Ser Met Glu Asn Gly Leu 1080 1085 1090 Asn Tyr Met Ala Val Ala Phe Ala Met Gln Leu Val Lys Ile Leu Leu 1095 1100 1105 Val Asp Glu Arg Ser Val Ala His Val Thr Glu Ala Asp Leu Phe His 1110 1115 1120 Thr Ile Glu Thr Leu Met Arg Ile Asn Ala His Ser Arg Gly Asn Ala 1125 1130 1135 Pro Glu Gly Leu Ser Gln Leu Met Glu Val Val Arg Ser Asn Tyr Glu 1140 1145 1150 1155 Ala Met Ile Asp Arg Ala His Gly Gly Pro Asn Phe Met Met His Ser 1160 1165 1170 Gly Ile Ser Gln Ala Ser Glu Tyr Asp Asp Pro Pro Gly Leu Arg Glu 1175 1180 1185 Lys Ala Glu Tyr Leu Leu Arg Glu Trp Val Asn Leu Tyr His Ser Ala 1190 1195 1200 Ala Ala Gly Arg Asp Ser Thr Lys Ala Phe Ser Ala Phe Val Gly Gln 1205 1210 1215 Met His Gln Gln Gly Ile Leu Lys Thr Asp Asp Leu Ile Thr Arg Phe 1220 1225 1230 1235 Phe Arg Leu Cys Thr Glu Met Cys Val Glu Ile Ser Tyr Arg Ala Gln 1240 1245 1250 Ala Glu Gln Gln His Asn Pro Ala Ala Asn Pro Thr Met Ile Arg Ala 1255 1260 1265 Lys Cys Tyr His Asn Leu Asp Ala Phe Val Arg Leu Ile Ala Leu Leu 1270 1275 1280 Val Lys His Ser Gly Glu Ala Thr Asn Thr Val Thr Lys Ile Asn Leu 1285 1290 1295 Leu Asn Lys Val Leu Gly Ile Val Val Gly Val Leu Leu Gln Asp His 1300 1305 1310 1315 Asp Val Arg Gln Ser Glu Phe Gln Gln Leu Pro Tyr His Arg Ile Phe 1320 1325 1330 Ile Met Leu Leu Leu Glu Leu Asn Ala Pro Glu His Val Leu Glu Thr 1335 1340 1345 Ile Asn Phe Gln Thr Leu Thr Ala Phe Cys Asn Thr Phe His Ile Leu 1350 1355 1360 Arg Pro Thr Lys Ala Pro Gly Phe Val Tyr Ala Trp Leu Glu Leu Ile 1365 1370 1375 Ser His Arg Ile Phe Ile Ala Arg Met Leu Ala His Thr Pro Gln Gln 1380 1385 1390 1395 Lys Gly Trp Pro Met Tyr Ala Gln Leu Leu Ile Asp Leu Phe Lys Tyr 1400 1405 1410 Leu Ala Pro Phe Leu Arg Asn Val Glu Leu Thr Lys Pro Met Gln Ile 1415 1420 1425 Leu Tyr Lys Gly Thr Leu Arg Val Leu Leu Val Leu Leu His Asp Phe 1430 1435 1440 Pro Glu Phe Leu Cys Asp Tyr His Tyr Gly Phe Cys Asp Val Ile Pro 1445 1450 1455 Pro Asn Cys Ile Gln Leu Arg Asn Leu Ile Leu Ser Ala Phe Pro Arg 1460 1465 1470 1475 Asn Met Arg Leu Pro Asp Pro Phe Thr Pro Asn Leu Lys Val Asp Met 1480 1485 1490 Leu Ser Glu Ile Asn Ile Ala Pro Arg Ile Leu Thr Asn Phe Thr Gly 1495 1500 1505 Val Met Pro Pro Gln Phe Lys Lys Asp Leu Asp Ser Tyr Leu Lys Thr 1510 1515 1520 Arg Ser Pro Val Thr Phe Leu Ser Asp Leu Arg Ser Asn Leu Gln Val 1525 1530 1535 Ser Asn Glu Pro Gly Asn Arg Tyr Asn Leu Gln Leu Ile Asn Ala Leu 1540 1545 1550 1555 Val Leu Tyr Val Gly Thr Gln Ala Ile Ala His Ile His Asn Lys Gly 1560 1565 1570 Ser Thr Pro Ser Met Ser Thr Ile Thr His Ser Ala His Met Asp Ile 1575 1580 1585 Phe Gln Asn Leu Ala Val Asp Leu Asp Thr Glu Gly Arg Tyr Leu Phe 1590 1595 1600 Leu Asn Ala Ile Ala Asn Gln Leu Arg Tyr Pro Asn Ser His Thr His 1605 1610 1615 Tyr Phe Ser Cys Thr Met Leu Tyr Leu Phe Ala Glu Ala Asn Thr Glu 1620 1625 1630 1635 Ala Ile Gln Glu Gln Ile Thr Arg Val Leu Leu Glu Arg Leu Ile Val 1640 1645 1650 Asn Arg Pro His Pro Trp Gly Leu Leu Ile Thr Phe Ile Glu Leu Ile 1655 1660 1665 Lys Asn Pro Ala Phe Lys Phe Trp Asn His Glu Phe Val His Cys Ala 1670 1675 1680 Pro Glu Ile Glu Lys Leu Phe Gln Ser Val Ala Gln Cys Cys Met Gly 1685 1690 1695 Gln Lys Gln Ala Gln Gln Val Met Glu Gly Thr Gly Ala Ser 1700 1705 1710 <210> SEQ ID NO 59 <211> LENGTH: 5178 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 59 atgttggcct gtctgcaagc ttgtgcaggg agtgtttctc aggagctatc agaaactatc 60 ctcaccatgg tagccaattg cagtaatgtt atgaataagg ccagacaacc accacctgga 120 gttatgccaa aaggacgtcc tcctagtgct agcagcttag atgccatttc tcctgttcag 180 attgaccctc ttgctggaat gacatctctt agtataggtg gttcagctgc ccctcacacc 240 cagagtatgc agggttttcc tccaaatttg ggttctgcat tcagtacccc tcagtcacca 300 gcaaaagcat ttccacccct ttcaaccccc aatcagacca ctgcattcag tggtattgga 360 ggactttcat cacagcttcc agtaggtggt cttggcacag gcagcctgac tggtatagga 420 actggtgctc ttggactccc tgcagtgaat aacgaccctt ttgtacagag gaaactgggc 480 acctctggac tgaatcagcc tacattccag cagagtaaga tgaaaccttc ggacttgtct 540 caggtgtggc cagaggcaaa ccagcacttt agtaaagaga tagatgatga agcaaacagc 600 tatttccagc gaatatataa tcatccacca catccaacca tgtctgttga tgaggtatta 660 gaaatgctgc agagatttaa agactctact ataaagaggg aacgagaagt atttaactgt 720 atgctaagga acttgtttga agaatatcgt ttttttcccc agtatcctga taaagagtta 780 catataacag cctgcctatt tggtggtata attgagaaag gactggtcac ttacatggca 840 ctaggtctgg ctctacgata tgttcttgaa gccttacgca agccttttgg atccaaaatg 900 tattatttcg ggattgctgc actagataga tttaaaaaca gattgaagga ctatccccag 960 tattgtcaac atttggcttc tatcagtcac tttatgcaat ttccacatca tttacaggag 1020 tatattgagt atggacagca gtctagagat cctcctgtga aaatgcaagg ctctatcaca 1080 acccctggaa gtattgcact ggctcaggcc caggctcagg cccaggttcc agcaaaagct 1140 cctcttgctg gtcaagttag cactatggta accacctcaa caactaccac tgttgctaaa 1200 acggttacgg tcaccaggcc aactggagtc agctttaaga aagatgtgcc accttctatt 1260 aatactacaa atatagatac gttgcttgtg gccacagatc aaactgagag aattgtggag 1320 cccccagaaa atatccagga gaaaattgct tttattttca ataatctctc acagtcaaat 1380 atgacacaaa aggttgaaga gctaaaggaa acggtgaaag aagaatttat gccttgggtt 1440 tcacagtatc tggttatgaa gagagtcagt attgagccaa actttcatag cctgtattca 1500 aacttccttg acacgctgaa gaatcctgaa tttaacaaga tggttctgaa tgagacctac 1560 agaaacatta aagtgctcct gacctctgat aaagctgcag ccaatttctc agatcgttct 1620 ttgctgaaga acttgggaca ttggctagga atgatcacat tagctaaaaa caaacccatc 1680 ttacacactg acttggatgt gaaatcattg ctgctagagg cttatgttaa aggacaacaa 1740 gaattgctct atgtagtgcc ctttgttgcc aaagtcttag aatctagcat tcgtagtgtg 1800 gtttttaggc caccaaaccc ttggacaatg gcaattatga atgtattagc tgagctacat 1860 caggagcatg acttaaagtt aaacttgaag tttgaaatcg aggttctctg caagaacctt 1920 gcattagaca tcaatgagct aaaacctgga aacctcctaa aggataaaga tcgcctgaag 1980 aatttagatg agcaactctc tgctccaaag aaagatgtca agcagccaga agaactccct 2040 cccatcacaa ccacaacaac ttctactaca ccagctacca acaccacttg tacagccacg 2100 gttccaccac agccacagta cagctaccac gacatcaatg tctattccct tgcgggcttg 2160 gcaccacaca ttactctgaa tccaacaatt cccttgtttc aggcccatcc acagttgaag 2220 cagtgtgtgc gtcaggcaat tgaacgggct gtccaggagc tggtccatcc tgtggtggat 2280 cgatcaatta agattgccat gactacttgt gagcaaatag tcaggaagga ttttgccctg 2340 gattcggagg aatctcgaat gcgaatagca gctcatcaca tgatgcgtaa cttgacagct 2400 ggaatggcta tgattacatg cagggaacct ttgctcatga gcatatctac caacttaaaa 2460 aacagttttg cctcagccct tcgtactgct tccccacaac aaagagaaat gatggatcag 2520 gcagctgctc aattagctca ggacaattgt gagttggctt gctgttttat tcagaagact 2580 gcagtagaaa aagcaggccc tgagatggac aagagattag caactgaatt tgagctgaga 2640 aaacatgcta ggcaagaagg acgcagatac tgtgatcctg ttgttttaac atatcaagct 2700 gaacggatgc cagagcaaat caggctgaaa gttggtggtg tggacccaaa gcagttggct 2760 gtttatgaag agtttgcacg caatgttcct ggcttcttac ctacaaatga cttaagtcag 2820 cccacgggat ttttagccca gcccatgaag caagcttggg caacagatga tgtagctcag 2880 atttatgata agtgtattac agaactggag caacatctac atgccatccc accaactttg 2940 gccatgaacc ctcaagctca ggctcttcga agtctcttgg aggttgtagt tttatctcga 3000 aactctcggg atgccatagc tgctcttgga ttgctccaaa aggctgtaga gggcttacta 3060 gatgccacaa gtggtgctga tgctgacctt ctgctgcgct acagggaatg ccacctcttg 3120 gtcctaaaag ctctgcagga tggccgggca tatgggtctc catggtgcaa caaacagatc 3180 acaaggtgcc taattgaatg tcgagatgaa tataaatata atgtggaggc tgtggagctg 3240 ctaattcgca atcatttggt taatatgcag cagtatgatt ttcacctagc gcagtcaatg 3300 gagaatggct taaactacat ggctgtggca tttgctatgc agttagtaaa aatcctgctg 3360 gtggatgaaa ggagtgttgc tcatgttact gaggcagatc tgttccacac cattgaaacc 3420 ctcatgagga ttaatgctca ttccagaggc aatgctccag aaggattgtc ccagctgatg 3480 gaagtagtgc gatccaacta tgaagcaatg attgatcgtg ctcatggagg cccaaacttt 3540 atgatgcatt ctgggatctc tcaagcctca gagtatgatg accctccagg cctgagggag 3600 aaggcagagt atcttctgag ggaatgggtg aatctctacc attcagcagc agctggccgc 3660 gacagtacca aagctttctc tgcatttgtt ggacagatgc accagcaagg aatactgaag 3720 accgatgatc tcataacaag gttctttcgt ctgtgtactg aaatgtgtgt tgaaatcagt 3780 taccgtgctc aggctgagca gcagcacaat cctgctgcca atcccaccat gatccgagcc 3840 aagtgctatc acaacctgga tgcctttgtt cgactcattg cactgctcgt gaaacactca 3900 ggggaggcca ccaacactgt cacaaagatt aatctgctga acaaggtcct tggtatagta 3960 gtgggagttc tccttcagga tcatgatgtt cgtcagagtg aatttcagca acttccctac 4020 catcgaattt ttatcatgct tctcttggaa ctcaatgcac ctgagcatgt gttggaaacc 4080 attaatttcc agacacttac agctttctgc aatacattcc acatcttgag gcctaccaaa 4140 gctcctggct ttgtatatgc ctggcttgaa ctgatttccc atcggatatt tattgcaaga 4200 atgctggcac atacgccaca gcagaagggg tggcctatgt atgcacagct actgattgat 4260 ttattcaaat atttagcgcc tttccttaga aatgtggaac tcaccaaacc tatgcaaatc 4320 ctctacaagg gcactttaag agtgctgctg gttcttttgc atgatttccc agagttcctt 4380 tgtgattacc attatgggtt ctgtgatgtg atcccaccta attgtatcca gttaagaaat 4440 ttgatcctga gtgcctttcc aagaaacatg aggctccccg acccattcac tcctaatcta 4500 aaggtggaca tgttgagtga aattaacatt gctccccgga ttctcaccaa tttcactgga 4560 gtaatgccac ctcagttcaa aaaggatttg gattcctatc ttaaaactcg atcaccagtc 4620 actttcctgt ctgatctgcg cagcaaccta caggtatcca atgaacctgg gaatcgctac 4680 aacctccagc tcatcaatgc actggtgctc tatgtcggga ctcaggccat tgcgcacatc 4740 cacaacaagg gcagcacacc ttcaatgagc accatcactc actcagcaca catggatatc 4800 ttccagaatt tggctgtgga cttggacact gagggtcgct atctcttttt gaatgcaatt 4860 gcaaatcagc tccggtaccc aaatagccac actcactact tcagttgcac catgctgtac 4920 ctttttgcag aggccaatac ggaagccatc caagaacaga tcacaagagt tctcttggaa 4980 cggttgattg taaataggcc acatccttgg ggtcttctta ttaccttcat tgagctgatt 5040 aaaaacccag cgtttaagtt ctggaaccat gaatttgtac actgtgcccc agaaatcgaa 5100 aagttattcc agtcggtcgc acagtgctgc atgggacaga agcaggccca gcaagtaatg 5160 gaagggacag gtgccagt 5178 <210> SEQ ID NO 60 <211> LENGTH: 5457 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: sig_peptide <222> LOCATION: (8)..(46) <221> NAME/KEY: mat_peptide <222> LOCATION: (47)..(5185) <221> NAME/KEY: CDS <222> LOCATION: (8)..(5185) <400> SEQUENCE: 60 ggcgaca atg ttg gcc tgt ctg caa gct tgt gca ggg agt gtt tct cag 49 Met Leu Ala Cys Leu Gln Ala Cys Ala Gly Ser Val Ser Gln -10 -5 -1 1 gag cta tca gaa act atc ctc acc atg gta gcc aat tgc agt aat gtt 97 Glu Leu Ser Glu Thr Ile Leu Thr Met Val Ala Asn Cys Ser Asn Val 5 10 15 atg aat aag gcc aga caa cca cca cct gga gtt atg cca aaa gga cgt 145 Met Asn Lys Ala Arg Gln Pro Pro Pro Gly Val Met Pro Lys Gly Arg 20 25 30 cct cct agt gct agc agc tta gat gcc att tct cct gtt cag att gac 193 Pro Pro Ser Ala Ser Ser Leu Asp Ala Ile Ser Pro Val Gln Ile Asp 35 40 45 cct ctt gct gga atg aca tct ctt agt ata ggt ggt tca gct gcc cct 241 Pro Leu Ala Gly Met Thr Ser Leu Ser Ile Gly Gly Ser Ala Ala Pro 50 55 60 65 cac acc cag agt atg cag ggt ttt cct cca aat ttg ggt tct gca ttc 289 His Thr Gln Ser Met Gln Gly Phe Pro Pro Asn Leu Gly Ser Ala Phe 70 75 80 agt acc cct cag tca cca gca aaa gca ttt cca ccc ctt tca acc ccc 337 Ser Thr Pro Gln Ser Pro Ala Lys Ala Phe Pro Pro Leu Ser Thr Pro 85 90 95 aat cag acc act gca ttc agt ggt att gga gga ctt tca tca cag ctt 385 Asn Gln Thr Thr Ala Phe Ser Gly Ile Gly Gly Leu Ser Ser Gln Leu 100 105 110 cca gta ggt ggt ctt ggc aca ggc agc ctg act ggt ata gga act ggt 433 Pro Val Gly Gly Leu Gly Thr Gly Ser Leu Thr Gly Ile Gly Thr Gly 115 120 125 gct ctt gga ctc cct gca gtg aat aac gac cct ttt gta cag agg aaa 481 Ala Leu Gly Leu Pro Ala Val Asn Asn Asp Pro Phe Val Gln Arg Lys 130 135 140 145 ctg ggc acc tct gga ctg aat cag cct aca ttc cag cag agt aag atg 529 Leu Gly Thr Ser Gly Leu Asn Gln Pro Thr Phe Gln Gln Ser Lys Met 150 155 160 aaa cct tcg gac ttg tct cag gtg tgg cca gag gca aac cag cac ttt 577 Lys Pro Ser Asp Leu Ser Gln Val Trp Pro Glu Ala Asn Gln His Phe 165 170 175 agt aaa gag ata gat gat gaa gca aac agc tat ttc cag cga ata tat 625 Ser Lys Glu Ile Asp Asp Glu Ala Asn Ser Tyr Phe Gln Arg Ile Tyr 180 185 190 aat cat cca cca cat cca acc atg tct gtt gat gag gta tta gaa atg 673 Asn His Pro Pro His Pro Thr Met Ser Val Asp Glu Val Leu Glu Met 195 200 205 ctg cag aga ttt aaa gac tct act ata aag agg gaa cga gaa gta ttt 721 Leu Gln Arg Phe Lys Asp Ser Thr Ile Lys Arg Glu Arg Glu Val Phe 210 215 220 225 aac tgt atg cta agg aac ttg ttt gaa gaa tat cgt ttt ttt ccc cag 769 Asn Cys Met Leu Arg Asn Leu Phe Glu Glu Tyr Arg Phe Phe Pro Gln 230 235 240 tat cct gat aaa gag tta cat ata aca gcc tgc cta ttt ggt ggt ata 817 Tyr Pro Asp Lys Glu Leu His Ile Thr Ala Cys Leu Phe Gly Gly Ile 245 250 255 att gag aaa gga ctg gtc act tac atg gca cta ggt ctg gct cta cga 865 Ile Glu Lys Gly Leu Val Thr Tyr Met Ala Leu Gly Leu Ala Leu Arg 260 265 270 tat gtt ctt gaa gcc tta cgc aag cct ttt gga tcc aaa atg tat tat 913 Tyr Val Leu Glu Ala Leu Arg Lys Pro Phe Gly Ser Lys Met Tyr Tyr 275 280 285 ttc ggg att gct gca cta gat aga ttt aaa aac aga ttg aag gac tat 961 Phe Gly Ile Ala Ala Leu Asp Arg Phe Lys Asn Arg Leu Lys Asp Tyr 290 295 300 305 ccc cag tat tgt caa cat ttg gct tct atc agt cac ttt atg caa ttt 1009 Pro Gln Tyr Cys Gln His Leu Ala Ser Ile Ser His Phe Met Gln Phe 310 315 320 cca cat cat tta cag gag tat att gag tat gga cag cag tct aga gat 1057 Pro His His Leu Gln Glu Tyr Ile Glu Tyr Gly Gln Gln Ser Arg Asp 325 330 335 cct cct gtg aaa atg caa ggc tct atc aca acc cct gga agt att gca 1105 Pro Pro Val Lys Met Gln Gly Ser Ile Thr Thr Pro Gly Ser Ile Ala 340 345 350 ctg gct cag gcc cag gct cag gcc cag gtt cca gca aaa gct cct ctt 1153 Leu Ala Gln Ala Gln Ala Gln Ala Gln Val Pro Ala Lys Ala Pro Leu 355 360 365 gct ggt caa gtt agc act atg gta acc acc tca aca act acc act gtt 1201 Ala Gly Gln Val Ser Thr Met Val Thr Thr Ser Thr Thr Thr Thr Val 370 375 380 385 gct aaa acg gtt acg gtc acc agg cca act gga gtc agc ttt aag aaa 1249 Ala Lys Thr Val Thr Val Thr Arg Pro Thr Gly Val Ser Phe Lys Lys 390 395 400 gat gtg cca cct tct att aat act aca aat ata gat acg ttg ctt gtg 1297 Asp Val Pro Pro Ser Ile Asn Thr Thr Asn Ile Asp Thr Leu Leu Val 405 410 415 gcc aca gat caa act gag aga att gtg gag ccc cca gaa aat atc cag 1345 Ala Thr Asp Gln Thr Glu Arg Ile Val Glu Pro Pro Glu Asn Ile Gln 420 425 430 gag aaa att gct ttt att ttc aat aat ctc tca cag tca aat atg aca 1393 Glu Lys Ile Ala Phe Ile Phe Asn Asn Leu Ser Gln Ser Asn Met Thr 435 440 445 caa aag gtt gaa gag cta aag gaa acg gtg aaa gaa gaa ttt atg cct 1441 Gln Lys Val Glu Glu Leu Lys Glu Thr Val Lys Glu Glu Phe Met Pro 450 455 460 465 tgg gtt tca cag tat ctg gtt atg aag aga gtc agt att gag cca aac 1489 Trp Val Ser Gln Tyr Leu Val Met Lys Arg Val Ser Ile Glu Pro Asn 470 475 480 ttt cat agc ctg tat tca aac ttc ctt gac acg ctg aag aat cct gaa 1537 Phe His Ser Leu Tyr Ser Asn Phe Leu Asp Thr Leu Lys Asn Pro Glu 485 490 495 ttt aac aag atg gtt ctg aat gag acc tac aga aac att aaa gtg ctc 1585 Phe Asn Lys Met Val Leu Asn Glu Thr Tyr Arg Asn Ile Lys Val Leu 500 505 510 ctg acc tct gat aaa gct gca gcc aat ttc tca gat cgt tct ttg ctg 1633 Leu Thr Ser Asp Lys Ala Ala Ala Asn Phe Ser Asp Arg Ser Leu Leu 515 520 525 aag aac ttg gga cat tgg cta gga atg atc aca tta gct aaa aac aaa 1681 Lys Asn Leu Gly His Trp Leu Gly Met Ile Thr Leu Ala Lys Asn Lys 530 535 540 545 ccc atc tta cac act gac ttg gat gtg aaa tca ttg ctg cta gag gct 1729 Pro Ile Leu His Thr Asp Leu Asp Val Lys Ser Leu Leu Leu Glu Ala 550 555 560 tat gtt aaa gga caa caa gaa ttg ctc tat gta gtg ccc ttt gtt gcc 1777 Tyr Val Lys Gly Gln Gln Glu Leu Leu Tyr Val Val Pro Phe Val Ala 565 570 575 aaa gtc tta gaa tct agc att cgt agt gtg gtt ttt agg cca cca aac 1825 Lys Val Leu Glu Ser Ser Ile Arg Ser Val Val Phe Arg Pro Pro Asn 580 585 590 cct tgg aca atg gca att atg aat gta tta gct gag cta cat cag gag 1873 Pro Trp Thr Met Ala Ile Met Asn Val Leu Ala Glu Leu His Gln Glu 595 600 605 cat gac tta aag tta aac ttg aag ttt gaa atc gag gtt ctc tgc aag 1921 His Asp Leu Lys Leu Asn Leu Lys Phe Glu Ile Glu Val Leu Cys Lys 610 615 620 625 aac ctt gca tta gac atc aat gag cta aaa cct gga aac ctc cta aag 1969 Asn Leu Ala Leu Asp Ile Asn Glu Leu Lys Pro Gly Asn Leu Leu Lys 630 635 640 gat aaa gat cgc ctg aag aat tta gat gag caa ctc tct gct cca aag 2017 Asp Lys Asp Arg Leu Lys Asn Leu Asp Glu Gln Leu Ser Ala Pro Lys 645 650 655 aaa gat gtc aag cag cca gaa gaa ctc cct ccc atc aca acc aca aca 2065 Lys Asp Val Lys Gln Pro Glu Glu Leu Pro Pro Ile Thr Thr Thr Thr 660 665 670 act tct act aca cca gct acc aac acc act tgt aca gcc acg gtt cca 2113 Thr Ser Thr Thr Pro Ala Thr Asn Thr Thr Cys Thr Ala Thr Val Pro 675 680 685 cca cag cca cag tac agc tac cac gac atc aat gtc tat tcc ctt gcg 2161 Pro Gln Pro Gln Tyr Ser Tyr His Asp Ile Asn Val Tyr Ser Leu Ala 690 695 700 705 ggc ttg gca cca cac att act ctg aat cca aca att ccc ttg ttt cag 2209 Gly Leu Ala Pro His Ile Thr Leu Asn Pro Thr Ile Pro Leu Phe Gln 710 715 720 gcc cat cca cag ttg aag cag tgt gtg cgt cag gca att gaa cgg gct 2257 Ala His Pro Gln Leu Lys Gln Cys Val Arg Gln Ala Ile Glu Arg Ala 725 730 735 gtc cag gag ctg gtc cat cct gtg gtg gat cga tca att aag att gcc 2305 Val Gln Glu Leu Val His Pro Val Val Asp Arg Ser Ile Lys Ile Ala 740 745 750 atg act act tgt gag caa ata gtc agg aag gat ttt gcc ctg gat tcg 2353 Met Thr Thr Cys Glu Gln Ile Val Arg Lys Asp Phe Ala Leu Asp Ser 755 760 765 gag gaa tct cga atg cga ata gca gct cat cac atg atg cgt aac ttg 2401 Glu Glu Ser Arg Met Arg Ile Ala Ala His His Met Met Arg Asn Leu 770 775 780 785 aca gct gga atg gct atg att aca tgc agg gaa cct ttg ctc atg agc 2449 Thr Ala Gly Met Ala Met Ile Thr Cys Arg Glu Pro Leu Leu Met Ser 790 795 800 ata tct acc aac tta aaa aac agt ttt gcc tca gcc ctt cgt act gct 2497 Ile Ser Thr Asn Leu Lys Asn Ser Phe Ala Ser Ala Leu Arg Thr Ala 805 810 815 tcc cca caa caa aga gaa atg atg gat cag gca gct gct caa tta gct 2545 Ser Pro Gln Gln Arg Glu Met Met Asp Gln Ala Ala Ala Gln Leu Ala 820 825 830 cag gac aat tgt gag ttg gct tgc tgt ttt att cag aag act gca gta 2593 Gln Asp Asn Cys Glu Leu Ala Cys Cys Phe Ile Gln Lys Thr Ala Val 835 840 845 gaa aaa gca ggc cct gag atg gac aag aga tta gca act gaa ttt gag 2641 Glu Lys Ala Gly Pro Glu Met Asp Lys Arg Leu Ala Thr Glu Phe Glu 850 855 860 865 ctg aga aaa cat gct agg caa gaa gga cgc aga tac tgt gat cct gtt 2689 Leu Arg Lys His Ala Arg Gln Glu Gly Arg Arg Tyr Cys Asp Pro Val 870 875 880 gtt tta aca tat caa gct gaa cgg atg cca gag caa atc agg ctg aaa 2737 Val Leu Thr Tyr Gln Ala Glu Arg Met Pro Glu Gln Ile Arg Leu Lys 885 890 895 gtt ggt ggt gtg gac cca aag cag ttg gct gtt tat gaa gag ttt gca 2785 Val Gly Gly Val Asp Pro Lys Gln Leu Ala Val Tyr Glu Glu Phe Ala 900 905 910 cgc aat gtt cct ggc ttc tta cct aca aat gac tta agt cag ccc acg 2833 Arg Asn Val Pro Gly Phe Leu Pro Thr Asn Asp Leu Ser Gln Pro Thr 915 920 925 gga ttt tta gcc cag ccc atg aag caa gct tgg gca aca gat gat gta 2881 Gly Phe Leu Ala Gln Pro Met Lys Gln Ala Trp Ala Thr Asp Asp Val 930 935 940 945 gct cag att tat gat aag tgt att aca gaa ctg gag caa cat cta cat 2929 Ala Gln Ile Tyr Asp Lys Cys Ile Thr Glu Leu Glu Gln His Leu His 950 955 960 gcc atc cca cca act ttg gcc atg aac cct caa gct cag gct ctt cga 2977 Ala Ile Pro Pro Thr Leu Ala Met Asn Pro Gln Ala Gln Ala Leu Arg 965 970 975 agt ctc ttg gag gtt gta gtt tta tct cga aac tct cgg gat gcc ata 3025 Ser Leu Leu Glu Val Val Val Leu Ser Arg Asn Ser Arg Asp Ala Ile 980 985 990 gct gct ctt gga ttg ctc caa aag gct gta gag ggc tta cta gat gcc 3073 Ala Ala Leu Gly Leu Leu Gln Lys Ala Val Glu Gly Leu Leu Asp Ala 995 1000 1005 aca agt ggt gct gat gct gac ctt ctg ctg cgc tac agg gaa tgc cac 3121 Thr Ser Gly Ala Asp Ala Asp Leu Leu Leu Arg Tyr Arg Glu Cys His 1010 1015 1020 1025 ctc ttg gtc cta aaa gct ctg cag gat ggc cgg gca tat ggg tct cca 3169 Leu Leu Val Leu Lys Ala Leu Gln Asp Gly Arg Ala Tyr Gly Ser Pro 1030 1035 1040 tgg tgc aac aaa cag atc aca agg tgc cta att gaa tgt cga gat gaa 3217 Trp Cys Asn Lys Gln Ile Thr Arg Cys Leu Ile Glu Cys Arg Asp Glu 1045 1050 1055 tat aaa tat aat gtg gag gct gtg gag ctg cta att cgc aat cat ttg 3265 Tyr Lys Tyr Asn Val Glu Ala Val Glu Leu Leu Ile Arg Asn His Leu 1060 1065 1070 gtt aat atg cag cag tat gat ttt cac cta gcg cag tca atg gag aat 3313 Val Asn Met Gln Gln Tyr Asp Phe His Leu Ala Gln Ser Met Glu Asn 1075 1080 1085 ggc tta aac tac atg gct gtg gca ttt gct atg cag tta gta aaa atc 3361 Gly Leu Asn Tyr Met Ala Val Ala Phe Ala Met Gln Leu Val Lys Ile 1090 1095 1100 1105 ctg ctg gtg gat gaa agg agt gtt gct cat gtt act gag gca gat ctg 3409 Leu Leu Val Asp Glu Arg Ser Val Ala His Val Thr Glu Ala Asp Leu 1110 1115 1120 ttc cac acc att gaa acc ctc atg agg att aat gct cat tcc aga ggc 3457 Phe His Thr Ile Glu Thr Leu Met Arg Ile Asn Ala His Ser Arg Gly 1125 1130 1135 aat gct cca gaa gga ttg tcc cag ctg atg gaa gta gtg cga tcc aac 3505 Asn Ala Pro Glu Gly Leu Ser Gln Leu Met Glu Val Val Arg Ser Asn 1140 1145 1150 tat gaa gca atg att gat cgt gct cat gga ggc cca aac ttt atg atg 3553 Tyr Glu Ala Met Ile Asp Arg Ala His Gly Gly Pro Asn Phe Met Met 1155 1160 1165 cat tct ggg atc tct caa gcc tca gag tat gat gac cct cca ggc ctg 3601 His Ser Gly Ile Ser Gln Ala Ser Glu Tyr Asp Asp Pro Pro Gly Leu 1170 1175 1180 1185 agg gag aag gca gag tat ctt ctg agg gaa tgg gtg aat ctc tac cat 3649 Arg Glu Lys Ala Glu Tyr Leu Leu Arg Glu Trp Val Asn Leu Tyr His 1190 1195 1200 tca gca gca gct ggc cgc gac agt acc aaa gct ttc tct gca ttt gtt 3697 Ser Ala Ala Ala Gly Arg Asp Ser Thr Lys Ala Phe Ser Ala Phe Val 1205 1210 1215 gga cag atg cac cag caa gga ata ctg aag acc gat gat ctc ata aca 3745 Gly Gln Met His Gln Gln Gly Ile Leu Lys Thr Asp Asp Leu Ile Thr 1220 1225 1230 agg ttc ttt cgt ctg tgt act gaa atg tgt gtt gaa atc agt tac cgt 3793 Arg Phe Phe Arg Leu Cys Thr Glu Met Cys Val Glu Ile Ser Tyr Arg 1235 1240 1245 gct cag gct gag cag cag cac aat cct gct gcc aat ccc acc atg atc 3841 Ala Gln Ala Glu Gln Gln His Asn Pro Ala Ala Asn Pro Thr Met Ile 1250 1255 1260 1265 cga gcc aag tgc tat cac aac ctg gat gcc ttt gtt cga ctc att gca 3889 Arg Ala Lys Cys Tyr His Asn Leu Asp Ala Phe Val Arg Leu Ile Ala 1270 1275 1280 ctg ctc gtg aaa cac tca ggg gag gcc acc aac act gtc aca aag att 3937 Leu Leu Val Lys His Ser Gly Glu Ala Thr Asn Thr Val Thr Lys Ile 1285 1290 1295 aat ctg ctg aac aag gtc ctt ggt ata gta gtg gga gtt ctc ctt cag 3985 Asn Leu Leu Asn Lys Val Leu Gly Ile Val Val Gly Val Leu Leu Gln 1300 1305 1310 gat cat gat gtt cgt cag agt gaa ttt cag caa ctt ccc tac cat cga 4033 Asp His Asp Val Arg Gln Ser Glu Phe Gln Gln Leu Pro Tyr His Arg 1315 1320 1325 att ttt atc atg ctt ctc ttg gaa ctc aat gca cct gag cat gtg ttg 4081 Ile Phe Ile Met Leu Leu Leu Glu Leu Asn Ala Pro Glu His Val Leu 1330 1335 1340 1345 gaa acc att aat ttc cag aca ctt aca gct ttc tgc aat aca ttc cac 4129 Glu Thr Ile Asn Phe Gln Thr Leu Thr Ala Phe Cys Asn Thr Phe His 1350 1355 1360 atc ttg agg cct acc aaa gct cct ggc ttt gta tat gcc tgg ctt gaa 4177 Ile Leu Arg Pro Thr Lys Ala Pro Gly Phe Val Tyr Ala Trp Leu Glu 1365 1370 1375 ctg att tcc cat cgg ata ttt att gca aga atg ctg gca cat acg cca 4225 Leu Ile Ser His Arg Ile Phe Ile Ala Arg Met Leu Ala His Thr Pro 1380 1385 1390 cag cag aag ggg tgg cct atg tat gca cag cta ctg att gat tta ttc 4273 Gln Gln Lys Gly Trp Pro Met Tyr Ala Gln Leu Leu Ile Asp Leu Phe 1395 1400 1405 aaa tat tta gcg cct ttc ctt aga aat gtg gaa ctc acc aaa cct atg 4321 Lys Tyr Leu Ala Pro Phe Leu Arg Asn Val Glu Leu Thr Lys Pro Met 1410 1415 1420 1425 caa atc ctc tac aag ggc act tta aga gtg ctg ctg gtt ctt ttg cat 4369 Gln Ile Leu Tyr Lys Gly Thr Leu Arg Val Leu Leu Val Leu Leu His 1430 1435 1440 gat ttc cca gag ttc ctt tgt gat tac cat tat ggg ttc tgt gat gtg 4417 Asp Phe Pro Glu Phe Leu Cys Asp Tyr His Tyr Gly Phe Cys Asp Val 1445 1450 1455 atc cca cct aat tgt atc cag tta aga aat ttg atc ctg agt gcc ttt 4465 Ile Pro Pro Asn Cys Ile Gln Leu Arg Asn Leu Ile Leu Ser Ala Phe 1460 1465 1470 cca aga aac atg agg ctc ccc gac cca ttc act cct aat cta aag gtg 4513 Pro Arg Asn Met Arg Leu Pro Asp Pro Phe Thr Pro Asn Leu Lys Val 1475 1480 1485 gac atg ttg agt gaa att aac att gct ccc cgg att ctc acc aat ttc 4561 Asp Met Leu Ser Glu Ile Asn Ile Ala Pro Arg Ile Leu Thr Asn Phe 1490 1495 1500 1505 act gga gta atg cca cct cag ttc aaa aag gat ttg gat tcc tat ctt 4609 Thr Gly Val Met Pro Pro Gln Phe Lys Lys Asp Leu Asp Ser Tyr Leu 1510 1515 1520 aaa act cga tca cca gtc act ttc ctg tct gat ctg cgc agc aac cta 4657 Lys Thr Arg Ser Pro Val Thr Phe Leu Ser Asp Leu Arg Ser Asn Leu 1525 1530 1535 cag gta tcc aat gaa cct ggg aat cgc tac aac ctc cag ctc atc aat 4705 Gln Val Ser Asn Glu Pro Gly Asn Arg Tyr Asn Leu Gln Leu Ile Asn 1540 1545 1550 gca ctg gtg ctc tat gtc ggg act cag gcc att gcg cac atc cac aac 4753 Ala Leu Val Leu Tyr Val Gly Thr Gln Ala Ile Ala His Ile His Asn 1555 1560 1565 aag ggc agc aca cct tca atg agc acc atc act cac tca gca cac atg 4801 Lys Gly Ser Thr Pro Ser Met Ser Thr Ile Thr His Ser Ala His Met 1570 1575 1580 1585 gat atc ttc cag aat ttg gct gtg gac ttg gac act gag ggt cgc tat 4849 Asp Ile Phe Gln Asn Leu Ala Val Asp Leu Asp Thr Glu Gly Arg Tyr 1590 1595 1600 ctc ttt ttg aat gca att gca aat cag ctc cgg tac cca aat agc cac 4897 Leu Phe Leu Asn Ala Ile Ala Asn Gln Leu Arg Tyr Pro Asn Ser His 1605 1610 1615 act cac tac ttc agt tgc acc atg ctg tac ctt ttt gca gag gcc aat 4945 Thr His Tyr Phe Ser Cys Thr Met Leu Tyr Leu Phe Ala Glu Ala Asn 1620 1625 1630 acg gaa gcc atc caa gaa cag atc aca aga gtt ctc ttg gaa cgg ttg 4993 Thr Glu Ala Ile Gln Glu Gln Ile Thr Arg Val Leu Leu Glu Arg Leu 1635 1640 1645 att gta aat agg cca cat cct tgg ggt ctt ctt att acc ttc att gag 5041 Ile Val Asn Arg Pro His Pro Trp Gly Leu Leu Ile Thr Phe Ile Glu 1650 1655 1660 1665 ctg att aaa aac cca gcg ttt aag ttc tgg aac cat gaa ttt gta cac 5089 Leu Ile Lys Asn Pro Ala Phe Lys Phe Trp Asn His Glu Phe Val His 1670 1675 1680 tgt gcc cca gaa atc gaa aag tta ttc cag tcg gtc gca cag tgc tgc 5137 Cys Ala Pro Glu Ile Glu Lys Leu Phe Gln Ser Val Ala Gln Cys Cys 1685 1690 1695 atg gga cag aag cag gcc cag caa gta atg gaa ggg aca ggt gcc agt 5185 Met Gly Gln Lys Gln Ala Gln Gln Val Met Glu Gly Thr Gly Ala Ser 1700 1705 1710 tagacgaaac tgcatctctg ttgtacgtgt cagtctagag gtctcactgc accgagttca 5245 taaactgact gaagaatcct ttcagctctt cctgactttc ccagcccttt ggtttgtggg 5305 tatctgcccc aactactgtt gggatcagcc tcctgtctta tgtgggcacg ttccaaagtt 5365 taaatgcatt tttttgactc ttggccaaaa tttagaagat gctgtgaata tcattttgaa 5425 cttgtgtaaa tacatgaaaa aaaaaaaaaa aa 5457 <210> SEQ ID NO 61 <211> LENGTH: 453 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 61 Met Lys Leu Leu Val Ile Leu Leu Phe Ser Gly Leu Ile Thr Gly Phe -15 -10 -5 -1 1 Arg Ser Asp Ser Ser Ser Ser Leu Pro Pro Lys Leu Leu Leu Val Ser 5 10 15 Phe Asp Gly Phe Arg Ala Asp Tyr Leu Lys Asn Tyr Glu Phe Pro His 20 25 30 Leu Gln Asn Phe Ile Lys Glu Gly Val Leu Val Glu His Val Lys Asn 35 40 45 Val Phe Ile Thr Lys Thr Phe Pro Asn His Tyr Ser Ile Val Thr Gly 50 55 60 65 Leu Tyr Glu Glu Ser His Gly Ile Val Ala Asn Ser Met Tyr Asp Ala 70 75 80 Val Thr Lys Lys His Phe Ser Asp Ser Asn Asp Lys Asp Pro Phe Trp 85 90 95 Trp Asn Glu Ala Val Pro Ile Trp Val Thr Asn Gln Leu Gln Glu Asn 100 105 110 Arg Ser Ser Ala Ala Ala Met Trp Pro Gly Thr Asp Val Pro Ile His 115 120 125 Asp Thr Ile Ser Ser Tyr Phe Met Asn Tyr Asn Ser Ser Val Ser Phe 130 135 140 145 Glu Glu Arg Leu Asn Asn Ile Thr Met Trp Leu Asn Asn Ser Asn Pro 150 155 160 Pro Val Thr Phe Ala Thr Leu Tyr Trp Glu Glu Pro Asp Ala Ser Gly 165 170 175 His Lys Tyr Gly Pro Glu Asp Lys Glu Asn Met Ser Arg Val Leu Lys 180 185 190 Lys Ile Asp Asp Leu Ile Gly Asp Leu Val Gln Arg Leu Lys Met Leu 195 200 205 Gly Leu Trp Glu Asn Leu Asn Val Ile Ile Thr Ser Asp His Gly Met 210 215 220 225 Thr Gln Cys Ser Gln Asp Arg Leu Ile Asn Leu Asp Ser Cys Ile Asp 230 235 240 His Ser Tyr Tyr Thr Leu Ile Asp Leu Ser Pro Val Ala Ala Ile Leu 245 250 255 Pro Lys Ile Asn Arg Thr Glu Val Tyr Asn Lys Leu Lys Asn Cys Ser 260 265 270 Pro His Met Asn Val Tyr Leu Lys Glu Asp Ile Pro Asn Arg Phe Tyr 275 280 285 Tyr Gln His Asn Asp Arg Ile Gln Pro Ile Ile Leu Val Ala Asp Glu 290 295 300 305 Gly Trp Thr Ile Val Leu Asn Glu Ser Ser Gln Lys Leu Gly Asp His 310 315 320 Gly Tyr Asp Asn Ser Leu Pro Ser Met His Pro Phe Leu Ala Ala His 325 330 335 Gly Pro Ala Phe His Lys Gly Tyr Lys His Ser Thr Ile Asn Ile Val 340 345 350 Asp Ile Tyr Pro Met Met Cys His Ile Leu Gly Leu Lys Pro His Pro 355 360 365 Asn Asn Gly Thr Phe Gly His Thr Lys Cys Leu Leu Val Asp Gln Trp 370 375 380 385 Cys Ile Asn Leu Pro Glu Ala Ile Ala Ile Val Ile Gly Ser Leu Leu 390 395 400 Val Leu Thr Met Leu Thr Cys Leu Ile Ile Ile Met Gln Asn Arg Leu 405 410 415 Ser Val Pro Arg Pro Phe Ser Arg Leu Gln Leu Gln Glu Asp Asp Asp 420 425 430 Asp Pro Leu Ile Gly 435 <210> SEQ ID NO 62 <211> LENGTH: 1359 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 62 atgaagttat tagtaatact tttgttttct ggacttataa ctggttttag aagtgactct 60 tcctctagtt tgccacctaa gttactacta gtatcctttg atggcttcag agctgattat 120 ctgaagaact atgaatttcc tcatctccag aattttatca aagaaggtgt tttggtagag 180 catgttaaaa atgtttttat cacaaaaaca tttccaaacc actacagtat tgtgacaggc 240 ttgtatgaag aaagccatgg cattgtggct aattccatgt atgatgcagt cacaaagaaa 300 cacttttctg actctaatga caaggatcct ttttggtgga atgaggcagt acctatttgg 360 gtgaccaatc agcttcagga aaacagatca agtgctgctg ctatgtggcc tggtactgat 420 gtacccattc acgataccat ctcttcctat tttatgaatt acaactcctc agtgtcattt 480 gaggaaagac taaataatat tactatgtgg ctaaacaatt cgaacccacc agtcaccttt 540 gcaacactat attgggaaga accagatgca agtggccaca aatacggacc tgaagataaa 600 gaaaacatga gcagagtgtt gaaaaaaata gatgatctta tcggtgactt agtccaaaga 660 ctcaagatgt tagggctatg ggaaaatctt aatgtgatca ttacaagtga tcatgggatg 720 acccagtgtt ctcaggacag actgataaac ctggattcct gcatcgatca ttcatactac 780 actcttatag atttgagccc agttgctgca atacttccca aaataaatag aacagaggtt 840 tataacaaac tgaaaaactg tagccctcat atgaatgttt atctcaaaga agacattcct 900 aacagatttt attaccaaca taatgatcga attcagccca ttattttggt tgccgatgaa 960 ggctggacaa ttgtgctaaa tgaatcatca caaaaattag gtgaccatgg ttatgataat 1020 tctttgccta gtatgcatcc atttctagct gcccacggac ctgcatttca caaaggctac 1080 aagcatagca caattaacat tgtggatatt tatccaatga tgtgccacat cctgggatta 1140 aaaccacatc ccaataatgg gacctttggt catactaagt gcttgttagt tgaccagtgg 1200 tgcattaatc tcccagaagc catcgcgatt gttatcggtt cactcttggt gttaaccatg 1260 ctaacatgcc tcataataat catgcagaat agactttctg tacctcgtcc attttctcga 1320 cttcagctac aagaagatga tgatgatccc ttaattggg 1359 <210> SEQ ID NO 63 <211> LENGTH: 2044 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: sig_peptide <222> LOCATION: (70)..(114) <221> NAME/KEY: mat_peptide <222> LOCATION: (115)..(1428) <221> NAME/KEY: CDS <222> LOCATION: (70)..(1428) <400> SEQUENCE: 63 gttccgcgca ttggaaagaa gcgaccgcgg cggctggaac cctgattgct gtccttcaac 60 gtgttcatt atg aag tta tta gta ata ctt ttg ttt tct gga ctt ata act 111 Met Lys Leu Leu Val Ile Leu Leu Phe Ser Gly Leu Ile Thr -15 -10 -5 ggt ttt aga agt gac tct tcc tct agt ttg cca cct aag tta cta cta 159 Gly Phe Arg Ser Asp Ser Ser Ser Ser Leu Pro Pro Lys Leu Leu Leu -1 1 5 10 15 gta tcc ttt gat ggc ttc aga gct gat tat ctg aag aac tat gaa ttt 207 Val Ser Phe Asp Gly Phe Arg Ala Asp Tyr Leu Lys Asn Tyr Glu Phe 20 25 30 cct cat ctc cag aat ttt atc aaa gaa ggt gtt ttg gta gag cat gtt 255 Pro His Leu Gln Asn Phe Ile Lys Glu Gly Val Leu Val Glu His Val 35 40 45 aaa aat gtt ttt atc aca aaa aca ttt cca aac cac tac agt att gtg 303 Lys Asn Val Phe Ile Thr Lys Thr Phe Pro Asn His Tyr Ser Ile Val 50 55 60 aca ggc ttg tat gaa gaa agc cat ggc att gtg gct aat tcc atg tat 351 Thr Gly Leu Tyr Glu Glu Ser His Gly Ile Val Ala Asn Ser Met Tyr 65 70 75 gat gca gtc aca aag aaa cac ttt tct gac tct aat gac aag gat cct 399 Asp Ala Val Thr Lys Lys His Phe Ser Asp Ser Asn Asp Lys Asp Pro 80 85 90 95 ttt tgg tgg aat gag gca gta cct att tgg gtg acc aat cag ctt cag 447 Phe Trp Trp Asn Glu Ala Val Pro Ile Trp Val Thr Asn Gln Leu Gln 100 105 110 gaa aac aga tca agt gct gct gct atg tgg cct ggt act gat gta ccc 495 Glu Asn Arg Ser Ser Ala Ala Ala Met Trp Pro Gly Thr Asp Val Pro 115 120 125 att cac gat acc atc tct tcc tat ttt atg aat tac aac tcc tca gtg 543 Ile His Asp Thr Ile Ser Ser Tyr Phe Met Asn Tyr Asn Ser Ser Val 130 135 140 tca ttt gag gaa aga cta aat aat att act atg tgg cta aac aat tcg 591 Ser Phe Glu Glu Arg Leu Asn Asn Ile Thr Met Trp Leu Asn Asn Ser 145 150 155 aac cca cca gtc acc ttt gca aca cta tat tgg gaa gaa cca gat gca 639 Asn Pro Pro Val Thr Phe Ala Thr Leu Tyr Trp Glu Glu Pro Asp Ala 160 165 170 175 agt ggc cac aaa tac gga cct gaa gat aaa gaa aac atg agc aga gtg 687 Ser Gly His Lys Tyr Gly Pro Glu Asp Lys Glu Asn Met Ser Arg Val 180 185 190 ttg aaa aaa ata gat gat ctt atc ggt gac tta gtc caa aga ctc aag 735 Leu Lys Lys Ile Asp Asp Leu Ile Gly Asp Leu Val Gln Arg Leu Lys 195 200 205 atg tta ggg cta tgg gaa aat ctt aat gtg atc att aca agt gat cat 783 Met Leu Gly Leu Trp Glu Asn Leu Asn Val Ile Ile Thr Ser Asp His 210 215 220 ggg atg acc cag tgt tct cag gac aga ctg ata aac ctg gat tcc tgc 831 Gly Met Thr Gln Cys Ser Gln Asp Arg Leu Ile Asn Leu Asp Ser Cys 225 230 235 atc gat cat tca tac tac act ctt ata gat ttg agc cca gtt gct gca 879 Ile Asp His Ser Tyr Tyr Thr Leu Ile Asp Leu Ser Pro Val Ala Ala 240 245 250 255 ata ctt ccc aaa ata aat aga aca gag gtt tat aac aaa ctg aaa aac 927 Ile Leu Pro Lys Ile Asn Arg Thr Glu Val Tyr Asn Lys Leu Lys Asn 260 265 270 tgt agc cct cat atg aat gtt tat ctc aaa gaa gac att cct aac aga 975 Cys Ser Pro His Met Asn Val Tyr Leu Lys Glu Asp Ile Pro Asn Arg 275 280 285 ttt tat tac caa cat aat gat cga att cag ccc att att ttg gtt gcc 1023 Phe Tyr Tyr Gln His Asn Asp Arg Ile Gln Pro Ile Ile Leu Val Ala 290 295 300 gat gaa ggc tgg aca att gtg cta aat gaa tca tca caa aaa tta ggt 1071 Asp Glu Gly Trp Thr Ile Val Leu Asn Glu Ser Ser Gln Lys Leu Gly 305 310 315 gac cat ggt tat gat aat tct ttg cct agt atg cat cca ttt cta gct 1119 Asp His Gly Tyr Asp Asn Ser Leu Pro Ser Met His Pro Phe Leu Ala 320 325 330 335 gcc cac gga cct gca ttt cac aaa ggc tac aag cat agc aca att aac 1167 Ala His Gly Pro Ala Phe His Lys Gly Tyr Lys His Ser Thr Ile Asn 340 345 350 att gtg gat att tat cca atg atg tgc cac atc ctg gga tta aaa cca 1215 Ile Val Asp Ile Tyr Pro Met Met Cys His Ile Leu Gly Leu Lys Pro 355 360 365 cat ccc aat aat ggg acc ttt ggt cat act aag tgc ttg tta gtt gac 1263 His Pro Asn Asn Gly Thr Phe Gly His Thr Lys Cys Leu Leu Val Asp 370 375 380 cag tgg tgc att aat ctc cca gaa gcc atc gcg att gtt atc ggt tca 1311 Gln Trp Cys Ile Asn Leu Pro Glu Ala Ile Ala Ile Val Ile Gly Ser 385 390 395 ctc ttg gtg tta acc atg cta aca tgc ctc ata ata atc atg cag aat 1359 Leu Leu Val Leu Thr Met Leu Thr Cys Leu Ile Ile Ile Met Gln Asn 400 405 410 415 aga ctt tct gta cct cgt cca ttt tct cga ctt cag cta caa gaa gat 1407 Arg Leu Ser Val Pro Arg Pro Phe Ser Arg Leu Gln Leu Gln Glu Asp 420 425 430 gat gat gat ccc tta att ggg tgacatgtgc tagggcttat acaaagtgtc 1458 Asp Asp Asp Pro Leu Ile Gly 435 tttgattaat cacaaaacta agaatacatc caaagaatag tgttgtaact atgaaaaaga 1518 atactttgaa agacaaagaa cttagactaa gcatgttaaa attattactt tgttttcctt 1578 gtgttttgtt tcggtgcatt tgctaataag ataacgctga ccatagtaaa attgttagta 1638 aatcattagg taacatcttg tggtaggaaa tcattaggta acatcaatcc taactagaaa 1698 tactaaaaat ggcttttgag aaaaatactt cctctgcttg tattttgcga tgaagatgtg 1758 atacatcttt aaatgaaaat ataccaaaat ttagtaggca tgtttttcta ataaatttat 1818 atatttgtaa agaaaacaac agaaatcttt atgcaatttg tgaattttgt atattaggga 1878 ggaaaagctt cctatatttt tatatttacc tttaattagt ttgtatctca agtaccctct 1938 tgaggtagga aatgctctgt gatggtaaat aaaattggag cagacagaaa agatatagca 1998 aatgaagaaa tattttaagg aaacctattt gaaaaaaaaa aacaaa 2044 <210> SEQ ID NO 64 <211> LENGTH: 708 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 64 Met Lys Asp Met Pro Leu Arg Ile His Val Leu Leu Gly Leu Ala Ile -20 -15 -10 Thr Thr Leu Val Gln Ala Val Asp Lys Lys Val Asp Cys Pro Arg Leu -5 -1 1 5 10 Cys Thr Cys Glu Ile Arg Pro Trp Phe Thr Pro Arg Ser Ile Tyr Met 15 20 25 Glu Ala Ser Thr Val Asp Cys Asn Asp Leu Gly Leu Leu Thr Phe Pro 30 35 40 Ala Arg Leu Pro Ala Asn Thr Gln Ile Leu Leu Leu Gln Thr Asn Asn 45 50 55 Ile Ala Lys Ile Glu Tyr Ser Thr Asp Phe Pro Val Asn Leu Thr Gly 60 65 70 Leu Asp Leu Ser Gln Asn Asn Leu Ser Ser Val Thr Asn Ile Asn Val 75 80 85 90 Lys Lys Met Pro Gln Leu Leu Ser Val Tyr Leu Glu Glu Asn Lys Leu 95 100 105 Thr Glu Leu Pro Glu Lys Cys Leu Ser Glu Leu Ser Asn Leu Gln Glu 110 115 120 Leu Tyr Ile Asn His Asn Leu Leu Ser Thr Ile Ser Pro Gly Ala Phe 125 130 135 Ile Gly Leu His Asn Leu Leu Arg Leu His Leu Asn Ser Asn Arg Leu 140 145 150 Gln Met Ile Asn Ser Lys Trp Phe Asp Ala Leu Pro Asn Leu Glu Ile 155 160 165 170 Leu Met Ile Gly Glu Asn Pro Ile Ile Arg Ile Lys Asp Met Asn Phe 175 180 185 Lys Pro Leu Ile Asn Leu Arg Ser Leu Val Ile Ala Gly Ile Asn Leu 190 195 200 Thr Glu Ile Pro Asp Asn Ala Leu Val Gly Leu Glu Asn Leu Glu Ser 205 210 215 Ile Ser Phe Tyr Asp Asn Arg Leu Ile Lys Val Pro His Val Ala Leu 220 225 230 Gln Lys Val Val Asn Leu Lys Phe Leu Asp Leu Asn Lys Asn Pro Ile 235 240 245 250 Asn Arg Ile Arg Arg Gly Asp Phe Ser Asn Met Leu His Leu Lys Glu 255 260 265 Leu Gly Ile Asn Asn Met Pro Glu Leu Ile Ser Ile Asp Ser Leu Ala 270 275 280 Val Asp Asn Leu Pro Asp Leu Arg Lys Ile Glu Ala Thr Asn Asn Pro 285 290 295 Arg Leu Ser Tyr Ile His Pro Asn Ala Phe Phe Arg Leu Pro Lys Leu 300 305 310 Glu Ser Leu Met Leu Asn Ser Asn Ala Leu Ser Ala Leu Tyr His Gly 315 320 325 330 Thr Ile Glu Ser Leu Pro Asn Leu Lys Glu Ile Ser Ile His Ser Asn 335 340 345 Pro Ile Arg Cys Asp Cys Val Ile Arg Trp Met Asn Met Asn Lys Thr 350 355 360 Asn Ile Arg Phe Met Glu Pro Asp Ser Leu Phe Cys Val Asp Pro Pro 365 370 375 Glu Phe Gln Gly Gln Asn Val Arg Gln Val His Phe Arg Asp Met Met 380 385 390 Glu Ile Cys Leu Pro Leu Ile Ala Pro Glu Ser Phe Pro Ser Asn Leu 395 400 405 410 Asn Val Glu Ala Gly Ser Tyr Val Ser Phe His Cys Arg Ala Thr Ala 415 420 425 Glu Pro Gln Pro Glu Ile Tyr Trp Ile Thr Pro Ser Gly Gln Lys Leu 430 435 440 Leu Pro Asn Thr Leu Thr Asp Lys Phe Tyr Val His Ser Glu Gly Thr 445 450 455 Leu Asp Ile Asn Gly Val Thr Pro Lys Glu Gly Gly Leu Tyr Thr Cys 460 465 470 Ile Ala Thr Asn Leu Val Gly Ala Asp Leu Lys Ser Val Met Ile Lys 475 480 485 490 Val Asp Gly Ser Phe Pro Gln Asp Asn Asn Gly Ser Leu Asn Ile Lys 495 500 505 Ile Arg Asp Ile Gln Ala Asn Ser Val Leu Val Ser Trp Lys Ala Ser 510 515 520 Ser Lys Ile Leu Lys Ser Ser Val Lys Trp Thr Ala Phe Val Lys Thr 525 530 535 Glu Asn Ser His Ala Ala Gln Ser Ala Arg Ile Pro Ser Asp Val Lys 540 545 550 Val Tyr Asn Leu Thr His Leu Asn Pro Ser Thr Glu Tyr Lys Ile Cys 555 560 565 570 Ile Asp Ile Pro Thr Ile Tyr Gln Lys Asn Arg Lys Lys Cys Val Asn 575 580 585 Val Thr Thr Lys Gly Leu His Pro Asp Gln Lys Glu Tyr Glu Lys Asn 590 595 600 Asn Thr Thr Thr Leu Met Ala Cys Leu Gly Gly Leu Leu Gly Ile Ile 605 610 615 Gly Val Ile Cys Leu Ile Ser Cys Leu Ser Pro Glu Met Asn Cys Asp 620 625 630 Gly Gly His Ser Tyr Val Arg Asn Tyr Leu Gln Lys Pro Thr Phe Ala 635 640 645 650 Leu Gly Glu Leu Tyr Pro Pro Leu Ile Asn Leu Trp Glu Ala Gly Lys 655 660 665 Glu Lys Ser Thr Ser Leu Lys Val Lys Ala Thr Val Ile Gly Leu Pro 670 675 680 Thr Asn Met Ser 685 <210> SEQ ID NO 65 <211> LENGTH: 2124 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 65 atgaaggaca tgccactccg aattcatgtg ctacttggcc tagctatcac tacactagta 60 caagctgtag ataaaaaagt ggattgtcca cggttatgta cgtgtgaaat caggccttgg 120 tttacaccca gatccattta tatggaagca tctacagtgg attgtaatga tttaggtctt 180 ttaactttcc cagccagatt gccagctaac acacagattc ttctcctaca gactaacaat 240 attgcaaaaa ttgaatactc cacagacttt ccagtaaacc ttactggcct ggatttatct 300 caaaacaatt tatcttcagt caccaatatt aatgtaaaaa agatgcctca gctcctttct 360 gtgtacctag aggaaaacaa acttactgaa ctgcctgaaa aatgtctgtc cgaactgagc 420 aacttacaag aactctatat taatcacaac ttgctttcta caatttcacc tggagccttt 480 attggcctac ataatcttct tcgacttcat ctcaattcaa atagattgca gatgatcaac 540 agtaagtggt ttgatgctct tccaaatcta gagattctga tgattgggga aaatccaatt 600 atcagaatca aagacatgaa ctttaagcct cttatcaatc ttcgcagcct ggttatagct 660 ggtataaacc tcacagaaat accagataac gccttggttg gactggaaaa cttagaaagc 720 atctcttttt acgataacag gcttattaaa gtaccccatg ttgctcttca aaaagttgta 780 aatctcaaat ttttggatct aaataaaaat cctattaata gaatacgaag gggtgatttt 840 agcaatatgc tacacttaaa agagttgggg ataaataata tgcctgagct gatttccatc 900 gatagtcttg ctgtggataa cctgccagat ttaagaaaaa tagaagctac taacaaccct 960 agattgtctt acattcaccc caatgcattt ttcagactcc ccaagctgga atcactcatg 1020 ctgaacagca atgctctcag tgccctgtac catggtacca ttgagtctct gccaaacctc 1080 aaggaaatca gcatacacag taaccccatc aggtgtgact gtgtcatccg ttggatgaac 1140 atgaacaaaa ccaacattcg attcatggag ccagattcac tgttttgcgt ggacccacct 1200 gaattccaag gtcagaatgt tcggcaagtg catttcaggg acatgatgga aatttgtctc 1260 cctcttatag ctcctgagag ctttccttct aatctaaatg tagaagctgg gagctatgtt 1320 tcctttcact gtagagctac tgcagaacca cagcctgaaa tctactggat aacaccttct 1380 ggtcaaaaac tcttgcctaa taccctgaca gacaagttct atgtccattc tgagggaaca 1440 ctagatataa atggcgtaac tcccaaagaa gggggtttat atacttgtat agcaactaac 1500 ctagttggcg ctgacttgaa gtctgttatg atcaaagtgg atggatcttt tccacaagat 1560 aacaatggct ctttgaatat taaaataaga gatattcagg ccaattcagt tttggtgtcc 1620 tggaaagcaa gttctaaaat tctcaaatct agtgttaaat ggacagcctt tgtcaagact 1680 gaaaattctc atgctgcgca aagtgctcga ataccatctg atgtcaaggt atataatctt 1740 actcatctga atccatcaac tgagtataaa atttgtattg atattcccac catctatcag 1800 aaaaacagaa aaaaatgtgt aaatgtcacc accaaaggtt tgcaccctga tcaaaaagag 1860 tatgaaaaga ataataccac aacacttatg gcctgtcttg gaggccttct ggggattatt 1920 ggtgtgatat gtcttatcag ctgcctctct ccagaaatga actgtgatgg tggacacagc 1980 tatgtgagga attacttaca gaaaccaacc tttgcattag gtgagcttta tcctcctctg 2040 ataaatctct gggaagcagg aaaagaaaaa agtacatcac tgaaagtaaa agcaactgtt 2100 ataggtttac caacaaatat gtcc 2124 <210> SEQ ID NO 66 <211> LENGTH: 3068 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: sig_peptide <222> LOCATION: (894)..(959) <221> NAME/KEY: mat_peptide <222> LOCATION: (960)..(3017) <221> NAME/KEY: CDS <222> LOCATION: (894)..(3017) <400> SEQUENCE: 66 gtctgaagcg attggctcct ctctggggag tggagggtgt tcagttatta atgaccgctg 60 agcaggcagc accatgtcag tgtgacaact gatcgggtga acgatgcacc actaaccacc 120 atggaaacaa ggaaaaataa agccagctca caggatctct cttcactgga ttgagagcct 180 cagcctgccg actgagaaaa agagttccag gaaaaagaag gaatcccggc tgcagcctcc 240 tgccttcctt tatattttaa aatagagaga taagattgcg tgcatgtgtg catatctata 300 gtatatattt tgtacacttt gttacacaga cacacaaatg cacctattta taccgggcaa 360 gaacacaacc atgtgattat ctcaaccaag gaactgagga atccagcacg caaggacatc 420 ggaggtgggc tagcactgaa actgcttttc aagacgagga agaggaggag aaagagaaag 480 aagaggaaga tgttgggcaa catttattta acatgctcca cagcccggac cctggcatca 540 tgctgctatt cctgcaaata ctgaagaagc atgggattta aatattttac ttctaaataa 600 atgaattact caatctccta tgaccatcta tacatactcc accttcaaaa agtacatcaa 660 tattatatca ttaaggaaat agtaaccttc tcttctccaa tatgcatgac atttttggac 720 aatgcaattg tggcactggc acttatttca gtgaagaaaa actttgtggt tctatggcat 780 tcatcatttg acaaatgcaa gcatcttcct tatcaatcag ctcctattga acttactagc 840 actgactgtg gaatccttaa gggcccatta catttctgaa gaagaaagct aag atg 896 Met aag gac atg cca ctc cga att cat gtg cta ctt ggc cta gct atc act 944 Lys Asp Met Pro Leu Arg Ile His Val Leu Leu Gly Leu Ala Ile Thr -20 -15 -10 aca cta gta caa gct gta gat aaa aaa gtg gat tgt cca cgg tta tgt 992 Thr Leu Val Gln Ala Val Asp Lys Lys Val Asp Cys Pro Arg Leu Cys -5 -1 1 5 10 acg tgt gaa atc agg cct tgg ttt aca ccc aga tcc att tat atg gaa 1040 Thr Cys Glu Ile Arg Pro Trp Phe Thr Pro Arg Ser Ile Tyr Met Glu 15 20 25 gca tct aca gtg gat tgt aat gat tta ggt ctt tta act ttc cca gcc 1088 Ala Ser Thr Val Asp Cys Asn Asp Leu Gly Leu Leu Thr Phe Pro Ala 30 35 40 aga ttg cca gct aac aca cag att ctt ctc cta cag act aac aat att 1136 Arg Leu Pro Ala Asn Thr Gln Ile Leu Leu Leu Gln Thr Asn Asn Ile 45 50 55 gca aaa att gaa tac tcc aca gac ttt cca gta aac ctt act ggc ctg 1184 Ala Lys Ile Glu Tyr Ser Thr Asp Phe Pro Val Asn Leu Thr Gly Leu 60 65 70 75 gat tta tct caa aac aat tta tct tca gtc acc aat att aat gta aaa 1232 Asp Leu Ser Gln Asn Asn Leu Ser Ser Val Thr Asn Ile Asn Val Lys 80 85 90 aag atg cct cag ctc ctt tct gtg tac cta gag gaa aac aaa ctt act 1280 Lys Met Pro Gln Leu Leu Ser Val Tyr Leu Glu Glu Asn Lys Leu Thr 95 100 105 gaa ctg cct gaa aaa tgt ctg tcc gaa ctg agc aac tta caa gaa ctc 1328 Glu Leu Pro Glu Lys Cys Leu Ser Glu Leu Ser Asn Leu Gln Glu Leu 110 115 120 tat att aat cac aac ttg ctt tct aca att tca cct gga gcc ttt att 1376 Tyr Ile Asn His Asn Leu Leu Ser Thr Ile Ser Pro Gly Ala Phe Ile 125 130 135 ggc cta cat aat ctt ctt cga ctt cat ctc aat tca aat aga ttg cag 1424 Gly Leu His Asn Leu Leu Arg Leu His Leu Asn Ser Asn Arg Leu Gln 140 145 150 155 atg atc aac agt aag tgg ttt gat gct ctt cca aat cta gag att ctg 1472 Met Ile Asn Ser Lys Trp Phe Asp Ala Leu Pro Asn Leu Glu Ile Leu 160 165 170 atg att ggg gaa aat cca att atc aga atc aaa gac atg aac ttt aag 1520 Met Ile Gly Glu Asn Pro Ile Ile Arg Ile Lys Asp Met Asn Phe Lys 175 180 185 cct ctt atc aat ctt cgc agc ctg gtt ata gct ggt ata aac ctc aca 1568 Pro Leu Ile Asn Leu Arg Ser Leu Val Ile Ala Gly Ile Asn Leu Thr 190 195 200 gaa ata cca gat aac gcc ttg gtt gga ctg gaa aac tta gaa agc atc 1616 Glu Ile Pro Asp Asn Ala Leu Val Gly Leu Glu Asn Leu Glu Ser Ile 205 210 215 tct ttt tac gat aac agg ctt att aaa gta ccc cat gtt gct ctt caa 1664 Ser Phe Tyr Asp Asn Arg Leu Ile Lys Val Pro His Val Ala Leu Gln 220 225 230 235 aaa gtt gta aat ctc aaa ttt ttg gat cta aat aaa aat cct att aat 1712 Lys Val Val Asn Leu Lys Phe Leu Asp Leu Asn Lys Asn Pro Ile Asn 240 245 250 aga ata cga agg ggt gat ttt agc aat atg cta cac tta aaa gag ttg 1760 Arg Ile Arg Arg Gly Asp Phe Ser Asn Met Leu His Leu Lys Glu Leu 255 260 265 ggg ata aat aat atg cct gag ctg att tcc atc gat agt ctt gct gtg 1808 Gly Ile Asn Asn Met Pro Glu Leu Ile Ser Ile Asp Ser Leu Ala Val 270 275 280 gat aac ctg cca gat tta aga aaa ata gaa gct act aac aac cct aga 1856 Asp Asn Leu Pro Asp Leu Arg Lys Ile Glu Ala Thr Asn Asn Pro Arg 285 290 295 ttg tct tac att cac ccc aat gca ttt ttc aga ctc ccc aag ctg gaa 1904 Leu Ser Tyr Ile His Pro Asn Ala Phe Phe Arg Leu Pro Lys Leu Glu 300 305 310 315 tca ctc atg ctg aac agc aat gct ctc agt gcc ctg tac cat ggt acc 1952 Ser Leu Met Leu Asn Ser Asn Ala Leu Ser Ala Leu Tyr His Gly Thr 320 325 330 att gag tct ctg cca aac ctc aag gaa atc agc ata cac agt aac ccc 2000 Ile Glu Ser Leu Pro Asn Leu Lys Glu Ile Ser Ile His Ser Asn Pro 335 340 345 atc agg tgt gac tgt gtc atc cgt tgg atg aac atg aac aaa acc aac 2048 Ile Arg Cys Asp Cys Val Ile Arg Trp Met Asn Met Asn Lys Thr Asn 350 355 360 att cga ttc atg gag cca gat tca ctg ttt tgc gtg gac cca cct gaa 2096 Ile Arg Phe Met Glu Pro Asp Ser Leu Phe Cys Val Asp Pro Pro Glu 365 370 375 ttc caa ggt cag aat gtt cgg caa gtg cat ttc agg gac atg atg gaa 2144 Phe Gln Gly Gln Asn Val Arg Gln Val His Phe Arg Asp Met Met Glu 380 385 390 395 att tgt ctc cct ctt ata gct cct gag agc ttt cct tct aat cta aat 2192 Ile Cys Leu Pro Leu Ile Ala Pro Glu Ser Phe Pro Ser Asn Leu Asn 400 405 410 gta gaa gct ggg agc tat gtt tcc ttt cac tgt aga gct act gca gaa 2240 Val Glu Ala Gly Ser Tyr Val Ser Phe His Cys Arg Ala Thr Ala Glu 415 420 425 cca cag cct gaa atc tac tgg ata aca cct tct ggt caa aaa ctc ttg 2288 Pro Gln Pro Glu Ile Tyr Trp Ile Thr Pro Ser Gly Gln Lys Leu Leu 430 435 440 cct aat acc ctg aca gac aag ttc tat gtc cat tct gag gga aca cta 2336 Pro Asn Thr Leu Thr Asp Lys Phe Tyr Val His Ser Glu Gly Thr Leu 445 450 455 gat ata aat ggc gta act ccc aaa gaa ggg ggt tta tat act tgt ata 2384 Asp Ile Asn Gly Val Thr Pro Lys Glu Gly Gly Leu Tyr Thr Cys Ile 460 465 470 475 gca act aac cta gtt ggc gct gac ttg aag tct gtt atg atc aaa gtg 2432 Ala Thr Asn Leu Val Gly Ala Asp Leu Lys Ser Val Met Ile Lys Val 480 485 490 gat gga tct ttt cca caa gat aac aat ggc tct ttg aat att aaa ata 2480 Asp Gly Ser Phe Pro Gln Asp Asn Asn Gly Ser Leu Asn Ile Lys Ile 495 500 505 aga gat att cag gcc aat tca gtt ttg gtg tcc tgg aaa gca agt tct 2528 Arg Asp Ile Gln Ala Asn Ser Val Leu Val Ser Trp Lys Ala Ser Ser 510 515 520 aaa att ctc aaa tct agt gtt aaa tgg aca gcc ttt gtc aag act gaa 2576 Lys Ile Leu Lys Ser Ser Val Lys Trp Thr Ala Phe Val Lys Thr Glu 525 530 535 aat tct cat gct gcg caa agt gct cga ata cca tct gat gtc aag gta 2624 Asn Ser His Ala Ala Gln Ser Ala Arg Ile Pro Ser Asp Val Lys Val 540 545 550 555 tat aat ctt act cat ctg aat cca tca act gag tat aaa att tgt att 2672 Tyr Asn Leu Thr His Leu Asn Pro Ser Thr Glu Tyr Lys Ile Cys Ile 560 565 570 gat att ccc acc atc tat cag aaa aac aga aaa aaa tgt gta aat gtc 2720 Asp Ile Pro Thr Ile Tyr Gln Lys Asn Arg Lys Lys Cys Val Asn Val 575 580 585 acc acc aaa ggt ttg cac cct gat caa aaa gag tat gaa aag aat aat 2768 Thr Thr Lys Gly Leu His Pro Asp Gln Lys Glu Tyr Glu Lys Asn Asn 590 595 600 acc aca aca ctt atg gcc tgt ctt gga ggc ctt ctg ggg att att ggt 2816 Thr Thr Thr Leu Met Ala Cys Leu Gly Gly Leu Leu Gly Ile Ile Gly 605 610 615 gtg ata tgt ctt atc agc tgc ctc tct cca gaa atg aac tgt gat ggt 2864 Val Ile Cys Leu Ile Ser Cys Leu Ser Pro Glu Met Asn Cys Asp Gly 620 625 630 635 gga cac agc tat gtg agg aat tac tta cag aaa cca acc ttt gca tta 2912 Gly His Ser Tyr Val Arg Asn Tyr Leu Gln Lys Pro Thr Phe Ala Leu 640 645 650 ggt gag ctt tat cct cct ctg ata aat ctc tgg gaa gca gga aaa gaa 2960 Gly Glu Leu Tyr Pro Pro Leu Ile Asn Leu Trp Glu Ala Gly Lys Glu 655 660 665 aaa agt aca tca ctg aaa gta aaa gca act gtt ata ggt tta cca aca 3008 Lys Ser Thr Ser Leu Lys Val Lys Ala Thr Val Ile Gly Leu Pro Thr 670 675 680 aat atg tcc taaaaaccac caaggaaacc tactccaaaa atgaacaaaa 3057 Asn Met Ser 685 aaaaaaaaaa a 3068 <210> SEQ ID NO 67 <211> LENGTH: 255 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 67 Met Ser Tyr Tyr Gly Ser Ser Tyr His Ile Ile Asn Ala Asp Ala Lys 1 5 10 15 Tyr Pro Gly Tyr Pro Pro Glu His Ile Ile Ala Glu Lys Arg Arg Ala 20 25 30 Arg Arg Arg Leu Leu His Lys Asp Gly Ser Cys Asn Val Tyr Phe Lys 35 40 45 His Ile Phe Gly Glu Trp Gly Ser Tyr Val Val Asp Ile Phe Thr Thr 50 55 60 Leu Val Asp Thr Lys Trp Arg His Met Phe Val Ile Phe Ser Leu Ser 65 70 75 80 Tyr Ile Leu Ser Trp Leu Ile Phe Gly Ser Val Phe Trp Leu Ile Ala 85 90 95 Phe His His Gly Asp Leu Leu Asn Asp Pro Asp Ile Thr Pro Cys Val 100 105 110 Asp Asn Val His Ser Phe Thr Gly Ala Phe Leu Phe Ser Leu Glu Thr 115 120 125 Gln Thr Thr Ile Gly Tyr Gly Tyr Arg Cys Val Thr Glu Glu Cys Ser 130 135 140 Val Ala Val Leu Met Val Ile Leu Gln Ser Ile Leu Ser Cys Ile Ile 145 150 155 160 Asn Thr Phe Ile Ile Gly Ala Ala Leu Ala Lys Met Ala Thr Ala Arg 165 170 175 Lys Arg Ala Gln Thr Ile Arg Phe Ser Tyr Phe Ala Leu Ile Gly Met 180 185 190 Arg Asp Gly Lys Leu Cys Leu Met Trp Arg Ile Gly Asp Phe Arg Pro 195 200 205 Asn His Val Val Glu Gly Thr Val Arg Ala Gln Leu Leu Arg Tyr Thr 210 215 220 Glu Asp Ser Glu Gly Arg Met Thr Met Ala Phe Lys Asp Leu Lys Leu 225 230 235 240 Val Asn Asp Gln Ile Ile Leu Val Thr Pro Val Thr Ile Val Pro 245 250 255 <210> SEQ ID NO 68 <211> LENGTH: 765 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 68 atgagctatt acggcagcag ctatcatatt atcaatgcgg acgcaaaata cccaggctac 60 ccgccagagc acattatagc tgagaagaga agagcaagaa gacgattact tcacaaagat 120 ggcagctgta atgtctactt caagcacatt tttggagaat ggggaagcta tgtggttgac 180 atcttcacca ctcttgtgga caccaagtgg cgccatatgt ttgtgatatt ttctttatct 240 tatattctct cgtggttgat atttggctct gtcttttggc tcatagcctt tcatcatggc 300 gatctattaa atgatccaga catcacacct tgtgttgaca acgtccattc tttcacaggg 360 gcctttttgt tctccctaga gacccaaacc accataggat atggttatcg ctgtgttact 420 gaagaatgtt ctgtggccgt gctcatggtg atcctccagt ccatcttaag ttgcatcata 480 aataccttta tcattggagc tgccttggcc aaaatggcaa ctgctcgaaa gagagcccaa 540 accattcgtt tcagctactt tgcacttata ggtatgagag atgggaagct ttgcctcatg 600 tggcgcattg gtgattttcg gccaaaccac gtggtagaag gaacagttag agcccaactt 660 ctccgctata cagaagacag tgaagggagg atgacgatgg catttaaaga cctcaaatta 720 gtcaacgacc aaatcatcct ggtcaccccg gtaactattg tccca 765 <210> SEQ ID NO 69 <211> LENGTH: 907 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (78)..(842) <400> SEQUENCE: 69 caaaccaaga aatagcaaca agtctagaat tcttactact acaaaactca cctggatccc 60 taagggcaca gcaaaga atg agc tat tac ggc agc agc tat cat att atc 110 Met Ser Tyr Tyr Gly Ser Ser Tyr His Ile Ile 1 5 10 aat gcg gac gca aaa tac cca ggc tac ccg cca gag cac att ata gct 158 Asn Ala Asp Ala Lys Tyr Pro Gly Tyr Pro Pro Glu His Ile Ile Ala 15 20 25 gag aag aga aga gca aga aga cga tta ctt cac aaa gat ggc agc tgt 206 Glu Lys Arg Arg Ala Arg Arg Arg Leu Leu His Lys Asp Gly Ser Cys 30 35 40 aat gtc tac ttc aag cac att ttt gga gaa tgg gga agc tat gtg gtt 254 Asn Val Tyr Phe Lys His Ile Phe Gly Glu Trp Gly Ser Tyr Val Val 45 50 55 gac atc ttc acc act ctt gtg gac acc aag tgg cgc cat atg ttt gtg 302 Asp Ile Phe Thr Thr Leu Val Asp Thr Lys Trp Arg His Met Phe Val 60 65 70 75 ata ttt tct tta tct tat att ctc tcg tgg ttg ata ttt ggc tct gtc 350 Ile Phe Ser Leu Ser Tyr Ile Leu Ser Trp Leu Ile Phe Gly Ser Val 80 85 90 ttt tgg ctc ata gcc ttt cat cat ggc gat cta tta aat gat cca gac 398 Phe Trp Leu Ile Ala Phe His His Gly Asp Leu Leu Asn Asp Pro Asp 95 100 105 atc aca cct tgt gtt gac aac gtc cat tct ttc aca ggg gcc ttt ttg 446 Ile Thr Pro Cys Val Asp Asn Val His Ser Phe Thr Gly Ala Phe Leu 110 115 120 ttc tcc cta gag acc caa acc acc ata gga tat ggt tat cgc tgt gtt 494 Phe Ser Leu Glu Thr Gln Thr Thr Ile Gly Tyr Gly Tyr Arg Cys Val 125 130 135 act gaa gaa tgt tct gtg gcc gtg ctc atg gtg atc ctc cag tcc atc 542 Thr Glu Glu Cys Ser Val Ala Val Leu Met Val Ile Leu Gln Ser Ile 140 145 150 155 tta agt tgc atc ata aat acc ttt atc att gga gct gcc ttg gcc aaa 590 Leu Ser Cys Ile Ile Asn Thr Phe Ile Ile Gly Ala Ala Leu Ala Lys 160 165 170 atg gca act gct cga aag aga gcc caa acc att cgt ttc agc tac ttt 638 Met Ala Thr Ala Arg Lys Arg Ala Gln Thr Ile Arg Phe Ser Tyr Phe 175 180 185 gca ctt ata ggt atg aga gat ggg aag ctt tgc ctc atg tgg cgc att 686 Ala Leu Ile Gly Met Arg Asp Gly Lys Leu Cys Leu Met Trp Arg Ile 190 195 200 ggt gat ttt cgg cca aac cac gtg gta gaa gga aca gtt aga gcc caa 734 Gly Asp Phe Arg Pro Asn His Val Val Glu Gly Thr Val Arg Ala Gln 205 210 215 ctt ctc cgc tat aca gaa gac agt gaa ggg agg atg acg atg gca ttt 782 Leu Leu Arg Tyr Thr Glu Asp Ser Glu Gly Arg Met Thr Met Ala Phe 220 225 230 235 aaa gac ctc aaa tta gtc aac gac caa atc atc ctg gtc acc ccg gta 830 Lys Asp Leu Lys Leu Val Asn Asp Gln Ile Ile Leu Val Thr Pro Val 240 245 250 act att gtc cca tgaccctgcc aaatccccct ctgtgagaaa cacccaaaaa 882 Thr Ile Val Pro 255 aaaaaaaaaa aaaaaaaaaa aaaaa 907 <210> SEQ ID NO 70 <211> LENGTH: 859 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 70 Met Ala Cys Arg Trp Ser Thr Lys Glu Ser Pro Arg Trp Arg Ser Ala -25 -20 -15 Leu Leu Leu Leu Phe Leu Ala Gly Val Tyr Gly Asn Gly Ala Leu Ala -10 -5 -1 1 5 Glu His Ser Glu Asn Val His Ile Ser Gly Val Ser Thr Ala Cys Gly 10 15 20 Glu Thr Pro Glu Gln Ile Arg Ala Pro Ser Gly Ile Ile Thr Ser Pro 25 30 35 Gly Trp Pro Ser Glu Tyr Pro Ala Lys Ile Asn Cys Ser Trp Phe Ile 40 45 50 Arg Ala Asn Pro Gly Glu Ile Ile Thr Ile Ser Phe Gln Asp Phe Asp 55 60 65 Ile Gln Gly Ser Arg Arg Cys Asn Leu Asp Trp Leu Thr Ile Glu Thr 70 75 80 85 Tyr Lys Asn Ile Glu Ser Tyr Arg Ala Cys Gly Ser Thr Ile Pro Pro 90 95 100 Pro Tyr Ile Ser Ser Gln Asp His Ile Trp Ile Arg Phe His Ser Asp 105 110 115 Asp Asn Ile Ser Arg Lys Gly Phe Arg Leu Ala Tyr Phe Ser Gly Lys 120 125 130 Ser Glu Glu Pro Asn Cys Ala Cys Asp Gln Phe Arg Cys Gly Asn Gly 135 140 145 Lys Cys Ile Pro Glu Ala Trp Lys Cys Asn Asn Met Asp Glu Cys Gly 150 155 160 165 Asp Ser Ser Asp Glu Glu Ile Cys Ala Lys Glu Ala Asn Pro Pro Thr 170 175 180 Ala Ala Ala Phe Gln Pro Cys Ala Tyr Asn Gln Phe Gln Cys Leu Ser 185 190 195 Arg Phe Thr Lys Val Tyr Thr Cys Leu Pro Glu Ser Leu Lys Cys Asp 200 205 210 Gly Asn Ile Asp Cys Leu Asp Leu Gly Asp Glu Ile Asp Cys Asp Val 215 220 225 Pro Thr Cys Gly Gln Trp Leu Lys Tyr Phe Tyr Gly Thr Phe Asn Ser 230 235 240 245 Pro Asn Tyr Pro Asp Phe Tyr Pro Pro Gly Ser Asn Cys Thr Trp Leu 250 255 260 Ile Asp Thr Gly Asp His Arg Lys Val Ile Leu Arg Phe Thr Asp Phe 265 270 275 Lys Leu Asp Gly Thr Gly Tyr Gly Asp Tyr Val Lys Ile Tyr Asp Gly 280 285 290 Leu Glu Glu Asn Pro His Lys Leu Leu Arg Val Leu Thr Ala Phe Asp 295 300 305 Ser His Ala Pro Leu Thr Val Val Ser Ser Ser Gly Gln Ile Arg Val 310 315 320 325 His Phe Cys Ala Asp Lys Val Asn Ala Ala Arg Gly Phe Asn Ala Thr 330 335 340 Tyr Gln Val Asp Gly Phe Cys Leu Pro Trp Glu Ile Pro Cys Gly Gly 345 350 355 Asn Trp Gly Cys Tyr Thr Glu Gln Gln Arg Cys Asp Gly Tyr Trp His 360 365 370 Cys Pro Asn Gly Arg Asp Glu Thr Asn Cys Thr Met Cys Gln Lys Glu 375 380 385 Glu Phe Pro Cys Ser Arg Asn Gly Val Cys Tyr Pro Arg Ser Asp Arg 390 395 400 405 Cys Asn Tyr Gln Asn His Cys Pro Asn Gly Ser Asp Glu Lys Asn Cys 410 415 420 Phe Phe Cys Gln Pro Gly Asn Phe His Cys Lys Asn Asn Arg Cys Val 425 430 435 Phe Glu Ser Trp Val Cys Asp Ser Gln Asp Asp Cys Gly Asp Gly Ser 440 445 450 Asp Glu Glu Asn Cys Pro Val Ile Val Pro Thr Arg Val Ile Thr Ala 455 460 465 Ala Val Ile Gly Ser Leu Ile Cys Gly Leu Leu Leu Val Ile Ala Leu 470 475 480 485 Gly Cys Thr Cys Lys Leu Tyr Ser Leu Arg Met Phe Glu Arg Arg Ser 490 495 500 Phe Glu Thr Gln Leu Ser Arg Val Glu Ala Glu Leu Leu Arg Arg Glu 505 510 515 Ala Pro Pro Ser Tyr Gly Gln Leu Ile Ala Gln Gly Leu Ile Pro Pro 520 525 530 Val Glu Asp Phe Pro Val Cys Ser Pro Asn Gln Ala Ser Val Leu Glu 535 540 545 Asn Leu Arg Leu Ala Val Arg Ser Gln Leu Gly Phe Thr Ser Val Arg 550 555 560 565 Leu Pro Met Ala Gly Arg Ser Ser Asn Ile Trp Asn Arg Ile Phe Asn 570 575 580 Phe Ala Arg Ser Arg His Ser Gly Ser Leu Ala Leu Val Ser Ala Asp 585 590 595 Gly Asp Glu Val Val Pro Ser Gln Ser Thr Ser Arg Glu Pro Glu Arg 600 605 610 Asn His Thr His Arg Ser Leu Phe Ser Val Glu Ser Asp Asp Thr Asp 615 620 625 Thr Glu Asn Glu Arg Arg Asp Met Ala Gly Ala Ser Gly Gly Val Ala 630 635 640 645 Ala Pro Leu Pro Gln Lys Val Pro Pro Thr Thr Ala Val Glu Ala Thr 650 655 660 Val Gly Ala Cys Ala Ser Ser Ser Thr Gln Ser Thr Arg Gly Gly His 665 670 675 Ala Asp Asn Gly Arg Asp Val Thr Ser Val Glu Pro Pro Ser Val Ser 680 685 690 Pro Ala Arg His Gln Leu Thr Ser Ala Leu Ser Arg Met Thr Gln Gly 695 700 705 Leu Arg Trp Val Arg Phe Thr Leu Gly Arg Ser Ser Ser Leu Ser Gln 710 715 720 725 Asn Gln Ser Pro Leu Arg Gln Leu Asp Asn Gly Val Ser Gly Arg Glu 730 735 740 Asp Asp Asp Asp Val Glu Met Leu Ile Pro Ile Ser Asp Gly Ser Ser 745 750 755 Asp Phe Asp Val Asn Asp Cys Ser Arg Pro Leu Leu Asp Leu Ala Ser 760 765 770 Asp Gln Gly Gln Gly Leu Arg Gln Pro Tyr Asn Ala Thr Asn Pro Gly 775 780 785 Val Arg Pro Ser Asn Arg Asp Gly Pro Cys Glu Arg Cys Gly Ile Val 790 795 800 805 His Thr Ala Gln Ile Pro Asp Thr Cys Leu Glu Val Thr Leu Lys Asn 810 815 820 Glu Thr Ser Asp Asp Glu Ala Leu Leu Leu Cys 825 830 <210> SEQ ID NO 71 <211> LENGTH: 2577 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 71 atggcctgtc gctggagcac aaaagagtct ccgcggtgga ggtctgcgtt gctcttgctt 60 ttcctcgctg gggtgtacgg aaatggtgct cttgcagaac attctgaaaa tgtgcatatt 120 tcaggagtgt caactgcttg tggagagact ccagagcaaa tacgagcacc aagtggcata 180 atcacaagcc caggctggcc ttctgaatat cctgcaaaaa tcaactgtag ctggttcata 240 agggcaaacc caggcgaaat cattactata agttttcagg attttgatat tcaaggatcc 300 agaaggtgca atttggactg gttgacaata gaaacataca agaatattga aagttacaga 360 gcttgtggtt ccacaattcc acctccgtat atctcttcac aagaccacat ctggattagg 420 tttcattcgg atgacaacat ctctagaaag ggtttcagac tggcatattt ttcagggaaa 480 tctgaggaac caaattgtgc ttgtgatcag tttcgttgtg gtaatggaaa gtgtatacca 540 gaagcctgga aatgtaataa catggatgaa tgtggagata gttccgatga agagatctgt 600 gccaaagaag caaatcctcc aactgctgct gcttttcaac cctgtgctta caaccagttc 660 cagtgtttat cccgttttac caaagtttac acttgcctcc ccgaatcttt aaaatgtgat 720 gggaacattg actgccttga cctaggagat gagatagact gtgatgtgcc aacatgtggg 780 caatggctaa aatattttta tggtactttt aattctccca attatccaga cttttatcct 840 cctggaagca attgcacctg gttaatagac actggtgatc accgtaaagt cattttacgc 900 ttcactgact ttaaacttga tggtactggt tatggtgatt atgtcaaaat atatgatgga 960 ttagaggaga atccacacaa gcttttgcgt gtgttgacag cttttgattc tcatgcacct 1020 cttacagttg tttcttcttc tggacagata agggtacatt tttgtgctga taaagtgaat 1080 gctgcaaggg gatttaatgc tacttaccaa gtagatgggt tctgtttgcc atgggaaata 1140 ccctgtggag gtaactgggg gtgttatact gagcagcagc gttgtgatgg gtattggcat 1200 tgcccaaatg gaagggatga aaccaattgt accatgtgcc agaaggaaga atttccatgt 1260 tcccgaaatg gtgtctgtta tcctcgttct gatcgctgca actaccagaa tcattgccca 1320 aatggctcag atgaaaaaaa ctgctttttt tgccaaccag gaaatttcca ttgtaaaaac 1380 aatcgttgtg tgtttgaaag ttgggtgtgt gattctcaag atgactgtgg tgatggcagc 1440 gatgaagaaa attgcccagt aatcgtgcct acaagagtca tcactgctgc cgtcataggg 1500 agcctcatct gtggcctgtt actcgtcata gcattgggat gtacttgtaa gctttattct 1560 ctgagaatgt ttgaaagaag atcatttgaa acacagttgt caagagtgga agcagaattg 1620 ttaagaagag aagctcctcc ctcgtatgga caattgattg ctcagggttt aattccacca 1680 gttgaagatt ttcctgtttg ttcacctaat caggcttctg ttttggaaaa tctgaggcta 1740 gcggtacgat ctcagcttgg atttacttca gtcaggcttc ctatggcagg cagatcaagc 1800 aacatttgga accgtatttt taattttgca agatcacgtc attctgggtc attggctttg 1860 gtctcagcag atggagatga ggttgtccct agtcagagta ccagtagaga acctgagaga 1920 aatcatactc acagaagttt gttttccgtg gagtctgatg atacagacac agaaaatgag 1980 agaagagata tggcaggagc atctggtggg gttgcagctc ctttgcctca aaaagtccct 2040 cccacaacgg cagtagaagc gacagtagga gcatgtgcaa gttcctcaac tcagagtacc 2100 cgaggtggcc atgcagataa tggaagggat gtgacaagtg tggaaccccc aagtgtgagt 2160 ccagcacgtc accagcttac aagtgcactc agtcgtatga ctcaggggct acgctgggta 2220 cgttttacat taggacgatc aagttcccta agtcagaacc agagtccttt gagacaactt 2280 gataatgggg taagtggaag agaagatgat gatgatgttg aaatgctaat tccaatttct 2340 gatggatctt cagactttga tgtgaatgac tgctccagac ctcttcttga tcttgcctca 2400 gatcaaggac aagggcttag acaaccatat aatgcaacaa atcctggagt aaggccaagt 2460 aatcgagatg gcccctgtga gcgctgtggt attgtccaca ctgcccagat accagacact 2520 tgcttagaag taacactgaa aaacgaaacg agtgatgatg aggctttgtt actttgt 2577 <210> SEQ ID NO 72 <211> LENGTH: 3088 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (41)..(2617) <221> NAME/KEY: sig_peptide <222> LOCATION: (41)..(121) <221> NAME/KEY: mat_peptide <222> LOCATION: (122)..(2617) <400> SEQUENCE: 72 ctcctccgtc tcctcctctc tctctccatc tgctgtggtt atg gcc tgt cgc tgg 55 Met Ala Cys Arg Trp -25 agc aca aaa gag tct ccg cgg tgg agg tct gcg ttg ctc ttg ctt ttc 103 Ser Thr Lys Glu Ser Pro Arg Trp Arg Ser Ala Leu Leu Leu Leu Phe -20 -15 -10 ctc gct ggg gtg tac gga aat ggt gct ctt gca gaa cat tct gaa aat 151 Leu Ala Gly Val Tyr Gly Asn Gly Ala Leu Ala Glu His Ser Glu Asn -5 -1 1 5 10 gtg cat att tca gga gtg tca act gct tgt gga gag act cca gag caa 199 Val His Ile Ser Gly Val Ser Thr Ala Cys Gly Glu Thr Pro Glu Gln 15 20 25 ata cga gca cca agt ggc ata atc aca agc cca ggc tgg cct tct gaa 247 Ile Arg Ala Pro Ser Gly Ile Ile Thr Ser Pro Gly Trp Pro Ser Glu 30 35 40 tat cct gca aaa atc aac tgt agc tgg ttc ata agg gca aac cca ggc 295 Tyr Pro Ala Lys Ile Asn Cys Ser Trp Phe Ile Arg Ala Asn Pro Gly 45 50 55 gaa atc att act ata agt ttt cag gat ttt gat att caa gga tcc aga 343 Glu Ile Ile Thr Ile Ser Phe Gln Asp Phe Asp Ile Gln Gly Ser Arg 60 65 70 agg tgc aat ttg gac tgg ttg aca ata gaa aca tac aag aat att gaa 391 Arg Cys Asn Leu Asp Trp Leu Thr Ile Glu Thr Tyr Lys Asn Ile Glu 75 80 85 90 agt tac aga gct tgt ggt tcc aca att cca cct ccg tat atc tct tca 439 Ser Tyr Arg Ala Cys Gly Ser Thr Ile Pro Pro Pro Tyr Ile Ser Ser 95 100 105 caa gac cac atc tgg att agg ttt cat tcg gat gac aac atc tct aga 487 Gln Asp His Ile Trp Ile Arg Phe His Ser Asp Asp Asn Ile Ser Arg 110 115 120 aag ggt ttc aga ctg gca tat ttt tca ggg aaa tct gag gaa cca aat 535 Lys Gly Phe Arg Leu Ala Tyr Phe Ser Gly Lys Ser Glu Glu Pro Asn 125 130 135 tgt gct tgt gat cag ttt cgt tgt ggt aat gga aag tgt ata cca gaa 583 Cys Ala Cys Asp Gln Phe Arg Cys Gly Asn Gly Lys Cys Ile Pro Glu 140 145 150 gcc tgg aaa tgt aat aac atg gat gaa tgt gga gat agt tcc gat gaa 631 Ala Trp Lys Cys Asn Asn Met Asp Glu Cys Gly Asp Ser Ser Asp Glu 155 160 165 170 gag atc tgt gcc aaa gaa gca aat cct cca act gct gct gct ttt caa 679 Glu Ile Cys Ala Lys Glu Ala Asn Pro Pro Thr Ala Ala Ala Phe Gln 175 180 185 ccc tgt gct tac aac cag ttc cag tgt tta tcc cgt ttt acc aaa gtt 727 Pro Cys Ala Tyr Asn Gln Phe Gln Cys Leu Ser Arg Phe Thr Lys Val 190 195 200 tac act tgc ctc ccc gaa tct tta aaa tgt gat ggg aac att gac tgc 775 Tyr Thr Cys Leu Pro Glu Ser Leu Lys Cys Asp Gly Asn Ile Asp Cys 205 210 215 ctt gac cta gga gat gag ata gac tgt gat gtg cca aca tgt ggg caa 823 Leu Asp Leu Gly Asp Glu Ile Asp Cys Asp Val Pro Thr Cys Gly Gln 220 225 230 tgg cta aaa tat ttt tat ggt act ttt aat tct ccc aat tat cca gac 871 Trp Leu Lys Tyr Phe Tyr Gly Thr Phe Asn Ser Pro Asn Tyr Pro Asp 235 240 245 250 ttt tat cct cct gga agc aat tgc acc tgg tta ata gac act ggt gat 919 Phe Tyr Pro Pro Gly Ser Asn Cys Thr Trp Leu Ile Asp Thr Gly Asp 255 260 265 cac cgt aaa gtc att tta cgc ttc act gac ttt aaa ctt gat ggt act 967 His Arg Lys Val Ile Leu Arg Phe Thr Asp Phe Lys Leu Asp Gly Thr 270 275 280 ggt tat ggt gat tat gtc aaa ata tat gat gga tta gag gag aat cca 1015 Gly Tyr Gly Asp Tyr Val Lys Ile Tyr Asp Gly Leu Glu Glu Asn Pro 285 290 295 cac aag ctt ttg cgt gtg ttg aca gct ttt gat tct cat gca cct ctt 1063 His Lys Leu Leu Arg Val Leu Thr Ala Phe Asp Ser His Ala Pro Leu 300 305 310 aca gtt gtt tct tct tct gga cag ata agg gta cat ttt tgt gct gat 1111 Thr Val Val Ser Ser Ser Gly Gln Ile Arg Val His Phe Cys Ala Asp 315 320 325 330 aaa gtg aat gct gca agg gga ttt aat gct act tac caa gta gat ggg 1159 Lys Val Asn Ala Ala Arg Gly Phe Asn Ala Thr Tyr Gln Val Asp Gly 335 340 345 ttc tgt ttg cca tgg gaa ata ccc tgt gga ggt aac tgg ggg tgt tat 1207 Phe Cys Leu Pro Trp Glu Ile Pro Cys Gly Gly Asn Trp Gly Cys Tyr 350 355 360 act gag cag cag cgt tgt gat ggg tat tgg cat tgc cca aat gga agg 1255 Thr Glu Gln Gln Arg Cys Asp Gly Tyr Trp His Cys Pro Asn Gly Arg 365 370 375 gat gaa acc aat tgt acc atg tgc cag aag gaa gaa ttt cca tgt tcc 1303 Asp Glu Thr Asn Cys Thr Met Cys Gln Lys Glu Glu Phe Pro Cys Ser 380 385 390 cga aat ggt gtc tgt tat cct cgt tct gat cgc tgc aac tac cag aat 1351 Arg Asn Gly Val Cys Tyr Pro Arg Ser Asp Arg Cys Asn Tyr Gln Asn 395 400 405 410 cat tgc cca aat ggc tca gat gaa aaa aac tgc ttt ttt tgc caa cca 1399 His Cys Pro Asn Gly Ser Asp Glu Lys Asn Cys Phe Phe Cys Gln Pro 415 420 425 gga aat ttc cat tgt aaa aac aat cgt tgt gtg ttt gaa agt tgg gtg 1447 Gly Asn Phe His Cys Lys Asn Asn Arg Cys Val Phe Glu Ser Trp Val 430 435 440 tgt gat tct caa gat gac tgt ggt gat ggc agc gat gaa gaa aat tgc 1495 Cys Asp Ser Gln Asp Asp Cys Gly Asp Gly Ser Asp Glu Glu Asn Cys 445 450 455 cca gta atc gtg cct aca aga gtc atc act gct gcc gtc ata ggg agc 1543 Pro Val Ile Val Pro Thr Arg Val Ile Thr Ala Ala Val Ile Gly Ser 460 465 470 ctc atc tgt ggc ctg tta ctc gtc ata gca ttg gga tgt act tgt aag 1591 Leu Ile Cys Gly Leu Leu Leu Val Ile Ala Leu Gly Cys Thr Cys Lys 475 480 485 490 ctt tat tct ctg aga atg ttt gaa aga aga tca ttt gaa aca cag ttg 1639 Leu Tyr Ser Leu Arg Met Phe Glu Arg Arg Ser Phe Glu Thr Gln Leu 495 500 505 tca aga gtg gaa gca gaa ttg tta aga aga gaa gct cct ccc tcg tat 1687 Ser Arg Val Glu Ala Glu Leu Leu Arg Arg Glu Ala Pro Pro Ser Tyr 510 515 520 gga caa ttg att gct cag ggt tta att cca cca gtt gaa gat ttt cct 1735 Gly Gln Leu Ile Ala Gln Gly Leu Ile Pro Pro Val Glu Asp Phe Pro 525 530 535 gtt tgt tca cct aat cag gct tct gtt ttg gaa aat ctg agg cta gcg 1783 Val Cys Ser Pro Asn Gln Ala Ser Val Leu Glu Asn Leu Arg Leu Ala 540 545 550 gta cga tct cag ctt gga ttt act tca gtc agg ctt cct atg gca ggc 1831 Val Arg Ser Gln Leu Gly Phe Thr Ser Val Arg Leu Pro Met Ala Gly 555 560 565 570 aga tca agc aac att tgg aac cgt att ttt aat ttt gca aga tca cgt 1879 Arg Ser Ser Asn Ile Trp Asn Arg Ile Phe Asn Phe Ala Arg Ser Arg 575 580 585 cat tct ggg tca ttg gct ttg gtc tca gca gat gga gat gag gtt gtc 1927 His Ser Gly Ser Leu Ala Leu Val Ser Ala Asp Gly Asp Glu Val Val 590 595 600 cct agt cag agt acc agt aga gaa cct gag aga aat cat act cac aga 1975 Pro Ser Gln Ser Thr Ser Arg Glu Pro Glu Arg Asn His Thr His Arg 605 610 615 agt ttg ttt tcc gtg gag tct gat gat aca gac aca gaa aat gag aga 2023 Ser Leu Phe Ser Val Glu Ser Asp Asp Thr Asp Thr Glu Asn Glu Arg 620 625 630 aga gat atg gca gga gca tct ggt ggg gtt gca gct cct ttg cct caa 2071 Arg Asp Met Ala Gly Ala Ser Gly Gly Val Ala Ala Pro Leu Pro Gln 635 640 645 650 aaa gtc cct ccc aca acg gca gta gaa gcg aca gta gga gca tgt gca 2119 Lys Val Pro Pro Thr Thr Ala Val Glu Ala Thr Val Gly Ala Cys Ala 655 660 665 agt tcc tca act cag agt acc cga ggt ggc cat gca gat aat gga agg 2167 Ser Ser Ser Thr Gln Ser Thr Arg Gly Gly His Ala Asp Asn Gly Arg 670 675 680 gat gtg aca agt gtg gaa ccc cca agt gtg agt cca gca cgt cac cag 2215 Asp Val Thr Ser Val Glu Pro Pro Ser Val Ser Pro Ala Arg His Gln 685 690 695 ctt aca agt gca ctc agt cgt atg act cag ggg cta cgc tgg gta cgt 2263 Leu Thr Ser Ala Leu Ser Arg Met Thr Gln Gly Leu Arg Trp Val Arg 700 705 710 ttt aca tta gga cga tca agt tcc cta agt cag aac cag agt cct ttg 2311 Phe Thr Leu Gly Arg Ser Ser Ser Leu Ser Gln Asn Gln Ser Pro Leu 715 720 725 730 aga caa ctt gat aat ggg gta agt gga aga gaa gat gat gat gat gtt 2359 Arg Gln Leu Asp Asn Gly Val Ser Gly Arg Glu Asp Asp Asp Asp Val 735 740 745 gaa atg cta att cca att tct gat gga tct tca gac ttt gat gtg aat 2407 Glu Met Leu Ile Pro Ile Ser Asp Gly Ser Ser Asp Phe Asp Val Asn 750 755 760 gac tgc tcc aga cct ctt ctt gat ctt gcc tca gat caa gga caa ggg 2455 Asp Cys Ser Arg Pro Leu Leu Asp Leu Ala Ser Asp Gln Gly Gln Gly 765 770 775 ctt aga caa cca tat aat gca aca aat cct gga gta agg cca agt aat 2503 Leu Arg Gln Pro Tyr Asn Ala Thr Asn Pro Gly Val Arg Pro Ser Asn 780 785 790 cga gat ggc ccc tgt gag cgc tgt ggt att gtc cac act gcc cag ata 2551 Arg Asp Gly Pro Cys Glu Arg Cys Gly Ile Val His Thr Ala Gln Ile 795 800 805 810 cca gac act tgc tta gaa gta aca ctg aaa aac gaa acg agt gat gat 2599 Pro Asp Thr Cys Leu Glu Val Thr Leu Lys Asn Glu Thr Ser Asp Asp 815 820 825 gag gct ttg tta ctt tgt taggtacgaa tcacataagg gagattgtat 2647 Glu Ala Leu Leu Leu Cys 830 acaagttgga gcaatatcca tttattattt tgtaacttta cagttaaact agttttagtt 2707 taaaaagaaa aaatgcaggg tgatttctta ttattatatg ttagcctgca tggttaaatt 2767 cgacaacttg taactctatg aacttagagt ttactatttt agcagctaaa aatgcatcac 2827 atattcatat tgttcaataa tgtcctttca tttgtttctg attgttttca tcctgatact 2887 gtagttcact gtagaaatgt ggctgctgaa actcatttga ttgtcatttt tatctatcct 2947 atgttaaatg gtttgttttt acaaaataat accttatttt aattgaaacg tttatgcttt 3007 tgccaacaca tcttgtaact taatatacta gatgttaagg ttgttaatgt acaaaaaaaa 3067 aaaaaaaaaa aaaaaaaaaa a 3088 <210> SEQ ID NO 73 <211> LENGTH: 687 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 73 Met Thr Pro Gln Ser Leu Leu Gln Thr Thr Leu Phe Leu Leu Ser Leu -25 -20 -15 -10 Leu Phe Leu Val Gln Gly Ala His Gly Arg Gly His Arg Glu Asp Phe -5 -1 1 5 Arg Phe Cys Ser Gln Arg Asn Gln Thr His Arg Ser Ser Leu His Tyr 10 15 20 Lys Pro Thr Pro Asp Leu Arg Ile Ser Ile Glu Asn Ser Glu Glu Ala 25 30 35 Leu Thr Val His Ala Pro Phe Pro Ala Ala His Pro Ala Ser Arg Ser 40 45 50 55 Phe Pro Asp Pro Arg Gly Leu Tyr His Phe Cys Leu Tyr Trp Asn Arg 60 65 70 His Ala Gly Arg Leu His Leu Leu Tyr Gly Lys Arg Asp Phe Leu Leu 75 80 85 Ser Asp Lys Ala Ser Ser Leu Leu Cys Phe Gln His Gln Glu Glu Ser 90 95 100 Leu Ala Gln Gly Pro Pro Leu Leu Ala Thr Ser Val Thr Ser Trp Trp 105 110 115 Ser Pro Gln Asn Ile Ser Leu Pro Ser Ala Ala Ser Phe Thr Phe Ser 120 125 130 135 Phe His Ser Pro Pro His Thr Ala Ala His Asn Ala Ser Val Asp Met 140 145 150 Cys Glu Leu Lys Arg Asp Leu Gln Leu Leu Ser Gln Phe Leu Lys His 155 160 165 Pro Gln Lys Ala Ser Arg Arg Pro Ser Ala Ala Pro Ala Ser Gln Gln 170 175 180 Leu Gln Ser Leu Glu Ser Lys Leu Thr Ser Val Arg Phe Met Gly Asp 185 190 195 Met Val Ser Phe Glu Glu Asp Arg Ile Asn Ala Thr Val Trp Lys Leu 200 205 210 215 Gln Pro Thr Ala Gly Leu Gln Asp Leu His Ile His Ser Arg Gln Glu 220 225 230 Glu Glu Gln Ser Glu Ile Met Glu Tyr Ser Val Leu Leu Pro Arg Thr 235 240 245 Leu Phe Gln Arg Thr Lys Gly Arg Arg Gly Glu Ala Glu Lys Arg Leu 250 255 260 Leu Leu Val Asp Phe Ser Ser Gln Ala Leu Phe Gln Asp Lys Asn Ser 265 270 275 Ser Gln Val Leu Gly Glu Lys Val Leu Gly Ile Val Val Gln Asn Thr 280 285 290 295 Lys Val Ala Asn Leu Thr Glu Pro Val Val Leu Thr Phe Gln His Gln 300 305 310 Leu Gln Pro Lys Asn Val Thr Leu Gln Cys Val Phe Trp Val Glu Asp 315 320 325 Pro Thr Leu Ser Ser Pro Gly His Trp Ser Ser Ala Gly Cys Glu Thr 330 335 340 Val Arg Arg Glu Thr Gln Thr Ser Cys Phe Cys Asn His Leu Thr Tyr 345 350 355 Phe Ala Val Leu Met Val Ser Ser Val Glu Val Asp Ala Val His Lys 360 365 370 375 His Tyr Leu Ser Leu Leu Ser Tyr Val Gly Cys Val Val Ser Ala Leu 380 385 390 Ala Cys Leu Val Ser Ile Ala Ala Tyr Leu Cys Ser Arg Arg Lys Pro 395 400 405 Arg Asp Tyr Thr Ile Lys Val His Met Asn Leu Leu Leu Ala Val Phe 410 415 420 Leu Leu Asp Thr Ser Phe Leu Leu Ser Glu Pro Val Ala Leu Thr Gly 425 430 435 Ser Glu Ala Gly Cys Arg Ala Ser Ala Ile Phe Leu His Phe Ser Leu 440 445 450 455 Leu Thr Cys Leu Ser Trp Met Gly Leu Glu Gly Tyr Asn Leu Tyr Arg 460 465 470 Leu Val Val Glu Val Phe Gly Thr Tyr Val Pro Gly Tyr Leu Leu Lys 475 480 485 Leu Ser Ala Met Gly Trp Gly Phe Pro Ile Phe Leu Val Thr Leu Val 490 495 500 Ala Leu Val Asp Val Asp Asn Tyr Gly Pro Ile Ile Leu Ala Val His 505 510 515 Arg Thr Pro Glu Gly Val Ile Tyr Pro Ser Met Cys Trp Ile Arg Asp 520 525 530 535 Ser Leu Val Ser Tyr Ile Thr Asn Leu Gly Leu Phe Ser Leu Val Phe 540 545 550 Leu Phe Asn Met Ala Met Leu Ala Thr Met Val Val Gln Ile Leu Arg 555 560 565 Leu Arg Pro His Thr Gln Lys Trp Ser His Val Leu Thr Leu Leu Gly 570 575 580 Leu Ser Leu Val Leu Gly Leu Pro Trp Ala Leu Ile Phe Phe Ser Phe 585 590 595 Ala Ser Gly Thr Phe Gln Leu Val Val Leu Tyr Leu Phe Ser Ile Ile 600 605 610 615 Thr Ser Phe Gln Gly Phe Leu Ile Phe Ile Trp Tyr Trp Ser Met Arg 620 625 630 Leu Gln Ala Arg Gly Gly Pro Ser Pro Leu Lys Ser Asn Ser Asp Ser 635 640 645 Ala Arg Leu Pro Ile Ser Ser Gly Ser Thr Ser Ser Ser Arg Ile 650 655 660 <210> SEQ ID NO 74 <211> LENGTH: 2061 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 74 atgactcccc agtcgctgct gcagacgaca ctgttcctgc tgagtctgct cttcctggtc 60 caaggtgccc acggcagggg ccacagggaa gactttcgct tctgcagcca gcggaaccag 120 acacacagga gcagcctcca ctacaaaccc acaccagacc tgcgcatctc catcgagaac 180 tccgaagagg ccctcacagt ccatgcccct ttccctgcag cccaccctgc ttcccgatcc 240 ttccctgacc ccaggggcct ctaccacttc tgcctctact ggaaccgaca tgctgggaga 300 ttacatcttc tctatggcaa gcgtgacttc ttgctgagtg acaaagcctc tagcctcctc 360 tgcttccagc accaggagga gagcctggct cagggccccc cgctgttagc cacttctgtc 420 acctcctggt ggagccctca gaacatcagc ctgcccagtg ccgccagctt caccttctcc 480 ttccacagtc ctccccacac ggccgctcac aatgcctcgg tggacatgtg cgagctcaaa 540 agggacctcc agctgctcag ccagttcctg aagcatcccc agaaggcctc aaggaggccc 600 tcggctgccc ccgccagcca gcagttgcag agcctggagt cgaaactgac ctctgtgaga 660 ttcatggggg acatggtgtc cttcgaggag gaccggatca acgccacggt gtggaagctc 720 cagcccacag ccggcctcca ggacctgcac atccactccc ggcaggagga ggagcagagc 780 gagatcatgg agtactcggt gctgctgcct cgaacactct tccagaggac gaaaggccgg 840 aggggggagg ctgagaagag actcctcctg gtggacttca gcagccaagc cctgttccag 900 gacaagaatt ccagccaagt cctgggtgag aaggtcttgg ggattgtggt acagaacacc 960 aaagtagcca acctcacgga gcccgtggtg ctcaccttcc agcaccagct acagccgaag 1020 aatgtgactc tgcaatgtgt gttctgggtt gaagacccca cattgagcag cccggggcat 1080 tggagcagtg ctgggtgtga gaccgtcagg agagaaaccc aaacatcctg cttctgcaac 1140 cacttgacct actttgcagt gctgatggtc tcctcggtgg aggtggacgc cgtgcacaag 1200 cactacctga gcctcctctc ctacgtgggc tgtgtcgtct ctgccctggc ctgccttgtc 1260 agcattgccg cctacctctg ctccaggagg aaacctcggg actacaccat caaggtgcac 1320 atgaacctgc tgctggccgt cttcctgctg gacacgagct tcctgctcag cgagccggtg 1380 gccctgacag gctctgaggc tggctgccga gccagtgcca tcttcctgca cttctccctg 1440 ctcacctgcc tttcctggat gggcctcgag gggtacaacc tctaccgact cgtggtggag 1500 gtctttggca cctatgtccc tggctaccta ctcaagctga gcgccatggg ctggggcttc 1560 cccatctttc tggtgacgct ggtggccctg gtggatgtgg acaactatgg ccccatcatc 1620 ttggctgtgc ataggactcc agagggcgtc atctaccctt ccatgtgctg gatccgggac 1680 tccctggtca gctacatcac caacctgggc ctcttcagcc tggtgtttct gttcaacatg 1740 gccatgctag ccaccatggt ggtgcagatc ctgcggctgc gcccccacac ccaaaagtgg 1800 tcacatgtgc tgacactgct gggcctcagc ctggtccttg gcctgccctg ggccttgatc 1860 ttcttctcct ttgcttctgg caccttccag cttgtcgtcc tctacctttt cagcatcatc 1920 acctccttcc aaggcttcct catcttcatc tggtactggt ccatgcggct gcaggcccgg 1980 ggtggcccct cccctctgaa gagcaactca gacagcgcca ggctccccat cagctcgggc 2040 agcacctcgt ccagccgcat c 2061 <210> SEQ ID NO 75 <211> LENGTH: 3564 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: sig_peptide <222> LOCATION: (43)..(2103) <221> NAME/KEY: mat_peptide <222> LOCATION: (118)..(2103) <221> NAME/KEY: CDS <222> LOCATION: (43)..(2103) <400> SEQUENCE: 75 attacaggtg gtgacttcca agagtgactc cgtcggagga aa atg act ccc cag 54 Met Thr Pro Gln -25 tcg ctg ctg cag acg aca ctg ttc ctg ctg agt ctg ctc ttc ctg gtc 102 Ser Leu Leu Gln Thr Thr Leu Phe Leu Leu Ser Leu Leu Phe Leu Val -20 -15 -10 caa ggt gcc cac ggc agg ggc cac agg gaa gac ttt cgc ttc tgc agc 150 Gln Gly Ala His Gly Arg Gly His Arg Glu Asp Phe Arg Phe Cys Ser -5 -1 1 5 10 cag cgg aac cag aca cac agg agc agc ctc cac tac aaa ccc aca cca 198 Gln Arg Asn Gln Thr His Arg Ser Ser Leu His Tyr Lys Pro Thr Pro 15 20 25 gac ctg cgc atc tcc atc gag aac tcc gaa gag gcc ctc aca gtc cat 246 Asp Leu Arg Ile Ser Ile Glu Asn Ser Glu Glu Ala Leu Thr Val His 30 35 40 gcc cct ttc cct gca gcc cac cct gct tcc cga tcc ttc cct gac ccc 294 Ala Pro Phe Pro Ala Ala His Pro Ala Ser Arg Ser Phe Pro Asp Pro 45 50 55 agg ggc ctc tac cac ttc tgc ctc tac tgg aac cga cat gct ggg aga 342 Arg Gly Leu Tyr His Phe Cys Leu Tyr Trp Asn Arg His Ala Gly Arg 60 65 70 75 tta cat ctt ctc tat ggc aag cgt gac ttc ttg ctg agt gac aaa gcc 390 Leu His Leu Leu Tyr Gly Lys Arg Asp Phe Leu Leu Ser Asp Lys Ala 80 85 90 tct agc ctc ctc tgc ttc cag cac cag gag gag agc ctg gct cag ggc 438 Ser Ser Leu Leu Cys Phe Gln His Gln Glu Glu Ser Leu Ala Gln Gly 95 100 105 ccc ccg ctg tta gcc act tct gtc acc tcc tgg tgg agc cct cag aac 486 Pro Pro Leu Leu Ala Thr Ser Val Thr Ser Trp Trp Ser Pro Gln Asn 110 115 120 atc agc ctg ccc agt gcc gcc agc ttc acc ttc tcc ttc cac agt cct 534 Ile Ser Leu Pro Ser Ala Ala Ser Phe Thr Phe Ser Phe His Ser Pro 125 130 135 ccc cac acg gcc gct cac aat gcc tcg gtg gac atg tgc gag ctc aaa 582 Pro His Thr Ala Ala His Asn Ala Ser Val Asp Met Cys Glu Leu Lys 140 145 150 155 agg gac ctc cag ctg ctc agc cag ttc ctg aag cat ccc cag aag gcc 630 Arg Asp Leu Gln Leu Leu Ser Gln Phe Leu Lys His Pro Gln Lys Ala 160 165 170 tca agg agg ccc tcg gct gcc ccc gcc agc cag cag ttg cag agc ctg 678 Ser Arg Arg Pro Ser Ala Ala Pro Ala Ser Gln Gln Leu Gln Ser Leu 175 180 185 gag tcg aaa ctg acc tct gtg aga ttc atg ggg gac atg gtg tcc ttc 726 Glu Ser Lys Leu Thr Ser Val Arg Phe Met Gly Asp Met Val Ser Phe 190 195 200 gag gag gac cgg atc aac gcc acg gtg tgg aag ctc cag ccc aca gcc 774 Glu Glu Asp Arg Ile Asn Ala Thr Val Trp Lys Leu Gln Pro Thr Ala 205 210 215 ggc ctc cag gac ctg cac atc cac tcc cgg cag gag gag gag cag agc 822 Gly Leu Gln Asp Leu His Ile His Ser Arg Gln Glu Glu Glu Gln Ser 220 225 230 235 gag atc atg gag tac tcg gtg ctg ctg cct cga aca ctc ttc cag agg 870 Glu Ile Met Glu Tyr Ser Val Leu Leu Pro Arg Thr Leu Phe Gln Arg 240 245 250 acg aaa ggc cgg agg ggg gag gct gag aag aga ctc ctc ctg gtg gac 918 Thr Lys Gly Arg Arg Gly Glu Ala Glu Lys Arg Leu Leu Leu Val Asp 255 260 265 ttc agc agc caa gcc ctg ttc cag gac aag aat tcc agc caa gtc ctg 966 Phe Ser Ser Gln Ala Leu Phe Gln Asp Lys Asn Ser Ser Gln Val Leu 270 275 280 ggt gag aag gtc ttg ggg att gtg gta cag aac acc aaa gta gcc aac 1014 Gly Glu Lys Val Leu Gly Ile Val Val Gln Asn Thr Lys Val Ala Asn 285 290 295 ctc acg gag ccc gtg gtg ctc acc ttc cag cac cag cta cag ccg aag 1062 Leu Thr Glu Pro Val Val Leu Thr Phe Gln His Gln Leu Gln Pro Lys 300 305 310 315 aat gtg act ctg caa tgt gtg ttc tgg gtt gaa gac ccc aca ttg agc 1110 Asn Val Thr Leu Gln Cys Val Phe Trp Val Glu Asp Pro Thr Leu Ser 320 325 330 agc ccg ggg cat tgg agc agt gct ggg tgt gag acc gtc agg aga gaa 1158 Ser Pro Gly His Trp Ser Ser Ala Gly Cys Glu Thr Val Arg Arg Glu 335 340 345 acc caa aca tcc tgc ttc tgc aac cac ttg acc tac ttt gca gtg ctg 1206 Thr Gln Thr Ser Cys Phe Cys Asn His Leu Thr Tyr Phe Ala Val Leu 350 355 360 atg gtc tcc tcg gtg gag gtg gac gcc gtg cac aag cac tac ctg agc 1254 Met Val Ser Ser Val Glu Val Asp Ala Val His Lys His Tyr Leu Ser 365 370 375 ctc ctc tcc tac gtg ggc tgt gtc gtc tct gcc ctg gcc tgc ctt gtc 1302 Leu Leu Ser Tyr Val Gly Cys Val Val Ser Ala Leu Ala Cys Leu Val 380 385 390 395 agc att gcc gcc tac ctc tgc tcc agg agg aaa cct cgg gac tac acc 1350 Ser Ile Ala Ala Tyr Leu Cys Ser Arg Arg Lys Pro Arg Asp Tyr Thr 400 405 410 atc aag gtg cac atg aac ctg ctg ctg gcc gtc ttc ctg ctg gac acg 1398 Ile Lys Val His Met Asn Leu Leu Leu Ala Val Phe Leu Leu Asp Thr 415 420 425 agc ttc ctg ctc agc gag ccg gtg gcc ctg aca ggc tct gag gct ggc 1446 Ser Phe Leu Leu Ser Glu Pro Val Ala Leu Thr Gly Ser Glu Ala Gly 430 435 440 tgc cga gcc agt gcc atc ttc ctg cac ttc tcc ctg ctc acc tgc ctt 1494 Cys Arg Ala Ser Ala Ile Phe Leu His Phe Ser Leu Leu Thr Cys Leu 445 450 455 tcc tgg atg ggc ctc gag ggg tac aac ctc tac cga ctc gtg gtg gag 1542 Ser Trp Met Gly Leu Glu Gly Tyr Asn Leu Tyr Arg Leu Val Val Glu 460 465 470 475 gtc ttt ggc acc tat gtc cct ggc tac cta ctc aag ctg agc gcc atg 1590 Val Phe Gly Thr Tyr Val Pro Gly Tyr Leu Leu Lys Leu Ser Ala Met 480 485 490 ggc tgg ggc ttc ccc atc ttt ctg gtg acg ctg gtg gcc ctg gtg gat 1638 Gly Trp Gly Phe Pro Ile Phe Leu Val Thr Leu Val Ala Leu Val Asp 495 500 505 gtg gac aac tat ggc ccc atc atc ttg gct gtg cat agg act cca gag 1686 Val Asp Asn Tyr Gly Pro Ile Ile Leu Ala Val His Arg Thr Pro Glu 510 515 520 ggc gtc atc tac cct tcc atg tgc tgg atc cgg gac tcc ctg gtc agc 1734 Gly Val Ile Tyr Pro Ser Met Cys Trp Ile Arg Asp Ser Leu Val Ser 525 530 535 tac atc acc aac ctg ggc ctc ttc agc ctg gtg ttt ctg ttc aac atg 1782 Tyr Ile Thr Asn Leu Gly Leu Phe Ser Leu Val Phe Leu Phe Asn Met 540 545 550 555 gcc atg cta gcc acc atg gtg gtg cag atc ctg cgg ctg cgc ccc cac 1830 Ala Met Leu Ala Thr Met Val Val Gln Ile Leu Arg Leu Arg Pro His 560 565 570 acc caa aag tgg tca cat gtg ctg aca ctg ctg ggc ctc agc ctg gtc 1878 Thr Gln Lys Trp Ser His Val Leu Thr Leu Leu Gly Leu Ser Leu Val 575 580 585 ctt ggc ctg ccc tgg gcc ttg atc ttc ttc tcc ttt gct tct ggc acc 1926 Leu Gly Leu Pro Trp Ala Leu Ile Phe Phe Ser Phe Ala Ser Gly Thr 590 595 600 ttc cag ctt gtc gtc ctc tac ctt ttc agc atc atc acc tcc ttc caa 1974 Phe Gln Leu Val Val Leu Tyr Leu Phe Ser Ile Ile Thr Ser Phe Gln 605 610 615 ggc ttc ctc atc ttc atc tgg tac tgg tcc atg cgg ctg cag gcc cgg 2022 Gly Phe Leu Ile Phe Ile Trp Tyr Trp Ser Met Arg Leu Gln Ala Arg 620 625 630 635 ggt ggc ccc tcc cct ctg aag agc aac tca gac agc gcc agg ctc ccc 2070 Gly Gly Pro Ser Pro Leu Lys Ser Asn Ser Asp Ser Ala Arg Leu Pro 640 645 650 atc agc tcg ggc agc acc tcg tcc agc cgc atc taggcctcca gcccacctgc 2123 Ile Ser Ser Gly Ser Thr Ser Ser Ser Arg Ile 655 660 ccatgtgatg aagcagagat gcggcctcgt cgcacactgc ctgtggcccc cgagccaggc 2183 ccagccccag gccagtcagc cgcagacttt ggaaagccca acgaccatgg agagatgggc 2243 cgttgccatg gtggacggac tcccgggctg ggcttttgaa ttggccttgg ggactactcg 2303 gctctcactc agctcccacg ggactcagaa gtgcgccgcc atgctgccta gggtactgtc 2363 cccacatctg tcccaaccca gctggaggcc tggtctctcc ttacaacccc tgggcccagc 2423 cctcattgct gggggccagg ccttggatct tgagggtctg gcacatcctt aatcctgtgc 2483 ccctgcctgg gacagaaatg tggctccagt tgctctgtct ctcgtggtca ccctgagggc 2543 actctgcatc ctctgtcatt ttaacctcag gtggcaccca gggcgaatgg ggcccagggc 2603 agaccttcag ggccagagcc ctggcggagg agaggccctt tgccaggagc acagcagcag 2663 ctcgcctacc tctgagccca ggccccctcc ctccctcagc cccccagtcc tccctccatc 2723 ttccctgggg ttctcctcct ctcccagggc ctccttgctc cttcgttcac agctgggggt 2783 ccccgattcc aatgctgttt tttggggagt ggtttccagg agctgcctgg tgtctgctgt 2843 aaatgtttgt ctactgcaca agcctcggcc tgcccctgag ccaggctcgg taccgatgcg 2903 tgggctgggc taggtccctc tgtccatctg ggcctttgta tgagctgcat tgcccttgct 2963 caccctgacc aagcacacgc ctcagagggg ccctcagcct ctcctgaagc cctcttgtgg 3023 caagaactgt ggaccatgcc agtcccgtct ggtttccatc ccaccactcc aaggactgag 3083 actgacctcc tctggtgaca ctggcctaga gcctgacact ctcctaagag gttctctcca 3143 agcccccaaa tagctccagg cgccctcggc cgcccatcat ggttaattct gtccaacaaa 3203 cacacacggg tagattgctg gcctgttgta ggtggtaggg acacagatga ccgacctggt 3263 cactcctcct gccaacattc agtctggtat gtgaggcgtg cgtgaagcaa gaactcctgg 3323 agctacaggg acagggagcc atcattcctg cctgggaatc ctggaagact tcctgcagga 3383 gtcagcgttc aatcttgacc ttgaagatgg gaaggatgtt ctttttacgt accaattctt 3443 ttgtcttttg atattaaaaa gaagtacatg ttcattgtag agaatttgga aactgtagaa 3503 gagaatcaag aagaaaaata aaaatcagct gttgtaatcg cctagcaaaa aaaaaaaaaa 3563 a 3564 <210> SEQ ID NO 76 <211> LENGTH: 704 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 76 Met Phe Thr Phe Leu Leu Thr Cys Ile Phe Leu Pro Leu Leu Arg Gly -15 -10 -5 -1 His Ser Leu Phe Thr Cys Glu Pro Ile Thr Val Pro Arg Cys Met Lys 1 5 10 15 Met Ala Tyr Asn Met Thr Phe Phe Pro Asn Leu Met Gly His Tyr Asp 20 25 30 Gln Ser Ile Ala Ala Val Glu Met Glu His Phe Leu Pro Leu Ala Asn 35 40 45 Leu Glu Cys Ser Pro Asn Ile Glu Thr Phe Leu Cys Lys Ala Phe Val 50 55 60 Pro Thr Cys Ile Glu Gln Ile His Val Val Pro Pro Cys Arg Lys Leu 65 70 75 80 Cys Glu Lys Val Tyr Ser Asp Cys Lys Lys Leu Ile Asp Thr Phe Gly 85 90 95 Ile Arg Trp Pro Glu Glu Leu Glu Cys Asp Arg Leu Gln Tyr Cys Asp 100 105 110 Glu Thr Val Pro Val Thr Phe Asp Pro His Thr Glu Phe Leu Gly Pro 115 120 125 Gln Lys Lys Thr Glu Gln Val Gln Arg Asp Ile Gly Phe Trp Cys Pro 130 135 140 Arg His Leu Lys Thr Ser Gly Gly Gln Gly Tyr Lys Phe Leu Gly Ile 145 150 155 160 Asp Gln Cys Ala Pro Pro Cys Pro Asn Met Tyr Phe Lys Ser Asp Glu 165 170 175 Leu Glu Phe Ala Lys Ser Phe Ile Gly Thr Val Ser Ile Phe Cys Leu 180 185 190 Cys Ala Thr Leu Phe Thr Phe Leu Thr Phe Leu Ile Asp Val Arg Arg 195 200 205 Phe Arg Tyr Pro Glu Arg Pro Ile Ile Tyr Tyr Ser Val Cys Tyr Ser 210 215 220 Ile Val Ser Leu Met Tyr Phe Ile Gly Phe Leu Leu Gly Asp Ser Thr 225 230 235 240 Ala Cys Asn Lys Ala Asp Glu Lys Leu Glu Leu Gly Asn Thr Val Val 245 250 255 Leu Asp Ser Gln Asn Lys Ala Cys Thr Val Leu Phe Met Leu Leu Tyr 260 265 270 Phe Phe Thr Met Ala Gly Thr Val Trp Trp Val Ile Leu Thr Ile Thr 275 280 285 Trp Phe Leu Ala Ala Gly Arg Lys Trp Ser Cys Glu Ala Ile Glu Gln 290 295 300 Lys Ala Val Trp Phe His Ala Val Ala Trp Gly Thr Pro Gly Phe Leu 305 310 315 320 Thr Val Met Leu Leu Ala Met Asn Lys Val Glu Gly Asp Asn Ile Ser 325 330 335 Gly Val Cys Phe Val Gly Leu Tyr Asp Leu Asp Ala Ser Arg Tyr Phe 340 345 350 Val Leu Leu Pro Leu Cys Leu Cys Val Phe Val Gly Leu Ser Leu Leu 355 360 365 Leu Ala Gly Ile Ile Ser Leu Asn His Val Arg Gln Val Ile Gln His 370 375 380 Asp Gly Arg Asn Gln Glu Lys Leu Lys Lys Phe Met Ile Arg Ile Gly 385 390 395 400 Val Phe Ser Gly Leu Tyr Leu Val Pro Leu Val Thr Leu Leu Gly Cys 405 410 415 Tyr Val Tyr Glu Gln Val Asn Arg Ile Thr Trp Glu Ile Thr Trp Val 420 425 430 Ser Asp His Cys Arg Gln Tyr His Ile Pro Cys Pro Tyr Gln Ala Lys 435 440 445 Ala Lys Ala Arg Pro Glu Leu Ala Leu Phe Met Ile Lys Tyr Leu Met 450 455 460 Thr Leu Ile Val Gly Ile Ser Ala Val Phe Trp Val Gly Ser Lys Lys 465 470 475 480 Thr Cys Thr Glu Trp Ala Gly Phe Phe Lys Arg Asn Arg Lys Arg Asp 485 490 495 Pro Ile Ser Glu Ser Arg Arg Val Leu Gln Glu Ser Cys Glu Phe Phe 500 505 510 Leu Lys His Asn Ser Lys Val Lys His Lys Lys Lys His Tyr Lys Pro 515 520 525 Ser Ser His Lys Leu Lys Val Ile Ser Lys Ser Met Gly Thr Ser Thr 530 535 540 Gly Ala Thr Ala Asn His Gly Thr Ser Ala Val Ala Ile Thr Ser His 545 550 555 560 Asp Tyr Leu Gly Gln Glu Thr Leu Thr Glu Ile Gln Thr Ser Pro Glu 565 570 575 Thr Ser Met Arg Glu Val Lys Ala Asp Gly Ala Ser Thr Pro Arg Leu 580 585 590 Arg Glu Gln Asp Cys Gly Glu Pro Ala Ser Pro Ala Ala Ser Ile Ser 595 600 605 Arg Leu Ser Gly Glu Gln Val Asp Gly Lys Gly Gln Ala Gly Ser Val 610 615 620 Ser Glu Ser Ala Arg Ser Glu Gly Arg Ile Ser Pro Lys Ser Asp Ile 625 630 635 640 Thr Asp Thr Gly Leu Ala Gln Ser Asn Asn Leu Gln Val Pro Ser Ser 645 650 655 Ser Glu Pro Ser Ser Leu Lys Gly Ser Thr Ser Leu Leu Val His Pro 660 665 670 Val Ser Gly Val Arg Lys Glu Gln Gly Gly Gly Cys His Ser Asp Thr 675 680 685 <210> SEQ ID NO 77 <211> LENGTH: 2112 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 77 atgtttacat ttttgttgac gtgtattttt ctacccctcc taagagggca cagtctcttc 60 acctgtgaac caattactgt tcccagatgt atgaaaatgg cctacaacat gacgtttttc 120 cctaatctga tgggtcatta tgaccagagt attgccgcgg tggaaatgga gcattttctt 180 cctctcgcaa atctggaatg ttcaccaaac attgaaactt tcctctgcaa agcatttgta 240 ccaacctgca tagaacaaat tcatgtggtt ccaccttgtc gtaaactttg tgagaaagta 300 tattctgatt gcaaaaaatt aattgacact tttgggatcc gatggcctga ggagcttgaa 360 tgtgacagat tacaatactg tgatgagact gttcctgtaa cttttgatcc acacacagaa 420 tttcttggtc ctcagaagaa aacagaacaa gtccaaagag acattggatt ttggtgtcca 480 aggcatctta agacttctgg gggacaagga tataagtttc tgggaattga ccagtgtgcg 540 cctccatgcc ccaacatgta ttttaaaagt gatgagctag agtttgcaaa aagttttatt 600 ggaacagttt caatattttg tctttgtgca actctgttca cattccttac ttttttaatt 660 gatgttagaa gattcagata cccagagaga ccaattatat attactctgt ctgttacagc 720 attgtatctc ttatgtactt cattggattt ttgctaggcg atagcacagc ctgcaataag 780 gcagatgaga agctagaact tggtaacact gttgtcctag actctcaaaa taaggcttgc 840 accgttttgt tcatgctttt gtattttttc acaatggctg gcactgtgtg gtgggtgatt 900 cttaccatta cttggttctt agctgcagga agaaaatgga gttgtgaagc catcgagcaa 960 aaagcagtgt ggtttcatgc tgttgcatgg ggaacaccag gtttcctgac tgttatgctt 1020 cttgctatga acaaagttga aggagacaac attagtggag tttgctttgt tggcctttat 1080 gacctggatg cttctcgcta ctttgtactc ttgccactgt gcctttgtgt gtttgttggg 1140 ctctctcttc ttttagctgg cattatttcc ttaaatcatg ttcgacaagt catacaacat 1200 gatggccgga accaagaaaa actaaagaaa tttatgattc gaattggagt cttcagcggc 1260 ttgtatcttg tgccattagt gacacttctc ggatgttacg tctatgagca agtgaacagg 1320 attacctggg agataacttg ggtctctgat cattgtcgtc agtaccatat cccatgtcct 1380 tatcaggcaa aagcaaaagc tcgaccagaa ttggctttat ttatgataaa atacctgatg 1440 acattaattg ttggcatctc tgctgtcttc tgggttggaa gcaaaaagac atgcacagaa 1500 tgggctgggt tttttaaacg aaatcgcaag agagatccaa tcagtgaaag tcgaagagta 1560 ctacaggaat catgtgagtt tttcttaaag cacaattcta aagttaaaca caaaaagaag 1620 cactataaac caagttcaca caagctgaag gtcatttcca aatccatggg aaccagcaca 1680 ggagctacag caaatcatgg cacttctgca gtagcaatta ctagccatga ttacctagga 1740 caagaaactt tgacagaaat ccaaacctca ccagaaacat caatgagaga ggtgaaagcg 1800 gacggagcta gcacccccag gttaagagaa caggactgtg gtgaacctgc ctcgccagca 1860 gcatccatct ccagactctc tggggaacag gtcgacggga agggccaggc aggcagtgta 1920 tctgaaagtg cgcggagtga aggaaggatt agtccaaaga gtgatattac tgacactggc 1980 ctggcacaga gcaacaattt gcaggtcccc agttcttcag aaccaagcag cctcaaaggt 2040 tccacatctc tgcttgttca cccggtttca ggagtgagaa aagagcaggg aggtggttgt 2100 cattcagata ct 2112 <210> SEQ ID NO 78 <211> LENGTH: 3492 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: sig_peptide <222> LOCATION: (6)..(53) <221> NAME/KEY: mat_peptide <222> LOCATION: (54)..(2117) <221> NAME/KEY: CDS <222> LOCATION: (6)..(2117) <400> SEQUENCE: 78 tggaa atg ttt aca ttt ttg ttg acg tgt att ttt cta ccc ctc cta aga 50 Met Phe Thr Phe Leu Leu Thr Cys Ile Phe Leu Pro Leu Leu Arg -15 -10 -5 ggg cac agt ctc ttc acc tgt gaa cca att act gtt ccc aga tgt atg 98 Gly His Ser Leu Phe Thr Cys Glu Pro Ile Thr Val Pro Arg Cys Met -1 1 5 10 15 aaa atg gcc tac aac atg acg ttt ttc cct aat ctg atg ggt cat tat 146 Lys Met Ala Tyr Asn Met Thr Phe Phe Pro Asn Leu Met Gly His Tyr 20 25 30 gac cag agt att gcc gcg gtg gaa atg gag cat ttt ctt cct ctc gca 194 Asp Gln Ser Ile Ala Ala Val Glu Met Glu His Phe Leu Pro Leu Ala 35 40 45 aat ctg gaa tgt tca cca aac att gaa act ttc ctc tgc aaa gca ttt 242 Asn Leu Glu Cys Ser Pro Asn Ile Glu Thr Phe Leu Cys Lys Ala Phe 50 55 60 gta cca acc tgc ata gaa caa att cat gtg gtt cca cct tgt cgt aaa 290 Val Pro Thr Cys Ile Glu Gln Ile His Val Val Pro Pro Cys Arg Lys 65 70 75 ctt tgt gag aaa gta tat tct gat tgc aaa aaa tta att gac act ttt 338 Leu Cys Glu Lys Val Tyr Ser Asp Cys Lys Lys Leu Ile Asp Thr Phe 80 85 90 95 ggg atc cga tgg cct gag gag ctt gaa tgt gac aga tta caa tac tgt 386 Gly Ile Arg Trp Pro Glu Glu Leu Glu Cys Asp Arg Leu Gln Tyr Cys 100 105 110 gat gag act gtt cct gta act ttt gat cca cac aca gaa ttt ctt ggt 434 Asp Glu Thr Val Pro Val Thr Phe Asp Pro His Thr Glu Phe Leu Gly 115 120 125 cct cag aag aaa aca gaa caa gtc caa aga gac att gga ttt tgg tgt 482 Pro Gln Lys Lys Thr Glu Gln Val Gln Arg Asp Ile Gly Phe Trp Cys 130 135 140 cca agg cat ctt aag act tct ggg gga caa gga tat aag ttt ctg gga 530 Pro Arg His Leu Lys Thr Ser Gly Gly Gln Gly Tyr Lys Phe Leu Gly 145 150 155 att gac cag tgt gcg cct cca tgc ccc aac atg tat ttt aaa agt gat 578 Ile Asp Gln Cys Ala Pro Pro Cys Pro Asn Met Tyr Phe Lys Ser Asp 160 165 170 175 gag cta gag ttt gca aaa agt ttt att gga aca gtt tca ata ttt tgt 626 Glu Leu Glu Phe Ala Lys Ser Phe Ile Gly Thr Val Ser Ile Phe Cys 180 185 190 ctt tgt gca act ctg ttc aca ttc ctt act ttt tta att gat gtt aga 674 Leu Cys Ala Thr Leu Phe Thr Phe Leu Thr Phe Leu Ile Asp Val Arg 195 200 205 aga ttc aga tac cca gag aga cca att ata tat tac tct gtc tgt tac 722 Arg Phe Arg Tyr Pro Glu Arg Pro Ile Ile Tyr Tyr Ser Val Cys Tyr 210 215 220 agc att gta tct ctt atg tac ttc att gga ttt ttg cta ggc gat agc 770 Ser Ile Val Ser Leu Met Tyr Phe Ile Gly Phe Leu Leu Gly Asp Ser 225 230 235 aca gcc tgc aat aag gca gat gag aag cta gaa ctt ggt aac act gtt 818 Thr Ala Cys Asn Lys Ala Asp Glu Lys Leu Glu Leu Gly Asn Thr Val 240 245 250 255 gtc cta gac tct caa aat aag gct tgc acc gtt ttg ttc atg ctt ttg 866 Val Leu Asp Ser Gln Asn Lys Ala Cys Thr Val Leu Phe Met Leu Leu 260 265 270 tat ttt ttc aca atg gct ggc act gtg tgg tgg gtg att ctt acc att 914 Tyr Phe Phe Thr Met Ala Gly Thr Val Trp Trp Val Ile Leu Thr Ile 275 280 285 act tgg ttc tta gct gca gga aga aaa tgg agt tgt gaa gcc atc gag 962 Thr Trp Phe Leu Ala Ala Gly Arg Lys Trp Ser Cys Glu Ala Ile Glu 290 295 300 caa aaa gca gtg tgg ttt cat gct gtt gca tgg gga aca cca ggt ttc 1010 Gln Lys Ala Val Trp Phe His Ala Val Ala Trp Gly Thr Pro Gly Phe 305 310 315 ctg act gtt atg ctt ctt gct atg aac aaa gtt gaa gga gac aac att 1058 Leu Thr Val Met Leu Leu Ala Met Asn Lys Val Glu Gly Asp Asn Ile 320 325 330 335 agt gga gtt tgc ttt gtt ggc ctt tat gac ctg gat gct tct cgc tac 1106 Ser Gly Val Cys Phe Val Gly Leu Tyr Asp Leu Asp Ala Ser Arg Tyr 340 345 350 ttt gta ctc ttg cca ctg tgc ctt tgt gtg ttt gtt ggg ctc tct ctt 1154 Phe Val Leu Leu Pro Leu Cys Leu Cys Val Phe Val Gly Leu Ser Leu 355 360 365 ctt tta gct ggc att att tcc tta aat cat gtt cga caa gtc ata caa 1202 Leu Leu Ala Gly Ile Ile Ser Leu Asn His Val Arg Gln Val Ile Gln 370 375 380 cat gat ggc cgg aac caa gaa aaa cta aag aaa ttt atg att cga att 1250 His Asp Gly Arg Asn Gln Glu Lys Leu Lys Lys Phe Met Ile Arg Ile 385 390 395 gga gtc ttc agc ggc ttg tat ctt gtg cca tta gtg aca ctt ctc gga 1298 Gly Val Phe Ser Gly Leu Tyr Leu Val Pro Leu Val Thr Leu Leu Gly 400 405 410 415 tgt tac gtc tat gag caa gtg aac agg att acc tgg gag ata act tgg 1346 Cys Tyr Val Tyr Glu Gln Val Asn Arg Ile Thr Trp Glu Ile Thr Trp 420 425 430 gtc tct gat cat tgt cgt cag tac cat atc cca tgt cct tat cag gca 1394 Val Ser Asp His Cys Arg Gln Tyr His Ile Pro Cys Pro Tyr Gln Ala 435 440 445 aaa gca aaa gct cga cca gaa ttg gct tta ttt atg ata aaa tac ctg 1442 Lys Ala Lys Ala Arg Pro Glu Leu Ala Leu Phe Met Ile Lys Tyr Leu 450 455 460 atg aca tta att gtt ggc atc tct gct gtc ttc tgg gtt gga agc aaa 1490 Met Thr Leu Ile Val Gly Ile Ser Ala Val Phe Trp Val Gly Ser Lys 465 470 475 aag aca tgc aca gaa tgg gct ggg ttt ttt aaa cga aat cgc aag aga 1538 Lys Thr Cys Thr Glu Trp Ala Gly Phe Phe Lys Arg Asn Arg Lys Arg 480 485 490 495 gat cca atc agt gaa agt cga aga gta cta cag gaa tca tgt gag ttt 1586 Asp Pro Ile Ser Glu Ser Arg Arg Val Leu Gln Glu Ser Cys Glu Phe 500 505 510 ttc tta aag cac aat tct aaa gtt aaa cac aaa aag aag cac tat aaa 1634 Phe Leu Lys His Asn Ser Lys Val Lys His Lys Lys Lys His Tyr Lys 515 520 525 cca agt tca cac aag ctg aag gtc att tcc aaa tcc atg gga acc agc 1682 Pro Ser Ser His Lys Leu Lys Val Ile Ser Lys Ser Met Gly Thr Ser 530 535 540 aca gga gct aca gca aat cat ggc act tct gca gta gca att act agc 1730 Thr Gly Ala Thr Ala Asn His Gly Thr Ser Ala Val Ala Ile Thr Ser 545 550 555 cat gat tac cta gga caa gaa act ttg aca gaa atc caa acc tca cca 1778 His Asp Tyr Leu Gly Gln Glu Thr Leu Thr Glu Ile Gln Thr Ser Pro 560 565 570 575 gaa aca tca atg aga gag gtg aaa gcg gac gga gct agc acc ccc agg 1826 Glu Thr Ser Met Arg Glu Val Lys Ala Asp Gly Ala Ser Thr Pro Arg 580 585 590 tta aga gaa cag gac tgt ggt gaa cct gcc tcg cca gca gca tcc atc 1874 Leu Arg Glu Gln Asp Cys Gly Glu Pro Ala Ser Pro Ala Ala Ser Ile 595 600 605 tcc aga ctc tct ggg gaa cag gtc gac ggg aag ggc cag gca ggc agt 1922 Ser Arg Leu Ser Gly Glu Gln Val Asp Gly Lys Gly Gln Ala Gly Ser 610 615 620 gta tct gaa agt gcg cgg agt gaa gga agg att agt cca aag agt gat 1970 Val Ser Glu Ser Ala Arg Ser Glu Gly Arg Ile Ser Pro Lys Ser Asp 625 630 635 att act gac act ggc ctg gca cag agc aac aat ttg cag gtc ccc agt 2018 Ile Thr Asp Thr Gly Leu Ala Gln Ser Asn Asn Leu Gln Val Pro Ser 640 645 650 655 tct tca gaa cca agc agc ctc aaa ggt tcc aca tct ctg ctt gtt cac 2066 Ser Ser Glu Pro Ser Ser Leu Lys Gly Ser Thr Ser Leu Leu Val His 660 665 670 ccg gtt tca gga gtg aga aaa gag cag gga ggt ggt tgt cat tca gat 2114 Pro Val Ser Gly Val Arg Lys Glu Gln Gly Gly Gly Cys His Ser Asp 675 680 685 act tgaagaacat tttctctcgt tactcagaag caaatttgtg ttacactgga 2167 Thr agtgacctat gcactgtttt gtaagaatca ctgttacgtt cttcttttgc acttaaagtt 2227 gcattgccta ctgttatact ggaaaaaata gagttcaaga ataatatgac tcatttcaca 2287 caaaggttaa tgacaacaat atacctgaaa acagagatgt gcaggttaat aatatttttt 2347 taatagtgtg ggaggacaga gttagaggaa tcttcctttt ctatttatga agattctact 2407 cttggtaaga gtattttaag atgtactatg ctattttact tttttgatat aaaatcaaga 2467 tatttctttg ctgaagtatt taaatcttat ccttgtatct ttttatacat atttgaaaat 2527 aagcttatat gtatttgaac ttttttgaaa tcctattcaa gtatttttat catgctattg 2587 tgatatttta gcactttggt agcttttaca ctgaatttct aagaaaattg taaaatagtc 2647 ttcttttata ctgtaaaaaa agatatacca aaaagtctta taataggaat ttaactttaa 2707 aaacccactt attgatacct taccatctaa aatgtgtgat ttttatagtc tcgttttagg 2767 aatttcacag atctaaatta tgtagctgaa ataaggtgct tactcaaaga gtgtccacta 2827 ttgattgtat tatgctgctc actgatcctt ctgcatattt aaaataaaat gtcctaaagg 2887 gttagtagac aaaatgttag tcttttgtat attaggccaa gtgcaattga cttccctttt 2947 ttaatgtttc atgaccaccc attgattgta ttataaccac ttacagttgc ttatattttt 3007 tgttttaact tttgtttttt aacatttaga atattacatt ttgtattata cagtaccttt 3067 ctcagacatt ttgtagaatt catttcggca gctcactagg attttgctga acattaaaaa 3127 gtgtgatagc gatattagtg ccaatcaaat ggaaaaaagg tagtcttaat aaacaagaca 3187 caacgttttt atacaacata ctttaaaata ttaaggagtt ttcttaattt tgtttcctat 3247 taagtattat tctttgggca agattttctg atgcttttga ttttctctca atttagcatt 3307 tgcttttggt ttttttctct atttagcatt ctgttaaggc acaaaaacta tgtactgtat 3367 gggaaatgtt gtaaatatta ccttttccac attttaaaca gacaactttg aatacaaaaa 3427 ctttgttttg tgtgatcttt tcattaataa aattatcttt gtataagaaa aaaaaaaaaa 3487 aaaaa 3492 <210> SEQ ID NO 79 <211> LENGTH: 551 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 79 Met Leu Cys Ser Leu Leu Leu Cys Glu Cys Leu Leu Leu Val Ala Gly -15 -10 -5 Tyr Ala His Asp Asp Asp Trp Ile Asp Pro Thr Asp Met Leu Asn Tyr -1 1 5 10 Asp Ala Ala Ser Gly Thr Met Arg Lys Ser Gln Ala Lys Tyr Gly Ile 15 20 25 30 Ser Gly Glu Lys Asp Val Ser Pro Asp Leu Ser Cys Ala Asp Glu Ile 35 40 45 Ser Glu Cys Tyr His Lys Leu Asp Ser Leu Thr Tyr Lys Ile Asp Glu 50 55 60 Cys Glu Lys Lys Lys Arg Glu Asp Tyr Glu Ser Gln Ser Asn Pro Val 65 70 75 Phe Arg Arg Tyr Leu Asn Lys Ile Leu Ile Glu Ala Gly Lys Leu Gly 80 85 90 Leu Pro Asp Glu Asn Lys Gly Asp Met His Tyr Asp Ala Glu Ile Ile 95 100 105 110 Leu Lys Arg Glu Thr Leu Leu Glu Ile Gln Lys Phe Leu Asn Gly Glu 115 120 125 Asp Trp Lys Pro Gly Ala Leu Asp Asp Ala Leu Ser Asp Ile Leu Ile 130 135 140 Asn Phe Lys Phe His Asp Phe Glu Thr Trp Lys Trp Arg Phe Glu Asp 145 150 155 Ser Phe Gly Val Asp Pro Tyr Asn Val Leu Met Val Leu Leu Cys Leu 160 165 170 Leu Cys Ile Val Val Leu Val Ala Thr Glu Leu Trp Thr Tyr Val Arg 175 180 185 190 Trp Tyr Thr Gln Leu Arg Arg Val Leu Ile Ile Ser Phe Leu Phe Ser 195 200 205 Leu Gly Trp Asn Trp Met Tyr Leu Tyr Lys Leu Ala Phe Ala Gln His 210 215 220 Gln Ala Glu Val Ala Lys Met Glu Pro Leu Asn Asn Val Cys Ala Lys 225 230 235 Lys Met Asp Trp Thr Gly Ser Ile Trp Glu Trp Phe Arg Ser Ser Trp 240 245 250 Thr Tyr Lys Asp Asp Pro Cys Gln Lys Tyr Tyr Glu Leu Leu Leu Val 255 260 265 270 Asn Pro Ile Trp Leu Val Pro Pro Thr Lys Ala Leu Ala Val Thr Phe 275 280 285 Thr Thr Phe Val Thr Glu Pro Leu Lys His Ile Gly Lys Gly Thr Gly 290 295 300 Glu Phe Ile Lys Ala Leu Met Lys Glu Ile Pro Ala Leu Leu His Leu 305 310 315 Pro Val Leu Ile Ile Met Ala Leu Ala Ile Leu Ser Phe Cys Tyr Gly 320 325 330 Ala Gly Lys Ser Val His Val Leu Arg His Ile Gly Gly Pro Glu Ser 335 340 345 350 Glu Pro Pro Gln Ala Leu Arg Pro Arg Asp Arg Arg Arg Gln Glu Glu 355 360 365 Ile Asp Tyr Arg Pro Asp Gly Gly Ala Gly Asp Ala Asp Phe His Tyr 370 375 380 Arg Gly Gln Met Gly Pro Thr Glu Gln Gly Pro Tyr Ala Lys Thr Tyr 385 390 395 Glu Gly Arg Arg Glu Ile Leu Arg Glu Arg Asp Val Asp Leu Arg Phe 400 405 410 Gln Thr Gly Asn Lys Ser Pro Glu Val Leu Arg Ala Phe Asp Val Pro 415 420 425 430 Asp Ala Glu Ala Arg Glu His Pro Thr Val Val Pro Ser His Lys Ser 435 440 445 Pro Val Leu Asp Thr Lys Pro Lys Glu Thr Gly Gly Ile Leu Gly Glu 450 455 460 Gly Thr Pro Lys Glu Ser Ser Thr Glu Ser Ser Gln Ser Ala Lys Pro 465 470 475 Val Ser Gly Gln Asp Thr Ser Gly Asn Thr Glu Gly Ser Pro Ala Ala 480 485 490 Glu Lys Ala Gln Leu Lys Ser Glu Ala Ala Gly Ser Pro Asp Gln Gly 495 500 505 510 Ser Thr Tyr Ser Pro Ala Arg Gly Val Ala Gly Pro Arg Gly Gln Asp 515 520 525 Pro Val Ser Ser Pro Cys Gly 530 <210> SEQ ID NO 80 <211> LENGTH: 1653 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 80 atgctgtgtt ctttgctcct ttgtgaatgt ctgttgctgg tagctggtta tgctcatgat 60 gatgactgga ttgaccccac agacatgctt aactatgatg ctgcttcagg aacaatgaga 120 aaatctcagg caaaatatgg tatttcaggg gaaaaggatg tcagtcctga cttgtcatgt 180 gctgatgaaa tatcagaatg ttatcacaaa cttgattctt taacttataa gattgatgag 240 tgtgaaaaga aaaagaggga agactatgaa agtcaaagca atcctgtttt taggagatac 300 ttaaataaga ttttaattga agctggaaag cttggacttc ctgatgaaaa caaaggcgat 360 atgcattatg atgctgagat tatccttaaa agagaaactt tgttagaaat acagaagttt 420 ctcaatggag aagactggaa accaggtgcc ttggatgatg cactaagtga tattttaatt 480 aattttaagt ttcatgattt tgaaacatgg aagtggcgat tcgaagattc ctttggagtg 540 gatccatata atgtgttaat ggtacttctt tgtctgctct gcatcgtggt tttagtggct 600 accgagctgt ggacatatgt acgttggtac actcagttga gacgtgtttt aatcatcagc 660 tttctgttca gtttgggatg gaattggatg tatttatata agctagcttt tgcacagcat 720 caggctgaag tcgccaagat ggagccatta aacaatgtgt gtgccaaaaa gatggactgg 780 actggaagta tctgggaatg gtttagaagt tcatggacct ataaggatga cccatgccaa 840 aaatactatg agctcttact agtcaaccct atttggttgg tcccaccaac aaaggcactt 900 gcagttacat tcaccacatt tgtaacggag ccattgaagc atattggaaa aggaactggg 960 gaatttatta aagcactcat gaaggaaatt ccagcgctgc ttcatcttcc agtgctgata 1020 attatggcat tagccatcct gagtttctgc tatggtgctg gaaaatcagt tcatgtgctg 1080 agacatatag gcggtcctga gagcgaacct ccccaggcac ttcggccacg ggatagaaga 1140 cggcaggagg aaattgatta tagacctgat ggtggagcag gtgatgccga tttccattat 1200 aggggccaaa tgggccccac tgagcaaggc ccttatgcca aaacgtatga gggtagaaga 1260 gagattttga gagagagaga tgttgacttg agatttcaga ctggcaacaa gagccctgaa 1320 gtgctccggg catttgatgt accagacgca gaggcacgag agcatcccac ggtggtaccc 1380 agtcataaat cacctgtttt ggatacaaag cccaaggaga caggtggaat cctgggggaa 1440 ggcacaccga aagaaagcag tactgaaagc agccagtcgg ccaagcctgt ctctggccaa 1500 gacacatcag ggaatacaga aggttcaccc gcagcggaaa aggcccagct caagtctgaa 1560 gccgcaggca gcccagacca aggcagcaca tacagccccg caagaggtgt ggctggacca 1620 cgtggacagg atccggtcag cagcccctgt ggc 1653 <210> SEQ ID NO 81 <211> LENGTH: 2000 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: sig_peptide <222> LOCATION: (82)..(135) <221> NAME/KEY: mat_peptide <222> LOCATION: (136)..(1734) <221> NAME/KEY: CDS <222> LOCATION: (82)..(1734) <400> SEQUENCE: 81 gcggcggcaa gctgtgcgac ctcttctgcg gccggcctgg gcaggtgtct tcctcgagag 60 gcaggcaggg gatcccggac g atg ctg tgt tct ttg ctc ctt tgt gaa tgt 111 Met Leu Cys Ser Leu Leu Leu Cys Glu Cys -15 -10 ctg ttg ctg gta gct ggt tat gct cat gat gat gac tgg att gac ccc 159 Leu Leu Leu Val Ala Gly Tyr Ala His Asp Asp Asp Trp Ile Asp Pro -5 -1 1 5 aca gac atg ctt aac tat gat gct gct tca gga aca atg aga aaa tct 207 Thr Asp Met Leu Asn Tyr Asp Ala Ala Ser Gly Thr Met Arg Lys Ser 10 15 20 cag gca aaa tat ggt att tca ggg gaa aag gat gtc agt cct gac ttg 255 Gln Ala Lys Tyr Gly Ile Ser Gly Glu Lys Asp Val Ser Pro Asp Leu 25 30 35 40 tca tgt gct gat gaa ata tca gaa tgt tat cac aaa ctt gat tct tta 303 Ser Cys Ala Asp Glu Ile Ser Glu Cys Tyr His Lys Leu Asp Ser Leu 45 50 55 act tat aag att gat gag tgt gaa aag aaa aag agg gaa gac tat gaa 351 Thr Tyr Lys Ile Asp Glu Cys Glu Lys Lys Lys Arg Glu Asp Tyr Glu 60 65 70 agt caa agc aat cct gtt ttt agg aga tac tta aat aag att tta att 399 Ser Gln Ser Asn Pro Val Phe Arg Arg Tyr Leu Asn Lys Ile Leu Ile 75 80 85 gaa gct gga aag ctt gga ctt cct gat gaa aac aaa ggc gat atg cat 447 Glu Ala Gly Lys Leu Gly Leu Pro Asp Glu Asn Lys Gly Asp Met His 90 95 100 tat gat gct gag att atc ctt aaa aga gaa act ttg tta gaa ata cag 495 Tyr Asp Ala Glu Ile Ile Leu Lys Arg Glu Thr Leu Leu Glu Ile Gln 105 110 115 120 aag ttt ctc aat gga gaa gac tgg aaa cca ggt gcc ttg gat gat gca 543 Lys Phe Leu Asn Gly Glu Asp Trp Lys Pro Gly Ala Leu Asp Asp Ala 125 130 135 cta agt gat att tta att aat ttt aag ttt cat gat ttt gaa aca tgg 591 Leu Ser Asp Ile Leu Ile Asn Phe Lys Phe His Asp Phe Glu Thr Trp 140 145 150 aag tgg cga ttc gaa gat tcc ttt gga gtg gat cca tat aat gtg tta 639 Lys Trp Arg Phe Glu Asp Ser Phe Gly Val Asp Pro Tyr Asn Val Leu 155 160 165 atg gta ctt ctt tgt ctg ctc tgc atc gtg gtt tta gtg gct acc gag 687 Met Val Leu Leu Cys Leu Leu Cys Ile Val Val Leu Val Ala Thr Glu 170 175 180 ctg tgg aca tat gta cgt tgg tac act cag ttg aga cgt gtt tta atc 735 Leu Trp Thr Tyr Val Arg Trp Tyr Thr Gln Leu Arg Arg Val Leu Ile 185 190 195 200 atc agc ttt ctg ttc agt ttg gga tgg aat tgg atg tat tta tat aag 783 Ile Ser Phe Leu Phe Ser Leu Gly Trp Asn Trp Met Tyr Leu Tyr Lys 205 210 215 cta gct ttt gca cag cat cag gct gaa gtc gcc aag atg gag cca tta 831 Leu Ala Phe Ala Gln His Gln Ala Glu Val Ala Lys Met Glu Pro Leu 220 225 230 aac aat gtg tgt gcc aaa aag atg gac tgg act gga agt atc tgg gaa 879 Asn Asn Val Cys Ala Lys Lys Met Asp Trp Thr Gly Ser Ile Trp Glu 235 240 245 tgg ttt aga agt tca tgg acc tat aag gat gac cca tgc caa aaa tac 927 Trp Phe Arg Ser Ser Trp Thr Tyr Lys Asp Asp Pro Cys Gln Lys Tyr 250 255 260 tat gag ctc tta cta gtc aac cct att tgg ttg gtc cca cca aca aag 975 Tyr Glu Leu Leu Leu Val Asn Pro Ile Trp Leu Val Pro Pro Thr Lys 265 270 275 280 gca ctt gca gtt aca ttc acc aca ttt gta acg gag cca ttg aag cat 1023 Ala Leu Ala Val Thr Phe Thr Thr Phe Val Thr Glu Pro Leu Lys His 285 290 295 att gga aaa gga act ggg gaa ttt att aaa gca ctc atg aag gaa att 1071 Ile Gly Lys Gly Thr Gly Glu Phe Ile Lys Ala Leu Met Lys Glu Ile 300 305 310 cca gcg ctg ctt cat ctt cca gtg ctg ata att atg gca tta gcc atc 1119 Pro Ala Leu Leu His Leu Pro Val Leu Ile Ile Met Ala Leu Ala Ile 315 320 325 ctg agt ttc tgc tat ggt gct gga aaa tca gtt cat gtg ctg aga cat 1167 Leu Ser Phe Cys Tyr Gly Ala Gly Lys Ser Val His Val Leu Arg His 330 335 340 ata ggc ggt cct gag agc gaa cct ccc cag gca ctt cgg cca cgg gat 1215 Ile Gly Gly Pro Glu Ser Glu Pro Pro Gln Ala Leu Arg Pro Arg Asp 345 350 355 360 aga aga cgg cag gag gaa att gat tat aga cct gat ggt gga gca ggt 1263 Arg Arg Arg Gln Glu Glu Ile Asp Tyr Arg Pro Asp Gly Gly Ala Gly 365 370 375 gat gcc gat ttc cat tat agg ggc caa atg ggc ccc act gag caa ggc 1311 Asp Ala Asp Phe His Tyr Arg Gly Gln Met Gly Pro Thr Glu Gln Gly 380 385 390 cct tat gcc aaa acg tat gag ggt aga aga gag att ttg aga gag aga 1359 Pro Tyr Ala Lys Thr Tyr Glu Gly Arg Arg Glu Ile Leu Arg Glu Arg 395 400 405 gat gtt gac ttg aga ttt cag act ggc aac aag agc cct gaa gtg ctc 1407 Asp Val Asp Leu Arg Phe Gln Thr Gly Asn Lys Ser Pro Glu Val Leu 410 415 420 cgg gca ttt gat gta cca gac gca gag gca cga gag cat ccc acg gtg 1455 Arg Ala Phe Asp Val Pro Asp Ala Glu Ala Arg Glu His Pro Thr Val 425 430 435 440 gta ccc agt cat aaa tca cct gtt ttg gat aca aag ccc aag gag aca 1503 Val Pro Ser His Lys Ser Pro Val Leu Asp Thr Lys Pro Lys Glu Thr 445 450 455 ggt gga atc ctg ggg gaa ggc aca ccg aaa gaa agc agt act gaa agc 1551 Gly Gly Ile Leu Gly Glu Gly Thr Pro Lys Glu Ser Ser Thr Glu Ser 460 465 470 agc cag tcg gcc aag cct gtc tct ggc caa gac aca tca ggg aat aca 1599 Ser Gln Ser Ala Lys Pro Val Ser Gly Gln Asp Thr Ser Gly Asn Thr 475 480 485 gaa ggt tca ccc gca gcg gaa aag gcc cag ctc aag tct gaa gcc gca 1647 Glu Gly Ser Pro Ala Ala Glu Lys Ala Gln Leu Lys Ser Glu Ala Ala 490 495 500 ggc agc cca gac caa ggc agc aca tac agc ccc gca aga ggt gtg gct 1695 Gly Ser Pro Asp Gln Gly Ser Thr Tyr Ser Pro Ala Arg Gly Val Ala 505 510 515 520 gga cca cgt gga cag gat ccg gtc agc agc ccc tgt ggc tagaggaaca 1744 Gly Pro Arg Gly Gln Asp Pro Val Ser Ser Pro Cys Gly 525 530 ccagcacaaa cgacagcctc aagtctcctt cgagctttat atccatttgg ggatgaagtc 1804 tactttgaca gctagcaagg cgacatgcaa ctgttgttga atgatgacag caattcagga 1864 aagacttaaa tatgaaagca aattgaacac atcgggtgtt tgttatcaga aaagagatga 1924 gatgagataa gacttgttta ttgactagcc aatatgtcat taaaattaag gtttaaaaaa 1984 aaaaaaaaaa aaaaaa 2000 <210> SEQ ID NO 82 <211> LENGTH: 35 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: XhoI-randam 9mer to synthesize doble strands cDNA <221> NAME/KEY: modified_base <222> LOCATION: (1)..(35) <223> OTHER INFORMATION: “n” represents a, t, c, or g <400> SEQUENCE: 82 cgattgaatt ctagacctgc ctcgagnnnn nnnnn 35 <210> SEQ ID NO 83 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: biotin- conjugated 0N056-F1 primer <400> SEQUENCE: 83 aacatgaatc tttcgctcgt cctggct 27 <210> SEQ ID NO 84 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: biotin- conjugated 0N034-F1 primer <400> SEQUENCE: 84 tgaagcccat cactacatcg ccattacg 28 <210> SEQ ID NO 85 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: OX003-F1 primer <400> SEQUENCE: 85 caaaacccac aagaaattca ccaaggc 27 <210> SEQ ID NO 86 <211> LENGTH: 23 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: OX003-F2 primer <400> SEQUENCE: 86 tcaccaaggc taacatggtg gcc 23 <210> SEQ ID NO 87 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: OA052-F1 primer <400> SEQUENCE: 87 atgcctagaa gaggactgat tcttcac 27 <210> SEQ ID NO 88 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: OC004-F1 primer <400> SEQUENCE: 88 atgaggaaag ggaaccttct gctgagc 27 <210> SEQ ID NO 89 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: OC004-F2 primer <400> SEQUENCE: 89 tgagcttcca gagctgtc 18 <210> SEQ ID NO 90 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: OM017-F3 primer <400> SEQUENCE: 90 gggaaatgaa acatttctgt aacctgc 27 <210> SEQ ID NO 91 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: OM017-F1 primer <400> SEQUENCE: 91 atgaaacatt tctgtaacct gctttgt 27 <210> SEQ ID NO 92 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: OM101-F3 primer <400> SEQUENCE: 92 tgaagttgca gataatgagg acttacc 27 <210> SEQ ID NO 93 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: OM101-F1 primer <400> SEQUENCE: 93 atgaggactt accattatat accatta 27 <210> SEQ ID NO 94 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: OM126-F3 primer <400> SEQUENCE: 94 aggaaggatg aggaagacca ggctctg 27 <210> SEQ ID NO 95 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: biotin- conjugated OM160-F1 primer <400> SEQUENCE: 95 atgcttcagt ggaggagaag acactgc 27 <210> SEQ ID NO 96 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: OMA016-F1 primer <400> SEQUENCE: 96 agaaatggtg aatgcctgct ggtgtgg 27 <210> SEQ ID NO 97 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: OMB130-F1 primer <400> SEQUENCE: 97 tcctctgact tttcttctgc aagctcc 27 <210> SEQ ID NO 98 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: OMB142-F2 primer <400> SEQUENCE: 98 gcccaaggtc aaggagatgg tacggat 27 <210> SEQ ID NO 99 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: OMB142-F1 primer <400> SEQUENCE: 99 ggagatggta cggatcttaa ggactgtg 28 <210> SEQ ID NO 100 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: OTB033-F1 primer <400> SEQUENCE: 100 tgcactatcc aaaagctcca tgtacac 27 <210> SEQ ID NO 101 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: OTB003-F2 primer <400> SEQUENCE: 101 ccatgtacac agtgggggc 19 <210> SEQ ID NO 102 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: OVB100-F1 primer <400> SEQUENCE: 102 cacttggtgt ttgatttacc taagcac 27 <210> SEQ ID NO 103 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: OAF062-F2 primer <400> SEQUENCE: 103 gagtttcgta agcaaaatag aggacag 27 <210> SEQ ID NO 104 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: OAF062-F3 primer <400> SEQUENCE: 104 tagaggacag aaatgcagtt catgaac 27 <210> SEQ ID NO 105 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: OAF075-F1 primer <400> SEQUENCE: 105 gacatgaggt ggatactgtt cattgggg 28 <210> SEQ ID NO 106 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: OAG119-F1 primer <400> SEQUENCE: 106 tggcgtgtaa ctatgctcat cattgttc 28 <210> SEQ ID NO 107 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: OAH040-F1 primer <400> SEQUENCE: 107 ttagcccacc catgttgata gaacaccc 28 <210> SEQ ID NO 108 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: OAH058-F1 primer <400> SEQUENCE: 108 acaatgttgg cctgtctgca agcttgtg 28 <210> SEQ ID NO 109 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: biotin- conjugated OM011-F1 primer <400> SEQUENCE: 109 gaagtgactc ttcctctagt ttgccac 27 <210> SEQ ID NO 110 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: biotin- conjugated OM028-F1 primer <400> SEQUENCE: 110 atgaaggaca tgccactccg aattcat 27 <210> SEQ ID NO 111 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: OMB092-F1 primer <400> SEQUENCE: 111 actcacctgg atccctaagg gcacagc 27 <210> SEQ ID NO 112 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: OMB092-F2 primer <400> SEQUENCE: 112 agaatgagct attacggcag cagctatc 28 <210> SEQ ID NO 113 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: OMB108-F1 primer <400> SEQUENCE: 113 ctctctccat ctgctgtggt tatggcc 27 <210> SEQ ID NO 114 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: OMB108-F2 primer <400> SEQUENCE: 114 tggttatggc ctgtcgctgg ag 22 <210> SEQ ID NO 115 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: biotin- conjugated OT007-F1 primer <400> SEQUENCE: 115 aaaatgactc cccagtcgct gctgcag 27 <210> SEQ ID NO 116 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: OAG051-F1 primer <400> SEQUENCE: 116 ggaaatgttt acatttttgt tgacgtg 27 <210> SEQ ID NO 117 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: biotin- conjugated OUB068-F1 primer <400> SEQUENCE: 117 cactcatgaa ggaaattcca gcgctgc 27 

1. A substantially purified form of the polypeptide comprising the amino acid sequence shown in SEQ ID NOS. 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 73, 76 or 79, homologue thereof, fragment thereof or homologue of the fragment.
 2. A polypeptide according to claim 1 comprising the amino acid sequence shown in SEQ ID NOS. 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 73, 76 or
 79. 3. A cDNA encoding the polypeptide according to claim
 1. 4. A cDNA according to claim 3 comprising the nucleotide sequence shown in SEQ ID NOS. 2, 5, 8, 11, 14, 17, 20, 23, 26, 29, 32, 35, 38, 41, 44, 47, 50, 53, 56, 59, 62, 65, 68, 71, 74, 77 or 80, or a fragment cDNA selectively hybridized to the cDNA.
 5. A cDNA according to claim 3 comprising the nucleotide sequence shown in SEQ ID NOS. 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78 or 81, or a fragment cDNA selectively hybridized to the cDNA.
 6. A replication or expression vector carrying the cDNA according to claims 3 to
 5. 7. A host cell transformed with the replication or expression vector according to claim
 6. 8. A method for producing the polypeptide according to claim 1 or 2 which comprises culturing a host cell according to claim 7 under a condition effective to express the polypeptide according to claim 1 or
 2. 9. A monoclonal or polyclonal antibody against the polypeptide according to claim 1 or
 2. 10. A pharmaceutical composition containing the polypeptide according to claim 1 or 2 or the antibody according to claim 9, in association with pharmaceutically acceptable diluent and/or carrier. 